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ABSTRACT 
Introduction: Maternal recto-vaginal colonization with Group B Streptococcus (GBS) is 
the major risk factor for invasive GBS disease in newborn’s. Maternal vaccination against 
GBS during pregnancy may prevent or reduce subsequent recto-vaginal colonization in 
women, which could lower fetal/newborn exposure to GBS and contribute to reducing 
GBS associated infections during early infancy. In this study we determined the 
immunological correlates of protection against GBS colonization in black African pregnant 
women. 
    
Methods: We compared GBS serotype-specific serum IgG, mucosal IgG, mucosal IgA 
and cellular immune responses in relation to GBS rectovaginal acquisition and clearance in 
pregnant women from 20 to 37+ weeks of gestational age. Furthermore, we also evaluated 
different media for isolation of GBS from vaginal and rectal swabs. 
 
Results: The prevalence of recto-vaginal GBS colonization was 33.0%, 32.7%, 28.7% and 
28.4% at 20-25 weeks, 26-30 weeks, 31-35 weeks and 37+ weeks of gestational age, 
respectively. The most common identified serotypes were Ia (39.2%), III (32.8%) and V 
(12.4%). The cumulative overall recto-vaginal acquisition rate of new serotypes during the 
study was 27.9%, including 11.2%, 8.2% and 4.3% for serotypes Ia, III and V, 
respectively. The recovery of GBS from rectal swabs was significantly higher from direct 
plating on chromogenic medium (p<0.0001) than from selective broth method.  
 
New-acquisition of GBS was inversely correlated with serotype-specific serum IgG 
concentration for serotype III (p=0.009) and OPA titer for serotype Ia and III (p<0.001 for 
both) at time of enrolment. Serum IgG concentration significantly associated with 
viii 
 
protection against recto-vaginal acquisition of the homotypic serotype was ≥1 μg/ml for 
serotype V (p=0.039), ≥3 μg/ml for serotype Ia (p=0.043) and III (p=0.023). Mucosal IgG 
correlated significantly with serum IgG with Rho values of 0.839, 0.621 and 0.426 (all 
p<0.001) for serotype Ia, III and V, respectively. The clearance of serotype-specific GBS 
recto-vaginal colonization during pregnancy was positively associated with presence of 
homotypic capsular ELISpot IFN-γ positivity for serotype III (p=0.008) 
 
Conclusion: Maternal GBS colonization could be used as end point to evaluate efficacy of 
GBS vaccine. A serotype-specific capsular polysaccharide based GBS vaccine able to elicit 
both humoral and cell-mediated capsular immune responses could confer protection 
against EOD by reducing the exposure of the newborn’s to GBS colonization during the 
peri-partum period. 
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PREFACE 
 
This thesis is presented to the reader in the University of the Witwatersrand’s 
recommended “divided block” format. In this format, the thesis consists of two parts: the 
first part includes the Introduction and Methods chapters that are written in the traditional 
thesis format, and second part in which the Results and Discussion of the study’s 
objectives are presented as individual chapters. 
 
This thesis aimed to identify GBS serotype-specific capsular antibody thresholds that 
correlate with protection against colonization in pregnant women, which may assist in the 
licensure of the maternal GBS polysaccharide-protein conjugate vaccine undergoing 
development. 
             
In the Introduction chapter, I will briefly describe the epidemiology of invasive GBS 
disease, risk factors and the strategies to prevent it. I will further briefly describe 
prevalence of maternal GBS colonization and methods for its detection. Thereafter, I will 
discuss the concept of vaccination to prevent or reduce maternal GBS colonization as an 
alternative strategy to prevent GBS disease in young infants. In Chapter 2, material and 
methods are described. 
 
Chapter’s 3-8 presents the results and discussion of my work. In Chapter three, meta-
analysis and systematic review on prevalence of maternal GBS colonization is reported. In 
chapter four, the comparison of different media for isolation and detection of GBS from 
maternal specimens is described. In chapter 5, dynamics of GBS colonization in later half 
of the pregnancy is presented. Chapter 6, details the association between natural occurring 
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serotype-specific serum IgG and risk of new acquisition of GBS. Chapter 7, details the 
association between natural occurring serotype-specific cellular immune responses and 
clearance of existing GBS colonization. Chapter 8, details the association between natural 
occurring serotype-specific serum IgG and mucosal IgG as well as mucosal IgG and IgA 
association with maternal GBS colonization. 
 
The thesis concludes with chapter 9, with a summary of the main findings of my research 
in the context of maternal GBS colonization as surrogate marker for evaluating GBS 
vaccine. 
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Chapter 1 Introduction 
 
1.1 Epidemiology of Group B Streptococcus disease 
Streptococcus agalactiae, also known as Group B Streptococcus (GBS), is a 
leading cause of neonatal invasive bacterial disease (Stoll et al., 2011). It is a common 
commensal bacterium colonizing the gastrointestinal and genitourinary tracts of women 
(Stoll and Schuchat, 1998). Historically GBS was associated with  bovine mastitis and  
only reported as a human pathogen in the 1960’s, following which it became recognized as 
the leading cause of neonatal invasive disease (Eickhoff et al., 1964). Invasive GBS 
disease in neonates manifest primarily as bacteremia, pneumonia or meningitis (Burman et 
al., 1992). Developmental abnormalities such mental retardness, blindness and deafness 
have also been reported in half of GBS meningitis survivors (Bedford et al., 2001, Libster 
et al., 2012, Edwards et al., 1985).   
  
The burden of invasive GBS disease is highest in infants less than three months of 
age and the incidence is substantially higher in developing countries with limited or no 
preventive strategies. The incidence (per 1000 live births) of invasive GBS disease 
globally in infants less than 90 days  was  reviewed by Edmond et al, with a reported 
overall incidence of 0.53 globally (Edmond et al., 2012). However, variability in incidence 
of GBS disease between regions as well as within regions was observed. Among the 
regions, Africa region reported highest incidence (1.21), followed by America (0.67) and 
Europe (0.57); whereas Southeast Asia reported the lowest incidence (0.02). The low 
incidence  in Southeast Asia may be an underestimate due to large number of deliveries 
occurring outside health care facilities which coupled with a high proportion of babies 
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dying within 24 hours of birth, results in many newborn’s deaths not being investigated for 
bacterial sepsis including in epidemiological studies (Montagu et al., 2011). Furthermore, it 
should be noted that only five studies from low-income countries were reported in the review, 
accounting for 5% of the total studies of those included in the review. In a separate review on 
studies conducted in developing countries, Africa region reported the highest incidence, 
including an incidence of 3.0 in  South Africa (Dagnew et al., 2012).      
   
In neonates, GBS disease is stratified into cases which occur within the first seven 
days of life (0-6 days) that are defined as early-onset disease (EOD) and account for 70-
80% of total GBS disease cases. Of the EOD, 80% cases present within first 24 hours of 
life (Madhi et al., 2013, Schuchat et al., 2000). In the remaining cases among infants, 
invasive GBS disease primarily occurs from seven days to three months of life, these are 
defined as late-onset disease(Chan SHS, 2000).  
 
The global incidence (per 1000 live births) of EOD has been reported to be 0.43,  
with Africa region reporting the highest incidence (0.53), followed by America (0.50) and 
Europe (0.45) (Edmond et al., 2012); whereas the incidence in Southeast Asia was 
reportedly only 0.11 (95%CI: 0.012-0.220). The incidence of EOD in South African 
infants has been reported in three previous studies (Haffejee et al., 1991, Madhi et al., 
2003, Cutland et al., 2015). The first study was conducted from 1986 to 1989 and reported 
an incidence of 2.09/1000 for EOD in women of Indian descent  (Haffejee et al., 1991), 
and similar incidences for EOD (2.06/1000) was reported ten years later in Black-African 
women  (Madhi et al., 2003). Between 2004 and 2008, the incidence of EOD among 
Black-African Sowetan women in South Africa has declined marginally to 1.5 (95%CI: 
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1.31-1.71) (Cutland et al., 2015). In developed countries such as the USA, the incidence 
(per 1000 live births) of EOD in full-term newborns  declined by approximately 90% 
(1.7in 1993 to 0.26/in 2010) due to routine screening of pregnant women for GBS recto-
vaginal colonization at 35-37 weeks of gestational age, which was coupled  with 
intrapartum antibiotic prophylaxis (IAP) provided to colonized women 4 hours prior to 
delivery (Schrag and Schuchat, 2004). Nevertheless, GBS is the main cause of EOD (38-
43%) in USA, followed by E.coli (24-29%) (Stoll et al., 2011, Weston et al., 2011).  
    
The global incidence (per 1000 live births) of LOD has been reported to be 0.24, 
with highest in Africa (0.7) (Edmond et al., 2012). There has been an increase in the 
incidence of LOD in South Africa from 0.67 to 1.22 in the past 20 years (Madhi et al., 
2003, Cutland et al., 2015, Haffejee et al., 1991). The increase in LOD infection might be 
due to increase in HIV infection rate among pregnant women from 1.4% in 1991 to 29.5% 
in 2011(Health, 2011). In developed countries despite implementation of IAP strategy, the 
incidence of LOD unlike EOD has remained unchanged (0.3-0.4/1000 live births) over the 
past 20 years (Schrag and Verani, 2013). Furthermore, whilst GBS is the leading cause of 
invasive disease in newborn infants, the incidence of GBS related disease in elderly adults 
also appears to be on the increase (Edwards and Baker, 2005). 
        
1.2 Risk factors for GBS neonatal disease 
Group B Streptococcus is a normal commensal of gastrointestinal and genitourinary 
tracts of pregnant women and vertical acquisition of GBS by the fetus in-utero or newborn 
(during labor) from recto-vaginally colonized mothers is the major risk factor for EOD in 
infants (Verani et al., 2010). Approximately 10% to 40% of pregnant women are colonized 
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with GBS in the vagina or rectum (Picard and Bergeron, 2004). Vertical transmission of 
GBS occurs in approximately 50% of newborn’s of GBS-colonized mothers, of whom 1–
2% develop EOD (Beal and Dancer, 2006, Heath and Feldman, 2005). In comparison to 
other microorganisms, GBS bind very efficiently to human vaginal epithelium (Sobel et 
al., 1982).  It is however, unclear how asymptomatic colonization in mothers, become 
invasive and pathogenic in the infant. Mechanisms such as bacterial overgrowth and 
changes in gene expression have been proposed that could increase the invasive potential 
of GBS in the infants (Rajagopal, 2009).  
       
GBS colonization in the infant may ascend in-utero by penetrating into amniotic 
cavity regardless of whether membrane has been ruptured or not (Whidbey et al., 2013). 
Studies have also shown that GBS can grow rapidly in amniotic fluid both in vivo and in 
vitro experiments (Hemming et al., 1985). Furthermore, rapid onset of EOD in neonates, 
particularly cases presenting at the time of delivery or a few hours after birth, suggests that 
the GBS infection process possibly started in-utero rather than during delivery (Madhi et 
al., 2013). Studies have demonstrated concordance of 90.7% in serotypes between the 
mother and newborn pairs who were colonized by GBS whereas 100% of infants with 
EOD had the same serotype at presentation as the maternal colonizing serotype (Dillon et 
al., 1987, Madzivhandila et al., 2011).    
 
The risk factors for the development of LOD as compared to EOD are poorly 
understood with maternal colonization is still thought to be primary source. Studies have 
demonstrated that almost half of infants with LOD had the same serotype at presentation as 
the mother was colonized with at birth, (Dillon et al., 1987) and the same genotype was  
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isolated from the mother-infant pairs as late as 8 weeks post-partum (Berardi et al., 2013). 
These studies suggest that delayed vertically transmission could be a source of infection 
resulting in LOD. It has also been shown that breast-milk feeding may be a source of 
transmission of GBS resulting in either late onset or recurrence of GBS disease (Kotiw et 
al., 2003). Nosocomial and community acquired transmission is also thought common 
source of GBS colonization of neonates, which too could result in LOD (Jordan et al., 
2008).  
          
1.3 Microbiology, Identifications and Growth conditions 
Streptococcus agalactiae (GBS) is a Gram-positive pathogen and belongs to genus 
streptococcus. The classification of group B is based upon specific cell wall polysaccharide 
antigens reacting to hyperimmune serum under the Lancefield grouping (Lancefield, 
1934). GBS are facultative anaerobes and exhibit β hemolytic pattern of growth when 
grown on blood agar, producing a clear zone around colonies (Nizet, 2002). Detection of 
GBS on blood agar is often superimposed by normal gram negative microflora. The 
selectivity of GBS on blood agar or other media is increased by supplementing the medium 
with antibiotics to maximize the recovery of GBS and minimizing the likelihood of culture 
of gram negative pathogens. The current CDC recommendation for the isolation of GBS 
from vaginal and rectal or recto-vaginal swabs is by growth in a selective broth medium 
(Todd-Hewitt broth with gentamicin and colistin or nalidixic acid), followed by subculture 
on blood agar or selective media (Verani et al., 2010). These GBS colonies are further 
confirmed by Christie Atkinson Munch-Petersen (CAMP) test (Fuchs et al., 1978), Bile 
esculin test (Chuard and Reller, 1998), catalase test and group B antigen latex 
agglutination (Elliott et al., 2004).  Verification of GBS colonies can also be done by using 
fluorescent antibodies (Boyer et al., 1981) or by genetic probes (Kong et al., 2005). 
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Christie Atkinson Munch-Petersen (CAMP) test is used for presumptive 
identification of GBS and involves the haemolytic activity of staphylococcal B-lysin on red 
blood cells which is enhanced by the factor produced only by GBS called CAMP factor. 
GBS produces a clear arrow-head shaped haemolysis at the junction with the line of 
staphylococcus (Fuchs et al., 1978). Occasionally  GBS on blood agar may be mistaken for 
Enterococcus faecalis, and in order to discriminate between the two, bile esculin test is 
performed (Chuard and Reller, 1998). Bile esculin medium favours growth of GBS and 
enterococcus both, however, by-products produced as a result of enterococcus growth react 
with the iron salts in the medium causing the medium to blacken. 
 
The selective broth method recommended by CDC has been reported to have 
sensitivity ranging from 82% to 99%. (Busetti et al., 2007, Craven et al., 2010, Gupta and 
Briski, 2004, Jones et al., 2006). There are, however, limitations to this approach including 
that the procedure requires at least 48-72 hours of culture time and identification of GBS-
like colonies on blood agar requires laboratory expertise, particularly when they are mixed 
with other microflora (Poisson et al., 2010). Studies have shown that direct plating on 
colistin and nalidixic agar (CNA) is a low-cost alternative for GBS recovery, albeit with a 
lower sensitivity (59%-83%) (Bosch-Mestres et al., 2003, El Aila et al., 2010, Louie et al., 
2010). In recent years, several commercial chromogenic media have been tested for their 
suitability for detecting GBS such as Granada medium, CHROMagar Strep B (CA) and 
Chrom ID Strepto B agar (El Aila et al., 2010, Poisson et al., 2011). CHROMagar Strep B 
is a commercially available selective chromogenic medium that inhibits most saprophytic 
bacteria and yeasts, and produces mauve-coloured GBS colonies in aerobic conditions 
irrespective of their haemolytic properties, allowing direct visual identification. The 
clinical sensitivity of CA ranges from 93%-98% (Charron, 2009, Poisson et al., 2010), 
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40%-91% for Granada Medium (El Aila et al., 2010, Gupta and Briski, 2004, Overman et 
al., 2002) and 88%-95% for Chrom ID Strepto B agar (El Aila et al., 2010, Craven et al., 
2010). In order to select suitable media for the study, we evaluated direct plating on CA, 
CNA and selective broth enrichment method for the isolation of GBS in swabs from 
pregnant women. 
 
1.4 Pathogenesis and virulence factors 
The development of GBS disease is complex process. Several virulence factors of GBS 
have been identified that are critical for its ability to cause disease (Rajagopal, 2009). The 
pathogenesis of invasive GBS disease has been broadly divided into following steps 
(Rajagopal, 2009).  
1. Adherence: GBS is a part of the common flora colonizing at the vagina, rectum, 
and gastrointestinal mucosa. The initial step in the pathogenesis of GBS is 
adherence to host cells. Surface proteins such as pili, C5a peptidase, α-C protein, 
Lmb, FbsA, BibA and Rib are linked to the firm adherence of GBS to host cells. 
2. Penetration of host cellular barriers: Penetration of GBS into host cells and/or 
tissues is the key step of GBS neonatal disease. Surface proteins such as Alpha C 
protein and FbsB can promote entry into host cells. Pore forming toxins such as 
CAMP factor and hemolysin are also a critical component of GBS pathogenesis 
promoting its entry into host cells and facilitating their intracellular survival and 
dissemination. Hyaluronatelyase a secreted protease is also thought to facilitate the 
spread of GBS during infection. 
3. Immune evasion: GBS escape from host immune clearance is an important step of 
GBS neonatal disease. GBS encodes a number of virulence factors which help them 
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to avoid host defence mechanisms such capsular polysaccharides (CPS), C5a 
peptidase and superoxide dismutase.  
4. Activate inflammatory reactions: GBS infection can induce host inflammatory 
reactions. Experiments showed that a GBS infection of human respiratory epithelial 
cell lines is associated with increased production of proinflammatory cytokines 
such as tumour necrosis factor alpha, interleukin (IL)-8 and IL-10 than for 
uninfected cells, suggesting inflammatory reaction of phagocytes to GBS infection 
(Henneke et al., 2005). Hemolysin also induces host inflammatory responses by 
inducing macrophage production of nitric oxide synthase and generation of nitric 
oxide which further contributes to neonatal sepsis (Ring et al., 2000). 
 
1.4.1 Capsular polysaccharides  
 Of all virulence factors, the role of capsular polysaccharide has been extensively 
studied. Capsular polysaccharide is one of the factors that enable GBS to survive in the 
host by preventing the activation of complement pathways involved in opsonophagocytosis 
(Edwards et al., 1982). Due to its importance in GBS pathogenesis, CPS is considered as a 
major epitope for vaccine development. Group B Streptococcus is classified into ten 
serotypes (Ia, Ib, II, III, IV, V, VI, VII, VIII and IX) based on the structure of the CPS 
(Arakere et al., 1999, Slotved et al., 2007). Structure analysis of CPS’s are now complete 
for all GBS serotypes. Despite being composed of only few sugars: glucose, galactose, N-
acetylglucosamine, and sialic acid, there is nevertheless structural and antigenic 
heterogenicity between the CPS of serotypes (Kogan et al., 1996). The capsular 
polysaccharide for serotype Ia, Ib, II, III, IV,V, and VII consists of glucose, galactose, N-
acetylglucosamine and N-acetylneuraminic acid (Jennings et al., 1983a, Jennings et al., 
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1983b, Kogan et al., 1995, Wessels et al., 1991, Wessels et al., 1987), while serotype VI 
and VIII contains rhamnose instead of N-acetylglucosamine (Kogan et al., 1996, von 
Hunolstein et al., 1993). Sialic acid which is present as a terminal side chain residue in the 
repeating structure of each GBS CPS, enhances GBS pathogenic abilities by interfering 
with the host innate immune recognition, specifically with opsonic components of the 
complement system(Campbell et al., 1991, Marques et al., 1992). Despite the degree of 
similarity between the serotype-specific CPS repeating unit, significant antigenic variation 
was observed at both the nucleotide and amino acids sequences (Cieslewicz et al., 2005). 
There are a number of GBS isolates which do not express a polysaccharide capsule on their 
surface and hence are nontypeable (NT) (Slotved et al., 2007). The loss of capsule 
expression has been linked to mutations in genes responsible for capsule expression (Sellin 
et al., 2000). Molecular based typing has been developed to overcome the limitations of 
serologically non-typeable techniques (Poyart et al., 2007).    
 
1.4.2 Surface proteins  
It is now apparent that most GBS strains express antigenic surface proteins that are 
critical for its  viability and  ability to cause invasive disease (Rajagopal, 2009). A number 
of surface protein antigens have been identified and evaluated as vaccine candidate, that 
include α and β antigen of the c protein complex (Madoff et al., 1991), R proteins (Flores 
and Ferrieri, 1989), Rib protein (Stalhammar-Carlemalm et al., 1993), C5a peptidase 
(Cheng et al., 2002), surface immunogenic protein (Sip) (Brodeur et al., 2000) and Group 
B protective surface protein (BPS) (Erdogan et al., 2002). Some of these surface proteins 
like C5a peptidase, SIP and BPS are present in the majority of strains regardless of GBS 
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serotype and have been evaluated for the immunogenicity, and likewise showed to elicit 
protective immunity in animal models (Brodeur et al., 2000, Cheng et al., 2002).  
    
1.4.3 Pili  
The presence of cell-surface appendages known as pili has been discovered on the 
surface of GBS (Lauer et al., 2005). Pili are long proteinaceous filaments strands attached 
to the bacterial surface that helps in colonization and invasion by facilitating the 
attachment and adherence of the pathogen to host cells (Rosini et al., 2006).  Pili also 
facilitate the penetration of GBS through the blood-brain barrier and play a role in biofilm 
formation (Banerjee et al., 2011, Borges et al., 2012). In GBS two genomic units have been 
identified : pilus island-1 ( PI-1) and pilus island-2 (PI-2) that are responsible for pilus like 
structures. Pilus island-2 further exists in two variants PI-2a and PI-2b (Rosini et al., 2006). 
Each pilus island genomic region consists of genes that encode three LPXTG motif 
carrying proteins, namely backbone protein (BP), two ancillary proteins (AP1 and AP2) 
and two sortase enzymes (Margarit et al., 2009). In figure 1.1, for PI-1, GBS80 represents 
the BP, while the other two pili structure, GBS104 and GBS52 are AP1 and AP2 
respectively. In PI-2a, GBS59 represents BP whereas GBS67 and GBS 150 are AP1 and 
AP2 respectively. In PI-2b, SAN1518 represents BP and SAN1519 and SAN1516 are AP1 
and AP2 respectively (Rosini et al., 2006).  
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Figure 1.1: Schematic representation of GBS pilus island regions.  
Genes coding for LPXTG-containing proteins are represented with orange arrows, sortases 
presented as black arrows (taken from Rosini et al, 2006  (Rosini et al., 2006)  
 
1.5 Prevalence of maternal GBS colonization      
Rectal and/or vaginal colonization with GBS among pregnant women varies 
worldwide (Picard and Bergeron, 2004). A systematic review of maternal GBS 
colonization from low and middle income countries undertaken in 1998 reported a regional 
prevalence range of 8% to 18% by geographic region. The microbiological method of GBS 
isolation was identified as a key driver of this variation (Stoll and Schuchat, 1998). 
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GBS colonization rates in pregnant women in Sub-Saharan Africa have been 
reported to vary from 1.8% to 32% (de Steenwinkel et al., 2008, Moyo et al., 2000). The 
investigation from South Africa has found 21% of pregnant women to be vaginally culture 
positive (Cutland et al., 2009). Lower colonization rates have been reported in other 
African countries such as in Nigeria (11.3%) (Onipede, 2012), Malawi (16.5%) (Dzowela 
T, 2005), Central African republic (17.5%) (Brochet et al., 2009) while high rates have 
been reported from the Gambia (22%) (Suara et al., 1994), Ethiopia (20.9%) (Musa 
Mohammed, 2012), Senegal (20%) (Brochet et al., 2009), Tanzania (23%) (Joachim et al., 
2009), Egypt (25.3%) (Shabayek et al., 2009) and Zimbabwe (31.5%) (Moyo et al., 2000, 
Onipede, 2012). Mozambique indicated a very low prevalence of GBS colonization of 
1.8% (de Steenwinkel et al., 2008). The variations between countries could possibly be due 
to differences in sampling sites. For instance some investigators have used vaginal swabs 
only (Onipede, 2012, Shabayek et al., 2009), high vaginal and rectal swabs (Joachim et al., 
2009) or rectovaginal swab (de Steenwinkel et al., 2008). Other variations in isolation 
frequency could be due to differences in culture methods.  
 
In recent years the sensitivity of culture methods has increased and there is now 
published guidance on recommended methods for specimen collection, processing and 
GBS isolation (Verani et al., 2010). This should allow a clearer interpretation of any 
population differences in colonization. I co-led a systematic review and meta-analysis with 
Marianne Cunnington (GSK ) of prospective epidemiological studies that detected GBS 
carriage which used recommended microbiology methods (Verani et al., 2010), to assess 
the prevalence of maternal GBS colonization across geographic regions (Chapter 3). 
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1.6 Dynamics of GBS colonization during pregnancy    
GBS colonization is highly dynamic during pregnancy and can be transient, 
intermittent or persistent (Verani et al., 2010), only few studies have reported on the 
dynamics  of GBS colonization by way of multiple sampling  (four or more time points) 
during pregnancy (Hansen et al., 2004, Goodman et al., 1997, Mavenyengwa et al., 2010). 
The overall GBS colonization found in these studies, showed half of the pregnant women 
enrolled in these studies are colonized with GBS at some point during pregnancy. A trend 
of decrease in colonization with increasing gestational age has also been reported 
(Goodman et al., 1997, Gilbert et al., 2002) whereas others have reported an increase in 
colonization with gestational age (Towers et al., 2010, Zamzami et al., 2011, Baker et al., 
1975). As one of my thesis objectives, I evaluated the serotype-specific dynamics of GBS 
colonization among pregnant women from 20 to 37+ weeks of gestational age. 
       
1.7 Serotype distribution associated with maternal GBS colonization 
Vaccination against GBS has been investigated as a tool for reducing maternal 
colonization as well as early-infancy GBS sepsis (Verani et al., 2010). Current vaccine 
strategies focus on antigens presented on the surface of GBS which includes CPS and 
surface proteins, therefore epidemiological studies on the serotype and surface antigen 
distribution among GBS colonizing strains are important for vaccine development as this 
could differ by geographic region (Johri et al., 2006). 
 
Serotypes Ia (6.8-28.5%), Ib (0-14.6%), II (0-28.1%), III (6.2-45.3%) and V (4.1-
44.0%) remains the major serotypes responsible for colonization in different geographical 
regions (Table 1.1) with  Ia and III being the most common . In South Africa, serotype III 
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has been the  dominant colonizing (37.3%) and invasive serotype followed by Ia 
(Madzivhandila et al., 2011). Recently, there has been the emergence of serotype V as 
major (10.2-44.0%) colonizing serotype in pregnant women from African countries like 
the Gambia, Senegal, Zimbabwe and Central African Republic (Brochet et al., 2009, Moyo 
et al., 2000, Suara et al., 1998). Collectively the major serotypes in Africa are Ia, III, V and 
II, except in The Gambia where serotypes III (6.2%) and Zimbabwe where serotype II 
(4.3%) are in minority. In contrast,  a study from United Arab Emirates reported serotype 
IV as a predominant serotype (26%), followed by Ia (24.6%) and III (17.5%) (Amin et al., 
2002). In Japan, serotype VI and VIII were found to be responsible for over 60% of GBS 
serotypes colonizing pregnant women (Lachenauer et al., 1999).  Due to inconsistency on 
the prevalence of GBS serotypes in different geographic region, continuous surveillance is 
necessary as the colonizing serotypes could inform serotype formulation included in 
capsular polysaccharide based vaccines.  
 
Studies have also reported difference in serotype distribution between maternal 
colonizing isolates and invasive isolates from neonates (Madzivhandila et al., 2011, 
Martins et al., 2007) with serotype III and Ia has been reported to be more invasive than 
serotype Ib, II and V in Africa as well as in Europe. However, in USA serotype V is 
responsible for high number of invasive cases among infants. The reason for variation in 
invasive potential between serotypes is unclear, however it has been suggested differences 
at the genotype level can influence invasive potential. Furthermore, identification of 
serotype Ia, Ib, II, III and V in both colonizing and invasive isolates supports formulation 
of a pentavalent vaccine, as including only common serotypes in a vaccine could cause 
shift in serotype distribution in colonizing and subsequently in invasive disease isolates.   
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Table 1. 1: Distribution of serotypes among GBS isolates from pregnant women  
 
Location  Total 
number  
of 
isolates 
Serotype distribution 
Ia Ib II III IV V VI VII VIII IX NT 
USA, 
(Ippolito et al., 
2010) 
207 59 
(28.5) 
25 
(12.1) 
25 
(12.1) 
56 
(27.1) 
4 
(1.9) 
35 
(16.9) 
2 
(1.0) 
0 0 0 0 
Germany 
(Brimil et al., 
2006) 
75 13 
(17.3) 
11 
(14.6) 
16 
(21.3) 
21 
(28.0) 
2 
(2.7) 
12 
(16.0) 
0 0 0 0 0 
Italy 
(Savoia et al., 
2008) 
73 16 
(20.5) 
5 
(6.8) 
4 
(5.5) 
23  
(32.9) 
6 
(8.2) 
19 
(26.1) 
0 0 0 0 0 
Sweden 
(Hakansson et 
al., 2008) 
69 16 
(23.2) 
2 
(2.9) 
6 
(8.7) 
22 
(31.9) 
1 
(1.4) 
5 
(7.2) 
0 0 0 0 17 
(24.6) 
Kuwait 
(Al-Sweih et 
al., 2005) 
124 11 
(8.9) 
3 
(2.4) 
10 
(8.1) 
33 
(26.6) 
1 
(0.8) 
27 
(21.8) 
11 
(8.9) 
6 
(4.8) 
0 0 22 
(17.7) 
United Arab 
Emirates 
(Amin et al., 
2002) 
 
 
57 14 
(24.6) 
0 2 
(3.5) 
10 
(17.5) 
15 
(26.3) 
7 
(12.3) 
0 0 0 0 9 
(15.8) 
Iran  
(Jannati et al., 
2012) 
56 4 
(7.1) 
5 
(8.9) 
7 
(12.5) 
6 
(10.7) 
7 
(12.5) 
11 
(19.6) 
6 
(10.7) 
3 
(5.3) 
3 
(5.3) 
0 4 
(7.1) 
Japan 
(Lachenauer et 
al., 1999) 
73 5 
(6.8) 
6 
(8.2) 
0 8 
(11.1) 
0 3 
(4.1) 
18 
(24.6) 
0 26 
(35.6) 
0 7 
(9.6) 
Gambia 
(Suara et al., 
1998) 
32 6  
(18.7) 
0 9 
(28.1) 
2  
(6.2) 
1 
(3.1) 
12 
(37.5) 
0 0 0 0 2 
(6.2) 
Zimbabwe 
(Moyo et al., 
2002) 
117 17 
(14.5) 
6 
(5.1) 
5 
(4.3) 
53 
(45.3) 
6 
(5.1) 
28 
(23.9) 
0 0 0 0 2 
(1.7) 
Senegal 
(Brochet et al., 
2009) 
75 13 
(17.3) 
4 
(5.3) 
9 
(12.0) 
16 
(21.3) 
0 33 
(44.0) 
0 0 0 0 0 
Central 
African 
Republic 
(Brochet et al., 
2009) 
   
 
88 24 
(27.3) 
7 
(7.9) 
20 
(22.7) 
15 
(17.1) 
0 22 
(25.0) 
0 0 0 0 0 
South Africa 
(Madzivhandil
a et al., 2011) 
 
541 163 
(30.1) 
36 
(6.6) 
61 
(11.3) 
202 
(37.3) 
20 
(3.7) 
55 
(10.2) 
0 0 0 0 4 
(0.7) 
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1.8 Relationship between GBS serotypes and pilus islands 
Pilus sequences are conserved with all GBS strains and all clinical GBS isolates 
carrying at least 1 of the 3 pilus islands and was associated with the presence of either PI-
2a or PI-2b identified alone or in combination with PI-1 (Madzivhandila et al., 2013, 
Margarit et al., 2009). Association between specific serotypes and pilus islands was also 
observed, with the majority of serotype III carried  in combination of PI-1 and PI-2b, 
serotype Ia were associated with PI-2a and most of the serotype Ib and V were associated 
with combination of PI-1 and PI-2a (Margarit et al. 2009). Difference in pilus island 
distribution with respect to source of isolates was also observed with majority of 
colonizing isolates from the adults carried both PI-1 and PI-2a, while invasive isolates 
from infant carried both PI-1 and PI-2b. 
 
1.9 Prevention of invasive GBS disease 
The preventative strategies against invasive GBS disease in newborn’s include 
intra-partum antibiotic prophylaxis (IAP), local antiseptics and immunoprophylaxis.  
 
1.9.1 Intrapartum antibiotic prophylaxis 
To date only maternal IAP has been shown to be effective against invasive GBS 
disease (Schrag and Verani, 2013). In the USA, IAP for colonized mothers reduced the 
burden (per 1000 live births) of EOD from 1.7 to 0.26 between 1993 and 2010. The 
incidence of LOD, however, remains unchanged for20 years since this strategy has been 
implemented (0.3-0.4/1000 live births) (Schrag and Verani, 2013). Other developed 
countries such as Spain and Australia have also adopted IAP strategies and documented a 
17 
 
decline in the EOD (Isaacs and Royle, 1999, Lopez Sastre et al., 2005). The 
implementation of IAP in developing and in low resource countries is, however, likely to 
be constrained  because of the large number of deliveries occurring  outside of health care 
facilities (Montagu et al., 2011), logistical and cost issues related to screening for GBS 
colonization and timeous administration of intravenous antibiotics (Schrag and Verani, 
2013). Additionally, IAP using intravenous antibiotic administration has been associated 
with an increased rate of illness from antibiotic non-susceptible bacteria in some settings 
(Verani et al., 2010). Furthermore, IAP does not prevent EOD in premature newborn’s, 
GBS associated stillbirths or premature births (Edwards and Gonik, 2013, Patten et al., 
2006). 
 
1.9.2 Local Antiseptic Agents 
A novel approach to prevention of neonatal invasive GBS disease is reduction of 
maternal vaginal colonization with antiseptic agents such as chlorohexidine during labor. A 
recent review of four studies that used vaginal chlorohexidine washes/douches during 
labour to prevent EOD, suggested that whilst it might reduce colonization of the 
newborn’s, it was not effective in preventing EOD (Ohlsson et al., 2014). 
 
1.9.3 Maternal immunization     
Another potential strategy for prevention of invasive GBS disease in young infants, 
is maternal vaccination against GBS aimed at enhancing transplacental transfer of GBS 
antibody to the foetus and possibly through reducing maternal colonization in the women 
(Baker and Edwards, 2003, Verani et al., 2010). A protective role for GBS serotype III 
18 
 
antibodies was described in the 1970s by Baker and Kasper (Baker and Kasper, 1976). 
These investigators showed that infants with invasive early-onset or late-onset GBS 
disease were born to mothers with very low levels of serum type III CPS specific 
antibodies at delivery. Furthermore, findings such as human sera containing  sufficient 
concentration of CPS specific IgG promoted efficient opsonization and phagocytosis 
(Edwards et al., 1979) and protection from lethal experimental infection in animal models, 
(Gotoff et al., 1986, Klegerman et al., 1983) confirmed the importance of capsular serotype 
specific antibodies. This information, coupled with the  success of maternal tetanus 
vaccination during pregnancy in reducing neonatal tetanus  (Steinhoff, 2013) suggested 
that active immunization of pregnant women with GBS vaccine in the 2nd -3rd trimester 
could potentially protect young infants against invasive GBS disease (Baker et al., 2003, 
Edwards et al., 2012). 
 
1.10 GBS Vaccines 
The "first generation" GBS vaccines consisted of purified CPS of serotypes III 
(Baker et al., 1978). In contrast to the excellent immunogenicity observed in adults 
immunized with pneumococcal polysaccharide vaccine, GBS polysaccharide vaccine, 
while well tolerated, had variable immunogenicity (Baker and Kasper, 1985). The  safety 
of GBS CPS vaccines enabled progress to phase 1 trials in pregnant women, which  
supported  the feasibility of maternal immunization as an approach to prevent invasive 
GBS disease in infants; and subsequently led to the development of polysaccharide-protein 
conjugate GBS vaccines with enhanced immunogenicity (Baker et al., 1988). The "second 
generation" GBS vaccines consisted of purified serotype specific CPS covalently coupled 
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to carrier protein such as tetanus toxoid or CRM197 carrier protein (Baker et al., 1999, 
Baker et al., 2004, Baker et al., 2003, Kasper et al., 1996).  
 
Most of the polysaccharide-protein conjugate vaccines have been administrated 
safely to healthy adults, including administration of serotype III-TT vaccine in pregnant 
women during the third trimester. The study demonstrated excellent immunogenicity with 
a maternal GMC of type-III specific of 9.8µg/ml at delivery and correlated well with infant 
cord values (rho = 0.91). Additionally antibody from the infants of vaccinated individuals 
promoted opsonophagocytosis and persisted up to 2 months of age (Baker et al., 2003). In 
order to provide sufficient coverage against dominant serotypes, a CPS conjugate vaccine 
will need to be multivalent. In murine models up to four serotypes have been combined 
(Paoletti et al., 1994) whereas in pregnant women a trivalent vaccine composed of capsular 
serotypes Ia, Ib and III has recently completed phase I and II trials in South Africa (Madhi 
et al., 2013). 
  
The "third generation" of GBS vaccines currently under development targets the 
GBS surface protein antigens, which contribute to the pathogenesis of GBS disease. 
Although the importance of surface proteins in immunity to Streptococcus pyogenes has 
long been appreciated, their role in immunity against GBS was only recognized in the 
1970s, when Lancefield described the cross serotype protection afforded by rabbit 
antiserum to protease sensitive epitopes (Lancefield et al., 1975). The intervening years 
have witnessed considerable research exploring diversity of GBS surface proteins and 
increased awareness of their roles in immunity and pathogenicity. Much of the interest in 
these proteins arises from a desire to identify protective antigens for inclusion in GBS 
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vaccines as vaccine candidates or carrier proteins for specific GBS polysaccharides. 
Recently, three variants of pilus like structures has been discovered on the GBS, each 
encoded by a distinct pathogenicity island (Lauer et al., 2005). It has been shown that pilus 
sequences are conserved with all GBS strains carrying at least 1 of the 3 pilus island (PI) 
and a combination of the components from three PI conferred protection against all tested 
GBS challenge strains. This indicates that pilus based vaccine can be developed to prevent 
GBS infection (Margarit et al., 2009). 
 
1.11 Licensure of GBS vaccine 
Since 1996 conjugate vaccines to each of the clinically significant GBS serotypes 
have been developed (Baker et al., 2004, Baker et al., 1999, Baker et al., 2003). One of the 
biggest challenges in the licensure of a GBS vaccine is to demonstrate efficacy. Due to low 
incidence of invasive disease, a sample size of approximately 60,000 pregnant women 
would be required to demonstrate modest efficacy, such a trial would be large and costly 
(Madhi et al., 2013). Moreover, with the introduction of IAP in some developed countries, 
efficacy trials become even more challenging as vaccine would need to prove effective in a 
group already receiving IAP, which would require even larger sample size in the efficacy 
trials. Therefore, there are limited localities where such a study could be undertaken to 
measure vaccine efficacy against the clinical endpoint of invasive GBS disease (Madhi et 
al., 2013). Additionally, undertaking studies of GBS vaccine in pregnant women is 
complicated by concerns about the potential liability issues of vaccinating pregnant women 
where birth defects could be falsely attributed to  vaccination (Robbins et al., 1995)  
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Consequently, for licensure of GBS vaccine targeted at pregnant women, alternate 
strategies need to be explored. This could include immunogenicity studies that measure 
protective levels of antibodies, as it is the major mechanism by which vaccines provide 
protection (Siber, 1997). It is theoretically possible to establish protective antibody 
concentration in an immunized population and such licensure-pathway strategy is accepted 
for vaccines including meningococcal vaccines, inactivated influenza vaccine and newer 
formulations of pneumococcal conjugate vaccine (Frasch et al., 2009, World Health 
Organization Immunization Vaccines and Biologicals, 2012, The European Agency for the 
Evaluation of Medicinal Products, 1997). 
 
1.12 Immunologic correlates of protection  
Because of the difficulty of conducting efficacy trials for GBS vaccine, 
identification of surrogate immunologic measures of efficacy is necessary. Maternal 
colonization with GBS is believed to be the principal source of infection for neonatal early-
onset GBS disease and occurs in approximately 50% of newborn’s born to GBS-colonized 
mothers (Cutland et al., 2009). Therefore by targeting the removal of vaginal colonization 
with GBS prior to childbirth, the source of infection can be eliminated, and thus at least 
early-onset neonatal sepsis caused by this organism can be prevented (Heath and Feldman, 
2005). The concept of vaccine preventing acquisition of target organisms was first 
demonstrated with Hib conjugate vaccine (Takala et al., 1991) and later with 
pneumococcal conjugate vaccines (O'Brien and Dagan, 2003). A similar phenomenon will 
be expected for GBS vaccines and vaccination may be used as an approach for reducing 
the prevalence of GBS colonization in healthy women, possibly by inducing high levels of 
type-specific serum and subsequent reduction in the transmission of GBS to the newborn. 
Furthermore, should vaccination prevent or reduce recto-vaginal colonization in the 
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women, this could also have indirect protective effect on community as a whole by 
reducing transmission of GBS within the community. Already, a monovalent GBS 
serotype III conjugate vaccine has been reported to significantly reduce the rate of recto-
vaginal GBS acquisition among non-pregnant women (Hillier, 2009 ). 
   
The proof of principle of the effect of reduction of colonization upon subsequent 
indirect protection of non-vaccinated individuals has been demonstrated through the 
introduction of polysaccharide conjugate vaccines, against bacterial pathogens, such as 
Streptococcus pneumoniae. Whilst a putative serological correlate of direct protection 
against invasive pneumococcal disease has been established (Siber et al., 2007), the 
indirect effects among unvaccinated portions of the population is thought to be due to the 
effect of the polysaccharide-protein conjugate vaccines against colonization in the 
vaccinated child and subsequent interruption of transmission of the bacteria in the 
community (Isaacman et al., 2007). This highlights the importance of targeting 
colonization which is the reservoir of infection. 
 
1.12.1 Humoral immune response 
Although spontaneous clearance and acquisition of GBS has been reported in 
pregnant women with new acquisition rate of 8.5% to 17.6% between the first trimester 
and birth, there is a paucity of data on host immune mediators  affecting  GBS colonization 
(Hansen et al., 2004, Goodman et al., 1997). There are limited, mainly cross sectional 
studies, which have evaluated the association between serum serotype specific capsular 
antibody and GBS recto-vaginal colonization in women. (Beachler et al., 1979, Cleat et al., 
23 
 
1980, Linden et al., 1982, Campbell et al., 2000, Davies et al., 2001, Hordnes et al., 1996, 
Baker et al., 1980, Anthony et al., 1984, Skidmore et al., 1985, Ratei et al., 1990, 
Matsubara et al., 2002, Matsubara et al., 2003). These studies reported higher 
concentration of serotype-specific antibodies among colonized as compared to uncolonized 
to the homotypic serotype. These studies were not designed to address whether CPS 
antibody reduces the risk of GBS colonization during pregnancy. We are, however, 
unaware of any longitudinal cohort study which evaluated the association between 
serotype-specific CPS antibody and subsequent risk of GBS recto-vaginal acquisition 
during the latter half of pregnancy. The likely efficacy of GBS polysaccharide-protein 
conjugate vaccines against maternal recto-vaginal colonization could be inferred through 
study of whether there is any association of capsular antibody titers and new acquisition of 
homotypic GBS serotypes in pregnant women.  
 
The antibodies to GBS CPS protect the host by opsonising and thus facilitating 
phagocytosis. The ability of antibodies in serum sample to opsonize bacteria can be 
measured by in vitro opsonophagocytosis assays (OPA) (Romero-Steiner et al., 2006). 
These assays are designed to quantify functional antibodies in human serum samples that 
enable phagocytic effector cells (such differentiated HL-60 cells) to recognize and destroy 
bacteria in the presence of a complement source (Guttormsen et al., 2008). As the host’s 
protection is mediated mainly by phagocytosis, the functional activity of antibodies rather 
than only  the concentration, may correlate better with reduced risk of  colonization 
(Johnson et al., 1999). For pneumococcal conjugate vaccine (PCV), OPA titers have been 
shown to be the best functional correlate of protection against invasive disease at a 
threshold of ≥1:8 (Jodar et al., 2003). A good correlation between an OPA assay and the 
IgG antibodies measured by ELISA was also observed (Nurkka et al., 2001). 
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The GBS vaccine elicits functional antibodies measured by OPA assay and persists 
for up to 2 years post-vaccination (Edwards et al., 2012). There is limited data on presence 
of functional antibody and GBS colonization in pregnant women. As part of my research, I 
investigated the association between serotype-specific functional antibody measured by 
OPA assay and risk of new acquisition by homotypic serotype during pregnancy. We also 
assessed the correlation between serum IgG and OPA activity. 
    
1.12.2 Mucosal immune response    
Haemophilus influenzae type b conjugate vaccines (Takala et al., 1991) and PCV 
(Dagan et al., 2002)  has been shown to reduce nasopharyngeal colonization by the 
vaccine-serotypes. The mechanisms of protection against colonization by conjugate 
vaccines are not completely understood. Conjugate vaccines elicit IgA and IgG in saliva, 
suggesting a possible role of mucosal antibodies (Choo et al., 2000, Kauppi et al., 1995, 
Nurkka et al., 2001). A strong positive correlation was also observed between serum IgG 
and salivary IgG (Nurkka et al., 2001), suggests transudation of serum IgG onto the 
nasopharyngeal mucosal surface, which may prevent colonization by creating a steric 
inhibition of the pneumococcal surface proteins with binding sites on host cells (Dagan et 
al., 2005).  
 
Hordes et al studied the association between maternal GBS colonization and 
mucosal IgG and IgA antibodies (Hordnes et al., 1996). The study demonstrated 
colonization with serotype-specific GBS in rectum or cervix had pronounced effect on the 
local immune responses in terms of IgG and IgA in the genital tract. In my research, I 
investigated the association between serotype-specific mucosal IgG and IgA and new 
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acquisition of homotypic serotype GBS colonization as well as correlation between serum 
IgG and mucosal IgG.  
               
1.12.3 Cellular Immune Response             
Host immune factors that affect duration of colonization are poorly understood. 
Studies were conducted that showed a limited role of antibodies in clearance of 
Streptococcus pneumoniae colonization existing at the time of vaccination, suggesting 
involvement of other mechanisms (McCool and Weiser, 2004).  In the murine model it was 
demonstrated by Van Rossum et al, that innate and CD4+ lymphocyte cell mediated 
immunity rather than a humoral immune response is important for clearance of 
Streptococcus pneumoniae colonization from the murine nasopharynx (van Rossum et al., 
2005). It has been suggested that exposure to microbial antigens leads to induction of 
effector T-cells that migrate to peripheral tissues resulting in the pathogen elimination 
(Reiner et al., 2007). Identification of cell-mediated immune factors that influence GBS 
colonization is likely to affect the GBS transmission and overall incidence of GBS disease.  
 
There is no data on association of cellular immune response and GBS colonization 
among pregnant women. In my research, I investigated the role cellular immunity in 
clearance of existing GBS colonization. In order to access effector T-cell responses freshly 
isolated PBMC were assayed for cells that produce interferon gamma using ELISpot assay 
in response to GBS CPS antigens.  
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1.13 Aims and Objectives 
The overall theme of this research was to determine the immunological correlates 
of protection for vaginal and/or rectal GBS colonization in pregnant women.  
Study Objectives: 
i. To undertake a systematic review and meta-analysis on prevalence of maternal 
GBS colonization across geographic regions. 
ii. To compare different media for the isolation of GBS from vaginal and rectal swabs 
from pregnant women in our clinical setting.  
iii. To determine the dynamics of GBS colonization in pregnant women between the 
20th and 37+ weeks, in terms of new acquisition and clearance of serotype-specific 
colonization rates. 
iv. To determine the concentration of GBS serotype-specific capsular polysaccharide 
IgG antibodies in serum associated with risk of recto-vaginal GBS acquisition. 
v. To determine the association between GBS serotype-specific cellular immunity and 
acquisition and clearance of existing GBS colonization in pregnant women during 
the latter half of pregnancy. 
vi. To determine the association between GBS serotype-specific capsular 
polysaccharide IgG and IgA antibodies in vaginal mucosal secretions and GBS 
colonization in pregnant women.  
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Chapter 2 Material and methods for GBS colonization studies 
 
2.1 Participant demographics 
Participant recruitment and follow up was conducted at the local community ante-
natal clinics in Soweto, a peri-urban black African suburb of Johannesburg. These 
community clinics were mainly utilized by black African pregnant women who represent 
80% of the South African population group (Statistics, 2015). Pregnant women normally 
visit antenatal clinics close to their place of residence. Evaluation and screening of the 
pregnant women at study enrolment included documenting the health of the mother and 
foetus, gestational age of the foetus estimated based on last normal menstrual period 
(LMP) or sonar if available, HIV infection status (HIV status was determined by rapid 
ELISA screening test as a standard of care in the clinics or with HIV ELISA test 
undertaken if the rapid test was positive or indeterminate). The mother then followed up 5-
6 weeks later depending on the timing of her gestation.  
 
2.2 Ethics Approval    
The study was approved by the Human Research Ethics Committee of the 
University of the Witwatersrand (IRB/Protocol-M090937; Appendix 4) and informed 
written consent was obtained from all participants. This, observational study was registered 
with South African National Clinical Trials Register, number DOH-27-0210-3012. 
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2.3 Participant enrolment 
Community ante-natal clinics involved in the study were Pimville 
(MichealMaponya), Lillian Ngoyi, Diepkloof and Mofolo. Pregnant women were 
approached in these ante-natal clinics when they come for their routine ante-natal visit at 
20-25 weeks gestational age. Pregnant women were informed regarding the study, 
interested women were given informed consent form (ICF) to read and screened for 
eligibility criteria. Consenting and eligible women were allocated a unique identification 
number and thereafter demographic and pregnancy related data was collected. 
   
2.4 Inclusion and exclusion criteria 
All pregnant women were eligible for inclusion in the study if they meet the 
following criteria: 
2.4.1 Inclusion criteria: 
• Are in their 20th - 25th week of gestation. 
• Are able to provide informed consent. 
• Are confirmed to be HIV-uninfected as part of standard of care 
2.4.2 Exclusion Criteria: 
• Acute illness or a symptomatic vaginal discharge. 
• Antibiotic treatment in the previous two weeks. 
• Have a known or suspected condition in which vaginal exams are contraindicated, 
e.g. placenta previa. 
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2.5 Procedures conducted at enrolment (visit-1) and follow-up visits 
• Maternal case report forms were completed by the study nurse. 
• The gestation age of the mother was calculated based upon normal LMP or sonar, if 
available. In cases, where there was discordance between LMP and sonar results, 
the sonar results were used for estimation of gestational age. 
• Maternal pregnancy and medical history was obtained from the mothers available 
clinical records.  
• Blood was taken from the mother (5mL) to measure antibodies to the common CPS 
serotypes (Ia, ,III and V) 
• Vaginal secretion was collected from the mother to measure antibodies to the 
common CPS serotypes (Ia, III and V)       
• Blood was taken from the mother (5ml) in heparinsed tubes to measure cellular 
immune response against CPS serotypes (Ia, III and V).  
• The mother was swabbed (rectal and lower vaginal) for GBS culture. 
•  Duplicate vaginal and rectal swabs were collected from 130 participants to 
compare media for isolation of GBS. 
• The mother was given a copy of the informed consent form with a follow-up date 
to return at the next visit.  
 
2.5.1 Participant Follow-up 
All participants were followed-up at 5-6 weeks interval till 37+ weeks and the 
following samples were collected at follow-up visits (Table 2.1). 
Visit-2: Lower vaginal and rectal swab. 
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Visit-3: Lower vaginal and rectal swab. 
Visit-4: Lower vaginal swab, rectal swab, blood (5ml) and vaginal secretions. 
 
Sample collections were done by study nurses of RMPRU and were trained on sample 
collection using standard operating procedures available at RMPRU. Recruitment of 
participants, sample collection and follow up was overseen by Gaurav Kwatra and Dr 
Clare L. Cutland. 
Table 2.1: Sample collection at different study visits. 
 
Samples Gestation Period 
20-25 
weeks 
26-30 
weeks 
31-35 
weeks 
37+ 
weeks 
Clotted Blood a 
 
√ X X √ 
Heparinised Blood b √ X X X 
Vaginal and rectal 
swab*c 
√ √ √ √ 
Vaginal mucosal 
secretion swab d 
√ X X √ 
*For 130 participants duplicate vaginal and rectal swabs were collected at visit-1 to compare 
different media for isolation of GBS. 
a. Clotted blood was used for serum collection to measure serum IgG for CPS (Ia, III and V) 
and OPA assay for CPS (Ia and III). 
b. Heparinised blood was used to perform ELISpot assay for GBS CPS antigens (Ia, III and 
V). 
c. Vaginal and Rectal swabs were processed to detect GBS colonization. GBS isolates were 
serotyped and pilus typed.  
d. Mucosal secretions of the vaginal tract were collected with an ORACOL swab to measure 
mucosal IgA and IgG for GBS CPS (Ia, III and V). 
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2.6 Sample size 
 It was estimated that a sample size of 600 was required, (adjusted to 661 to 
allow for a 10% loss of follow up) to obtain sufficient numbers of mothers who became 
colonized during the course of the study. These numbers were based on the following 
assumptions. From previous studies, the number of new GBS acquisitions during 
pregnancy ranged from 9.9%-20%, with an average of 10% (Goodman et al., 1997, Towers 
et al., 2010, Chua et al., 1995). In a past study conducted by our unit, vaginal colonization 
prevalence of pregnant women during labor was 20.9% (Cutland et al., 2009), and was 
estimated to be about 26% if recto-vaginal swabbing is performed based on the increase in 
sensitivity of swabbing as compared to vaginal swabbing only.  
 
 With a sample size of 600, and an assumed acquisition rate of 10%, 
approximately 60 cases of new acquisition were expected, and assuming a colonization 
rate of 26%, 384 participants will remain un-colonized throughout the study. Hence, we 
anticipated a new acquisition and non-colonized ratio of 1:6.4. In order to compare the 
geometric mean antibody titres between the new acquisition and non-colonized by student 
t-test with natural log transformed data, the following sample size calculation was 
performed.  
 
 From previously published antibody data (Davies et al., 2001), the standard 
deviation for all serotypes was log=2.5. If one were to power the study to detect a 
difference of log=1.2, (translates to new acquisition having a median titres of 0.1µg/ml and 
the non-colonized control group having a median titre of 0.35 µg/ml) with p = 0.05 and 80 
% power, the minimum number of new acquisition cases (irrespective of GBS serotype) 
required was 40. Similarly, sample size required for similar analysis for single serotypes 
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was undertaken, This was premised on data from our setting which previously reported that 
serotype III accounted for 50 % of all clinical cases of invasive GBS disease and 33% of 
colonizing isolates in pregnant women at birth. Thus, if a third of all acquisitions were 
serotype III, the case to control ratio would be 1:19.2. From previously published antibody 
data of serotype III, the standard deviation for antibody titres was significantly lower than 
for multiple serotypes, and  estimated at log=1.85. Using a similar probability, power, and 
difference between means, 20 cases of single serotype colonization were required. Thus, 
with the above assumptions, a sample size of 600 was expected to yield approximately 60 
acquisitions of which 20 were the major serotype. This sample size was unlikely to be 
powered to evaluate the less common serotypes individually. 
    
2.7 Lab Methods       
2.7.1 Processing of Specimens     
2.7.1.1 Whole blood  
Whole blood was collected from mothers at 20-25 weeks of gestation and 37+ 
weeks. All blood samples were kept at room temperature to allow clotting, following 
which it was transported within 4-6 hours to the RMPRU lab for processing. Blood was 
centrifuged for 15 min at a 3220g relative centrifugal force. The serum was then aliquoted 
into 2 pre-labelled tubes and stored at –70ºC.  
 
2.7.1.2 Vaginal and rectal swabs  
Vaginal and rectal swabs were collected from the mothers, for isolation, 
identification and serotyping of Group B Streptococcus. Both vaginal and rectal specimens 
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were collected using rayon tipped swabs that were placed into Amies transport medium 
without charcoal (Transwab Amies, Medical wire, U.K.). The rectal swab was inserted 
approximately 2 cm passed the anal verge and rotated against the rectal mucosa. The 
vaginal swab was inserted approximately 2 cm passed the introitus towards the lower 
vagina mucosal wall and rotated. Once swabs are received in laboratory if not processed 
immediately, they were stored at 2-8˚C and were processed within 24 hours of collection.   
2.7.1.3 Heparinized blood   
Heparinized blood was collected from mothers at 20-25 weeks of gestation and was 
transported within 4-6 hours to the RMPRU lab for processing. In order to access effector 
T-cell responses freshly isolated PBMC from heparinized blood were assayed for cells that 
produce interferon-γ (IFN-γ) using ELISpot assay in response to GBS CPS antigens. 
    
2.7.1.4 Vaginal mucosal secretion  
Vaginal mucosal secretion was collected from mothers at 20-25 weeks of gestation 
and 37+ weeks.  All vaginal secretion samples were collected using ORACOL swabs and 
were kept at 2-8˚C after collection and transported on ice within 4-6 hours to the lab for 
processing. Mucosal secretions were extracted by adding 300µl of extraction buffer (10% 
FBS in PBS) and was centrifuged for 15 min at a 3220g relative centrifugal force at 4˚C. 
The mucosal secretion was then aliquoted into pre-labelled tubes and stored immediately at 
–70ºC.           
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2.8 Isolation of GBS     
For GBS isolation, swabs were inoculated onto CHROMagar Strep B (CA; Media 
Mage, Johannesburg, South Africa) according to the following procedure. 
 CHROMagar surface was dried in the 37°C ambient incubator for about 15 minutes, 
labelled with the participant number and divided into quadrants.  
 Swabs from the Amies transport medium were rubbed in a small circle onto the first 
quadrant of the agar plate. The swab was rotated whilst plating, to ensure that the entire 
surface (which could potentially contain GBS) comes into contact with the agar.  
 The CA plate was streaked as per standard plating out technique Divide the plate into 
four quadrants. Streak from the one quadrant to the next quadrant with a single line. 
Once in the new quadrant spread the growth by creating a zigzag line with 3-5 folds 
without re-entering the initial quadrant. Repeat the process across all 4 quadrants and 
change the loop after the completion of each quadrant. 
 After streaking, the CA plate was incubated at 37°C in the ambient incubator.  
 After 18-24 hours the plate was inspected for growth of GBS. If no GBS-like growth 
was present, it was incubated for an additional 24 hours and the plate was inspected  
again. Typical GBS colonies presented as mauve coloured colonies on CA (Figure 2.1). 
If at 48 hours, the plate yielded no GBS colonies, no further testing was done and NO 
GBS isolated was recorded.  
 The total amount of GBS isolated was quantified using the standard microbiology 
colony quantification method (Table 2.2) and secondary identification testing for GBS 
was done.  
 
 
35 
 
Table 2. 2: colony quantification method 
Scant growth < 25 colonies in 1st  quadrant only 
1+ ≥ 25 colonies in quadrant 1 plus < 25 colonies in quadrant 2nd 
2+ ≥ 25 colonies in quadrant 2nd  plus < 25 colonies in quadrant 3rd 
3+ ≥ 25 colonies in quadrant 3rd  plus < 25 colonies in quadrant 4th 
4+ ≥ 25 colonies in 4th  quadrant 
 
 
 
 
 
 
 
Figure 2.1: Mauve coloured colonies of Group B Streptococcus on CHROMagar Strep 
B 
 
 
  
2.9 Secondary Identification of Group B Streptococcus 
Some other microorganisms like Groups A, C, F and G streptococci and some 
strains of staphylococcus may also appear mauve, violet or pinkish and some colonies of 
enterococci may appear purplish, therefore mauve colonies were further tested by 
secondary tests (CAMP test, Bile esculin test, Catalase test and Group B antigen test) for 
further confirmation.  
 
36 
 
2.9.1 CAMP Test          
GBS produces a positive CAMP test result with clear arrow-head shaped hemolysis 
at the junction with the line of staphylococcus (Figure 2.2). All non-group B streptococci 
are CAMP negative although some strains of group A may produce a positive result if 
incubated in at increased CO2 concentration.  
 
 
Procedure:  
Pre-warmed 5% sheep blood agar plate was divided and labelled as indicated by the 
diagram below. A single streak of Staphylococcus aureus (ATCC 25923) was made down 
the middle of the plate and positive and negative controls on either side and perpendicular 
to the Staphylococcus aureus streak. GBS colonies were streaked from the edge of the 
plate toward the middle. Multiple isolates to be tested were added onto the plate. The plate 
was incubated at 37˚C in 5% CO2 for 18-24 hours.  
 
 
 
 
 
 
Figure 2.2: CAMP test results with clear arrow head hemolysis 
 
Reading and interpretation: 
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GBS produces a positive CAMP test result with clear arrow-head shaped 
haemolysis at the junction with the line of Staphylococcus aureus. Some Staphylococcus 
strains can produce a small arrow-head of lysis. If the arrow-head shaped haemolysis is not 
clear, the results were recorded as indeterminate. 
 
2.9.2 Bile aesculin test: 
Bile aesculin agar is used primarily to differentiate Enterococcus spp. (Group D 
Streptococcus) from GBS. Group B Streptococcus grows as clear, mucoid colonies on Bile 
esculin agar with no hydrolysis, resulting no blackening of the growth medium. 
Enterococcus species also grows well on bile aesculin agar, but cause blackening of the 
medium through aesculin hydrolysis. 
 
 
Procedure 
Pre-warmed bile esculin agar plates were divided into quadrants and labelled. The 
positive control (GBS) and negative control (E. faecalis) were streaked along with the test 
isolates   onto different quadrants of the bile esculin plate. The same colonies that have 
been streaked on the CAMP plate were streaked in the corresponding positions on the bile 
aesculin plate and incubated at 37˚C in 5% CO2 for 18-24 hours.  
 
Reading and interpretation    
GBS grows as clear, mucoid colonies with no blackening of the growth medium.  
 
Interpretation of CAMP and Bile-esculin tests (Figure 2.3) 
 If the CAMP test was negative and bile esculin hydrolysis was positive: no GBS 
isolated.  
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 If the CAMP test was positive and bile esculin hydrolysis is negative: Proceed with 
the catalase and group B streptex tests.  
 If the CAMP test and bile esculin hydrolysis is indeterminate: Proceed further with 
the catalase, group B streptex test and PCR test  
 
2.9.3 Catalase test:  
Catalase test was used to distinguish between Staphylococcus spp and GBS.  
 
Procedure 
A drop of the catalase reagent (hydrogen peroxide) was added to a glass slide. The 
GBS culture on the CAMP plate was touched with a sterile loop and mixed into the 
reagent. Immediate production of bubbles was interpreted as positive reaction. The absence 
of bubbling was interpreted as negative. 
 
Reading and Interpretation 
 GBS isolates are catalase negative when tested with catalase reagent.  
 
2.9.4 Group B antigen agglutination test: 
Colonies which were CAMP positive, Bile esculin negative and catalase negative were 
further tested for Group B antigen agglutination test using STREPTEX agglutination test 
kits as per kit instructions.  
       
Procedure    
 All the reagents of the kit were warmed up to room temperature prior to use. 
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 Two to three single colonies of the GBS culture were picked off and mixed in a tube 
containing 400μl of the extraction enzyme. 
 The suspension was incubated in a water bath or incubator at 37 ˚C for 10 minutes, 
with shaking after 5 minutes. 
 Reading card was labelled with the relevant information. 
 50μl of the bacterial extract was added to the circle on the reading card. 
 One drop of the pre-warmed latex reagent was added to the circle of the test card 
(already containing the drop of the bacterial extract) and was mixed with a clean 
mixing stick or pipette tip.  
 The card was gently rock for one minute and observed for agglutination. 
 
Reading and Interpretation  
Group B Streptococcus produce clear agglutination.  
 
2.9.5 Storage of GBS isolate:                 
All confirmed GBS isolates were stored in STGG storage medium at -70°C. 
 
 2.10 Group B Streptococcus serotyping by Latex agglutination 
All GBS isolates were serotyped with a latex agglutination method using specific 
antisera against type Ia, Ib, II to IX CPS antigens as described (Afshar et al., 2011). 
Procedure     
 GBS isolates in the STGG medium were thawed and 20μl were plated on a labelled, 
pre-warmed blood agar plate and streaked out for single colonies as per standard 
technique.  
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 The plates were incubated for 18-24 hours at 37°C in 5% CO2.  
 50μl of sterile PBS was pipetted into a sterile tube and a heavy suspension from the 
pure growth was made in the PBS. No clumps in the suspension were insured. 
 5μL of the suspension was pipetted onto the glass slide  
 5μL of the serotype-specific latex bead suspensions was added aseptically onto the 
corresponding slide and mixed with the bacterial suspension using a new clean mixing 
stick or sterile pipette tip.  
 The slide was gently rocked for 5 to 10 seconds to aid mixing. A positive reaction was 
scored when the sample agglutinated with a specific serum within 30 seconds. 
          
Interpretation and reporting   
Positive agglutination reaction with latex anti-sera of a particular serotype indicated 
the serotype of a GBS isolate. Any agglutination after 30 seconds was considered as 
indeterminate and further confirmation was done by PCR method. GBS Isolates that test 
negative by latex agglutination for all serotypes were further typed by a PCR method  
 
2.11 PCR method for the detection of Group B Streptococcus serotype 
GBS isolates that tested negative by latex agglutination for all serotypes were 
further typed by a single plex PCR method for serotypes Ia, Ib, II, III, IV and V using 
primer sequences described by Poyartet al (Table 2.3). Briefly, DNA was extracted from 
GBS isolates with the Easy Mag DNA Extraction Machine and added to the PCR reaction 
mixture (Table 2.4). The gene encoding dlts was used as a positive control for GBS 
identification. Negative control contained filtered dH2O (sterile) instead of DNA to give an 
indication of any false positive results.  
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Table 2.3: Primer and probe sequences 
 
 
Primer name Sequence (5’-3’) 
Ia Forward 5’- GGTCAGACTGGATTAATGGTATGC-3’ 
Reverse 5’ GTAGAAATAGCCTATATACGTTGAATGC- 3’ 
Ib Forward 5’- TAAACGAGAATGGAATATCACAAACC-3’ 
Reverse 5’ GAATTAACTTCAATCCCTAAACAATATCG- 3’ 
II Forward 5’- GCTTCAGTAAGTATTGTAAGACGATAG-3’ 
Reverse 5’ TTCTCTAGGAAATCAAATAATTCTATAGGG-3’ 
III Forward TCCGTACTACAACAGACTCATCC-3’ 
Reverse 5’ AGTAACCGTCCATACATTCTATAAGC-3’ 
IV Forward GGTGGTAATCCTAAGAGTGAACTGT-3’ 
Reverse 5’ CCTCCCCAATTTCGTCCATAATGGT-3’ 
V Forward GAGGCCAATCAGTTGCACGTAA-3’ 
Reverse 5’ AACCTTCTCCTTCACACTAATCCT-3’ 
Dlts Forward AGGAATACCAGGCGATGAACCGAT-3’ 
Reverse 5’ TGCTCTAATTCTCCCCTTATGGC-3’ 
 
 
Table 2.4: Reaction mixture 
 
 
 
 
 
Cycle Conditions 
The amplification of a target DNA was achieved through following 5 stages. 
• Stage 1: Activation of Taq DNA polymerase at 94°C for 2 min  
• Stage 2: Denaturing process of the DNA template for 30 sec at 94°C. 
• Stage 3: Annealing of the complementary primers at 55.1°C for 30 sec. 
• Stage 4: Extension period for 1min and 30 sec at 72°C.  
Reagents Stock 
concentration 
1 reaction 
(25 µl) 
Final Concentration 
EconoTaq 2X 12.5 1X 
Primer F 10µM 1 250 nM 
Primer R 10µM 1 300 nM 
DNA template  5  
dH2O (Sterile)  5.5  
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• Repeat stage 2 to stage 4 for 35 PCR cycles 
• Stage 5: Final extension for 10 min at 72°C.  
 
Interpretation of results 
The serotype of the GBS isolate was determined on the basis of matching band size 
of DNA fragment for capsular polysaccharide by agarose gel electrophoresis.  
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Figure 2.3: Algorithm for Group B Streptococcus isolation from vaginal and rectal 
swabs 
 
2.12 Pilus typing    
Pilus island (PI) typing of GBS isolates were done by real time PCR with Taqman 
probes for PI-1, PI-2a and PI-2b, with primers that target the genomic regions coding for 
the ancillary protein (AP)-1 of each PI as described previously (Madzivhandila et al., 
2013). Briefly, GBS isolates were sub-cultured and three GBS colonies were suspended in 
300 μl nuclease-free distilled water and the suspension was heated at 95°C for 10 minutes. 
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The suspension was centrifuged at 9000 g for 1 min to pellet the cell debris. Four 
microliters of the supernatant was added to each PCR. The PCRs were run on an AB 7500 
instrument (Applied Biosystems) in a 25 μl reaction volume with TaqMan universal PCR 
master (Applied Biosytems). The detection PI-1 and PI-2a were performed as a duplex 
reaction and PI-2b was performed as single-plex . GBS strains 2603 V/R (PI-1 and PI- 2a) 
and COH1 (PI-2b) were used as reference strains. The reaction mixture (25µl) consisted 
250nM of probe, 12.5µl of master mix, 4µl of DNA, primer (900 nM for PI-2b and 300nM 
and 110nM for forward and reverse primer for PI-1 and PI-2a, respectively). Cycle 
conditions included AmpErase activation at 30°C for 2 minutes, Taq DNA polymerase 
activation at 95°C for 10 minutes followed by 40 cycles of denaturation at 94°C for 15 
seconds and extension for 1 minute at 60°C.  Positive CT value was defined as the point 
where the amplification curve crosses a manually set threshold.  
 
 
2.13 Antibody measurement by Luminex assay 
We developed a multiplex bead-based immunoassay method for the simultaneous 
measurement of antibodies to 4 different GBS antigens present in the samples. With this 
assay, antibodies to four capsular polysaccharides can be quantified simultaneously. The 
Luminex assay was found to be less labour intensive and require less sample volume as 
compared to ELISA (Pang et al., 2005). 
 
 2.13.1 GBS capsular polysaccharides and reference serum 
Group B Streptococcus serotype-specific capsular polysaccharides were kindly 
provided by Novartis Vaccines, Italy. Polygam (pooled gamma globulin; National 
Bioproducts, South Africa) was used as in-house reference serum for IgG measurement 
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whereas pooled human serum was used for IgA measurement. Antibody concentrations 
were assigned to the reference serum by calibrating them with the standard serotype-
specific GBS reference serum kindly provided by Prof. Carol J. Baker. Serotype-specific 
antibody concentrations in the reference sera are shown in table 2.5    
     
Table 2.5: Antibody concentration in reference serum 
 
 
Reference Serum Serotype IgG IgA 
Ia 11.72 0.51 
Ib 4.33 0.18 
III 8.78 1.99 
V 6.41 5.58 
 
 
2.13.2 Validation of Luminex assay       
The Luminex multiplex assay for antibody analysis (both IgG and IgA) was 
validated using standard validation steps such as linearity of the assay, a multiplex versus 
single-plex comparison, determining lower limits of detection and the specificity of the in-
house reference serum.    
2.13.2.1 Linearity  
The first step of validation was to detect linearity as well as range of the assay. The 
standard curves were developed using Polygam (for IgG) or pooled serum (for IgA) as 
reference at different dilutions for each of the serotype-specific antibodies (Figure 2.4.1-
2.4.8). The dilutions in the figures below are represented by a standard (Std)  and were as 
follows: Std1- 1:100, Std2- 1:400, Std3- 1:1600, Std4- 1:6400, Std5- 1:25600, Std6-
1:102400 and Std7- 1:409600. 
46 
 
 
 
                          
Figure 2.4.1: Standard linearity curve for Serotype Ia, IgG 
 
    
  
Figure 2.4.2: Standard linearity curve for Serotype Ib, IgG 
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Figure 2.4.3: Standard linearity curve for Serotype III, IgG 
 
 
 
          
Figure 2.4.4: Standard linearity curve for Serotype V, IgG 
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Figure 2.4.5: Standard linearity curve for Serotype Ia, IgA 
 
 
 
 
Figure 2.4.6: Standard linearity curve for Serotype Ib, IgA 
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Figure 2.4.7: Standard linearity curve for Serotype III, IgA 
  
 
 
Figure 2.4.8: Standard linearity curve for Serotype V, IgA 
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2.13.2.2 The multiplex vs singleplex assay 
The multiplex assay was validated by comparing the Mean fluorescence intensity 
(MFI) values for reference serum (1:100 dilution) obtained with the multiplex assay as 
compared to those obtained by singleplex assays. We observed a maximum of 20% 
variation in with multiplex assay as compared to singleplex. 
 
Table 2.6: The MFI values with the multiplex assay as compared to singleplex assay 
for IgG 
 
 
 
 
 
 
 
Table 2.7: The MFI values with the multiplex assay as compared to singleplex assay 
for IgA 
 
 
 
 
 
 
 
Serotype Median % Min % Max % 
Ia 100 86 111 
Ib 85 79 97 
III 101 84 110 
V 103 82 112 
Serotype Median % Min % Max % 
Ia 106 91 119 
Ib 99 83 120 
III 99 73 119 
V 110 80 122 
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2.13.2.3 Detection limits     
Lower Limits of detection (LLD) for the multiplex assay were calculated from the 
fluorescence of the mean blank value plus 3 standard deviations. The LLD values were 
converted to antibody concentration from an “averaged” reference curve consisting of the 
mean fluorescence values at each concentration and the concentrations for the cut off were 
determined relative to the reference. For statistical purposes, any value that falls below the 
LLD was assigned a value of half of the LLD.   
  
Table 2.8: Detection limits for Serum IgG, Mucosal IgG and Mucosal IgA 
 
 
Serotype 
 
Ia Ib III V 
LLD (Serum IgG), µg/ml 0.0003 0.0016 0.005 0.009 
½  of LLD (Serum IgG) 0.00015 0.0008 0.0025 0.0045 
LLD (Mucosal IgG), ng/ml 0.007 0.033 0.091 0.22 
½  of LLD (Mucosal IgG) 0.003 0.016 0.045 0.11 
LLD (Mucosal IgA), ng/ml 0.010 0.018 0.032 0.64 
½ of LLD (Mucosal IgA) 0.005 0.009 0.016 0.32 
          LLD- Lower Limit of detection 
 
2.13.2.4 Specificity assay  
              To assess analytical specificity and to verify antigenic integrity of each GBS CPS 
antigen–microsphere set, each GBS CPS antigen (100 µg/ml) was incubated at 37˚C for 2 
hours as an inhibitor to different wells containing the multiplexed GBS–microsphere mix 
and reference serum added at 1:100 dilution. Following incubation, the serology assay was 
performed. Specificity results for each GBS antigen–microsphere using homologous and 
heterologous inhibition were determined by calculating the percent inhibition in MFI 
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signal in the presence of the GBS inhibitor relative to the MFI signal in the absence of the 
inhibitor using the following equation (Table 2.9 and Table 2.10)    
% inhibition =100 X ((MFI of reference serum )- (MFI of reference serum  + inhibitor antigen)) 
                                                                            MFI of reference serum  
   
Table 2.9: Specificity of the multiplexed GBS immunoassay for IgG 
 
Specificity assay for IgG using Polygam as reference 
                                      Antigen  
Inhibitor Antigen IA IB III V 
IA 99.20 40.90 11.16 9.91 
IB 0.00 97.05 1.69 4.40 
III -3.81 -9.61 94.77 18.30 
V -4.23 -9.22 -4.52 84.60 
 
For IgG, homologous inhibition was >90% for all serotypes, with the exception of 
serotype V (85%). Heterologous inhibition across serotypes was <10%, except for 
serotypes Ib and III, which were inhibited by 41% and 11% with type Ia CPS respectively, 
and serotype V (18%) was inhibited by serotype-III CPS. 
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Table 2.10: Specificity of the multiplexed GBS immunoassay for IgA 
 
Specificity assay for IgA using pooled human sera as reference 
                                     Antigen 
Inhibitor Antigen IA IB III V 
IA 99.68 80.88 21.58 -13.60 
IB 9.25 99.12 -4.63 3.73 
III 1.85 -2.30 99.22 6.95 
V -3.93 0.41 -8.65 98.44 
 
For IgA homologous inhibition was >95% for all serotypes. Heterologous 
inhibition across serotypes was <10%, except for serotypes Ib which was inhibited by 81% 
with type Ia CPS, along with 22% inhibition of serotype III.   
  
2.13.2.5 Non-specific binding  
In each experiment, for serum IgG, control beads were included to determine non-
specific binding. For control beads, the coupling procedure was followed, except that no 
GBS antigen was added. In case of non-specific binding, the mean fluorescence intensity 
(MFI) values were subtracted from the antigen-specific results.    
 
2.13.2.6 Sample and Secondary antibody Dilutions        
          The optimal serum dilutions were 1:100 for the measurement of antigen-specific IgG 
and 1:5 for the measurement of antigen-specific mucosal IgG and IgA.  The optimal 
secondary antibody dilutions were 1:100 for IgG and IgA.  
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2.13.3 Conjugation of antigens to the beads  
Capsular polysaccharides were coupled to the microsphere beads (Biorad, CA, 
U.S.A) with the crosslinking agent4-(4,6-dimethoxy[1,3,5]triazin-2-yl)-4-methyl-
morpholinium(DMTMM) as described (Schlottmann et al., 2006). Briefly, 40 mg of 
DMTMM was weighed out in a 5ml tube and 2.7 ml of GBS serotype-specific CPS 
solution (1mg/ml) was added, vortexed and incubated at RT on rotating shaker for 60 min. 
DMTMM modified CPS was purified using Sephadex G25 PD-10 columns and eluted in 
3.5 ml of PBS. 1ml of beads (centrifuged at 12000 rpm) were suspended in 500ul of 
DMTMM modified CPS and incubated overnight at RT on a shaker. After incubation 
beads were washed twice with wash buffer (Phosphate buffer solution (PBS)-Tween) and 
stored in assay buffer (PBS 7.2, 10% Fetal Bovine serum and 0.05% Sodium Azide) at 
4°C. 
 
2.13.4 Luminex assay Procedure 
The following steps were taken to run the assay           
 All samples, standards and controls were prepared in true duplicates in assay buffer  
 The 1.2 µm filter membrane plate (Pall) was saturated with 100μl of assay buffer. 
 GBS Antigen–microspheres (3500 per antigen) in a volume of 50 µl in assay buffer 
were added to the wells of a filter plate and aspirated by use of a vacuum manifold 
filtration system (Bio-Rad). 
 The plate was then washed twice with wash buffer (Phosphate buffer solution 7.2, 
0.5% Tween, 0.02% Sodium Azide). 
 Standards prepared from reference serum were serially diluted in four-fold dilutions 
beginning at1:100.    
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 The reference standard, controls and serum samples (50ul) were added to the GBS–
microspheres and incubated for 60 min at RT, with shaking.  
 After the incubation, the plate was washed three times with wash buffer.  
  Fifty microlitres of goat anti-human, phycoerythrin conjugated IgG or IgA (1:100 
dilution in wash buffer) (Jackson immunoresearch) was added into each well and 
incubated for 30 min at RT, with shaking.  
 After the incubation, the plate was washed three times with wash buffer and the 
contents of the plate were resuspended in 130µl of wash buffer. 
 Thereafter, 100-110 μl of wash buffer containing the beads was transferred to the 
reading plate. 
 Bead fluorescence was read with the Bioplex 200 instrument (Bio-Rad, Texas, 
U.S.A) using Bio-Plex manager 5.0, software (Bio-Rad) and data was analyzed 
using a 5 Parameter Logistic curve fit.  
 All over range and low range samples were re-tested with higher or lower dilutions 
(1:50-1:1000 for IgG and 1:2-1:10 for IgA). 
    
2.14 Serum IgG opsonophagocytic activity (OPA) assay 
The functional activity of serum IgG was determined by OPA assay for serotype Ia 
and III using the HL-60 cell line as described previously (Michon et al., 2006).  
  
2.14.1 HL-60 cells for OPA assay 
 Undifferentiated HL-60 cells were purchased from the American Type 
Culture Collection (ATCC) and were grown in 50 ml of growth media (500ml RPMI 1640, 
100ml inactivated FBS , 6.2 ml of L-glutamine (200mM), 5ml of penicillin-streptomycin 
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(10000 IU/ml) in 300 ml tissue culture flasks. The cells were counted, viability was 
determined and divided three times a week  (Mon, Wed and Fri) into a cell density of 3 × 
105 cells/ml (Monday and Wednesday) and  2 × 105 cells/ml (Friday) and fed twice a week 
(Tuesday and Thursday). All culture flasks were incubated at 37°C in 5% CO2 atmosphere 
in the upright position with loose caps. 
    
 Undifferentiated cells grown to a cell density of 4-10×105 cells/ml with a 
viability of > 90% were used for differentiation. Differentiation was carried out in cultures 
with a 200 ml volume at 2 x 105 cells/ml (600 ml flasks) of growth medium by the addition 
of 100 mM N,N-dimethylformamide (DMF) as the chemical inducer (1550 µl of DMF/ 
200 ml growth medium) and incubated for a period of 5 days at 37 °C, 5% CO2 in the 
slanted position with the cap loose. HL-60 cells were 90-95% differentiated into 
granulocytes by 5 days, and were ready to be used as phagocytes with a typical yield of 6-8 
×105 cells/ml.  After 5 days, a viable count was performed and cells with a viability of less 
than 70% were not used in the assay. Differentiated HL-60 cells were pre-washed twice 
with Hank’s Balanced Salt solution w/o Ca 2+ and Mg 2+ (HBSS-) + 0.2% BSA buffer (10 
ml/tube) and resuspended in Hank’s Balanced Salt solution w/o phenol red (HBSS+) + 
0.2% BSA (1 ml/tube). Total cell count and viability was determined and the cell 
suspension was diluted to a concentration of 1×107 cells/ml. 
 
2.14.2 Bacterial stocks         
Standard GBS strains (serotype Ia (A909) and serotype III (COH-1) from ATCC 
were used for the preparation of frozen stocks. Viable counts on random samples were 
performed to determine the concentration of GBS after freezing protocol and the dilution 
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factor required for the concentration of 1000 cfu/20ul (5x105cfu/ml) was calculated. Purity 
of bacterial suspension was also performed. 
 
2.14.3  Quality control sera 
Polygam with known reproducible OPA titre was included in each assay for quality 
control. 
       
2.14.4  Serum dilutions 
Starting serum dilutions were calculated on the basis of the antibody concentration 
of the sample as per table 2.11 
Table 2.11: Serum dilutions for OPA assay 
 
IgG concentration µg/ml  Sample dilution in OPA 
0–4 1/1 
4-7 1/2 
7-10 1/4 
10-15 1/8 
15-30 1/16 
30-50 1/32 
> 50 1/64 
 
2.14.5 Procedure for OPA assay   
 10 µl of Opsono buffer (HBSS+ + 0.1% gelatin) was added to each well of a 96-
well plate except for row A.   
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 20 µl of diluted or undiluted test serum was added to the wells of row A. (Test 
serum was heat inactivated at 56oC for 30 min prior to testing).  QC sera (Polygam) 
was added to wells A11 and A12.   
 Test and QC serum was serially diluted (2 fold) (rows A through H), except wells 
H9 through H12, which are reserved for the complement (C') controls.   
 20 µl of bacterial suspension was added to each well (1000 cfu/well). Frozen stock 
of bacteria was serially diluted in Opsono buffer to obtain 1000 cfu in 20 µl (5X 
104/ml). The bacterial suspension was kept on ice until ready to use.   
 The plate containing test serum and bacteria was incubated at 37°C for 15 min, 5% 
CO 2.  
 After incubation, to each well 10 µl of complement source (Baby Rabbit Serum) 
and 40 µl of differentiated HL-60 cells was added (4 x 105 cells/well).  
 The plate was incubated at 37°C for 45 minutes with horizontal shaking (220 rpm). 
After incubation the plate was cooled on ice for one minute to stop the reaction or 
kept on ice thereafter if more than two plates were run. 
 From each well 5µl was platted onto Todd Hewitt Yeast plates and incubated at 
37C and 5% CO2. 
 The colonies were counted after 18 hours after to avoid overgrowth and compared 
to the count in control wells which corresponds to the number of bacteria present in 
the each well after 45 minutes of incubation period in the presence of complement 
source.   
 Opsonophagocytic activity was expressed as the titer at which the serum dilution 
yielded 50% killing compared with the bacterial growth in the complement 
controls. The limit of detection was 8. For statistical analysis, samples below the 
detection limit were assigned an arbitrary titer of 4.  
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2.15 ELISpot assay for measure of cellular immune response 
Cellular immune response was determined at Visit-1 (enrolment) by Interferon-γ 
(IFN-γ) release assays, performed by Enzyme-linked Immunospot (ELISpot) assay kit for 
human IFN-γ as per manufacturer instructions (Cat no: 3420-2A, Mabtech, Sweden). 
Briefly, Peripheral blood mononuclear cells (PBMC) were isolated from the heparinised 
blood using ficoll gradient centrifugation and re-suspended in AIM-V medium (Gibco, 
Invitrogen, USA).   Approximately, 0.25-0.3 x 106 PBMS’s were added per well onto 
ELISpot plates (MAIP S4510; Millipore, Ireland) coated with IFN-γ capture antibody 
(Mabtech, Sweden). PBMC’s were stimulated with GBS serotype-specific capsular 
polysaccharide antigens separately (CPS-Ia, III and V) for 18-24 hours at 37°C in 5% CO2 
with a final concentration of 40µg/ml. After incubation, ELISpot plates were developed 
using biotinylated anti-IFN-γ detection antibody (Mabtech, Sweden) which was conjugated 
subsequently to streptavidin-alkaline phosphatase (Mabtech, Sweden), and visualized using 
an AP conjugate substrate kit (Bio-Rad, CA, USA). Checker board titrations were 
performed to optimize PBMC’s and antigen concentrations per well. AIM-V medium was 
used as negative control to assess background levels and phytohaemagglutinin (Sigma, 
USA) was used as a positive control. Cellular immune response against each antigen was 
detected in single well only. Spot forming units (SFU) were counted using the magnifying 
lens. Background (SFU in negative control) was subtracted and results were expressed as 
number of SFU/106 PBMC. An ELISpot response was considered as positive if the number 
of antigen-specific spots was ≥7 SFU/106 PBMC and at least double the number of spots in 
the negative control well.  
      
                
 
60 
 
Chapter 3 Prevalence of maternal Colonization with Group B 
Streptococcus: a systematic review and meta-analysis  
 
3.1 Abstract  
               
Background: The most important risk factor for early-onset (babies younger than 7 days) 
invasive group B streptococcal disease is rectovaginal colonisation of the mother at 
delivery. We aimed to assess whether differences in colonisation drive regional differences 
in the incidence of early-onset invasive disease. 
   
Methods: We did a systematic review of maternal group B streptococcus colonisation 
studies by searching MEDLINE, Embase, Pascal Biomed, WHOLIS, and African Index 
Medicus databases for studies published between January, 1997, and March 31, 2015, that 
reported the prevalence of group B streptococcus colonisation in pregnant women. We also 
reviewed reference lists of selected studies and contacted experts to identify additional 
studies. Prospective studies in which swabs were collected from pregnant women 
according to US Centers for Disease Control and Prevention guidelines that used selective 
culture methods were included in the analyses. We calculated mean prevalence estimates 
(with 95% CIs) of maternal colonisation across studies, by WHO region. We assessed 
heterogeneity using the I2 statistic and the Cochran Q test. 
   
Results: 221 full-text articles were assessed, of which 78 studies that included 73791 
pregnant women across 37 countries met prespecified inclusion criteria. The estimated 
mean prevalence of rectovaginal group B streptococcus colonisation was 17.9% (95% CI 
16.2–19.7) overall and was highest in Africa (22.4, 18.1–26.7) followed by the Americas 
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(19.7, 16.7–22.7) and Europe (19.0, 16.1–22.0). Studies from southeast Asia had the 
lowest estimated mean prevalence (11.1%, 95% CI 6.8–15.3). Significant heterogeneity 
was noted across and within regions (all p≤0.005). Differences in the timing of specimen 
collection in pregnancy, selective culture methods, and study sample size did not explain 
the heterogeneity. 
 
Conclusion: The country and regional heterogeneity in maternal group B streptococcus 
colonisation is unlikely to completely explain geographical variation in early-onset 
invasive disease incidence. The contribution of sociodemographic, clinical risk factor, and 
population differences in natural immunity need further investigation to understand these 
regional differences in group B streptococcus maternal colonisation and early-onset 
disease. 
  
3.2 Introduction     
Group B Streptococcus is a significant cause of severe infection in infants aged < 3 
months, most often manifesting as sepsis, pneumonia and meningitis. Infant invasive GBS 
disease occurs as a continuum over the first 3 months of life, but is commonly divided into 
early onset disease (EOD), occurring within 0-6 days of birth, or late onset disease (LOD), 
occurring within 7-90 days of birth.  Early onset disease is vertically acquired from the 
mother, whereas LOD can also be acquired nosocomially or in the community (Verani et 
al., 2010). Case fatality ratios remain as high as 36% even in high income settings such as 
Norway and USA (Hajdu et al., 2006, Jordan et al., 2008). Moreover, among survivors of 
GBS meningitis, 46-50 % develop moderate to severe neurological impairment (Bedford et 
al., 2001, Edwards et al., 1985, Libster et al., 2012). 
62 
 
Substantial variation in invasive disease incidence is reported both within and 
across geographic regions, ranging from 0.02 per 1000 live births (LB) in Southeast Asia 
to 1.21 per 1000 LB in Africa (Edmond et al., 2012).  Some variation may be attributable 
to the introduction of antibiotic based interventions: Intrapartum antibiotic prophylaxis 
(IAP), given to mothers rectovaginally colonized with GBS in late pregnancy, has resulted 
in substantial decreases in incidence of EOD (Schrag et al., 2000).  However, substantial 
variation in incidence of EOD remains in low and middle income countries, where the 
logistic and cost challenges associated with routine culture based screening and IAP have 
limited its implementation.  Factors underlying this variation may include differences in 
case ascertainment and laboratory diagnostics, or population differences in exposure and 
susceptibility (Dagnew et al., 2012).   
     
The most significant risk factor for invasive GBS EOD is rectovaginal colonization 
of the mother at the time of birth (Stoll et al., 2011). Vertical transmission of GBS occurs 
to approximately 50% of the newborns of GBS colonized mothers of whom 1-2% develops 
EOD.  If population-based differences in exposure are driving the observed differences in 
EOD incidence, one would expect to observe similar disparities in the prevalence of 
maternal colonization during pregnancy.  A previous systematic review of maternal GBS 
colonization data from low and middle income countries undertaken in 1998 reported a 
regional prevalence range of 8% to 18% by geographic region.  The microbiological 
method of GBS isolation was identified as a key driver of this variation (Stoll and 
Schuchat, 1998). In recent years the sensitivity of culture methods has increased and there 
is now published guidance on recommended methods for specimen collection, processing 
and GBS isolation (Verani et al., 2010). This should allow a clearer interpretation of any 
population differences in colonization. 
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We conducted a systematic review and meta-analysis of prospective 
epidemiological studies that detected GBS carriage and used recommended microbiology 
methods (Verani et al., 2010), to assess whether the prevalence of maternal GBS 
colonization matched the patterns of invasive disease incidence across geographic regions. 
          
3.3 Methods 
3.3.1 Literature search strategy and selection criteria 
We searched five literature databases (Medline, Embase, Pascal Biomed, WHOLIS 
and African Index Medicus) to identify studies reporting the prevalence of GBS 
colonization in pregnant women.  Searches were completed with the following terms: 
[‘Streptococcus agalactiae (MeSH/keyword) OR ‘Group B Streptococcus’ OR 
‘Streptococcus Group B’] AND [Colonization (MeSH/keyword) OR ‘Colonisation’]. The 
WHOLIS and African Index Medicus searches were completed using the following text: 
Group B Streptococcus colonization or Streptococcus agalactiae colonization. Searches 
were restricted to human studies published between January 1997 and March 2015 
(inclusive); the lower limit reflecting the dates of a previous systematic review on the same 
topic (Stoll and Schuchat, 1998). No language restrictions were applied.  After an initial 
selection, based on review of the publication titles and abstracts, a full-text review of 
remaining studies was completed against specific inclusion/exclusion criteria (Table 3.1). 
These criteria aimed to focus the review on studies with robust methods and to increase 
comparability across studies. Furthermore, we also screened bibliographies of selected 
studies and contacted experts for any potentially relevant studies that had not been 
identified through the search strategies. 
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Table 3.1: Inclusion criteria applied to literature search 
 
• Sufficient methodological detail to allow an assessment of specimen collection and 
microbiological methods 
• Consistent with guidelines from the Centers for Disease Control and Prevention 
(CDC) for specimen collection and microbiological identification of GBS: 
Collection of rectovaginal or vaginal and rectal swabs 
• Use of selective culture methods for GBS isolation and identification 
• Prospective data collection 
• Pregnant population 
• Original research article describing data not previously published   
    
3.3.2 Data Extraction  
The Preferred Reporting Items for Systematic Review and Meta-Analysis 
(PRISMA) checklist and flow diagram were used to identify, screen and exclude studies. 
Two authors (Gaurav Kwatra and Marianne C Cunnington) independently examined titles, 
abstracts, full text articles and abstracted data using the same data abstraction forms and 
selection criteria.  Disagreements were resolved by consensus among the authorship group. 
Data were abstracted on key study characteristics including geographic region (as defined 
by World Health Organization), study period, study population, timing (late pregnancy 
(35+ weeks of gestation) versus at delivery versus other) and site (single rectovaginal swab 
versus separate vaginal and rectal swabs) of specimen collection, method of GBS isolation 
(selective broth followed by subculture on blood agar or selective agar versus direct plating 
on selective media) sample size and the proportion of women colonized with GBS. Culture 
methods could include those recommended by the CDC (GBS growth on selective broth 
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followed by subculture on blood agar or selective media) or those outside of the CDC 
recommendations using some form of selectivity in the medium for GBS isolation (Verani 
et al., 2010). 
    
3.3.4 Statistical analyses   
A random effects meta-analysis was used to calculate the mean prevalence estimate 
of maternal colonization across studies and by region. Ninety-five percent confidence 
intervals were calculated around prevalence estimates. Studies were categorized by region, 
sorted by study size and heterogeneity between studies was assessed, first visually by the 
overlap of confidence intervals and then quantitatively by the I2 statistic (Higgins and 
Thompson, 2002) and the Cochran Q-test for heterogeneity with a significance level of 5% 
applied(WG, 1954). The I2 statistic is interpreted as the proportion of the total variation in 
the estimates of prevalence that is due to the heterogeneity between studies. Potential 
drivers of statistical variation (heterogeneity), including timing of specimen collection and 
culture method, were explored using descriptive stratified analyses.  A funnel plot was 
used to explore how prevalence estimates varied by study size, in case of “small study 
effects”(Sterne et al., 2000, Sterne et al., 2001) . Additionally for studies with available 
data on the distribution of serotypes, a random effects meta-analysis was used to calculate 
the mean prevalence of serotypes Ia, Ib or III; and serotypes Ia, Ib, II, III or V. Statistical 
analyses were completed using R software (version 2.15.2) and SAS (version 9.2). 
3.3.5 Sensitivity analysis 
The CDC recommendation for rectovaginal swab collection meant that studies in 
which lower vaginal swabs only were collected were excluded.  To investigate any 
potential bias introduced, studies meeting all pre-defined criteria, but reporting estimates 
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for lower vaginal colonization only were identified and a separate meta-analysis was 
completed. Studies were categorized by region, as classified by World Health Organization 
(WHO) criteria. As the Western Pacific region included an ethnically diverse range of 
countries (within this meta-analysis, Australia, China, including Hong Kong, Japan, Korea 
and New Zealand), an alternative categorization excluding Australia and New Zealand was 
also considered in a separate sensitivity analysis. 
              
3.4 Results  
3.4.1 Systematic Review  
A total of 1852 papers were identified from the literature search and 30 papers were 
identified through a search of paper bibliographies and expert opinion. Two hundred and 
twenty one papers were retained after an initial review of titles and abstracts and the 
removal of duplicates.  Seventy eight papers were included in the meta-analysis after full 
text review and application of pre-defined inclusion/exclusion criteria to the 221 papers 
(Figure 3.1).    
The majority of reports identified were from Europe and the Americas, whilst Africa had 
the fewest number (Table 3.2).  The proportion of studies meeting inclusion criteria was 
lowest for studies from Africa and Eastern Mediterranean regions (Table 3.2).  The most 
common reasons for exclusion were failure to follow CDC guidelines for specimen 
collection (lower vaginal and rectal swabbing) and selective culture methods or insufficient 
methodological detail (69.2% of total exclusions) (Verani et al., 2010). 
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Figure 3.1: Flow diagram of selected studies reporting on GBS colonization  
 
Records after removing duplicates 
(n=1225) 
Record of duplicates  
(n=657) 
Articles included by title and abstract 
read (n=337) 
Studies not meeting inclusion criteria (n=143) 
• Insufficient methodological details 44 
• Non selective culture methods 20 
• Specimen collection    35 
• Retrospective data collection  16 
• Duplicate data set   10 
• Other     18 
 
Full articles accessed for eligibility 
(n=221) 
Studies finally included in meta-
analysis (n=78) 
Records identified from database 
searching (n=1852) 
Medline n=784, EMBASE n=916, 
Pascal Biomed n=152, WHOLIS 
and African Index Medicus n=0 
From reference lists and 
experts n=30 
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Table 3.2: Inclusion/exclusion of studies by region 
 
Region Total Identified No. Included (%) No. Excluded* (%) 
Africa 14 4 (29) 10 (71) 
Americas 76 29 (38) 47 (62) 
Eastern Mediterranean 32 7 (22) 25 (78) 
Europe 59 23 (39) 36 (61) 
Southeast Asia 20 7 (35) 13 (65) 
Western Pacific 19 8 (42) 11 (58) 
International 1 0 (0) 1 (100) 
Total 221 78 (35) 143 (65) 
       
3.4.2 Prevalence of maternal colonization Meta-Analysis  
Overall, 73791 pregnant women were captured in 78 studies across 37 countries (median 
number of subjects per study of 391).  A total of 13 100 women were positive for 
rectovaginal colonization with GBS.  Twenty three studies from Europe captured the 
highest number of total subjects (n=31 642) while 7 studies from the Eastern 
Mediterranean region captured the lowest number (n= 2 729).  The highest median number 
of subjects per study was in Western Pacific (n=1 049), and the lowest in the Eastern 
Mediterranean (n=300). Study details are summarized table 3.3. The study-specific 
prevalence estimates ranged from 0.5% (95% CI, 0.0, 1.1) in Mexico (Romero Gutierrez et 
al., 2005) to 37.9% (95% CI, 25.4, 50.4) in Denmark (Hansen et al., 2004). Table 3.4 
summarizes the random-effects meta-analyses by region. Regional prevalence estimates 
ranged from 11.1% (95% CI, 6.8, 15.3) in Southeast Asia to 22.4% (95% CI, 18.1, 26.7) in 
Africa. The overall global prevalence estimate of 17.9% (95% CI, 16.2, 19.7) aligned with 
the two most studied regions: Europe and the Americas.  
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Table 3.3: Characteristics of Included Studies by region and study size 1  
 
Region Author Year Country Sample timing Study setting 
Study  
size 
Number of GBS  
positive cases 
Africa    TOTAL  2735 619 
 
Gray et al.(Gray et al., 
2011) 2012 Malawi Labour 
Pregnant women (≥16 years of age) in their third trimester of 
pregnancy were recruited from the labor ward of Queen 
Elizabeth Central Hospital, Blantyre (QECH), during October 
2008–March 2010. 1441 313 
 
Mavenyengwa et 
al.(Mavenyengwa et al., 
2010) 2010 Zimbabwe Delivery or Labour 
Between 2003 and 2005 at a maternity clinic and two district 
hospitals covering urban, urban-rural and rural communities 676 142 
 
Kwatra et al.(Kwatra et 
al., 2014) 2014 South Africa Late Pregnancy 
Between August 2010 and August 2011 at community 
antenatal clinics in Soweto 521 148 
 
Dzowela et al.(Dzowela 
T, 2005) 2005 Malawi Not Indicated 
June/July 2004, all women attending antenatal clinic and 
tertiary urban hospital without antibiotic use in previous 2 
weeks 97 16 
Americas    TOTAL  24892 4877 
 
Lin et al.(Lin et al., 
2011) 2011 US Delivery or Labour 
Between February 5, 2008 and February 4, 2009 at 3 hospitals 
in Houston, TX and Oakland, CA. 5497 1031 
 
Campbell et 
al.(Campbell et al., 
2000) 2000 US Delivery or Labour 
October 1992 and January 1995 from three hospitals in 
Houston (St. Luke’s Episcopal, the Methodist Hospital, and 
Ben Taub General Hospital) and from one hospital in Seattle 
(University of Washington Medical Center) 3307 856 
 
Gupta and Briski (Gupta 
and Briski, 2004) 2004 US Late Pregnancy 
St. John Hospital and Medical Center Laboratory, Detroit, 
Mich., for screening for GBS colonization were included in this 
prospective study. Specimens were received over 6 months, 
from July 2003 through December 2003. 1635 385 
 
Towers et al.(Towers et 
al., 2010) 2010 US Delivery or Labour Long Beach Memorial Women’s Hospital over a 3-year period 1472 296 
 
Larcher et al.(Larcher et 
al., 2005) 2005 Argentina Late Pregnancy 
Servicio de Ginecología y Obstetricia del Hospital Privado 
Centro Médico de Córdoba, Argentina, July 1st 2001 and 
December 31st 2002 1228 17 
 
Davies et al.(Davies et 
al., 2001) 2001 Canada Late Pregnancy 
From November 1998 through May 2000, from 16 
representative offices of obstetric care practitioners across 
Calgary 1207 235 
                                                 
 
1 Sample timing = Late pregnancy defined as ≥35 weeks gestation; Not indicated when not readily categorizable (e.g. including subjects <35 weeks gestation or a 
combination of subjects during late pregnancy and at delivery or labour); Other when  swabs collected at <35 weeks of gestation.  
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Di Bartolomeo et al.(Di 
Bartolomeo et al., 2005) 2005 Argentina Not applicable Posadas Hospital, April 2003 - May 2004 1203 113 
 
Montibello et 
al.(Montibello et al., 
2011) 2011 Argentina Late Pregnancy 
In the services of Bacteriology Hospital "Juan A. Fernandez" 
and the Naval Hospital "Pedro Mallo," both of the Autonomous 
City of Buenos Aires, and Hospital Piñeyro the town of Junin, 
Province of Buenos Aires 962 168 
 
Ocampo-Torres et 
al.(Ocampo-Torres et 
al., 2000) 2000 Mexico Delivery or Labour 
three public hospitals of San Cristobal de Las Casas, Chiapas, 
Between February and September 1999 910 78 
 
Gonzalez et al.(Alberto 
Gonzalez Padraza 
Aviles, 2002) 2002 Mexico Other 
Primary Health Center in Tlalpan, México, March 1999 and 
December 2001 691 97 
Region Author Year Country Sample timing Study setting 
Study  
size 
Number of GBS  
positive cases 
… 
    
 
  
 
Hickman et al.(Hickman 
et al., 1999) 1999 US Delivery or Labour 
January 26, 1994 through February 11, 1995 at four Houston 
hospitals. 546 153 
 
Gutierrez et al.(Romero 
Gutierrez et al., 2005) 2005 Mexico Late Pregnancy 
Hospital de Gineco-Pediatria num. 48, Leon, Guanajuato, 
November 2000 - March 2003 433 2 
 
Rocchetti et 
al.(Rocchetti et al., 
2011) 2011 Brazil Late Pregnancy 
Botucatu Medical School, Sao Paulo State University, UNESP, 
between February 2006 and January 2007. 405 103 
 
Price et al.(Price et al., 
2006) 2006 Canada Late Pregnancy 
Consecutive patients presenting between October 2003 and 
April 2005 to a maternity centre in Hamilton 330 62 
 
Simoes et al.(Simoes et 
al., 2007) 2011 Brazil Delivery or Labour November 2003 to May 2004, at the Jundiaí Teaching Hospital 316 46 
 
Jordan et al.(Jordan et 
al., 2010) 2010 US Late Pregnancy 
2 May 2006 through 14 August 2006, Washington, Pittsburgh 
and... 306 75 
 
Laufer et al.(Laufer et 
al., 2009) 2009 Uruguay Delivery or Labour Pereira Rossell Hospital, 2-month period in 2008 300 52 
 
Church et al.(Church et 
al., 2008) 2008 Canada Late Pregnancy 
large maternity clinic in the CHR (Maternity Care Clinic, 
Sunridge Professional Building, Calgary, Alberta, Canada) 279 50 
 
Madani et al.(Madani et 
al., 1998) 1998 Canada Other 
Pregnant women who attended the antenatal clinic at St. 
Boniface General Hospital in Winnipeg, Canada, from May 
1995 through April 1996 264 64 
 Garcia et al. 2003 Argentina Other 
Hospital de Clinicas Jose de San Martin de la universidad de 
Buenos Aires, April 2000 - March 2002 259 47 
 
Feuerschuette et 
al.(Feuerschuette et al., 
2012) 2012 Brazil Late Pregnancy 
Feuerschuette's clinic, Tubara, Brazil, December 2010 to 
August 2011 254 73 
 
Quinlan et al.(Quinlan et 
al., 2000) 2000 US Late Pregnancy 
Faculty practice of the Florida Hospital Family Practice 
Residency Program from April 1998 through April 1999 222 54 
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Nomura et al.(Nomura 
et al., 2005) 2005 Brazil Delivery or Labour 
Maternity of the State, Univeristy of Campinas, Brazil, Feb 
2003 - Jan 2004. 203 56 
 
Costa et al.(Costa et al., 
2008) 2008 Brazil Delivery or Labour 
public maternity center in the northeast region of Brazil (São 
Luís, Maranhão), Novenber 2005-March 2006. 201 41 
 
Orrett et al.(Orrett, 
2003) 2003 Trinidad Late Pregnancy 
Between 2000 and 2001 in antenatal clinics of general hospitals 
in north and south of the island 201 66 
 
Jamie et al.(Jamie et al., 
2004) 2004 US Other University of Florida clinic system, July 2003 to October 2003 200 71 
 
Orsello et al.(Orsello 
and Dommermuth, 
2003) 2003 US 35-37 
Naval Hospital Bremerton, Wash. 152 consecutive patients at 
35-37 weeks' gestation (7 excluded as only a single swab used) 145 35 
 
El Beitune et al.(El 
Beitune et al., 2006) 2006 Brazil Late Pregnancy 
Medicine School of Ribeirao Preto, University of Sao Paulo, 
Ribeirao Preto, SP, Brazil, November 2002 to April 2004 106 15 
 
Daimaru-Enoki et 
al.(Daimaru-Enoki et al., 
2005) 2005 US Late Pregnancy 
March 2001 through September 2002 involving routine 
obstetric patients who delivered at Cedars-Sinai Medical 
Center (CSMC),  81 19 
Eastern Mediterranean   TOTAL  2729 443 
 
Hammoud et 
al.(Hammoud et al., 
2003) 2003 Kuwait Delivery or Labour 
Maternity Hospital, was conducted between July 2000 and 
January 2001 1120 159 
 
Region 
 
Author 
 
Year 
 
Country 
 
Sample timing 
 
Study setting 
 
Study  
size 
 
Number of GBS  
positive cases 
… 
    
 
  
 
Zamzami et 
al.(Zamzami et al., 
2011) 2011 Saudi Arabia Delivery or Labour 
Delivery room at King Abdul-Aziz University Hospital 
(KAUH), Jeddah, Saudi Arabia; May 1 2009 - May 30 2010 326 103 
 
Hassanzadeh et 
al.(Parvin Hassanzedah, 
2011) 2011 Iran Delivery or Labour 
three teaching hospitals in Shiraz, southwest of Iran, April 
2006 to March 2007, 310 43 
 
Ferjani et al.(Ferjani et 
al., 2006) 2006 Tunisia Other 
maternité hospitalo-universitaire de la région de Sousse (centre 
tunisien). 1er janvier au 31 juillet 2003 300 39 
 
Jerbi et al.(Jerbi et al., 
2007) 2007 Tunisia Delivery or Labour Mar - May 2005 294 38 
 
Moghaddam(Moghaddam, 
2010) 2010 Iran Other 
Emam-Reza Hospital in Mashhad (Khorasan-Razavi 
Province - Iran) July 2005 - January 2007 201 25 
 
Seyyed et al.(Seyyed et 
al., 2013) 2013 Iran Delivery or Labour 
Two referral university hospitals (Al-Zahra and Shaheed 
Beheshty), Isfahan University of Medical Sciences, isfahan, 
Iran, March 2010 - May 2011 178 36 
Europe    TOTAL  30462 5925 
 
Cantoni et al.(Cantoni et 2013 Italy Late Pregnancy 
July 1, 2004-June 30, 2006, public hospitals of the region 
Friuli-Venezia Giulia in north-eastern Italy. 15239 3010 
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al., 2013) 
 
Busetti et al.(Busetti et al., 
2007) 2007 Italy Late Pregnancy 
1 January 2002 to 31 December 2005, Burlo Garofolo 
Institute, the mother-and-child hospital of Trieste, (North-
Eastern Italy) 5020 901 
 
Hakansson et 
al.(Hakansson et al., 
2008) 2008 Sweden Delivery or Labour 
National population based cohort of women giving birth in 
a single calendar week in 2005 1569 400 
 
Rausch et al.(Rausch et 
al., 2009) 2009 Switzerland Late Pregnancy 
Between March 2005 and September 2006 women at study 
hospital in Bern 1316 276 
 
Liebana-Martos(Maria del 
Carmen Liebana-Martos, 
2015) 2015 Spain Late Pregnancy Between 2009 and 2011 in antenatal clinics in Granada 1180 188 
 
Tsolia et al.(Tsolia et al., 
2003) 2003 Greece Not Indicated 
Between January 2000 and May 2001 at tertiary public 
hospital in Athens and 4 private hospitals in Athens or 
Drama in Northern Greece 1014 67 
 
Kunze et al.(Kunze et al., 
2011) 2011 Germany Late Pregnancy 
In 2005 at single tertiary hospital in Freiburg 
869 183 
 
Valkenburg van den Berg 
et al.(Valkenburg-van den 
Berg et al., 2006) 2006 
The 
Netherlands Delivery or Labour 
Between July 2000 and December 2002 convenience 
sampling from 3 obstetric outpatient hospital centers and 6 
midwifery practices in The Hague 761 174 
 
Jones et al.(Jones et al., 
2006) 2005 UK Other 
Between 2001 and 2003, women attending clinics attached 
to two hospitals in Oxford and Banbury 748 147 
 
Motlova et al.(Motlova et 
al., 2004) 2004 
Czech 
Republic Delivery or Labour 
Sep 2001 to May 2002, women at childbirth were screened 
for GBS carriage in two hospitals (Prague, Ceske 
Budejovice) of different regions 586 172 
 
Kieran et al. (Kieran et al., 
1998) 1998 Ireland Late Pregnancy 
 
504 129 
 
Eren et al.(Eren et al., 
2005) 2005 Turkey Delivery or Labour 
May 2000 to January 2001,Zeynep Kamil Women’s and 
Children’s Diseases Training and Research Hospital. 500 46 
 
Prosniewska et 
al.(Prosniewska M., 2014) 2014 Poland Other 
2010-2012, Clinic of Perinatology of the Faculty of 
Gynaecology and Obstetrics of the Medical University in 
Ludz, Poland 377 89 
Region Author Year Country Sample timing Study setting 
Study  
size 
Number of GBS  
positive cases 
… 
    
 
  
 
Jaureguy et al.(Jaureguy 
et al., 2003) 2004 France Other 
 
370 57 
 
Votava et al.(Votava et 
al., 2001) 2001 
Czech 
Republic Delivery or Labour 
Jan-july 2000, women in labor attending the Department of 
Gynecology and Obstetrics at Masaryk University 319 87 
 
Arisoy et al.(Arisoy et al., 
2003) 2003 Turkey Late Pregnancy March to Dec 2000, Social Security Hospital of Izmir 310 33 
 
Barbaros et al.(Barbaros 
et al., 2005) 2005 Turkey Delivery or Labour 
January 2002 to March 2003,  Maternity Department of 
Cerrahpasa Medical Faculty and Bakirkoy SSK Hospital, 
Istanbul, Turkey. 300 24 
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Strus et al.(Strus et al., 
2009) 2009 Poland Delivery or Labour 2004-2006, University Hospital in Cracow 250 43 
 
Tejerizo Lopez et al.(L.C. 
Tejerizo, 1998) 1998 Spain Delivery or Labour Hospital Virgen de la Vega, Salamanca 112 13 
        
 
El Aila et al.(El Aila et al., 
2010) 2010 Belgium Late Pregnancy 
Between June 2009 and January 2010 from women at 
university hospital in Ghent 100 22 
 
Romanik et al.(Romanik 
et al., 2011) 2011 Poland Late Pregnancy 
Department of gynocology and obstetrics, medical 
university of silesia, Tychy, Poland. 80 23 
 
Roccasalva et al.(L.S. 
Roccasalva, 2008) 2008 Italy Late Pregnancy 
Il Dipartimento de Scienze Microbiologiche e 
Ginecologiche dell'Universita di Catania, Feb 2007-May 
2008 60 7 
 
Hansen et al.(Hansen et 
al., 2004) 2004 Denmark Late Pregnancy 
Between May 1999 and June 2001 longitudinal cohort of 
women followed during pregnancy at Aarhus University 
Hospital 58 22 
Southeast Asia   TOTAL  3749 406 
 
Chan et al.(Chan et al., 
2013) 2013 Bangladesh Delivery or Labour 
Between January and October 2011, women attending 
maternity center in Dhaka 1219 94 
 
Patil et al.(Patil KP, 
2013) 2013 India Delivery or Labour 
June 2007 to May 2008,  tertiary care centre, pregnant 
women at labor 905 110 
 
Turner et al.(Turner et 
al., 2012) 2012 Thailand Delivery or Labour 
Shoklo Malaria Research Unit (SMRU) clinic between 
April 2009 and May 2010. All women who attended the 
antenatal clinic and were between 28 and 30 weeks 
gestation 549 47 
 
Tor-Udom et al.(Tor-
Udom et al., 2006) 2006 Thailand Late Pregnancy 
From September 2004 to February 2005, pregnant  women 
at the 35 to 37 weeks of gestation, receiving 
antenatal care at Thammasart Hospital 406 65 
 
Kovavisarach et 
al.(Kovavisarach et al., 
2007) 2007 Thailand Delivery or Labour 
The study was carried out in the labor room (LR) of the 
Rajavithi Hospital between October 
1and 30, 2004. 320 58 
 
Sharmila et al.(Sharmila 
et al., 2011) 2011 India Late Pregnancy 
September 2006 to June 2008, at Jawaharlal Institute of 
Postgraduate Medical Education and Research (JIPMER), a 
tertiary care teaching institute located at Puducherry, South 
India, Pregnant women with a gestational age of 35-37 
weeks, attending the antenatal out-patient department 300 7 
 
KonikKara et 
al.(Konikkara et al., 
2014) 2014 India Late Pregnancy 
January to June 2008 in the Diagnostic Microbiology 
Laboratory of a tertiary care referral hospital in South 
Kanara District of Karnataka,pregnant women who had 
come for antenatal check-up at 35 to 37 weeks 50 8 
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Region Author Year Country Sample timing Study setting 
Study  
size 
Number of GBS  
positive cases 
… 
    
 
  Western Pacific TOTAL  9773 1049
 
Lu et al.(Lu et al., 
2014) 2013 China Late Pregnancy 
Between September 2011 and February 2013, women 
attending tertiary teaching hospital in Beijing 2850 201 
 
Lee et al.(Lee et al., 
2010) 2010 South Korea Late Pregnancy 
Between January 2006 and May 2008 women attending for 
routine prenatal care at 2 hospitals in Daejeon and 2 hospitals 
in Seoul 2526 204 
 
Morita et al.(Morita et 
al., 2014) 2014 Japan Late Pregnancy 
Between November 2010 and October 2011 pregnant women 
attending Red Cross Medical Center for routine screening 1425 319 
 Gilbert et al.(Gilbert et al., 2002) 2002 Australia Delivery or Labour 
Women attending one community and one tertiary hospital in 
Sydney at delivery 1096 268 
 
Tsui et al.(Tsui et al., 
2009) 2009 Hong Kong Other 
Between January and May 2002 in tertiary obstetric centers 
across Hong Kong (serving population of 1 million).  First 20 
consecutive women attending antenatal booking clinics each 
day were enrolled. 1002 91 
 
Uh et al.(Uh et al., 
1997) 1997  Korea Other 
Between May 1995 and January 1996 women attending 
tertiary hospital for delivery in Wonju 459 26 
 
Grimwood et 
al.(Grimwood et al., 
2002) 2002 
New Zealand 
Late Pregnancy 
October-December 1998 and July-December 1999 volunteer 
midwives in Auckland hospitals recruited convenience sample 
of pregnant women 
240 52 
 
Park et al.(Park et al., 
2013) 2013 South Korea Late Pregnancy 
Women attending teaching and general hospitals in Seoul for 
routine prenatal care 175 15 
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Table 3.4: Meta-analysis of studies reporting prevalence of maternal colonization by 
region     
 
Region No. 
studies 
No. 
subjects 
Median 
subjects 
per 
study 
Number of 
GBS 
positive 
cases 
Estimated 
Prevalence 
(95% CI) 
Within 
region test 
for 
heterogeneity 
I2, p value 
Africa 4 2735 598.5 619 22.4 
(18.1,  26.7) 
82.7%, 
 p =0.005 
Americas 29 23163 316 4360 19.7 
(16.7,  22.7) 
98.4%,  
p < 0.0001 
Eastern 
Mediterranean 
7 2729 300 443 16.7 
(11.7,  21.7) 
91.9%,  
p < 0.0001 
Europe 23 31642 500 6113 19.0 
(16.1,  22.0) 
97.2%,  
p < 0.0001 
Southeast Asia 7 3749 406 389 11.1 
(6.8,  15.3) 
95.1%,  
p < 0.0001 
Western Pacific 8 9773 1049 1176 13.3 
(7.8,  18.8) 
98.7%,  
p < 0.0001 
Overall 78 73791 391 13100 17.9 
(16.2,  19.7) 
98.1%,  
p < 0.0001 
 
  The colonization prevalence estimates are summarized in more detail in the forest 
plot (Figure 3.2-3.7), by region, sorted by study size and further categorized by timing of 
specimen collection (delivery, late pregnancy (35wks-delivery) or other). The 
heterogeneity across estimates is immediately evident, with overall I2=98.1%. The level of 
heterogeneity remained significant within each region (lowest I2=82.7%, p=0.005 for 
Africa, with just four studies) and while prevalence estimates from the same country often 
coincided (e.g. Tunisia(Jerbi et al., 2007, Ferjani et al., 2006)) this was not always the case 
(e.g. India (Konikkara et al., 2014, Sharmila et al., 2011)).  
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Figure 3.2: Meta-analysis of studies that reported maternal GBS colonization in 
Africa   
 
 
 
Figure 3.3: Meta-analysis of studies that reported maternal GBS colonization in 
Eastern Mediterranean  
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Figure 3.4: Meta-analysis of studies that reported maternal GBS colonization in 
America    
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Figure 3.5: Meta-analysis of studies that reported maternal GBS colonization in 
Europe 
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Figure 3.6: Meta-analysis of studies that reported maternal GBS colonization in 
Southeast Asia 
 
 
 
Figure 3.7: Meta-analysis of studies that reported maternal GBS colonization in 
Western Pacific 
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 Additional sources of heterogeneity were investigated:  several different selective 
culture methods were reported including selective broth subcultured on sheep blood agar 
(SBSBA), selective broth subcultured on selective media (SBSSM) and direct plating on 
selective agar media (DPSM) (Table 3.5).   To explore the contribution of these methods to 
the observed heterogeneity, an analysis was restricted to studies with ≥400 subjects using 
selective broth subcultured on sheep blood agar culture (SBSBA) as the most common 
method (Table 3.6)  However, the patterns of mean prevalence across regions remained 
similar to the primary analysis with heterogeneity estimates high (I2 ≥90% across all 
regions).   
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Table 3. 5: For studies ≥ 400 subjects, details of the culture method used 
 
Region Author,  Country 
Study  
size 
Culture 
method Swabs comments 
Africa       
 
Mavenyengwa et al., 
2010(Mavenyengwa et 
al., 2010) Zimbabwe 767 
DPSM and 
SBSBA 
vaginal and 
rectal 
both DPSM and SBSBA was 
used for colonization rate 
 
Kwatra et al., 
2014(Kwatra et al., 
2014) 
South 
Africa 521 DPSM 
Vaginal and 
Rectal 
Direct plating on selective 
media only 
Americas       
 
Lin et al., 2011(Lin et 
al., 2011) USA 5497 SBSSM 
Vaginal and 
Rectal no comments 
 
Campbell et al., 
2000(Campbell et al., 
2000) USA 3307 SBSBA 
Vaginal and 
Rectal no comments 
 
Gupta, 2004(Gupta and 
Briski, 2004) USA 1635 
SB (23.5%) and 
DPSM (21.5%) 
combined 
recto-vaginal 
 SB the yield is high. Need to 
use only recto-vaginal data 
 
Towers et 
al.,2010(Towers et al., 
2010) USA 1472 SBSBA 
vginal and 
rectal no comments 
 
Larcher et 
al.,2005(Larcher et al., 
2005) Argentina 1228 SBSBA 
Vaginal and 
Rectal no comments 
 
Davies et 
al.,2001(Davies et al., 
2001) Canada 1207 SB 
combined 
vaginal and 
rectal 
subculture plate not 
mentioned 
 
Di Bartolomeo et al., 
2005(Di Bartolomeo et 
al., 2005) Argentina 1203 SBSBA 
Vaginal and 
Rectal no comments 
 Montibello et al., 2011 Argentina 962 
DPSM, 
SBABA,SBSSM 
vaginal and 
rectal  
DPSM was inferior to SBSBA 
and SBSBA was inferior to 
SBSSM 
 
Occampo-Torres et al., 
2000(Ocampo-Torres 
et al., 2000) Mexico 910 SBSBA 
vaginal and 
perianal no comments 
 
Gonzalez et al., 
2002(Alberto Gonzalez 
Padraza Aviles, 2002) Mexico 691 DPSM 
vaginal, rectal 
and urine 
rectal (2.7%) colonization is 
low as compared to vaginal 
colonization (11.1%) 
 
Hickman et al., 
1999(Hickman et al., 
1999) USA 546 SBSBA 
Vaginal and 
Rectal no comments 
 
Gutierrez et al., 
2005(Romero 
Gutierrez et al., 2005) Mexico 433 DPSM and SB 
Vaginal and 
Rectal 
In different language can't 
understand the complete paper 
 
Rocchetti et al., 
2011(Rocchetti et al., 
2011) Brazil 405 SBSBA 
Vaginal 
introitus, 
vaginal (high) 
and perianal 
Extra high vaginal swab was 
used 
Eastern Mediterranean      
 
Hammoud et al., 
2003 Kuwait 1120 
DPSM and 
SBSBA 
combined 
recto-vaginal 
both DPSM and SBSBA was 
used for colonization rate 
Europe       
 
Cantoni et al., 
2013(Cantoni et al., 
2013) Italy 15239 SBSBA 
combined 
recto-vaginal no comments 
 
Busetti et al., 
2007(Busetti et al., 
2007) Italy 5020 
DPSM and 
SBSBA 
Vaginal and 
rectal 
DPSM was inferior to 
SBSBA.  
 
Hakansson et al., 
2008(Hakansson et 
al., 2008) Sweden 1569 SBSBA 
combined 
recto-vaginal no comments 
 
Rausch et al.,  
2009(Rausch et al., 
2009) Switzerland 1316 SBSBA 
vaginal and 
rectal no comments 
 
Tsolia et al., 
2003(Tsolia et al., 
2003) Greece 1014 SBSBA 
vaginal and 
rectal no comments 
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Kunze et al., 
2011(Kunze et al., 
2011) Germany 869 SBSBA 
combined 
recto-vaginal no comments 
 
Valkenburg van den 
Berg et al., 
2006(Valkenburg-
van den Berg et al., 
2006) 
The 
Netherlands 761 SBSBA 
combined 
recto-vaginal no comments 
 
Jones et al., 
2005(Jones et al., 
2006) UK 748 SBSBA 
combined 
recto-vaginal 
DPSM was inferior to 
SBSBA.  
 
Motlova et al., 
2004(Motlova et al., 
2004) 
Czech 
Republic 586 SBSBA 
vaginal and 
rectal no comments 
 
Kieran et al., 
1998(Kieran et al., 
1998) Ireland 504 
SBSBA and 
SBSSM 
vaginal and 
peranal 
SBSSM (129/504-25.6%)5 
has higer sensitivity than 
SBSBA (112/504-22.2%) 
 
Eren et al., 
2005(Eren et al., 
2005) Turkey 500 SBSBA 
vaginal and 
rectal no comments 
Southeast Asia      
 
Chan et al., 
2013(Chan et al., 
2013) Bangladesh 1219 SBSBA 
vaginal and 
rectal no comments 
 
Patil et al., 
2013(Patil KP, 
2013) India 905 SBSBA 
vaginal and 
rectal no comments 
 
Turner et al., 
2012(Turner et al., 
2012) Thailand 549 SBSBA 
combined 
recto-vaginal no comments 
 
Tor-Udom et al., 
2006(Tor-Udom et 
al., 2006) Thailand 406 SBSBA 
vaginal and 
rectal (self 
collected) no comments 
Western Pacific      
 
Lu et al., 2013(Lu et 
al., 2014) China 2850 Unclear 
combined 
recto-vaginal 
CDC method mentioned in 
reference only(no description 
in the methods) 
 
Lee et al., 2010(Lee 
et al., 2010) 
South 
Korea 2526 SBSBA 
Vaginal and 
Rectal no comments 
 
Mortia et al., 
2014(Morita et al., 
2014) Japan 1425 
SBSBA and 
SBSSM 
combined 
recto-vaginal 
SBSSM (318/142-22.3%)5 
has higer sensitivity than 
SBSBA (299/1425-21.0%) 
 
Gilbert et al., 
2002(Gilbert et al., 
2002) Australia 1096 SBSBA 
vaginal and 
rectal no comments 
 
Tsui et al., 
2009(Tsui et al., 
2009) Hong Kong 1002 SBSBA 
High vaginal, 
low vaginal 
and rectal 
For consistency, we can 
remove high vaginal swab 
results, in that case 
colonization rate will become 
91/1004-9.1% 
 
Uh et al., 1997(Uh 
et al., 1997) 
South 
Korea 459 
DPSM and 
SBSBA 
Vaginal and 
Rectal 
DPSM was inferior to 
SBSBA.  
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Table 3. 6: Meta-analysis of studies using SBSBA culture method with studies ≥ 400 
subjects  
 
Region** Author,  Country 
Study  
size 
Number of GBS 
positive cases 
Estimated     
prevalence 
(95% CI) 
 
Americas 7 studies, I2=99.4% 9071 1616 16.8 (9.1, 24.6) 
 (Campbell et al., 2000) USA 3307 856 25.9 (24.4, 27.4) 
 (Towers et al., 2010) USA 1472 296 20.1 (18.1, 22.2) 
 (Larcher et al., 2005) Argentina 1228 17 1.4 (0.7, 2.0) 
 
(Di Bartolomeo et al., 
2005) Argentina 1203 113 9.4 (7.7, 11.0) 
 
(Ocampo-Torres et al., 
2000) Mexico 910 78 8.6 (6.8, 10.4) 
 (Hickman et al., 1999) USA 546 153 28.0 (24.3, 31.8) 
 (Rocchetti et al., 2011) Brazil 405 103 25.4 (21.2, 29.7) 
Europe 9 studies, I2=98.2% 22602 4475 19.4 (14.6, 24.1) 
 
(Cantoni et al., 2013) Italy 15239 3010 19.8 (19.1, 20.4) 
 (Hakansson et al., 2008) Sweden 1569 400 25.5 (23.3, 27.7) 
 (Rausch et al., 2009) Switzerland 1316 276 21.0 (18.8, 23.2) 
 (Tsolia et al., 2003) Greece 1014 67 6.6 (5.1, 8.1) 
 (Kunze et al., 2011) Germany 869 183 21.1 (18.3, 23.8) 
 
(Valkenburg-van den Berg 
et al., 2006) The Netherlands 761 174 22.9 (19.9, 25.8) 
 (Jones et al., 2006) UK 748 147 19.7 (16.8, 22.5) 
 (Motlova et al., 2004) Czech Republic 586 172 29.4 (25.7, 33.0) 
 (Eren et al., 2005) Turkey 500 46 9.2 (6.7, 11.7) 
Southeast Asia 4 studies, , I2=90.2% 3079 316 10.9 (7.3, 14.4) 
 (Chan et al., 2013) Bangladesh 1219 94 7.7 (6.2, 9.2) 
 (Patil KP, 2013) India 905 110 12.2 (10.0, 14.3) 
 (Turner et al., 2012) Thailand 549 47 8.6 (6.2, 10.9) 
 (Tor-Udom et al., 2006) Thailand 406 65 16.0 (12.4, 19.6) 
Western Pacific 3 studies, I2=99.1% 4624 563 13.8 (3.5, 24.2) 
 
(Lee et al., 2010) South Korea 2526 204 8.1 (7.0, 9.1) 
 (Gilbert et al., 2002) Australia 1096 268 24.5 (21.9, 27.0) 
 (Tsui et al., 2009) 
China (Hong 
Kong) 1002 91 9.1 (7.3, 10.9) 
Overall 23 studies, I2=99.0% 
   
39376 6970 16.4 (13.1, 19.8) 
*For all five I2 statistics presented, the associated test of heterogeneity p<0.0001 
** No studies meeting the relevant criteria were identified for Africa 
 
Stratification according to maternal demographic characteristics was explored but 
analyses were limited by variation in the ways studies reported this information. There 
were relatively few studies with adequate subject numbers that allowed stratification by 
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maternal age (<20 years versus ≥20 years) which precluded heterogeneity estimates for 
most regions (Table 3.7).  There was no difference in observed heterogeneity by study 
period (Table 3.8)    
       
    
 
85 
 
Table 3.7: Studies with ≥ 400 subjects and meta-analysis as stratified by age  
 
    
<20 yrs* >=20 yrs* 
Author Year Country Timing 
Study  
size 
Number of 
GBS 
positive cases % (95% CI) 
Study  
size 
Number of 
GBS 
positive cases % (95% CI) 
Africa 
         (Gray et al., 2011)  2011 Malawi Other 345 68 20 (16-24) 1494 322 22 (19-24) 
(Kwatra et al., 2014) 2014 South Africa Late Pregnancy 92 27 29 (20-39) 569 191 34 (30-37) 
          
Americas 
         (Campbell et al., 2000) 2000 US Delivery or Labour 575 149 26 (22-29) 2732 707 26 (24-28) 
(Larcher et al., 2005) 2005 Argentina Late Pregnancy 47 1 2 (0-6) 1197 16 1.3 (0.7-2.0) 
(Ocampo-Torres et al., 
2000) 2000 Mexico Delivery or Labour 212 16 8 (4-11) 698 62 9 (7-11) 
Europe 
         (Valkenburg-van den 
Berg et al., 2006) 2006 
The  
Netherlands Delivery or Labour 41 13 32 (17-46) 1660 353 21 (19-23) 
(Hakansson et al., 
2008) 2008 Sweden Delivery or Labour 17 4 24 (3-44) 1556 396 25 (23-28) 
(Tsolia et al., 2003) 2003 Greece Other 148 8 5 (2-9) 866 59 7 (5-8) 
SE Asia 
           (Chan et al., 2013) 2013 Bangladesh Delivery or Labour 601 217 36 (32-40) 618 237 38 (35-42) 
 
 
*<19yrs vs >=19 yrs for Occampo-Torres et al.; <=22 yrs vs >22 yrs for Chan et al. Late pregnancy: ≥35 weeks of gestation. Other: swabs collected at <35 weeks of 
gestation. 
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          Table 3. 8: Meta-analysis of studies stratified by year of publication after 2005  
 
Region Author Year Country 
Study  
Size 
Number of GBS 
positive cases 
Estimated prevalence 
(95% CI) 
2006-07 8 studies, I2=77.7% 7537 1352 17.0 (14.6, 19.4) 
Americas (Price et al., 2006) 2006 Canada 330 62 18.8 (14.6, 23.0) 
Americas (El Beitune et al., 2006) 2006 Brazil 106 15 14.2 (7.5, 20.8) 
E Med (Ferjani et al., 2006) 2006 Tunisia 300 39 13.0 (9.2, 16.8) 
Europe 
(Valkenburg-van den Berg et al., 
2006) 2006 The Netherlands 761 174 22.9 (19.9, 25.8) 
SE Asia (Tor-Udom et al., 2006) 2006 Thailand 406 65 16.0 (12.4, 19.6) 
E Med (Jerbi et al., 2007) 2007 Tunisia 294 38 12.9 (9.1, 16.8) 
Europe (Busetti et al., 2007) 2007 Italy 5020 901 17.9 (16.9, 19.0) 
SE Asia (Kovavisarach et al., 2007) 2007 Thailand 320 58 18.1 (13.9, 22.3) 
2008-09 8 studies, I2=91.2% 4977 960 17.7 (13.9, 21.6) 
Americas (Church et al., 2008) 2008 Canada 279 50 17.9 (13.4, 22.4) 
Americas (Costa et al., 2008) 2008 Brazil 201 41 20.4 (14.8, 26.0) 
Europe (Hakansson et al., 2008) 2008 Sweden 1569 400 25.5 (23.3, 27.7) 
Europe (L.S. Roccasalva, 2008) 2008 Italy 60 7 11.7 (3.5, 19.8) 
Americas (Laufer et al., 2009) 2009 Uruguay 300 52 17.3 (13.0, 21.6) 
Europe (Rausch et al., 2009) 2009 Switzerland 1316 276 21.0 (18.8, 23.2) 
Europe (Strus et al., 2009) 2009 Poland 250 43 17.2  (12.5, 21.9) 
W Pacific (Tsui et al., 2009) 2009 
China (Hong 
Kong) 1002 91 9.1 (7.3, 10.9) 
2010-11 15 studies, I2=97.4% 15787 2784 18.6 (15.0, 22.3) 
Africa (Mavenyengwa et al., 2010). 2010 Zimbabwe 676 142 21.0 (17.9, 24.1) 
Americas (Towers et al., 2010) 2010 US 1472 296 20.1 (18.1, 22.2 
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Americas (Jordan et al., 2010) 2010 US 306 75 24.5 (19.7, 29.3) 
E Med (Moghaddam, 2010) 2010 Iran 201 25 12.4 (7.9, 17.0) 
Europe (El Aila et al., 2010) 2010 Belgium 100 22 22.0 (13.9, 30.1) 
W Pacific (Lee et al., 2010) 2010 South Korea 2526 204 8.1 (7.0, 9.1) 
Africa (Gray et al., 2011) 2011 Malawi 1441 313 21.7 (19.6, 23.9) 
Americas (Lin et al., 2011) 2011 US 5497 1,031 18.8 (17.7, 19.8) 
Americas (Montibello et al., 2011) 2011 Argentina 962 168 17.5 (15.1, 19.9) 
Americas (Rocchetti et al., 2011) 2011 Brazil 405 103 25.4 (21.2, 29.7) 
Americas (Simoes et al., 2007) 2011 Brazil 316 46 14.6 (10.7, 18.4) 
E Med  (Zamzami et al., 2011) 2011 Saudi Arabia 326 103 31.6 (26.5, 36.6) 
E Med  (Parvin Hassanzedah, 2011) 2011 Iran 310 43 13.9 (10.0, 17.7) 
Europe (Kunze et al., 2011) 2011 Germany 869 183 21.1 (18.3, 23.8) 
Europe (Romanik et al., 2011) 2011 Poland 80 23 28.8 (18.8, 38.7) 
SE Asia (Sharmila et al., 2011) 2011 India 300 7 2.3 (0.6, 4.0) 
2012-13 8 studies, I2=98.9% 21369 3,586 13.8 (8.5, 19.1) 
Americas (Feuerschuette et al., 2012) 2012 Brazil 254 73 28.7 (23.2, 34.3) 
SE Asia (Turner et al., 2012) 2012 Thailand 549 47 8.6 (6.2, 10.9) 
E Med (Seyyed et al., 2013) 2013 Iran 178 36 20.2 (14.3, 26.1) 
Europe  (Cantoni et al., 2013) 2013 Italy 15239 3,010 19.8 (19.1, 20.4) 
W Pacific (Lu et al., 2014) 2013 China 2850 201 7.1 (6.1, 8.0) 
SE Asia (Chan et al., 2013) 2013 Bangladesh 1219 94 7.7 (6.2, 9.2) 
SE Asia  (Patil KP, 2013) 2013 India 905 110 12.2 (10.0, 14.3) 
W Pacific (Park et al., 2013) 2013 South Korea 175 15 8.6 (4.4, 12.7) 
2014-15 5 studies, I2=89.5% 3553 752 20.3 (13.7, 26.9) 
Africa (Kwatra et al., 2014)(Chapter 5) 2014 South Africa 521 148 28.4 (24.5, 32.3) 
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Europe (Prosniewska M., 2014) 2014 Poland 377 89 23.6 (19.3, 27.9) 
SE Asia (Konikkara et al., 2014) 2014 India 50 8 16.0 (5.8, 26.2) 
W Pacific (Morita et al., 2014) 2014 Japan 1425 319 22.4 (20.2, 24.6) 
Europe 
(Maria del Carmen Liebana-
Martos, 2015) 2015 Spain 1880 188 9.6 (5.4, 13.8) 
Overall 44 studies, I2=97.1% 53223 9434 17.5 (15.6, 19.4) 
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3.4.3 Sensitivity Analysis: 
To investigate any potential bias introduced by the exclusion of studies reporting 
colonization from lower vaginal swabs only, a separate meta-analysis was completed.  
Seventeen studies were identified capturing 18,495 subjects with a mean prevalence 
estimate was 14.2% (95% CI: 10.7, 17.6).  A similar heterogeneity to the primary meta-
analyses was observed (I2= 97.5%) (Table 3.9). Secondly, the ethnic diversity of the 
Western Pacific region was revisited. For this region, there were eight studies originally 
included, from China (including Hong Kong), Japan, Korea, Australia and New Zealand 
(Table 3.10). The two Australian and New Zealand studies accounted for 14% of subjects 
included in the original analysis (1336/9773). The exclusion of these two studies led to a 
non-significant reduction in the mean prevalence estimate from 13.3% (95% CI, 7.8, 18.8) 
to 10.1% (95% CI, 5.2, 15.1), aligning more closely with the Southeast Asian estimate of 
11.1% (95% CI, 6.8, 15.3).   
 
3.4.4 Serotype Distribution Meta-Analysis 
In total, 22 studies reported serotype distribution, but 5 were excluded due to reporting of 
combined serotypes only (n=2), combined maternal and neonatal isolate data (n=1), or 
failure to report raw data (n=2). The remaining 17 studies are summarized in Table 3.11. 
Studies from the Americas and Europe reported lower proportions of serotypes Ia, Ib or III 
isolates: 55.0% (95% CI: 52.3, 57.7) and 58.3% (95% CI: 52.2, 64.5) respectively, mainly 
reflecting a higher proportion of serotype II isolates in those regions. Serotypes VI, VII and 
VIII were rare everywhere, though one study from South Korea, (Lee et al., 2010) reported 
these for 7.3% (14/192) of vaginal and rectal GBS isolates. 
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3.4.5 Publication Bias 
To investigate how prevalence estimates varied by study size, a funnel plot was produced 
and showed little asymmetry on either side of the overall prevalence estimate (Figure 3.8, 
regression test with study size as a predictor, p=0.89). 
 
 
Figure 3.8:  Funnel plot to explore how prevalence estimates vary by study size 
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Table 3.9: Meta-analysis of studies estimating prevalence of vaginal-only GBS 
colonization 
 
Region Author Year Country 
Study  
Size 
Number of 
GBS 
positive cases 
Estimated 
prevalence 
(95% CI) 
Americas (Krohn et al., 
1999) 
1999 US 7806 1689 21.6 (20.7, 22.6) 
Americas (Zusman et al., 
2006) 
2006 Brazil 598 107 17.9 (14.8, 21.0) 
SE Asia (Das et al., 2003) 2003 India 200 15 7.5    (3.8, 11.2 
SE Asia (Goyal et al., 
2004) 
2004 India 304 4 1.3   (0.0,   2.6) 
SE Asia (Chaudhry et al., 
2010) 
2010 Pakistan 200 17 8.5   (4.6, 12.4) 
SE Asia (Sobhana Surya 
Pradeep M, 2013) 
2013 India 83 3 3.6   (0.0,   7.6) 
Africa (Cutland et al., 
2009) 
2009 South 
Africa 
3964 825 20.8 (19.5, 22.1) 
Africa (Okon, 2013) 2013 Nigeria 97 13 13.4   (6.6, 20.2) 
Africa 
(Mitima et al., 
2014) 
2014 
Democratic 
Republic  
Congo 
509 103 20.2 (16.7, 23.7) 
E Med (Ben Hamouda et 
al., 2008) 
2008 Tunisia 207 27 13.0   (8.5, 17.6) 
E Med (Farnaz Fatemi, 
2009) 
2009 Iran 330 68 20.6 (16.2, 25.0) 
E Med (S. Mansouri, 
2008) 
2008 Iran 602 55 9.1   (6.8, 11.4) 
E Med (Shabayek et al., 
2009) 
2009 Egypt 150 45 30.0 (22.7, 37.3) 
E Med (Tajbakhsh et al., 
2013) 
2013 Iran 285 27 9.5   (6.1, 12.9) 
Europe Krasmianin et al. 2009 Poland 100 19 19.0 (11.3, 26.7) 
Europe (Sensini et al., 
1997) 
1997 Italy 2300 260 11.3 (10.0, 12.6) 
Europe  (Verhoeven et al., 
2014) 
2014 France 760 127 16.7 (14.1, 19.4) 
Overall 17 studies, I2=98% 18495 3404 14.2 (10.7, 17.6) 
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    Table 3.10: Sensitivity analyses – impact of Australia and New Zealand within Western Pacific region   
    
Region No. studies 
No. 
subjects 
Median 
subjects 
per study 
(IQR) 
Number of 
GBS 
positive 
cases 
Estimated 
Prevalence 
(95% CI) 
Within region test 
for heterogeneity 
I2, p value 
Europe - original 23 31642 500 (275-942) 
6113 19.0 
(16.1,  22.0) 
97.2%, 
 p < 0.0001 
Europe including 
Australia and New 
Zealand 
25 32978 500 (250-1014) 
6433 19.3 
(16.6, 22.1) 
96.9%, p<0.0001 
Western Pacific – 
original 8 9773 
1049 (404-
1700) 
1176 13.3 
(7.8,  18.8) 
98.7%,  
p < 0.0001 
Western Pacific 
excluding Australia 
and New Zealand 
6 8437 
1213.5 
(595-
2251) 
856 10.1  
(5.2, 15.1) 
98.3%, 
 p<0.0001 
Australia and New 
Zealand 2 1336 
668 (454-
882) 
320 23.9 
(21.6, 26.2) 
No. of studies 
too small 
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Table 3. 11: Meta-analysis of serotype isolated  
  
Region 
  
Author 
  
Year 
  
Country 
Total  
serotypes  
isolated 
 Serotype Ia, Ib or III  Serotype Ia, Ib, II, III or V 
# % 95% CI I2 # % 95% CI I2 
 OVERALL, 17 studies 3391 2029 63.3 (57.7, 68.8) 90.4% 3105 91.5 (88.9, 94.0) 88.0% 
Africa (Kwatra et al., 2014) 2014 South Africa 152 115 75.7 (68.8, 82.5)   
  
88.1% 
144 94.7 (91.2, 98.3)   
  
46.2% 
Africa (Gray et al., 2011) 2012 Malawi 390 247 63.3 (58.6, 68.1) 380 97.4 (95.9, 99.0) 
 AFRICA, 2 studies  542 362 69.2 (57.2, 81.3) 524 96.6 (94.1, 99.0) 
Americas (Campbell et al., 2000) 2000 US 856 472 55.1 (51.8, 58.5) 
  
  
  
  
0.0% 
806 94.2 (92.6, 95.7) 
  
  
  
  
92.9% 
Americas (Davies et al., 2001) 2001 Canada 233 126 54.1 (47.7, 60.5) 201 86.3 (81.8, 90.7) 
Americas (Hickman et al., 1999) 1999 US 153 88 57.5 (49.7, 65.3) 146 95.4 (92.1, 98.7) 
Americas (Simoes et al., 2007) 2011 Brazil 47 23 48.9 (34.6, 63.2) 36 76.6 (64.5, 88.7) 
 AMERICAS, 4 studies  1289 709 55.0 (52.3, 57.7) 1189 89.6 (82.6, 96.6) 
Europe (Hakansson et al., 2008) 2008 Sweden 356 170 47.8 (42.6, 52.9) 
  
  
  
  
  
  
  
72.6% 
295 82.9 (79.0, 86.8) 
  
  
  
  
  
  
  
79.2% 
Europe (Tsolia et al., 2003) 2003 Greece 67 36 53.7 (41.8, 65.7) 60 89.6 (82.2, 96.9) 
Europe (Kunze et al., 2011) 2011 Germany 155 98 63.2 (55.6, 70.8) 140 90.3 (85.7, 95.0) 
Europe (Jones et al., 2006) 2005 UK 159 108 67.9 (60.7, 75.2) 153 96.2 (93.3, 99.2) 
Europe (Winifred and Hasker, 1972) 1998 Ireland 129 78 60.5 (52.0, 68.9) 116 89.9 (84.7, 95.1) 
Europe (L.S. Roccasalva, 2008) 2008 Italy 7 5 71.4 (38.0, 100.0) 7 93.8 (77.0, 100.0) 
Europe (Maria del Carmen Liebana-Martos, 2015) 2015 Spain 212 117 55.2 (48.5, 61.9) 175 82.5 (77.4, 87.7) 
 EUROPE, 7 studies  1085 612 58.3 (52.2, 64.5) 946 88.9 (84.7, 93.2) 
W Pacific (Lu et al., 2014) 2013 China 201 151 75.1 (69.1, 81.1) 
  
  
  
  
86.8% 
195 97.0 (94.7, 99.4) 
  
  
  
  
56.1% 
W Pacific (Uh et al., 1997) 1997 South Korea 193 132 68.4 (61.8, 75.0) 175 90.7 (86.6, 94.8) 
W Pacific (Grimwood et al., 2002) 2002 New Zealand 29 27 93.1 (83.9, 100.0) 27 93.1 (83.9, 100.0) 
W Pacific (Lee et al., 2010) 2010 South Korea 52 36 69.2 (56.7, 81.8) 49 94.2 (87.9, 100.0) 
 W PACIFIC, 4 studies  475 346 76.5 (65.4, 87.5) 446 94.2 (90.6, 97.7) 
1. For Jones et al. (ref 39), serotyping was performed on isolates that were positive between two different culture methods with overall GBS 
positive  only shown for CDC method
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3.5 Discussion     
    
      This systematic review and meta-analysis identified 78 studies reporting the 
prevalence of maternal recto-vaginal colonization with GBS in pregnancy.  The overall 
mean prevalence globally was 17.9% (95% CI: 16.2, 19.7) with the highest prevalence 
reported among African studies (22.4%, 95% CI 18.1, 26.7%). The mean prevalence 
reported from studies in the Americas, Europe and the Eastern Mediterranean regions was 
very similar and the lowest prevalence was reported from SouthEast Asia and Western 
Pacific studies.   
 
The criteria used to select studies for this meta-analysis, primarily based on CDC 
recommendations for GBS screening and identification using selective culture methods 
(Verani et al., 2010), aimed to focus on robust data while limiting between study 
heterogeneity due to methodological variation.  However, statistically significant 
heterogeneity was still observed across all studies and across studies within individual 
regions.  A sensitivity analysis considering studies with lower vaginal swab collection 
reflected the same pattern of regional heterogeneity.  Further stratification by variables 
poorly controlled for by inclusion criteria (e.g. timing of specimen collection and type of 
selective culture method) did not lead to a reduction in heterogeneity of prevalence 
estimates across studies. Additional variables, such as demographics, were difficult to 
explore as few studies reported these with sufficient detail.   The colonization prevalence 
range reported in the previous review was 8 to 18%, (Stoll and Schuchat, 1998) which was 
similar to the 11% to 22% observed in the current  meta-analysis. This, despite greater 
standardization in culture methods used in studies included in the current meta-analysis, 
and which was considered to be an important driver for the variability in colonization 
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between studies in the earlier meta-analysis. However, as these studies were not 
undertaken in the same places, a direct comparison of these estimates needs to be viewed 
with caution, considering even within country differences observed in colonization in the 
current meta-analysis. Nevertheless, these data suggest that other factors are likely 
contributing towards regional variations in maternal GBS colonization and consequently 
risk for early-onset disease in their newborns.  
 
Furthermore, the heterogeneity may have been driven by unmeasured variables: 
differences in study population selection may have led to higher or lower risk populations 
being represented which was difficult to assess across studies.  Several obstetric variables, 
such as parity and premature rupture of membranes, have been associated with higher risk 
of GBS colonization (Kwatra et al., 2014) ; but without access to individual level subject 
data this was difficult to explore.    
 
There have been reports of differential sensitivity of culture methods between 
populations.  For example, in South Africa one study reported that selective broth was not 
suitable for the recovery of GBS from rectal swabs due to masking of the GBS colonies by 
persistent microflora. In that population, direct plating on selective agar was reported as 
the most sensitive method of isolation (Kwatra et al., 2013). Studies from Brazil, Denmark 
and Spain have also reported increased GBS recovery using direct plating on selective 
media as compared to selective broth (Hansen and Sorensen, 2003, Gil et al., 1999, Chaves 
et al., 2010). Further optimization of microbiological techniques in different populations 
will contribute to a better understanding of potential ascertainment differences and their 
impact on GBS colonization prevalence estimates.  
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The pattern of GBS colonization prevalence, with the highest estimates from Africa 
and lowest from Southeast Asia and Western Pacific, matches the pattern of GBS neonatal 
disease incidence (Edmond et al., 2012). An algorithm to predict EOD incidence based on 
maternal colonization prevalence can be used to explore these patterns further: 50% of 
infants born to women colonized with GBS will themselves be colonized and 2% of those 
colonized infants will develop GBS EOD (Madhi et al., 2013, Schuchat et al., 2000). Data 
from South Africa and the United States, prior to the introduction of routine screening and 
IAP, where approximately 20% of pregnant women had GBS vaginal colonization, 
confirmed the expected 2 per 1000 live births EOD incidence (Madhi et al., 2013, Cutland 
et al., 2012, Cutland et al., 2009).  Based on this algorithm, and regional prevalence 
estimates from this meta-analysis, one would expect the incidence of EOD GBS in 
Southeast Asian and Western Pacific studies to be half that observed in African studies.  
However, the overall invasive disease incidence those regions is commonly reported to be 
much lower than the expected 1 per 1000 live births (Edmond et al., 2012). While 
differences in colonization prevalence may explain some of the regional differences in 
disease incidence, other factors including natural immunity, serotype distribution with 
varying virulence between serotypes and surveillance methods may contribute and need to 
be further investigated. 
 
This systematic review and meta-analysis aimed to identify studies from all 
geographic regions by searching five different literature databases and by allowing all 
language publications.  However, few studies from Africa, which has got high proportion 
of low income countries, were identified from initial searches and even fewer were eligible 
for inclusion. Thus, some publication is likely to remain.   
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To ensure quality and to guard against bias in the identified studies, this meta-
analysis had very stringent inclusion and exclusion criteria based upon rigorous 
methodology and aiming to standardise studies with respect to factors known to influence 
the estimate of colonisation prevalence (for example culture method for GBS isolation and 
identification). Nevertheless, this meta-analysis observed substantial variation in the 
prevalence of maternal colonization both within and across geographic regions.  The 
within region difference were not explained by differences in specimen collection and 
microbiological culture techniques; though additional analyses with subject level data are 
recommended to better understand the role of population selection, obstetric and 
sociodemographic risk factors.  A further limitation of the available data includes the 
limited serotype distribution by region, and we were only able to include 17 studies in this 
analysis with no studies from Southeast Asia and Eastern Mediterranean.  
 
Underlying population differences in natural immunity through transplacental 
acquisition of serotype-specific capsular antibody by the fetus remain an alternative 
explanation that should be explored in future studies to interrogate the disparity between 
exposure and incidence rates across geographic regions. A clearer understanding of the 
factors underlying this variation will be critical to the more efficient design of screening 
and prevention programs for maternal and infant GBS disease.    
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Chapter 4 Evaluation of Trans-Vag broth, CNA agar and CHROMagar 
StrepB for the detection of Group B Streptococcus in vaginal and rectal 
swabs from pregnant women in South Africa 
 
4.1 Abstract 
Background: Maternal vaginal colonization with Group B Streptococcus (GBS) is a major 
risk factor for invasive GBS infection in newborns. The CDC recommended method for 
detecting GBS colonization is to culture vaginal and rectal swabs in selective broth 
followed by subculture on blood agar or selective media. A high incidence of antimicrobial 
resistance in faecal microflora can compromise the recovery of GBS from selective broth.  
 
Methods: We compared CHROMagar StrepB (CA), Columbia colistin and nalidixic agar 
(CNA) and Trans-Vag selective broth enrichment for the isolation of GBS from 130 
vaginal and 130 rectal swabs from pregnant women. Swabs were randomized to be plated 
first on either CA or CNA, following which the swab was inoculated in Trans-Vag broth. 
 
Results: GBS was cultured from 37.7% of vaginal swabs and 33.1% of rectal swabs. There 
were no differences in the detection rate from vaginal swabs between CA (31.5%), CNA 
(26.2%) and selective broth (30.0%). The sensitivities in relation to a composite score were 
83.7%, 69.4% and 79.6% respectively. Recovery of GBS from rectal swabs was, however, 
significantly higher from CA (29.2%; p<0.0001) and CNA (23.8%; p=0.002) than from 
selective broth (9.2%). The sensitivities were 88.4%, 72.1% and 27.9%, respectively. The 
order of plating on solid medium was significant (p=0.003), with GBS detection rates of 
30.8% and 24.6% when plated first and second respectively.  
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Conclusion: These findings show that selective broth is not suitable for the recovery of 
GBS from rectal swabs in settings such as ours, due to masking of GBS colonies by other 
microflora.  
 
4.2 Introduction 
  Infection by Group B Streptococcus (GBS) is one of the most common infections 
in newborns (Van Dyke et al., 2009). Maternal colonization has been found to be major 
risk factor for invasive GBS disease within six days of birth. Approximately 10-40% of 
pregnant women are colonized with GBS either in the vagina or rectum or both (Picard and 
Bergeron, 2004). The rate of peripartum transmission of GBS to newborns of colonized 
women is approximately 50%, following which 1-3% of these newborns develop invasive 
GBS disease in the first week of life (Beal and Dancer, 2006, Heath and Feldman, 2005). 
The Centres for Disease Control and Prevention (CDC) has recommended that all pregnant 
women be screened for recto-vaginal carriage by GBS at 35-37 weeks gestation, to identify 
women who should receive intrapartum antimicrobial prophylaxis (IAP). The use of IAP 
targeted at GBS-colonized pregnant women has reduced the incidence of invasive GBS 
disease by 86-89% where successfully implemented (Brozanski et al., 2000, Lin et al., 
2001, Schrag et al., 2002). The sensitivity of screening methods for identification of 
maternal carriage of GBS depends on the timing of specimen collection, the source of the 
specimen and the culture technique used. Optimally, specimens should be collected as 
close to delivery as possible. The use of vaginal and rectal swab specimens has been shown 
to yield higher GBS culture-positivity rates compared to vaginal swabs alone or cervical 
specimens (Platt et al., 1995, Chan SHS, 2000, Quinlan et al., 2000). The current CDC 
recommendation for the isolation of GBS from vaginal and rectal or recto-vaginal swabs is 
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by growth in a selective broth medium (Todd-Hewitt broth with gentamicin and colistin or 
nalidixic acid), followed by subculture on blood agar or selective media (Verani et al., 
2010). The reported sensitivity of selective broth for culture of GBS is 82%-99% (Gupta 
and Briski, 2004, Craven et al., 2010, Jones et al., 2006, Busetti et al., 2007). There are 
however limitations to this approach. 
  
The procedure requires at least an additional 24 hours of culture time compared to 
direct plating on selective agar, and isolated GBS-like colonies require further 
identification with ancillary tests e.g. CAMP factor or B-antigen (Verani et al., 2010). 
Furthermore, identification of GBS-like colonies on blood agar requires laboratory 
expertise, particularly when they are mixed with other microflora (Poisson et al., 2010). 
Considering methods to decrease the GBS detection time, studies have shown that direct 
plating on colistin and nalidixic agar (CNA) is a low-cost alternative for GBS recovery, 
albeit with a lower sensitivity, ranging from 59%-83% (Bosch-Mestres et al., 2003, El Aila 
et al., 2010, Louie et al., 2010). In recent years, several commercial chromogenic media 
have been tested for their suitability for detecting GBS such as Granada medium, 
CHROMagar StrepB (CA) and Chrom ID Strepto B agar (El Aila et al., 2010, Poisson et 
al., 2011). 
  
CA is a commercially available selective chromogenic medium that inhibits most 
saprophytic bacteria and yeasts, and produces mauve-coloured GBS colonies in aerobic 
conditions irrespective of their haemolytic properties, allowing direct visual identification. 
The use of chromogenic media may improve the yield of GBS, while reducing labor costs 
and turnaround time. The clinical sensitivity of these media vary from study to study, with 
most studies reporting 93%-98% for CA (Charron, 2009, Poisson et al., 2010), 40%-91% 
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for Granada Medium (El Aila et al., 2010, Gupta and Briski, 2004, Overman et al., 2002) 
and 88%-95% for Chrom ID Strepto B agar (El Aila et al., 2010, Craven et al., 2010). The 
aim of this study was to evaluate direct plating on CA, CNA and selective broth 
enrichment for the isolation of GBS in swabs from pregnant women. 
  
4.3 Materials and Methods 
4.3.1 Study Design  
The study methods have been detailed in chapter 2. Briefly, the study was conducted at 
prenatal community clinics in Soweto, Johannesburg. Inclusion criteria were HIV-
uninfected pregnant women above 20 weeks of gestational age, able to provide informed 
consent for participation. Exclusion criteria were concurrent antibiotic use, acute illness, 
symptomatic vaginal discharge and a known or suspected condition in which clinical 
vaginal examinations were contraindicated. A convenience sampling of lower vaginal and 
rectal swabs was collected between Jan 2011 and April 2011, by trained study-nurses from 
130 pregnant women. Samples were collected with rayon tip swabs that were placed into 
5ml of Amies transport medium without charcoal. All samples were transported to the 
laboratory within 4 hours of collection, where they were processed within 2 hours. 
 
4.3.2 Randomization and processing of samples  
All vaginal and rectal swabs were randomized with a randomization log. The swab 
number was linked to three different random numbered labels, one for each culture 
medium type. Each sample was randomized to be plated first on either CNA or CA, 
following which the swab tip was inoculated into selective (Trans-Vag) broth (Todd 
Hewitt broth with gentamicin 8μg/ml and nalidixic acid 15μg/ml) and incubated for 24 
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hours before being plated on 5% sheep blood agar (SBA) (Figure 4.1). The randomization 
process ensured that the technician reading the plates and entering the data was blinded 
with respect to the participant, type of swab (rectal or vaginal), the order of plating, and the 
swab/plate pairs. The CNA and SBA plates were incubated at 37°C in 5% CO2 for 18-24 
hours and the CA plates were incubated at 37°C for 18-24 hours in aerobic conditions. If 
the expected colonies were not visible after 24 hours of incubation the plates were re-
incubated for an additional 24 hours and re-examined for growth. Up to four GBS-like 
colonies were isolated from the solid culture media on the basis of colony morphology and 
mauve colour on CA and colony morphology and beta-haemolysis on CNA and blood 
agar. Isolates were confirmed as GBS by testing for CAMP factor, inability to hydrolyze 
esculin, catalase negativity and group B antigen latex agglutination positivity. CA and 
CNA pre-poured plates were purchased from Media Mage, Johannesburg, South Africa.        
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Figure 4.1: Collection, randomization and laboratory handling of vaginal and rectal 
swabs for the isolation of Group B Streptococcus   
 
 
4.3.4 Statistical methods     
Descriptive statistics included statements of frequency with percentages, means ± 
standard deviations (SDs), and medians with interquartile ranges (IQRs). Sensitivities 
(detection rates) were calculated by comparing the proportion of positive samples for each 
medium in relation to a gold standard which was a composite positive for all test media. 
The McNemar test for correlated percentages and Chi-Square test with Yates' correction 
were used to compare the culture methods with p<0.05 considered statistically significant.  
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4.4 Results 
4.4.1 Study population 
The mean age of the women at swabbing was 25.7±5.9 years, and the mean 
gestational age was 23.8±3.2 weeks. The median parity and gravidity were 1 (IQR 0-1) and 
2 (IQR 1-2) respectively.  
 
4.4.2 CA and CNA vs Trans-Vag selective broth enrichment  
Overall, a total of 37.7% of vaginal swabs and 33.1% of rectal swabs tested 
positive for GBS (Table 4.1). There was no statistically significant difference in the 
detection rate for vaginal swabs between CA (31.5%), CNA (26.2%) and selective broth 
(30.0%). The sensitivities with respect to composite scores were 83.7%, 69.4% and 79.6% 
respectively. The recovery of GBS for rectal swabs was, however, significantly higher 
from CA (29.2%; p<0.0001) and CNA (23.8%; p=0.002) than with selective broth media 
(9.2%). The sensitivities were 88.4%, 72.1% and 27.9% respectively. Despite the higher 
sensitivity reported for CA over CNA for both vaginal and rectal swabs, these differences 
were not statistically significant (p>0.05). 
 
4.4.3 Accuracy 
The accuracy of a medium was defined as the percentage of isolated colonies that 
were identified as GBS by confirmatory testing, divided by the total number of GBS-like 
colonies that were isolated from a plate and subjected to confirmatory tests. The 
denominator includes both confirmed GBS (true positives) and colonies having similar 
colony appearances to GBS, but failed the confirmatory tests (false positives). For vaginal 
swabs, CA was the most accurate at discriminating between true positive and false positive 
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isolates (92.8%) followed by selective broth enrichment (90.6%) and CNA (84.3%). There 
were no significant differences in the accuracy of primary identification between CA and 
selective broth, and between CNA agar and selective broth. After direct plating colonies 
were, however, significantly more likely to be GBS following isolation with CA, than with 
CNA (p=0.026). 
  
The accuracy of GBS identification from rectal swabs was significantly better with 
CA (83.0%; p<0.0001) and CNA (77.3%; p=0.0004) than with selective broth enrichment 
(54.5%). CA was found to be more accurate than CNA, but these differences were not 
statistically significant (p=0.26). The number of GBS-like colonies that could be identified 
from cultured vaginal and rectal swabs was similar between CA (167 vaginal; 159 rectal) 
and CNA (153 vaginal; 150 rectal). Approximately half the number of GBS-like colonies 
could, however, be identified among the other flora following selective broth enrichment 
from rectal swabs (171 vaginal; 88 rectal). A higher percentage of false positive GBS 
isolates was reported from rectal swabs compared to vaginal swabs with CA (17.0% vs 
7.2%; p=0.01), CNA (22.7% vs 15.7%; p=0.16) and selective broth (45.5% vs 9.4%; 
p<0.0001) (Table 4.1)   
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Table 4. 1: Performance characteristics of CHROMagar Strep B, Colistin and 
Nalidixic agar and selective broth  
 
Medium 
 
 
                                                             Swab 
Vaginal, n=130 Rectal, n=130 
No. (%)  
positive 
for GBS 
 
Sensitivity
* 
(%) 
Accuracy† 
(%) 
No. (%)  
positive 
for GBS 
 
Sensitivity
* 
(%) 
Accuracy† 
(%) 
CA 41(31.5%) 83.7% 
 
155/167 
(92.8%) 
38(29.2%) 88.4% 
 
132/159 
(83.0%) 
CNA 34(26.2%) 69.4% 
 
129/153 
(84.3%) 
31(23.8%) 72.1% 
 
116/150 
(77.3%) 
Selective 
Broth 
39(30.0%) 79.6% 
 
155/171 
(90.6%) 
12(9.2%) 27.9% 
 
48/88 
(54.5%) 
Total GBS 
isolated 
49(37.7%)   43(33.1%)   
*Sensitivity was calculated in comparison to composite scores of all media. 
† Accuracy was calculated as the number of confirmed GBS colonies isolated / total number of GBS like 
colonies that were confirmed as either positive or negative for GBS. 
    
4.4.4 Impact of randomization and the order of plating  
The order in which swabs were plated onto the two selective media had a 
significant effect on the culture-positivity rate. Out of 260 swabs tested directly on CNA 
and CA, a total of 86 swabs (33.1%) were positive for GBS. Direct culture on CNA and 
CA yielded GBS from 80 (30.8%) swabs when plated first compared to 64 (24.6%) when 
plated second (p=0.003). GBS was isolated from both media in 58 (22.3%) of the swabs. 
The number of swabs from which GBS was isolated from a single medium was 22 (8.5%), 
and 6 (2.3%) from the first and second plating respectively. When CNA and CA were 
plated first, the sensitivities were 86.4% and 87.5% respectively, and when CNA and CA 
were plated second, the sensitivities were 57.4% and 82.2% respectively (Table 4.2).    
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Table 4. 2: Performance characteristics of CNA and CA with respect to the order of 
plating  
 
 
*After direct plating the swab was placed in Trans-Vag broth. 
    
 
 
 
Specimen 
 
                                                    Plated  first on CNA 
 CNA 
 
 
CA Trans-Vag*  
 
No. (%) 
positive 
for GBS 
 
Sensitivity 
(%) 
No. (%) 
positive 
for GBS 
 
Sensitivity 
(%) 
No. (%) 
positive 
for GBS 
 
Sensitivity 
(%) 
Total no. 
(%) 
positive 
GBS 
Vaginal, 
n=65 
20 
(30.8%) 
80% 21 
(32.3%) 
84% 23 
(35.4%) 
92% 25 
(38.5%) 
Rectal, 
n=65 
18 
(27.7%) 
94.7% 16 
(24.6%) 
84.2% 8 
(12.3%) 
42.1% 19 
(29.2%) 
Total, 
n=130 
38 
(29.2%) 
86.4% 37 
(28.5%) 
84.1% 31 
(23.8%) 
70.4% 44 
(33.8%) 
 
 
 
                                                   Plated first on CA 
 
CNA CA Trans-Vag*  
 
No. (%) 
positive 
for GBS 
Sensitivity 
(%) 
No. (%) 
positive 
for GBS 
 
Sensitivity 
(%) 
No. (%) 
positive 
for GBS 
 
Sensitivity 
(%) 
Total no. 
(%) 
positive 
GBS 
Vaginal, 
n=65 
14 
(21.5%) 
58.3% 20 
(30.8%) 
83.3% 16 
(24.6%) 
66.7% 24 
(36.9%) 
Rectal, 
n=65 
13 
(20%) 
54.2% 22 
(33.8%) 
91.7% 4 
(6.2%) 
16.7% 24 
(36.9%) 
Total, 
n=130 
27 
(20.8%) 
56.2% 42 
(32.3%) 
87.5% 20 
(15.4%) 
41.7% 48 
(36.9%) 
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4.5 Discussion  
Current CDC guidelines for prenatal GBS screening recommends the collection of 
a single recto-vaginal swab or separate vaginal and rectal swabs that are enriched overnight 
in Todd-Hewitt broth with antibiotics, followed by culture on blood agar or selective media 
(Verani et al., 2010). Whilst these guidelines have been developed within the context of 
high-income countries, there is very little data on the validity of this method in low to 
middle-income countries where there are differences in the distribution of saprophytic 
organisms and antimicrobial resistance is common (Nys et al., 2004, Newman and Seidu, 
2002, Shanahan et al., 1993, Pal, 2010). In this study we compared the recovery rate of 
GBS by standard methods with direct plating onto either CNA agar or CA from either 
vaginal or rectal swabs from pregnant South African women to determine whether these 
alternatives would provide better recovery rates. One of the main reasons for this 
comparison was the presence of vaginal flora that are resistant to antimicrobial agents, in 
particular Proteus sp., that occur in a small percentage of swabs and are able to persist in 
Trans-Vag broth and swarm the subcultured blood agar plate, rendering it unreadable (P.V. 
Adrian, personal communication). This necessitated the use of both Trans-Vag broth and 
direct plating on CNA in a previous study of vaginal swabs from South Africa (Cutland et 
al., 2009). 
 
In our study there were no statistically significant differences in the recovery of 
GBS from vaginal swabs between the different media, suggesting that any of these three 
options are valid in our clinical setting, and can be decided upon, based on cost, 
availability, and desired turnaround time. In contrast, the recovery of GBS from rectal 
swabs following selective broth enrichment was inferior to either of the direct plating 
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methods. The main reason for the poor recovery of GBS, was survival and overgrowth of 
non-GBS organisms in the Trans-Vag broth, which masked the presence of GBS on the 
subculture plates. The results of our study differ from several previously published reports, 
in which it had been shown that the selective broth method is more sensitive than direct 
plating on selective media for recovering GBS from rectal or recto-vaginal swabs (Jones et 
al., 2006, Gupta and Briski, 2004, Craven et al., 2010, Busetti et al., 2007). While these 
results may be valid in settings such as those where the studies were conducted, other 
studies from  Brazil, Denmark and Spain have demonstrated better recoveries of GBS from 
rectal swabs with a solid selective medium compared to selective broth (Hansen and 
Sorensen, 2003, Chaves et al., 2010, Gil et al., 1999). The use of pigmented enrichment 
broth such as Strep B carrot broth has been shown to increase the sensitivity of GBS 
detection by culture over LIM broth (Church et al., 2008), and when used as an enrichment 
step prior to PCR screening (Munson et al., 2010), however, GBS growth and pigment 
development can still be suppressed by the overgrowth of fecal bacteria and mask the 
presence of GBS on culture (Munson et al., 2010). Since the mechanism behind the poor 
recovery of GBS from rectal swabs is related to persistence and overgrowth of resistant 
faecal bacteria (Gil et al., 1999), it is likely that the collection of a single recto-vaginal 
swab or the co-processing of vaginal and rectal swabs may be severely compromised by 
the use of selective broth in our setting.  
 
Overall, CA produced the highest recovery of GBS from both vaginal and rectal 
swabs. One advantage of the chromogenic medium was that it was significantly easier to 
discriminate between GBS and Group D Streptococcus (GDS) in co-colonised samples due 
to differences in the colour development of the colonies. GBS turns mauve whereas GDS 
turns blue. This is particularly important in comparison with samples plated on blood agar, 
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where the GBS colonies are in the minority, and single GBS colonies can be overlooked 
amid large numbers of morphologically similar GDS. Despite CA being relatively more 
expensive than CNA or a selective broth blood agar combination, CA offers cost savings in 
terms of the reduced processing time, and the ease with which GBS colonies can be 
identified on the plates. Moreover, due to the increased accuracy of colony identification 
through pigment formation, the number of confirmatory tests required is reduced, as the 
need for additional tests to rule out the morphologically similar colonies of Group D 
streptococci is eliminated. While the calculated values of accuracy will vary with the skill 
and experience of the user, CA offers an easier learning curve compared to a blood-based 
isolation medium. In comparing the two selective solid agars, CA had a higher sensitivity 
and accuracy than CNA for both vaginal and rectal swabs, although these values were not 
statistically significant, most likely due to a limited sample size. 
 
From a review of the literature, no study in a clinical setting has considered the 
order of plating when comparing and reporting the sensitivity of culture media to isolate 
GBS. In this study, the order of plating had a significant effect on the recovery of GBS, 
and suggests that future studies where solid media are compared should follow randomised 
protocols to prevent detection bias based on plating order. Possible reasons for the lower 
recovery of GBS from swabs plated for a second time include removal of the organisms 
from the surface of the swab in the first plating, or blockage of the swab surface by sterile 
agar from the previous plating, preventing transfer of organisms. The sensitivity of direct 
plating on CNA when plated first in this study was similar to that described by Louie et al 
(Louie et al., 2010) in which swabs were inoculated first on CNA.  
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In conclusion, selective broth enrichment showed significantly lower sensitivity for 
the recovery of GBS from rectal swabs. This method is not suitable for recovery of GBS 
from rectal swabs or recto-vaginal swabs in regions with a high prevalence of 
antimicrobial resistant flora. The recovery of GBS from vaginal swabs plated on CA 
appears equal in sensitivity to selective broth, and offers a less time-consuming and less 
labour-intensive process.  
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Chapter 5 Serotype-Specific Acquisition and Loss of Group B 
Streptococcus Recto-vaginal Colonization in Late Pregnancy 
 
5.1 Abstract 
Background: Maternal recto-vaginal colonization with Group B Streptococcus (GBS) and 
consequent vertical transmission to the newborn predisposes neonates to early-onset 
invasive GBS disease. This study aimed to determine the acquisition and loss of serotype-
specific recto-vaginal GBS colonization from 20-37+ weeks of gestational age. 
Methods: Vaginal and rectal swabs were collected from HIV-uninfected women at 20-25 
weeks of gestation age and at 5-6 weekly intervals thereafter. Swabs were cultured for 
GBS and isolates were serotyped by latex agglutination. Serologically non-typable 
isolates and pilus islands were characterized by PCR. 
Results: The prevalence of recto-vaginal GBS colonization was 33.0%, 32.7%, 28.7% 
and 28.4% at 20-25 weeks, 26-30 weeks, 31-35 weeks and 37 + weeks of gestational age, 
respectively. The most common identified serotypes were Ia (39.2%), III (32.8%) and V 
(12.4%). Of 507 participants who completed all four study visits, the cumulative overall 
recto-vaginal acquisition rate of new serotypes during the study was 27.9%, including 
11.2%, 8.2% and 4.3% for serotypes Ia, III and V, respectively. Comparing the common 
colonizing serotypes, serotype III was more likely to be associated with persistent 
colonization throughout the study (29%) than Ia (18%; p=0.045) or V (6%; p=0.002). The 
median duration of recto-vaginal GBS colonization for serotype III was 6.35 weeks, which 
was longer than other serotypes. Pilus island proteins were detected in all GBS isolates and 
their subtype distribution was associated with specific serotypes. 
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Conclusion: South African pregnant women have a high prevalence of GBS recto-vaginal 
colonization from 20 weeks of gestational age onwards, including high GBS acquisition 
rates in the last pregnancy-trimesters. There are differences in specific-serotype 
colonization patterns during pregnancy.  
 
5.2 Introduction 
 
Maternal vaginal colonization with Group B Streptococcus (GBS) is the major risk 
factor for early onset invasive GBS disease (EOD) in newborns (Verani et al., 2010, Chan 
SHS, 2000). Screening of pregnant women for GBS colonization during the third trimester, 
coupled with targeted intrapartum antibiotic prophylaxis (IAP) of colonized women during 
labor, has reduced the incidence of invasive GBS disease in industrialized countries(Schrag 
and Schuchat, 2004). 
 
An alternate preventive strategy against EOD is vaccination of pregnant women, 
which could enhance transplacental transfer of GBS antibody to the fetus. Studies have 
identified an association between high maternal serotype-specific capsular polysaccharide 
(CPS) antibody concentrations with reduced risk of recto-vaginal colonization and reduced 
risk of newborns developing EOD (Baker and Kasper, 1976, Baker et al., 1981). Since 
GBS CPS-protein conjugate vaccines are serotype-specific, it is important to characterize 
the serotype distribution of GBS in different regions of the world as well as understand the 
changes which occur in GBS colonization during pregnancy (Ippolito et al., 2010). Other 
potential vaccine candidates include GBS surface protein antigens such as pilus island (PI) 
proteins that are present in all GBS isolates(Madzivhandila et al., 2013). Although it has 
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been shown that maternal GBS colonization during pregnancy may fluctuate (Hansen et 
al., 2004, Goodman et al., 1997, Mavenyengwa et al., 2010), there are limited longitudinal 
studies on the rate of serotype-specific GBS acquisition and duration of colonization 
during pregnancy. 
 
We aimed to determine the acquisition and loss of GBS recto-vaginal colonization, 
including serotype-specific changes, among South African pregnant women from 20 weeks 
to at least 37 weeks of gestational age. We also studied the PI distribution of recto-vaginal 
colonizing GBS isolates and their association with capsular serotype. 
 
5.3 Material and Methods    
The detailed methods of the study have been described in Chapter 2. Briefly, 
pregnant HIV-uninfected women aged 18-45 years and who were 20-25 weeks gestational 
age were enrolled at antenatal community clinics in Soweto, Johannesburg from August 
2010 to August 2011. Exclusion criteria included antibiotic treatment in the previous two 
weeks, any acute illness, symptomatic vaginal discharge and a known or suspected 
condition in which clinical vaginal examination was contraindicated. Study procedures 
included lower vaginal and rectal swabs collection for GBS culture starting at 20-25 weeks 
(visit-1), followed by three subsequent visits (visits 2-4) at 5-6 weekly intervals, up until 
37-40 weeks (visit-4) of gestational age. For GBS isolation, swabs were inoculated onto 
CA. Serotyping was performed by the latex agglutination method as described (Afshar et 
al., 2011). Isolates that tested negative by latex agglutination for all serotypes were further 
typed by a PCR method using primer sequences described by Poyart et al (Poyart et al., 
2007). Pilus island proteins of all GBS isolates were detected by PCR for PI-1, PI-2a and 
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PI-2b, with primers that target the genomic regions coding for the ancillary protein (AP)-1 
of each PI as described previously (Madzivhandila et al., 2013). 
 
5.3.1 Statistical analysis    
 
Data were analyzed using SAS version 9.2 software (SAS Institute, Inc., NC, 
USA). A visit sample pair of vaginal and rectal swabs was considered negative if no GBS 
growth was evident on either swab, and positive if GBS was grown from either swab. The 
pregnant women were grouped into transient, intermittent and persistent carriers according 
to the presence of GBS colonization and to individual serotypes at the four sampling time 
points. Transient carriers were defined as women who were colonized at only one of the 
four visits, intermittent carriers as those who were colonized at two or three of the visits 
and persistent carriers as those colonized at all four study visits. 
 
Descriptive statistics included the prevalence of colonization at individual time 
points and changes of recto-vaginal colonization status. Analysis of the changes in recto-
vaginal colonization over time was restricted to the 507 participants who completed all 
four study visits. New acquisition of GBS was defined as positive culture of a new 
serotype which was not previously present. The new acquisition rate was defined as the 
number of new serotype acquisitions divided by the number of participants who were at a 
risk of acquiring the new serotype. Thus, women who were already previously colonized 
by a particular serotype were excluded subsequently from the denominator for estimating 
acquisition rate for the homotypic serotype. The rate of new acquisitions by all GBS 
serotypes were calculated from the sum of acquisition rates for the individual serotypes, 
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and by using the above methods for GBS acquisition rates in a serotype independent 
manner. Clearance of colonization was defined as a negative GBS culture for a specific 
serotype following a positive sample at the previous visit for the homotypic serotype. The 
rate of colonization clearance was defined as the number of GBS-negative participants at 
the analyzed time point divided by the number of participants at the previous visit who 
were positive for that serotype, and was also calculated in a serotype independent manner. 
 
Survival analysis methods were used to estimate the duration of colonization of 
specific serotypes. A colonizing event was defined as the period of time between 
acquisition and clearance of a GBS serotype. Date of acquisition was calculated as the 
midpoint between the last visit without serotype-specific colonization and the first visit at 
which a positive sample was obtained for the homotypic serotype, while date for 
termination of serotype-specific colonization was calculated as the midpoint between the 
last visit with colonization and the subsequent negative visit for that serotype. In this 
analysis, if colonization occurred at the first visit, this was taken as the start of 
colonization, and if colonization occurred at the last visit, a right censoring approach was 
applied. We used the Kaplan-Meier method to estimate the duration of GBS colonization. 
The log-rank test was used to examine differences in duration of carriage between 
serotypes. 
Positive predictive value (PPV) and negative predictive value (NPV) were calculated for 
the culture results at different sampling points with the 37-40 week visit as the reference 
standard. For participants who were colonized with same serotype on multiple visits, only 
one serotype specific isolate was used to study PI association with capsular serotype. The 
chi-square test was used to compare proportions. Logistic regression analysis was used to 
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determine the association between GBS colonization and demographic characteristics at 
enrolment. A p-value of < 0.05 was considered significant.  
 
5.4 Results   
5.4.1 Demographic characteristics 
Of the 661 enrolled participants, 621 (93.9%), 595 (90.0%) and 521(78.8%) 
completed visits 2, 3 and 4, respectively. Five-hundred and seven (76.7%) women 
completed all four study visits. A detailed trial profile is indicated in Figure 5.1. The main 
reason for women not attending all four visits was birth of the baby (13%; 86/661) before 
the final visit. The demographic characteristics are displayed in Table 5.1. The mean age of 
the participants at enrolment was 25.9 (standard deviation; S.D±5.6) years. Only 5(0.76%) 
pregnant women have taken antibiotic treatment during the study. 
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     Visit-1, n=661 
81excluded  
    67 delivered baby 
    6 relocated to different province 
    4 lost to follow up 
    4 had a still born child 
    
 
32 excluded  
    5 delivered premature baby 
    12 relocated to different province 
    3 withdraw consent 
    5 lost to follow up 
    7 had a miscarriage 
 
 
 
27 excluded  
    14 delivered premature baby 
    6 relocated to different province 
    1withdraw consent 
    4 lost to follow up 
    2 had a still born child 
 
Visit-2, n=621 
8 missed Visit-2 
 
Visit-3, n=595 
6 missed Visit-3 and  
7 joined from Visit-1 
 
Visit-4, n=521 
1 joined from Visit-1 and 
6 joined from Visit-3 
 
 
 
507 Participants 
completed all 4 visits 
2913 women consented on 
arrival at antenatal clinics 
2252 did not meet the inclusion 
criteria of gestation age, HIV status 
and antibiotic use 
  
Figure 5.1: Trial Profile
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Table 5. 1: Demographics of the study population at time of enrolment (n=661) 
Demographic characteristic Overall 
(n=661) 
GBS 
Colonized 
GBS 
Uncolonized 
Age(years) <20 92 (13.9%)a 27 (29.3%)b 65 (70.7%)c 
Mean 
age:25.9(S.D±5.6) 
20-24 234 (35.4%) 78 (33.3%) 156 (66.6%) 
  25-28 161 (24.4%) 53 (32.9%) 108 (67.1%) 
29-32 95 (14.4%) 29 (30.5%) 66 (69.5%) 
33-35 40 (6.1%) 20 (50.0%) 20 (50.0%) 
36+ 39 (5.9%) 11 (28.2%) 28 (71.8%) 
Parity  0 338 (51.1%) 97 (28.7%) 241 (71.3%) 
Median parity:0 
(range; 0-5) 
1-2 304 (46.0%) 113 (37.2%) 191 (62.8%) 
  3-5 19 (2.9%) 8 (42.1%) 11 (57.9%) 
Gravidity  1 286 (43.3%) 80 (28.0%) 206 (72.0%) 
Median gravidity:2 
(range; 1-8) 
2 221(33.4%) 80 (36.2%) 141 (63.8%) 
  3 106 (16.0%) 38 (35.8%) 68 (64.2%) 
≥ 4 48 (7.3%) 20 (41.7%) 28(58.3%) 
Previous  Abortion 
(spontaneous) 
0 553 (83.7%) 176 (31.8%) 377 (68.2%) 
Median abortion:0 
(range; 0-3) 
1 88 (13.3%) 36 (40.9%) 52 (59.1%) 
  
2 19 (2.9%) 6 (31.6%) 13 (68.4%) 
3 1 (0.2%) 0 (0.0%) 1 (100%) 
Stillborn  0 651 (98.5%) 214 (32.9%) 437 (67.1%) 
Median stillbirths:0 
(range; 0-1) 
1 10 (1.5%) 4 (40.0%) 6 (60.0%) 
a Data are no (%) of total participants, b,c Data are row %  
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5.4.2 Prevalence of GBS colonization 
The overall prevalence of recto-vaginal GBS colonization was 33.0% (218), 32.7% 
(203), 28.7% (171) and 28.4% (148) at 20-25 weeks, 26-30 weeks, 31-35 weeks and 37+ 
weeks of gestational age, respectively. The lower prevalence of colonization associated 
with 31-35 weeks and 37+ weeks compared to 20-25 weeks and 26-30 weeks was 
specifically associated with a decrease in prevalence of vaginal colonization, table 5.2 
(23.3% to 19.0%). In the 86 women who gave birth before the final visit, vaginal GBS 
colonization was detected in 17(19.8%) at the last attended visit compared to 99/521 
(19.0%) who gave birth after visit-4 (p=0.867). The inclusion of rectal swab GBS-culture 
increased the overall detection of GBS colonization by approximately 10% across the four 
study time-points (p<0.0001) and the prevalence of rectal colonization remained similar at 
each study time-point.  
 Table 5.2: Prevalence of Group B Streptococcus colonization during the study visits 
 
 Site of 
colonization 
Visit-1 Visit-2 Visit-3 Visit-4 
(20-25 weeks) (26-30 weeks) (31-35 weeks) 37+ weeks) 
n=661 n=621 n=595 n=521 
Mean gestation 
age: 22.7 weeks 
Mean gestation 
age: 27.9 weeks 
Mean gestation 
age: 32.5 weeks 
Mean gestation 
age: 37.5 weeks 
Vaginal only 
(%; 95% CI) 
62 65 47 31 
(9.4%; 7.2-11.6) (10.5%; 8.1-12.9) (7.9%; 5.7-10.1) (5.9%; 3.9-7.9) 
Rectal only 
(%; 95% CI) 
64 62 56 49 
(9.7%; 7.5-12.0) (10%; 7.6-12.4) (9.4%; 7.1-12.0) (9.4%; 6.9-11.9) 
Both vaginal 
and rectal 
(%; 95% CI) 
92 76 68 68 
(13.9%; 11.3-
16.5) 
(12.2%; 9.63-
14.8) 
(11.4%; 8.9-14.0) (13.1%; 10.2-
16.0) 
Vaginal 
and/or rectal  
(%; 95% CI) 
218 203 171 148 
(33.0%; 29.4-
36.6) 
(32.7%; 29.0-
36.4) 
(28.7%; 25.1-
32.3) 
(28.4%; 24.5-
32.3) 
CI- Confidence interval, n=number of participants 
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Of several demographic characteristics evaluated at enrolment independently by 
univariate analysis, parity (OR: 1.22; 95% CI: 1.02-1.47; p=0.030) and gravidity (OR: 
1.17; 95% CI: 1.01-1.36; p=0.046), were positively associated with GBS recto-vaginal 
colonization, with the highest colonization prevalence among women with parity ≥3 
(42.1%) and gravidity of ≥4 (41.7%), (Table 5.3). In a multivariate analysis, none of the 
demographic characteristics were associated with GBS recto-vaginal colonization, Table 
5.3. In a serotype-specific univariate analysis at enrolment, multiparity was associated with 
a higher prevalence of serotype III colonization (OR: 1.37; 95% CI: 1.07-1.76; p=0.012), 
gravidity also showed possible association with serotype III colonization (p=0.068). In the 
multivariate analysis, higher parity was found to be positively associated with serotype III 
colonization (Adjusted OR: 6.69; 95% CI: 1.47-30.4; P=0.014).  Gravidity (p=0.053) and 
abortions (p=0.057) also showed a possible association with serotype III colonization at 
enrolment, Table 5.3. None of the demographic characteristics were found to be associated 
with serotype Ia colonization in the univariate or multivariate analysis. There were no 
identifiable factors associated with a higher prevalence of colonization with GBS at visit-4 
alone. 
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Table 5.3: Univariate and multivariate association between serotype-specific colonization at enrolment and observed demographic 
characteristics 
 
Characteristic Overall GBS colonization at enrolment Serotype III colonization at enrolment Serotype Ia colonization at enrolment 
Univariate Multivariate Univariate Multivariate Univariate Multivariate 
OR (95% CI), p AOR (95% CI), p OR (95% CI), p AOR (95% CI), p OR (95% CI), p AOR (95% CI), p 
Age 1.01(0.98-1.04), 0.98 (0.95-1.02), 1.01 (0.97-1.06), 0.98 (0.92-1.03), 1.00 (0.96-1.04), 0.99 (0.94-1.04), 
0.408 0.536 0.527 0.45 0.96 0.656 
Parity 1.22 (1.02-1.47), 1.99 (0.83-4.79), 1.37 (1.07-1.76), 6.69 (1.47-30.4), 1.05 (0.82-1.34), 0.71(0.27-1.90), 
0.03 0.121 0.012 0.014 0.69 0.499 
Gravidity 1.17 (1.01-1.36), 0.63 (0.27-1.50), 1.22 (0.99-1.51), 0.22 (0.05-1.02), 1.11 (0.91-1.35), 1.48 (0.57-3.81), 
0.046 0.296 0.068 0.053 0.317 0.422 
Abortion 1.18 (0.84-1.64), 1.77 (0.73-4.30), 1.10 (0.66-1.81), 4.14 (0.96-18.0), 1.25 (0.82-1.91), 0.86 (0.31-2.38), 
0.341 0.207 0.721 0.057 0.298 0.774 
Stillborn 1.36 (0.38-4.88), 1.25 (0.32-4.94), 0.94 (0.12-7.51), 0.76 (0.08-7.30), 2.60 (0.66-10.3), 2.14 (0.49- 9.29), 
0.635 0.741 0.951 0.813 0.171 0.309 
OR: odds ratio; AOR: adjusted OR; CI: confidence interval 
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      5.4.3 Serotype and pilus island distribution 
 The proportional representation of serotypes remained consistent at each of the 
consecutive sampling time-points. Of women colonized, the proportional representation of 
the major serotypes were 36.2% to 41.4% for Ia, 31.3% to 34.9% for III, 10.3% to 15.6% 
for V, 7.2% to 7.5% for II, 3.5%  to 4.6% for Ib, 2.0% to 4.0% for IV and 0.0% to 3.3% for 
IX (Table 5.4). The concordance of serotypes for GBS cultured concurrently from vaginal 
and rectal swabs was 91.3%, 89.5%, 94.1% and 94.1% for the four consecutive visits, 
respectively. Only 1.6% of GBS isolates were serologically non-typeable by latex 
agglutination and were serotyped by PCR. 
 
All GBS isolates harbored one or more PIs, either PI-2a on its own or with a 
combination of PI-2a or PI-2b in combination with PI-1.The most common PI arrangement 
was PI-2a on its own, which occurred in 103/227 (45.4%), 92/211 (43.6%), 79/175 
(45.1%) and 63/152 (41.5%) of isolates at visits 1-4, respectively, followed by PI 
combination PI-2b and PI-1, which occurred in 75/227(33.0%), 69/211(32.7%), 68/175 
(38.9%) and 58/152 (38.2%) of isolates at visits 1-4, respectively. The least common PI 
arrangement was a combination of PI-2a and PI-1 which occurred in 49/227 (21.6%), 
50/211 (23.7%), 29/175 (16.0%) and 31/152 (20.4%) of isolates at visits 1-4, respectively. 
There were no significant changes in the prevalence of PI distribution with respect to 
different visits, with the exception of PI-2a which was less common at visit-4 (18.0%, 
94/521) compared to visit-1 (23.0%, 152/661; p=0.007), and which was attributable to a 
lower prevalence of serotype Ia at visit-4 (10.6%, 55/521) compared to  visit-1 (14.2%, 
94/661). 
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There was a strong correlation between the presence of particular combinations of 
PI and the serotype; Figure 5.2. Most serotype Ia isolates were associated with PI-2a 
(94.9%; 148/156), whereas the majority of serotype III isolates were associated with the 
combination of PI-1 and PI-2b (88.2%; 105/119). The association between PIs and 
serotype V was more variable, with a PI-1+PI-2a combination occurring in 64.7% (33/51) 
and PI-2a alone occurring in 29.4% (15/51) of isolates.  
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Figure 5.2: Association of pilus island proteins and serotypes among Group B 
Streptococcus isolates 
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Table 5.4: Distribution of serotype associated with GBS recto-vaginal colonization 
 
Serotype Site Number of isolates per visit a 
Visit-1 Visit-2 Visit-3 Visit-4 
n=227 n=211 n=175 n=152 
Ia Vaginal only 36 (15.9%) 31 (14.7%) 29 (16.6%) 19 (12.5%) 
Rectal only 29 (12.8%) 26 (12.3%) 18 (10.3%) 18 (11.8%) 
Rectal and vaginal 29 (12.8%) 23 (10.9%) 24 (13.7%) 18 (11.8%) 
Overall 94 (41.4%) 80 (37.9%) 71 (40.6%) 55 (36.2%) 
Ib Vaginal only 1 (0.4%) 0 (0.0%) 2 (1.1%) 1 (0.7%) 
Rectal only 4 (1.8%) 4 (1.9%) 0 (0.0%) 3 (2.0%) 
Rectal and vaginal 3 (1.3%) 2 (0.9%) 2 (1.1%) 3 (2.0%) 
Overall 8 (3.5%) 6 (2.8%) 4 (2.3%) 7 (4.6%) 
II Vaginal only 6 (2.6%) 5 (2.4%) 3 (1.7%) 1 (0.7%) 
Rectal only 4 (1.8%) 4 (1.9%) 6 (3.4%) 6 (3.9%) 
Rectal and vaginal 7 (3.1%) 4 (1.9%) 4 (2.3%) 4 (2.6%) 
Overall 17 (7.5%) 13 (6.2%) 13 (7.4%) 11 (7.2%) 
III Vaginal only 17 (7.5%) 19 (9.0%) 12 (6.9%) 11 (7.2%) 
Rectal only 21 (9.3%) 24 (11.4%) 24 (13.7%) 17 (11.2%) 
Rectal and vaginal 33 (14.5%) 23 (10.9%) 25 (14.3%) 25 (16.4%) 
Overall 71 (31.3%) 66 (31.3%) 61 (34.9%) 53 (34.9%) 
IV Vaginal only 3 (1.3%) 2 (0.9%) 1 (0.6%) 0 (0.0%) 
Rectal only 3 (1.3%) 2 (0.9%) 3 (1.7%) 2 (1.3%) 
Rectal and vaginal 3 (1.3%) 3 (1.4%) 1 (0.6%) 1 (0.7%) 
Overall 9 (4.0%) 7 (3.3%) 5 (2.9%) 3 (2.0%) 
V Vaginal only 7 (3.1%) 11 (5.2%) 3 (1.7%) 4 (2.6%) 
Rectal only 10 (4.4%) 9 (4.3%) 7 (4.0%) 5 (3.3%) 
Rectal and vaginal 9 (4.0%) 13 (6.2%) 8 (4.6%) 9 (5.9%) 
Overall 26 (11.5%) 33 (15.6%) 18 (10.3%) 18 (11.8%) 
IX Vaginal only 1 (0.4%) 4 (1.9%) 0 (0.0%) 0 (0.0%) 
Rectal only 1 (0.4%) 1 (0.5%) 1 (0.6%) 0 (0.0%) 
Rectal and vaginal 0 (0.0%) 1 (0.5%) 2 (1.1%) 5 (3.3%) 
Overall 2 (0.9%) 6 (2.8%) 3 (1.7%) 5 (3.3%) 
aPercent serotype distribution was calculated using the total number of isolates at each visit as the 
denominator 
 
5.4.4 Changes in GBS colonization overtime 
Five hundred and seven participants who completed all four study visits were 
similar in their demographic characteristics compared to the 154 participants not included 
in this analysis. In the analyzed subset, the prevalence of recto-vaginal GBS colonization 
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was 32.1% (163), 30.4% (154) , 29.0% (147) and 27.8% (141) at 20-25 weeks, 26-30 
weeks, 31-35 weeks and 37 + weeks of gestational age, respectively. Two hundred and 
fifty-two (49.7%) women were colonized at least once during the study period, of whom 
70 (27.8%) were persistent carriers, 83 (32.9%) transient carriers and 99 (39.3%) were 
intermittently colonized for any serotype (Table 5.5) 
 
The cumulative serotype-specific prevalence across the study period was 23.7% 
(120/507) for Ia, 18.3% (93/507) for III, 7.1% (36/507) for V, 4.3% (22/507) for II and 
2.8% (14/507) for Ib. All GBS serotypes were variable in their colonization patterns. 
Comparing the three most common colonizing serotype carriers, 29% (27/93) of serotype 
III carriers were associated with persistent colonization compared to serotype Ia (18%; 
21/120; p=0.045) or V (6%; 2/36; p=0.002). Serotype V was the most dynamic, with 
94.4% (34/36) of colonized women either being transient or intermittent carriers compared 
to 82.5% (99/120; p=0.106) for Ia and 71.0% (66/93; p=0.004) for III. Only one serotype 
was detected in 83.3% (210/252) of GBS carriers during the study period, with 85.7% 
(60/70) of women persistently colonized being associated with the same serotype. 
      
Of the 16.7% (42/252) women in whom multiple serotypes were detected over the 
study period, two serotypes were detected in 9.5% (24/252) and three serotypes in 7.1% 
(18/252) participants. Among women in whom multiple serotypes were detected, a new 
serotype was observed at the immediate next visit in 85.7% (36/42) of cases, while a new 
serotype was detected following a period of no colonization by the preceding serotype in 
six women. 
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Table 5.5: Patterns of GBS recto-vaginal colonization overall, and by individual serotypes (n=507) 
 
Code* 
Any 
Serotype 
Serotypes 
Ia Ib II III IV V IX 
-,-,-,- 255(50.3%) 387(76.3%) 493(97.2%) 485(95.7%) 414(81.7%) 500(98.6%) 471(92.9%) 500(98.6%) 
-,+,-,- 14(2.8%) 10(2.0%) 0(0.0%) 2(0.4%0 7(1.4%) 0(0.0%) 5(1.0%) 3(0.6%) 
-,-,+,- 13(2.6%) 11(2.2%) 1(0.2%) 1(0.2%) 9(1.8%) 0(0.0%) 2(0.4%) 0(0.0%) 
-,-,-,+ 27(5.3%) 12(2.4%) 3(0.6%) 2(0.4%) 10(2%) 0(0.0%) 7(1.4%) 1(0.2%) 
-,+,+,- 8(1.6%) 4(0.8%) 0(0.0%) 0(0.0%) 2(0.4%) 1(0.2%) 0(0.0%) 0(0.0%) 
-,+,+,+ 14(2.8%) 6(1.2%) 2(0.4%) 2(0.4%) 1(0.2%) 0(0.0%) 5(1.0%) 1(0.2%) 
-,-,+,+ 9(1.8%) 4(0.8%) 0(0.0%) 2(0.4%) 6(1.2%) 0(0.0%) 1(0.2%) 0(0.0%) 
-,+,-,+ 4(0.8%) 2(0.4%) 0(0.0%) 0(0.0%) 2(0.4%) 0(0.0%) 1(0.2%) 0(0.0%) 
+,-,-,- 29(5.7%) 23(4.5%) 4(0.8%) 3(0.6%) 13(2.6%) 2(0.4%) 4(0.8%) 0(0.0%) 
+,+,-,- 20(3.9%) 10(2.0%) 2(0.4%) 3(0.6%) 4(0.8%) 1(0.2%) 3(0.6%) 0(0.0%) 
+,+,+,- 17(3.4%) 7(1.4%) 0(0.0%) 0(0.0%) 6(1.2%) 0(0.0%) 3(0.6%) 0(0.0%) 
+,+,+,+ 70(13.8%) 21(4.1%) 1(0.2%) 4(0.8%) 27(5.3%) 3(0.6%) 2(0.4%) 2(0.4%) 
+,-,+,- 10(2.0%) 5(1.0%) 0(0.0%) 2(0.4%) 0(0.0%) 0(0.0%) 1(0.2%) 0(0.0%) 
+,+,-,+ 7(1.4%) 1(0.2%) 1(0.2%) 0(0.0%) 2(0.4%) 0(0.0%) 2(0.4%) 0(0.0%) 
+,-,-,+ 4(0.8%) 2(0.4%0 0(0.0%) 0(0.0%) 2(0.4%) 0(0.0%) 0(0.0%) 0(0.0%) 
+,-,+,+ 6(1.2%) 2(0.4%) 0(0.0%) 1(0.2%) 2(0.4%) 0(0.0%) 0(0.0%) 0(0.0%) 
Code*: visit-1,visit-2,visit-3,visit-4 
Groups: Noncarrier:  (-,-,-,-), 
              Transient carrier: (-,+,-,-) (-,-,+,-) (-,-,-,+) (+,-,-,-) 
              Intermitent carrier: (-,+,+,-) (-,+,+,+) (-,-,+,+) (-,+,-,+) (+,+,-,-) (+,+,+,-) (+,-,+,-) (+,+,-,+) (+,-,-,+) (+,-,+,+) 
              Persistent carrier: (+,+,+,+) 
"-" Negative for GBS," +"Positive for GBS
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5.4.5 New acquisition and clearance of colonization 
Three hundred and forty-four participants who completed all four study visits were not 
colonized at visit-1, of whom 89 (25.9%) became colonized at one of the subsequent three 
visits. When including new serotype acquisition in those previously colonized by a 
heterotypic serotype (n=39), the cumulative overall recto-vaginal acquisition rate of new 
serotypes during the study, calculated from the sum of acquisition rates for the individual 
serotypes was 27.9%. The number of new acquisitions was highest for serotypes Ia 
(11.2%, 49/436), III (8.2%, 37/451) and V (4.3%, 21/492); Table 5.5. The mean new 
acquisition rate of GBS was 11.4% (S.D ±0.5%) at 5-6 week visit intervals, including 
11.6% between visit-1 and visit-2, and 10.8% and 11.7% in the intervals of subsequent 
consecutive visits. Of 163 participants who were colonized at visit-1, 76(46.6%) were no 
longer colonized by visit-4. The rate of colonization-clearance was 75% (6/8) for serotype 
Ib, 73.3% (11/15) for V and 63.4% (45/71) for Ia. The overall clearance of any GBS 
colonization was 30.1% (49/163), 29.2% (45/154) and 32.7% (48/147) between visits-1 
and -2, visits-2 and -3, and visits-3 and -4, respectively. No demographic characteristics 
were identified that were associated with either new acquisition or clearance of 
colonization. 
       
5.4.6 Duration of GBS colonization 
The median duration of recto-vaginal GBS colonization was 6.35 weeks for serotype III, 
which tended to be longer than other serotypes, including serotype Ia (median: 5.21 weeks; 
p=0.02; Table 5.6) which was the second most common colonizing serotype. The 
difference in duration of colonization between serotype III and less prevalent serotypes 
was generally longer, but not statistically significant. 
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Table 5.6: Estimated duration of Group B Streptococcus recto-vaginal colonization 
 
Serotype  Colonization duration (weeks) *  
Mean (95% CI) Median  p-valueϮ 
Ia 7.52(6.6-8.4) 5.21 0.026 
Ib 5.22(4.03-6.42) 3.62 0.358 
II 6.11(5.07-7.16) 4.24 0.736 
III 9.15(8.1-10.2) 6.35 Reference 
IV 6.94(3.8-10.0) 4.81 0.998 
V 8.60 (6.80-10.39) 5.96 0.332 
IX 6.21(4.7-7.7) 4.31 0.651 
       * Time from enrolment, CI- Confidence interval, Ϯ compared to serotype III 
 
5.4.7 Predictive values for each visit culture with respect culture status at visit-4 
Positive and negative predictive values of serotype-specific culture at 20-25 weeks, 
26-30 weeks and 31-35 weeks of gestational age compared to 37 + weeks colonization 
status are presented in Table 5.7. The overall positive predictive values were 53.4%, 61.7% 
and 67.4% for GBS-positive cultures at 20-25 weeks, 26-30 weeks and 31-35 weeks, 
respectively, relative to positivity at 37+ weeks, while the negative predictive values for  
20-25 weeks, 26-30 weeks and 31-35 weeks ranged from 84.3% to 88.3%. Serotypes Ia 
and V had lower PPVs compared with serotype III at each time-point. The observed PPVs 
at 31-35 weeks, were 55-70% for the three commonest serotype.
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Table 5.7: Predictive value for 20-25, 26-30 and 31-35 weeks cultures in relation to culture status at 37+ weeks 
 
Serotype 20-25 weeks 26-30 weeks 31-35 weeks 
PPV % (95% CI) NPV % (95% CI) PPV % (95% CI) NPV % (95% CI) PPV % (95% CI) NPV % (95% CI) 
Overall GBS 53.4(45.4-61.2) 84.3(80.0-88.0) 61.7(53.5-69.4) 87.0(83.0-90.3) 67.4(59.1-74.9) 88.3(84.6-91.5) 
Ia 36.6(25.5-48.9) 94.5(91.9-96.4) 49.2(36.1-62.3) 95.5(93.2-97.2) 55.0(41.7-67.9) 96.2(94.0-97.8) 
Ib 25.0(3.9-65.0) 99.0(97.7-99.7) 66.7(22.7-94.7) 99.4(98.3-99.9) 75.0(20.3-95.9) 99.2(98.0-99.8) 
II 38.5(14.0-68.4) 98.8(97.4-99.6) 54.6(23.5-83.1) 99.0(97.7-99.7) 75.0(42.8-94.2) 99.6(98.5-99.9) 
III 58.9(45.0-71.9) 95.8(93.5-97.4) 62.8(48.1-75.9) 95.6(93.3-97.3) 67.9(53.7-80.1) 96.5(94.3-98.0) 
IV 50.0(12.4-87.6) 100(99.2-100) 60.0(15.4-93.5) 100(99.2-100) 75.0(20.3-95.9) 100(99.3-100) 
V 26.7(8.0-55.1) 97.2(95.3-98.4) 47.6(25.8-70.2) 98.4(96.8-99.3) 57.1(28.9-82.2) 98.0(96.3-99.0) 
IX 100(19.3-100) 99.6(98.6-99.9) 50.0(12.4-87.6) 99.8(98.9-100) 100(30.5-100) 99.8(98.9-100) 
PPV: Positive predictive value, NPV: Negative predictive value, CI- Confidence interval 
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5.5 Discussion 
To our knowledge this is the first serotype-specific longitudinal study conducted of 
recto-vaginal GBS colonization in pregnant women, in whom we demonstrated a high 
prevalence and acquisition rate of GBS recto-vaginal colonization. The overall rate of new 
acquisition at 5-6 week interval is in agreement with a previous study of non-pregnant 
women, although, the serotype-specific rates differed (Foxman et al., 2006). All GBS 
serotypes were variable in their colonization patterns, possibly due to the complex 
interaction between immunity and specific GBS serotypes, which is still incompletely 
understood. It may be that the higher frequency of persistent colonization and longer 
overall duration of colonization by  serotype III, is related to a weaker natural immune 
response associated with its colonization compared to other serotypes (Davies et al., 2001). 
Consequently, there is a higher risk of exposure at birth to serotype III in our population, 
which corroborates with it being responsible for 49.2% to 57.7% of EOD in our setting 
(Madzivhandila et al., 2011, Madhi et al., 2003). The higher acquisition rate of serotype Ia 
may result in there being inadequate time for natural immunity to this serotype developing 
in the pregnant woman, which consequently increases the newborns’ risk of developing 
EOD from serotype Ia, which is associated with 22.6% to 31% of EOD cases in our setting 
(Madhi et al., 2003, Madzivhandila et al., 2011). 
    
The high incidence of new acquisition and loss of colonization during pregnancy 
highlights why  screening is required as late as 35-37 weeks’ gestational age for the IAP 
strategy to be effective, which is concordant with another study in pregnant 
women(Manning et al., 2008). In our study, if women had been screened at 31-35 weeks, 
29.1% (42/141) of those who were colonized at 37+ would not have had IAP offered to 
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them and a lesser proportion (13.3%; 48/366) may have unnecessarily received IAP as they 
were no longer colonized at 37+ weeks. Although we did not identify any demographic 
characteristics associated with new acquisition or clearance of GBS, additional risk factors 
such as sexual activity during pregnancy were not fully explored (Meyn et al., 2002). The 
PPV of GBS cultures obtained from 20-35 weeks varied in serotype distribution compared 
to that at 37+ weeks. The prevalence of different GBS serotypes in a particular population 
can affect the PPV of late antenatal GBS cultures.  
 
The high cumulative prevalence of GBS colonization (49.7%) found in our study is 
comparable to longitudinal studies (which were not serotype specific) from Denmark and 
Zimbabwe (Hansen et al., 2004, Mavenyengwa et al., 2010). Furthermore,  the prevalence 
of colonization observed by us at 37+ weeks of gestational age was 28.4% (148/521), 
which was  similar to that reported in cross-sectional studies from Europe (Motlova et al., 
2004) and USA (Campbell et al., 2000). The prevalence of GBS colonization from African 
countries ranges from 16.5% in Malawi, 21-23% in The Gambia, Ethiopia and Tanzania 
and 31.6% in Zimbabwe  (Suara et al., 1994, Joachim et al., 2009, Musa Mohammed, 
2012, Dzowela T, 2005, Moyo et al., 2000). Our results also showed a decrease in the 
prevalence of GBS colonization with respect to increase in gestational age. This finding 
agrees with studies from the USA and Australia (Goodman et al., 1997, Gilbert et al., 
2002), but contrasts with others that reported an increase in colonization with increasing 
gestational age (Zamzami et al., 2011, Baker et al., 1975).  
 
Our findings on the dominant serotypes are comparable with serotype distribution data 
of maternal colonizing isolates from high-income countries, including 13% to 35% for 
133 
 
serotype Ia and 15% to 44% for serotype III (Ippolito et al., 2010). The identification of 
serotype IX in our study was notable in that it is rarely reported in colonizing studies and 
not previously described in Africa. To our knowledge, only 8 GBS colonizing isolates have 
been identified as serotype IX, including three from Denmark, two from Germany and one 
each from Canada, Hong Kong and Australia (Slotved et al., 2007). Our data on PI 
distribution is comparable to earlier published studies (Madzivhandila et al., 2013, 
Margarit et al., 2009) showing that all GBS isolates carried at least one PI, and were 
associated with the presence of either PI-2a or PI-2b identified alone or in combination 
with PI-1. 
 
Our study is limited by the sensitivity of detection of GBS on selective media which is 
estimated at 85% (Chapter 4) and by the fact that in most cases only the dominant serotype 
was determined. This can lead to an underestimation of persistent colonization, an 
overestimation of new acquisitions and an underestimation of the duration of carriage. 
    
Recent  developments in the clinical evaluation of a tri-valent GBS polysaccharide-
protein conjugate vaccine has  renewed interest in the potential of this vaccine to protect 
neonates against invasive GBS disease by reducing  recto-vaginal colonization during 
pregnancy (Edwards and Gonik, 2013). The findings of this study will be important in 
considering study design when evaluating the efficacy of maternal GBS vaccination 
protecting against GBS recto-vaginal acquisition and colonization during pregnancy as 
surrogate information on clinical vaccine efficacy may be gained by determining the 
immune responses that correlate with protection against serotype-specific GBS acquisition 
and colonization during pregnancy. 
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Chapter 6 Natural acquired humoral immunity against serotype-
specific Group B Streptococcus recto-vaginal colonization acquisition in 
pregnant women. 
 
6.1 Abstract     
Background: Group B Streptococcus (GBS) recto-vaginal colonization in pregnant 
women is associated with invasive GBS disease in newborns, preterm delivery and 
stillbirths. We studied the association of GBS serotype-specific capsular polysaccharide 
(CPS) antibody on new acquisition and clearance of recto-vaginal GBS colonization in 
pregnant women from 20 weeks until 37-40 weeks of gestational age.  
 
Methods: Serum serotype-specific CPS IgG antibody concentration was measured by 
multiplex-ELISA and opsonophagocytic activity (OPA) titers. Recto-vaginal swabs were 
evaluated for GBS colonization, using standard culture methods and serotyping by latex 
agglutination, at 5-6 weekly intervals.  
 
Results: Higher serotype III CPS antibody concentration was associated with lower risk of 
recto-vaginal acquisition of serotype III during pregnancy (p=0.009).  Furthermore, 
serotype-specific OPA titers to Ia and III were higher in women who remained free of GBS 
colonization throughout the study compared to those who acquired the homotypic serotype 
(p<0.001 for both serotypes). Serum CPS IgG of ≥1 µg/ml for serotype V, ≥3 µg/ml for 
serotype Ia and III were significantly associated with protection against recto-vaginal 
acquisition of the homotypic serotype.  
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Conclusion: A GBS vaccine that induces sufficient capsular antibody in pregnant women, 
including high OPA titers, could protect against recto-vaginal colonization during the latter 
half of pregnancy.  
    
6.2 Introduction    
Maternal recto-vaginal colonization with Group B Streptococcus (GBS) is the 
major risk factor for GBS invasive disease in newborns’ under seven days of age (early-
onset disease; EOD) (Verani et al., 2010, Chan SHS, 2000). Vertical transmission of GBS 
occurs to approximately 50% of babies born to GBS-colonized pregnant women, of whom 
1–3% develop EOD in the absence of intrapartum antibiotic prophylaxis (IAP) (Beal and 
Dancer, 2006, Heath and Feldman, 2005). Recto-vaginal GBS colonization of pregnant 
women has also been associated with preterm birth and stillbirths (Edwards and Gonik, 
2013). Screening for GBS recto-vaginal colonization in pregnant women at 35-37 weeks of 
gestational age, coupled with IAP during labor, has reduced the incidence of EOD in high-
income settings(Schrag and Schuchat, 2004). Implementation of IAP would, however, be 
costly and logistically challenging for most resource-constrained countries (Colbourn et al., 
2007, Schrag, 2011). 
 
An alternate preventive strategy against invasive GBS disease in newborns’ and 
young infants, could be vaccination of pregnant women with a GBS vaccine to induce 
humoral immunity, with protective antibodies transplacentally transferred to the fetus 
(Robbins et al., 1995). An association between low maternal serotype-specific capsular 
antibody concentration and increased risk of invasive GBS disease among newborns has 
been observed (Baker et al., 1981, Baker et al., 2013, Lin et al., 2004). Furthermore, should 
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GBS vaccination prior or during early stages of pregnancy prevent or reduce subsequent 
recto-vaginal colonization in women, this could lower fetal/newborn exposure to GBS and 
contribute to reducing EOD among term and preterm births; and potentially also reduce 
GBS-associated LOD, premature labor and stillbirths.  
 
Although spontaneous clearance and acquisition of GBS has been reported in 
pregnant women, the association of host immune mediators and GBS colonization during 
pregnancy remains unclear (Hansen et al., 2004, Goodman et al., 1997). A few 
predominantly cross sectional studies, reported higher serotype-specific capsular 
polysaccharide (CPS) antibody in colonized compared to non-colonized women (Campbell 
et al., 2000, Davies et al., 2001, Anthony et al., 1984, Matsubara et al., 2003, Matsubara et 
al., 2002, Skidmore et al., 1985, Baker et al., 1980, Beachler et al., 1979). We are, 
however, unaware of any longitudinal cohort study which evaluated the association 
between serotype-specific CPS antibody and subsequent risk of GBS recto-vaginal 
acquisition during the latter half of pregnancy. 
 
The primary objective of our study was to evaluate the association between natural 
serotype-specific serum CPS IgG antibody and opsonophagocytic activity in relation to 
GBS recto-vaginal acquisition in pregnant women from 20 to 37+ weeks of gestational 
age. Furthermore, we evaluated the association between CPS antibody and clearance of 
GBS colonization.  
 
137 
 
6.3 Material and Methods 
The detailed methods of the study have been described in Chapter 2. Briefly, 
pregnant HIV-uninfected women aged 18-45 years and who were 20-25 weeks gestational 
age were enrolled at antenatal community clinics in Soweto, Johannesburg from August 
2010 to August 2011. Exclusion criteria included antibiotic treatment in the previous two 
weeks, any acute illness, symptomatic vaginal discharge and a known or suspected 
condition in which clinical vaginal examination was contraindicated. Study procedures 
included lower vaginal and rectal swabs collection for GBS culture starting at 20-25 weeks 
(visit-1), followed by three subsequent visits (visits 2-4) at 5-6 weekly intervals, up until 
37-40 weeks (visit-4) of gestational age. For GBS isolation, swabs were inoculated onto 
CA. Serotyping was performed by the latex agglutination method as described (Afshar et 
al., 2011). Isolates that tested negative by latex agglutination for all serotypes were further 
typed by a PCR method using primer sequences described by Poyart et al (Poyart et al., 
2007). 
 
6.3.1 Measurement of serotype-specific anti-capsular serum IgG 
Quantitative serum serotype-specific CPS IgG antibody concentrations were 
measured with multiplex Luminex platform and have been detailed in chapter 2. Briefly, 
blood was collected at enrolment and visit-4. Serum was separated by centrifugation and 
stored at −70 °C until analyzed. All GBS CPS antigens were kindly provided by Novartis 
Vaccines, Italy, and were coupled to the microsphere beads (Biorad, CA, U.S.A) with the 
crosslinking agent 4-(4,6-dimethoxy[1,3,5]triazin-2-yl)-4-methyl-morpholinium 
(DMTMM) as described (Schlottmann et al., 2006). An in-house reference serum 
composed of purified pooled human IgG (Polygam, National Bioproducts, South Africa) 
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was calibrated with the standard serotype-specific GBS reference serum kindly provided 
by Prof. Carol J. Baker. Assays were performed in true duplicate and each plate included 
high and low control sera. Bead fluorescence was read with the Bioplex 200 instrument 
(Bio-Rad, Texas, U.S.A) using Bio-Plex manager 5.0, software (Bio-Rad). In each assay, 
an uncoated control bead was included to determine non-specific binding. For control 
beads, the coupling procedure was followed, except that no GBS CPS was added. In case 
of non-specific binding, the fluorescence intensity (FI) values were subtracted from the 
antigen-specific results. The optimal serum and secondary antibody dilution was 1:100. 
The results for serum CPS IgG are given in µg per ml with lower detection limits of 
0.0003, 0.005 and 0.009 for serotype Ia, III and V, respectively. For statistical analysis, 
samples with values below these limits were assigned values of half of lower limit of 
detection. 
 
 The multiplex assay was validated by comparing the serotype-specific mean FI 
values for Polygam obtained with the multiplex assay with those for each serotype run in 
singleplex. The FI values obtained for Polygam with the multiplex assay were between 
79% and 112% (median 103%) of those obtained with the single-plex assays. To assess 
analytical specificity of each GBS–microsphere set, Polygam was incubated at 1:100 
dilution with each GBS CPS (100µg/ml) and incubated at 37˚C for 2 hours. The specificity 
was recorded as the difference in reactivity between the absorbed and unabsorbed sera in a 
multiplex assay. Homologous inhibition was >95% for all serotypes, with the exception of 
serotype V (85%). Heterologous inhibition across serotypes was <10%, except for 
serotypes Ib and III, which were inhibited by 41% and 11% with type Ia CPS respectively, 
and serotype V (18%) was inhibited by serotype-III CPS. 
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6.3.2 Serum IgG opsonophagocytic activity (OPA) assay 
 The functional activity of serum IgG was determined by opsonophagocytic activity 
(OPA) assay for serotype Ia and III using the HL-60 cell line and has been detailed in 
chapter 2. Briefly, 1000 cfu (20 µl of 5x104cfu/ml) of GBS type Ia strain(A909) or type III 
strain(COH-1) cells were mixed with an appropriate dilution of heat inactivated serum 
sample (10µl), then mixed and incubated for 15 min at 37°C in a 5% CO2 incubator. Baby 
rabbit complement (10µl) and HL-60 cells (40 µl of 1x107, cultured for 5 days in the 
presence of dimethyl formamide) were added to the mixture and incubated at 37°C with 
5% CO2 for 1 hour with gentle agitation. Aliquots were removed and plated on Todd-
Hewitt agar plates for quantitative culture. Opsonophagocytic activity was expressed as the 
titer at which the serum dilution yielded 50% killing compared with the bacterial growth in 
the complement controls. The limit of detection was 8. For statistical analysis, samples 
below the detection were assigned an arbitrary titer of 4. 
 
6.3.3 Study definitions 
 A participant was considered to be colonized at a visit if GBS was cultured on the 
vaginal and/or rectal swab, and non-colonized if no growth was detected from either swab. 
A new episode of serotype-specific GBS recto-vaginal colonization (i.e. “new-acquisition 
group”) was defined as a participant not colonized by a specific GBS serotype at visit-1, 
who was subsequently colonized by that specific-serotype (irrespective of the number of 
study-visits completed). Concurrent identification of different serotypes from the vaginal 
and rectal swabs at a visit among participants with new acquisitions were treated as 
individual events. Participants not colonized with a specific-serotype at any study visit 
were categorized as being the “non-colonized group” for that serotype; and used as the 
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comparator group when evaluating the association between CPS antibody and risk for 
serotype-specific recto-vaginal acquisition. 
 
The association of CPS antibody with clearance of serotype-specific GBS 
colonization was evaluated in participants who were colonized by the specific-serotype at 
visit-1 and who completed all study visits. The participants were stratified into those who 
remained colonized throughout (i.e. “persistently-colonized group”) and those in whom 
colonization of specific-serotype was cleared by visit-4 (i.e. “intermittent-colonized 
group”). Due to limitations associated with detecting multiple serotype carriage using 
traditional culture methods (Ferrieri et al., 2004), participants with GBS serotype 
colonization at visit-1 and who acquired different GBS serotype at subsequent visits were 
excluded from the analysis on CPS antibody and serotype-specific GBS acquisition or 
clearance. 
 
6.3.4 Statistical analysis 
 
Differences in geometric mean concentration (GMC) of serotype-specific CPS 
antibody and geometric mean OPA titer (GMOPT) between groups (new-acquisition 
versus non-colonized groups; and persistently-colonized versus intermittent-colonized 
groups) were analyzed on log transformed data by Student’s t-test. GMC’s at visit-1 and 
visit-4 for each group were analyzed by paired Student’s t-test. Evaluation of whether the 
serotype-specific CPS antibody was associated with new homotypic GBS acquisition, was 
undertaken using a univariate logistic regression analysis reporting the Odds ratio (OR) for 
the association between the serological variable and GBS acquisition, with logarithmic IgG 
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or OPA titer as a covariate. Univariate logistic regression analysis was also used for 
comparison between groups by demographics and obstetrical factors at visit-1. For 
categorical variables, groups were compared with either chi-square test or Fisher’s two 
tailed exact test as appropriate. Correlations between serum IgG and OPA titers were 
determined on log10 transformed data by Spearman rank correlation. Data was analyzed 
using SAS version 9.2 software (SAS Institute, Inc., NC, USA). A p-value of <0.05 was 
considered significant. 
 
6.4 Results          
Of 661 enrolled participants, 95.1% (n=629) completed at least two and 76.7% 
(n=507) all four study-visits. The main reasons for not completing all study visits were 
related to obstetric outcomes such as premature birth (n=86; 13.0%) and miscarriages 
(n=13; 2.0%; Figure 6.1). A detailed profile of subject follow-up, serotype distribution and 
dynamics of GBS colonization has been detailed in chapter 5. 
  
The overall prevalence of any-serotype GBS colonization at enrolment was 33.0% 
(218/661). Of those not colonized by GBS serotypes Ia, III or V at enrolment, 9.6% 
(52/541), 7.0% (39/560) and 2.8% (17/603) subsequently became colonized by the 
respective serotypes (i.e. new-acquisition group). This included 6 participants who cultured 
different serotypes from the vaginal and rectal site at the same visit and excluded 15 
participants who were colonized at visit-1 and acquired different serotypes at subsequent 
visit. Of 507 participants who completed all scheduled visits, participants not colonized 
with a specific-serotype at any visit were 387 (76.3%), 414(81.6%) and 471(92.9%) for 
serotypes Ia, III and V, respectively (i.e. non-colonized group). There were no differences 
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in the demographic characteristics between the new-acquisition and non-colonized groups 
(Table 6.1).  
    
         Of the 507 participants who completed all scheduled visits, the overall GBS 
colonization prevalence at enrolment was 32.1% (163/507), including 14.0% (n=71), 
11.1% (n=56) and 2.9% (n=15) for serotypes Ia, III and V, respectively.  The prevalence of 
serotypes Ia, III and V colonization among the persistently-colonized group were 4.1% 
(21/507), 5.3% (27/507) and 0.4% (2/507), respectively; and 8.5% (43/507), 3.6% (18/507) 
and 1.8% (9/507), respectively, in the intermittent-colonized group. This excluded 22 
intermittently colonized participants in whom colonization was not cleared by visit-4 or 
acquired new serotype at subsequent visits and remained colonized with that serotype 
thereafter. There were no differences in the demographic characteristics between the 
persistently-colonized and intermittent-colonized groups. 
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Figure 6.1: Selection of Groups 
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Table 6.1: Demographic characteristics new acquisition group compared to non-colonized group  
 
Demographics Serotype Ia Serotype III Serotype V 
New- 
acquisition
a 
n=52d 
Non-
colonizedb 
n=387 
p-
valuec 
New- 
acquisitio
n 
n=39 
Non-
colonized  
n=414 
p-
value 
New- 
acquisitio
n 
n=17 
Non-
colonized  
n=471 
p-
value 
Age (years) 
Mean± SDe 
25.65 
±5.76 
26.06    
± 5.54 
0.619 26.13 
± 6.2 
26.10  
± 5.6 
0.969 26.01 
±4.77 
26.06  
±5.66 
0.955 
Parity median(range) 1(0-5) 0(0-5) 0.582 0(0-3) 0(0-5) 0.556 1(0-1) 0(0-5) 0.751 
Gravidity median(range) 2(1-6) 2(1-8) 0.891 1(1-4) 2(1-8) 0.353 2(1-3) 2(1-8) 0.500 
Previous spontaneous  
abortion f 
6 (11.5%) 64 (16.5%) 0.358 4 (10.2%) 70 (16.9%) 0.289 1 (5.9%) 80 (17.0%) 0.253 
Previous Stillbirths g 2 (3.8%) 4 (1.0%) 0.127 0 (0.0%) 6 (1.4%) 0.449 0 (0.0%) 7 (1.5%) 0.612 
a New acquisition: women who acquired serotype-specific new acquisition; b Non-colonized: women who remain uncolonized by specific-serotype at all four study visits; c 
p-value by univariate logistic regression analysis d n: number of participants; e SD: Standard deviation; f Spontaneous abortion: The spontaneous abortion of pregnancy 
occurring before 28 gestational weeks; g Stillbirth:  Fetal death occurring at 28 gestational weeks or later. 
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6.4.1 Association between serotype-specific CPS IgG and new acquisition of the 
homotypic serotype 
The logistic regression analysis for the association between homotypic serotype 
acquisition and serotype-specific IgG concentration at enrolment demonstrated OR <1.00, 
indicating that the probability of a new acquisition decreased with increasing serotype-
specific IgG concentrations; Table 6.2. Homotypic serotype antibody GMC was higher at 
enrolment among the non-colonized than new-acquisition group for serotype III 
(0.33µg/ml versus 0.17µg/ml, respectively; p=0.009), with a similar trend for serotype V 
(0.75µg/ml versus 0.42µg/ml, respectively; p=0.057) (Table 6.2). 
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Table 6. 2: Comparison of serum geometric mean concentration of serotype-specific 
CPS antibodies (GMC; µg/ml) and geometric mean OPA titers (GMOPT) at visit-1 
for pregnant women who acquired (new-acquisition) compared to those who remain 
uncolonized (non-colonized group) for specific serotypes 
 
Serotype New-acquisition a 
 
Non-colonized b  
 
p-value c Odds Ratio 
d 
(95 % CI)* 
 GMCe (95% CI)a GMC (95% CI)b   
Ia 0.28 (0.17,  0.47); 
n=52f 
0.35  (0.27,  0.44); 
n=387 
0.529 0.91 (0.68, 1.21) 
III  0.17 (0.11,  0.26); 
n=39 
0.33 (0.28,  0.38); 
n=414 
0.009 0.47 (0.26, 0.84) 
V  0.42 (0.26, 0.65); 
n=17 
0.75 (0.66, 0.84); 
n=471 
0.057 0.39 (0.15, 1.01) 
OPA GMOPTg (95% CI) GMOPT (95% CI)   
Ia 5 (4, 6); n=52 14 (11, 17); n=387 <0.001 0.28 (0.12, 0.63) 
III 20 (11, 36); n=39 132 (105, 164); n=414 <0.001 0.43 (0.30, 0.62) 
a New acquisition: women who acquired serotype-specific new acquisition; b Non-
colonized: women who remained uncolonized by specific serotype; c p-value calculated by 
students-t test; d Odds ratio by  logistic regression analysis; e GMC : geometric mean 
concentration;  g GMOPT: geometric mean OPA titers; f  n: number of participants. 
 
Reverse cumulative distribution plots of serotype-specific CPS antibody 
concentrations of the non-colonized and new-acquisition groups are shown in Figures 5.2 
a-c. The lowest threshold of CPS antibody concentration associated with lower odds of 
acquisition of the homotypic serotype varied between serotypes. The lowest antibody 
threshold significantly associated with remaining non-colonized throughout the study was 
≥3 µg/ml for serotype Ia (22.0% in non-colonized versus 9.6% in new-acquisition group, 
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OR:0.37; 95%CI: 0.14,0.98), ≥3 µg/ml for serotype III (10.6% in non-colonized versus 
0.0% in new-acquisition group, OR:0.11; 95%CI: 0.01-1.75) and ≥1µg/ml for serotype V 
(36.5% in non-colonized versus 11.8% in new-acquisition group, OR:0.23; 95%CI: 0.05-
1.02; Table 6.3). This strength of association increased at higher CPS antibody thresholds 
for serotype Ia, and III (Table 6.3). None of the women who acquired serotype Ia had 
antibody concentration ≥15µg/ml (compared to 8.5% of non-colonized women, p=0.025) 
at enrolment; and none with new-acquisition of serotypes III had homotypic CPS antibody 
≥3µg/ml (compared to 10.6% (p=0.023) of those who remained non-colonized; Table 6.3).  
 
6.4.2 Association between serotype-specific opsonophagocytic activity and new 
acquisition of GBS       
Reverse cumulative distribution plots of serotype-specific OPA titers of the non-
colonized and new-acquisition for serotype Ia and III are shown in Figures 6.2 d-e. The 
logistic regression analysis for the probability of acquisition of GBS serotype Ia and III as 
a function of homotypic serotype OPA titer at enrolment had OR <1.00, indicating that the 
probability of a new acquisition decreased with increasing serotype-specific OPA titer; 
Table 6.2. Non-colonized women had higher serotype-specific GMOPT than the new-
acquisition group for serotypes Ia (GMOPT: 14 versus 5, respectively; p<0.001) and III 
(GMOPT: 132 versus 20, respectively, p<0.001; Table 6.2). The presence of detectable 
OPA titers (≥8) was significantly associated with lower odds of acquiring the homotypic 
serotype for Ia (p=0.002) and III (<0.001). The strength of association between OPA titers 
and odds of new-acquisitions trended to be stronger at higher OPA threshold for serotypes 
Ia and III; Table 6.3.  
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Figure 6.2: Reverse cumulative distribution curves of serotype-specific anticapsular 
serum IgG (a-c) and OPA titer (d-e) in participants who acquired GBS serotype (new 
acquisition) and those who remained uncolonized by the specific-serotype (Non-
colonized) 
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 Table 6. 3 : Association between serotype-specific capsular IgG antibody and acquisition of homotypic Group B Streptococcus in pregnant women  
Serotype Ia Serotype III Serotype V 
Antibody 
levels, 
µg/ml 
New 
acquisition 
n=52a 
Non-
colonized 
n=387 
Odds ratio 
(95%CI) 
p-valueb New 
acquisitio
n n=39 
Non-
colonized 
n=414 
Odds ratio 
(95%CI) 
p-value New 
acquisition    
n=17 
Non-
colonized 
n=471 
Odds ratio 
(95%CI) 
p-
value 
< 0.5 32  
(61.5 %) 
235 (60.7%) 1.04 
(0.57, 1.88) 
0.910 29  
(74.4%) 
283  
(68.4%) 
1.34,  
(0.64, 2.84) 
0.439 9  
(52.9%) 
184  
(39.3%) 
1.75 
(0.66, 4.61) 
0.25 
≥ 0.5 20  
(38.5%) 
152 
 (39.3%) 
0.98  
(0.54, 1.78) 
0.910 10  
(25.6%) 
131 
 (31.6%) 
0.74 
(0.35, 11.57) 
0.439 8  
(47.1%) 
287  
(60.9%) 
0.57  
(0.22, 1.51) 
0.25 
≥ 1 18  
(34.6%) 
131 
 (33.9%) 
1.03  
(0.56, 1.90) 
0.91 5 
(12.8%) 
84  
(20.3%) 
0.57 
(0.22, 1.52) 
0.396 2  
(11.8%) 
172  
(36.5%) 
0.23 
(0.05, 1.02) 
0.039 
≥ 2 8  
(15.4%) 
101  
(26.1%) 
0.51 
(0.23, 1.13) 
0.093 1 
 (2.6%) 
55  
(13.3%) 
0.17  
(0.02, 1.27) 
0.070 1  
(5.9%) 
81  
(17.2 %) 
0.30 
(0.04, 2.30) 
0.328 
≥ 3 5  
(9.6%) 
85  
(22.0%) 
0.37  
(0.14, 0.98) 
0.043 0  
(0%) 
 44 
(10.6%) 
 0.11 
(0.01, 1.75) 
 0.023  0  
(0%) 
55  
(11.7 %) 
 0.21 
(0.01, 3.62) 
0.239  
≥ 5 3  
(5.8%) 
70 
(18.1%) 
0.28 
(0.01, 0.91) 
0.027 0 
(0%) 
 26  
(6.3%) 
 0.19 
(0.01, 3.11) 
 0.151  0  
(0%) 
26  
(5.5 %) 
 0.48 
(0.02, 8.21) 
 1.000 
≥ 10 1 
 (1.9%) 
45  
(11.6%) 
0.15 
(0.02, 1.11) 
0.028 0  
(0%) 
 13  
(3.1%) 
 0.38 
(0.02, 6.46) 
 0.615  0  
(0%) 
18  
(3.8%) 
 0.70 
(0.04, 12.1) 
 1.000 
≥ 15 0  
(0%) 
 33 
(8.5%) 
 0.10 
(0.01,1.67) 
 
 0.025 0  
(0%) 
 6  
(1.4%) 
 0.79 
(0.04, 14.39) 
 1.000  0  
(0%) 
16  
(3.4%) 
 0.78 
(0.04, 13.7) 
 1.000 
OPA Titers   
    
< 8 45  
(86.5%) 
251  
(64.9%) 
3.46 
(0.64, 2.84) 
0.002 18  
(46.2%) 
92  
(22.2%) 
3.00 
(1.53, 5.87) 
<0.001 
  Not done     
≥ 8 7  
(13.5%) 
135  
(34.9%) 
0.29 
(0.13, 0.66) 
0.002 21  
(53.8%) 
322  
(77.8%) 
0.33 
(0.17, 0.65) 
<0.001 
  
  
  
≥ 16 6  
(11.5%) 
114 
(29.5%) 
0.31 
(0.13, 0.75) 
0.006 17 
 (43.6%) 
310  
(74.9%) 
0.26 
(0.13, 0.51) 
<0.001 
  
  
  
≥ 32 1  
(1.9%) 
104  
(26.9%) 
0.05 
(0.01, 0.39) 
<0.001 15  
(38.5%) 
302  
(72.3%) 
0.23 
(0.12, 0.46) 
<0.001 
  
  
  
≥ 64  0  
(0%) 
 88  
(22.7%) 
 0.03 
(0.00, 0.52) 
<0.001 12  
(30.8%) 
283  
(68.4%) 
0.21 
(0.10, 0.42) 
<0.001 
  
  
  
≥ 128  0  
(0%) 
 67  
(17.3%) 
 0.05 
(0.00, 0.74) 
<0.001 9  
(23.1%) 
244  
(58.9%) 
0.21 
(0.10, 0.45) 
<0.001 
  
  
  
≥ 256  0  
(0%) 
 51 
 (13.2%) 
 0.06 
(0.00, 1.02) 
 0.002 5 
 (12.8%) 
202  
(48.8%) 
0.15 
(0.06, 0.40) 
<0.001 
  
  
  
≥ 512  0  
(0%) 
 38  
(9.8%) 
 0.09 
(0.00, 1.43) 
 0.014 2 
 (5.1%) 
147  
(35.5%) 
0.01 
(0.02, 0.41) 
<0.001 
        
a n: number of participants; b p-value calculated by either chi-square test or fisher exact test as appropriate.
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There were significant correlations between serum IgG concentration and OPA titer with 
rho-values of 0.684 for serotype Ia and 0.393 for III, p<0.001 for both (Figure 6.3 a-b). 
OPA activity (titer ≥8) was detectable to the homotypic serotype in 92% (138/150) of 
serum samples with IgG concentration ≥3µg/ml for serotype Ia and 94.1% (192/204) of 
samples with IgG concentration ≥0.5µg/ml for serotype III. 
 
                            
-4 -2 0 2 4
0
1
2
3
4
5
r= 0.684, p<0.001
Serum IgG, µg/ml (log 10)
Serotype Ia
 O
PA
 ti
te
r (
lo
g 
10
)
-4 -2 0 2 4
0
1
2
3
4
5
r= 0.393, p<0.001
Serum IgG,µg/ml (log 10)
Serotype III
O
PA
 ti
tr
e 
(lo
g 
10
)
 
                            ( a )                                                                      ( b ) 
 
Figure 6.3: Correlation between serotype-specific serum IgG concentration and OPA 
titers at visit-1 for serotype Ia (a) and serotype III (b) irrespective of colonization 
status  
  
                                                              
6.4.3 Association between serotype-specific CPS IgG and clearance of colonization 
at enrolment 
Serotype specific CPS antibody concentration was greater among women colonized 
compared to those not colonized by the homotypic serotype at visit-1 for serotypes Ia 
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(p=0.025) and III (p=0.018); and at visit-4 for serotype-Ia (p<0.001) with similar trend for 
serotype-III (p=0.060); albeit not statistically significant for OPA at visit-1 (Table 6.4). 
Among women colonized at enrolment, higher CPS GMC (1.49 versus 0.44 µg/ml, 
p=0.049) and GMOPT (41 versus 12; p=0.025) were observed for serotype Ia in those 
categorised as persistently-colonized than those with intermittent-colonization, 
respectively, but not so for serotypes III and V (Table 6.5).   
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Table 6.4: Cross-sectional comparison of geometric mean concentration (GMC) of serotype-specific CPS antibody (µg/ml) in pregnant 
women who were colonized and not colonized by the homotypic serotype at visit-1 or visit-4  
 
Serotype Visit-1 Visit-4 
Serum 
IgG 
Colonized 
GMC a (95% CI)  
 
Not-colonized  
 GMC (95% CI) 
p-valueb Colonized 
GMC (95% CI) 
 
Not colonized  
GMC (95% CI) 
 
p-value 
Ia 0.71 
(0.40, 1.27); n=71c 
0.36 
(0.28, 0.45); n=436 
0.025 
 
 
1.52 
(0.80, 2.89); n=50 
0.43 
(0.12, 0.45); n=457 
<0.001 
 
 III 0.51 
(0.33, 0.79); n=56 
0.30 
(0.26, 0.35); n=451 
0.018 
 
 
0.47 
(0.30,0.76); n=52 
0.30 
(0.26, 0.35); n=455 
0.060 
 
 V 1.02 
(0.52, 2.00); n=15 
0.72 
(0.65, 0.82); n=492 
0.31 
 
 
1.07 
(0.66, 1.75); n=18 
0.83 
(0.74, 0.92); n=489 
0.372 
 
 OPA GMOPT 
d (95% CI) GMOPT (95% CI)  Not done 
Ia 
 
19 
(12, 32); n=71 
13 
(10, 15); n=436 
0.081 
 
III 
178 
(88, 359); n=56 
111 
(89, 138); n=451 
0.166 
          a GMC : geometric mean concentration; b p-value by students-t test; c n: number of participants; d GMOPT: geometric mean OPA titers. 
      *OPA was done at visit-1 for GBS serotype Ia and III 
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Table 6.5: Comparisons of geometric means of serum IgG (µg/ml) concentrations and 
OPA geometric mean titers at baseline in women who remained colonized throughout 
by particular serotype (persistent carriers) compared to those in whom colonization 
was cleared (intermittent carriers) 
 
Variable and 
Serotype 
Persistent carriers  
 
Intermittent carriers 
 
p-value a 
Serum IgG GMCb (95% CI) GMC (95% CI)  
Ia 1.49 (0.51-4.3); n=21c 0.44 (0.22,  0.88); n=43 0.049 
III 0.54 (0.28, 1.04); n=27 0.47 (0.19,  1.20); n=18 0.807 
V 1.67;* n=2 0.71 (0.25, 1.99); n=9 0.437 
OPA GMOPTd (95% CI) GMOPT (95% CI)  
Ia 41 (14, 116); n=21 12 (7, 21); n=43 0.025 
III 221 (74, 656); n=27 216 (65, 712); n=18 0.979 
    a p-value by student-t test;  b GMC : geometric mean concentration; c number of participants;   
   d GMOPT:  geometric mean OPA titers; * not presented due to very wide CI intervals. 
             
6.4.4 Effect of GBS colonization on kinetics of serotype-specific antibody 
Analyzing women who completed all four study visits and were not colonized by a 
specific-serotype at enrolment, serotype-specific new-acquisition was associated with 
increase in GMC’s and GMOPT between enrolment and visit-4. These increases were 
evident for GMCs for serotype Ia ( p=0.001), III (p=0.004) and V (p=0.034); as well as 
GMOPT for serotypes Ia and III ( p<0.001 for both; Table 6.6). For serotype Ia, a new 
acquisition event was also associated with an increase in correlation between serotype-
specific serum IgG concentration and OPA titers, with rho-values of 0.524 at enrollment 
(p<0.001) and 0.792 at visit-4 (p<0.001) (Figure 4.3 a-b). In contrast, for serotype III a 
decrease in correlation between enrollment (rho=0.354, p=0.037) and visit-4 (rho=0.266, 
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p=0.122) was observed, despite significant increases in OPA titres (Figure 6.4 c-d). No 
change was observed in GMC between visit-1 and visit-4 among women who remained 
non-colonized by the specific-serotype throughout the study for serotypes Ia or III, 
although an increase was observed for serotype V (0.83 versus 0.75 µg/ml, p=0.011). 
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Figure 6.4: Correlation between serotype-specific serum IgG concentration and OPA 
titers at visit-1 and after new acquisition event (visit-4) for serotype Ia (a-b) and for 
serotype III (c-d) 
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Table 6.6: Comparisons of serum geometric mean concentration (GMC) serotype-specific capsular IgG antibody (µg/ml) and 
geometric mean opsonophagocytic titer (GMOPT) at enrolment and visit 4 in pregnant women who acquired GBS and those who 
remained uncolonized throughout 
 
Participants with serotype-specific new acquisition Participants who remain uncolonized by specific serotype 
Serotype Visit 1 Visit 4 p-valuea Visit 1 Visit 4 p-value 
Serum IgG GMCb (95% CI) GMC (95% CI)   GMC (95% CI) GMC (95% CI)  
Ia  0.32 (0.18,  0.57); n=42c 0.86 (0.44,  1.70) 0.001 0.36 (0.28,  0.46); 
n=387 
0.40 (0.32,  0.51) 0.169 
III  0.14 (0.09,  0.22); n=35 0.26 (0.15,  0.46) 0.004 0.32 (0.28,  0.38); 
n=414 
0.30 (0.26,  0.36) 0.272 
V  0.38 (0.23, 0.61); n=15 0.76(0.43, 1.33) 0.034 0.75 (0.66, 0.84); n=471 0.83 (0.74, 0.93) 0.011 
OPA GMOPTc  (95% CI) GMOPT (95% CI)      
Ia 5 (4, 6); n=42 110 (53, 227) <0.0001                                     Not done* 
III 17 (9, 32); n=35 776 (528, 1143) <0.0001 
a p-value by paired students-t test; b GMC : geometric mean concentration; c n: number of participants;  d GMOPT: geometric mean OPA titers 
* OPA at visit-4 was done only for participants who acquired GBS serotype
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6.5 Discussion 
Our study demonstrated an association between natural-acquired serum serotype-
specific CPS antibody and the risk of subsequent recto-vaginal colonization by the 
homotypic- serotype in pregnant women not colonized at enrolment. New-acquisition of 
GBS was inversely correlated with serotype-specific CPS IgG concentration (serotype III 
and V) and OPA titer (serotype Ia and III) at time of enrolment. These data suggest that 
strategies such as vaccination of women with GBS capsular polysaccharide-protein 
conjugate vaccine which induces antibody responses could reduce the risk of GBS recto-
vaginal acquisition of vaccine-serotypes. The potential benefit to the women and their 
newborn would, however, be dependent on the timing of vaccination in the women and 
durability of persistence of sufficiently high antibody concentrations or OPA titers to 
prevent GBS acquisition during pregnancy. The potential of a protein-polysaccharide 
conjugate vaccine to induce mucosal immunity has been demonstrated for vaccines against 
Haemophilus influenzae type b, Streptococcus pneumoniae and Neisseria meningitidis in 
which reduced risks of nasopharyngeal mucosal-colonization acquisition of the targeted 
serotypes are evident (Barbour et al., 1995, Dagan et al., 2005, Maiden and Stuart, 2002). 
  
In our study, the CPS antibody, including functional antibody measured by OPA, 
was most likely induced by recto-vaginal colonization, as indicated by the rise in serotype-
specific GMCs and GMOPT among those with new-acquisitions of homotypic-serotypes. 
It is this increase in CPS antibody, which likely reduces the risk of these women becoming 
colonized by the same serotype. Although our study was not designed to establish the 
durability of this natural-acquired humoral-mediated immunity, the strengthening of 
association between higher serotype-specific antibody thresholds and OPA titers and the 
158 
 
reduced odds of becoming colonized by the homotypic serotype, indicates that this 
protection is likely to be transient with waning of antibody over time. Also, the 
paradoxically higher GMC and GMOPT in women colonized with serotype Ia at enrolment 
and who remained persistently-colonized thereafter compared to those who were only 
intermittently-colonized, indicates that the antibody which was likely induced by 
colonization, might not clear existing colonization. This clearance of established 
colonization may be due to other immune-mediators, including cell-mediated immunity.  
       
Our study indicated that the threshold of CPS antibody associated with significantly 
reduced odds of acquisition of GBS was ≥3 µg/ml for serotypes Ia and III, and ≥1µg/ml for 
serotype-V. Furthermore, serotype-specific OPA titers of ≥ 8 were associated with 
similarly reduced odds of new-acquisition of the homotypic serotype for serotypes Ia and 
III.  The OPA titers correlated more strongly than IgG concentrations in relation to new-
acquisition of serotype Ia and III. This shows the importance of measuring functional 
antibody in the evaluation of immune responses to GBS conjugate vaccine. Also, the 
correlation between OPA titers and CPS IgG concentration was modest, suggesting either 
impaired functional activity of antibody or limitations of the serology assay with respect to 
purity of antigens used or possible role of IgM antibodies in opsonophagocytosis (Simell et 
al., 2012).  
 
Previous studies on the association of GBS colonization and serum IgG antibody 
have mainly been cross-sectional studies and have generally reported higher serotype-
specific CPS antibody in colonized compared to non-colonized pregnant women for the 
homotypic serotype (Campbell et al., 2000, Davies et al., 2001, Anthony et al., 1984, 
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Baker et al., 1980, Beachler et al., 1979, Matsubara et al., 2003, Matsubara et al., 2002, 
Skidmore et al., 1985). These studies were, however, not designed to address whether CPS 
antibody reduces the risk of GBS colonization during pregnancy, as shown by us. 
Nevertheless, the findings of the previous studies are confirmed in our study, where higher 
serotype-specific CPS IgG concentrations were also observed in women colonized by the 
homotypic-serotype compared to those not colonized when analyzed cross-sectionally at 
either visit-1 or visit-4 for serotypes Ia and III. This higher antibody concentration in 
colonized women in such studies likely reflect recent acquisition of that serotype, which 
induced the higher antibody levels compared to women not colonized, as demonstrated in 
kinetics of antibody response to new acquisitions in our study.   
 
Our study has certain limitations. First, although we explored for thresholds of 
serotype-specific CPS IgG and OPA titers associated with reduced odds of new acquisition 
by homotypic  serotypes, the  findings need to be interpreted with caution in the absence of 
a standardized reference assay to measure either CPS antibody or OPA titers (Madhi et al., 
2013). We tried to optimize the comparability of our assay to that of other laboratories by 
calibrating our in-house reference (Polygam) with reference sera from Dr Baker who has 
published widely in the field. Second, the sensitivity of detection of GBS on selective 
media is estimated at 85% and mainly identifies the dominant colonizing serotype, with 
lower-density co-colonizing serotypes likely being missed (Chapter 4). Therefore, it is 
possible that we overestimated new-acquisition through missing colonization episodes not 
detectable by standard culture methods at visit-1; and similarly may also have missed some 
new-acquisitions.  
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In summary, our results indicate that the effect of GBS conjugate vaccine on recto-
vaginal GBS colonization warrants further investigation. This could provide recto-vaginal 
colonization as surrogate endpoint to evaluate the potential effect of GBS conjugate 
vaccine in protecting newborns (including those born prematurely) from exposure to GBS 
at birth and hence reduce their risk of EOD. Already, a monovalent GBS serotype III 
conjugate vaccine has been reported to significantly reduce the rate of recto-vaginal GBS 
acquisition among non-pregnant women (Hillier, 2009 ). This potential effect, of 
vaccination with GBS vaccine targeted at women, against recto-vaginal colonization may 
be over and above the additional protection of vaccination against invasive GBS disease in 
young infants born at full-term, which is likely to be conferred through transplacental 
acquisition of protective serotype-specific CPS antibody. Furthermore, it is plausible that 
reducing the risk of GBS acquisition during pregnancy, could reduce the incidence of 
GBS-associated chorio-amnionitis, premature labor and stillbirths (Edwards and Gonik, 
2013).  
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Chapter 7 Serotype specific cellular-mediated immunity associated with 
clearance of homotypic Group B Streptococcus recto-vaginal colonization 
in pregnant women 
 
7.1 Abstract       
 
Background: We investigated the association between Group B Streptococcus serotype-
specific capsular polysaccharide cellular immunity at 20 weeks gestational age in pregnant 
women, and effect thereof on recto-vaginal serotype-specific GBS colonization up to 37 
weeks of gestational age.  
 
Methods: Group B Streptococcus serotype-specific capsular polysaccharide cellular 
immunity was measured by ELISpot Interferon-γ (IFN-γ) release assay. Recto-vaginal 
swabs were evaluated for GBS colonization, using standard culture methods and 
serotyping by latex agglutination, at 5-6 weekly intervals.  
 
Results: Among women colonized by serotype III at enrolment, IFN-γ ELISpot positivity 
was more common in those in whom colonization was cleared (44.4%) than in those in 
whom colonization persisted (7.4%; p=0.008) with a similar trend observed for serotype Ia.  
 
Conclusion: Presence of serotype-specific capsular polysaccharide cell-mediated 
immunity contributes to the clearance of GBS recto-vaginal colonization.  
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7.2 Introduction        
Maternal recto-vaginal colonization with Group B Streptococcus (GBS) and its 
vertical transmission to newborns is the primary source of early-onset  (<7 days age; EOD) 
invasive GBS disease (Heath and Feldman, 2005), and has also been  associated with 
stillbirths and premature deliveries (Edwards and Gonik, 2013).  Spontaneous clearance 
and acquisition of GBS has been reported in pregnant women (Hansen et al., 2004, 
Goodman et al., 1997), however, the host immune mediators influencing the dynamics of 
GBS colonization remain to be fully elucidated. We recently established that capsular 
specific antibody and opsonophagocytic activity reduced the risk of new homotypic 
serotype acquisition between 20 to 37+ weeks of pregnancy, however, neither was 
associated with clearance of GBS colonization (Chapter 6). 
  
The aim of this study was to determine the association of presence of GBS cellular 
immunity as assessed by Interferon-γ (IFN-γ) release assays, performed by Enzyme-linked 
Immunospot (ELISpot) assay on the dynamics of GBS colonization in women during the 
latter half of pregnancy. 
 
7.3 Material and Methods  
The detailed methods of the study have been described in Chapter 2. Briefly, 
pregnant HIV-uninfected women aged 18-45 years and who were 20-25 weeks gestational 
age were enrolled at antenatal community clinics in Soweto, Johannesburg from August 
2010 to August 2011. Exclusion criteria included antibiotic treatment in the previous two 
weeks, any acute illness, symptomatic vaginal discharge and a known or suspected 
condition in which clinical vaginal examination was contraindicated.  
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Study procedures included lower vaginal and rectal swabs collection for GBS 
culture starting at 20-25 weeks (visit-1), followed by three subsequent visits (visits 2-4) at 
5-6 weekly intervals, up until 37-40 weeks (visit-4) of gestational age. For GBS isolation, 
swabs were inoculated onto CHROMagar StrepB (CA; Media Mage, Johannesburg, South 
Africa). Serotyping was performed by the latex agglutination method as described (Afshar 
et al., 2011). Isolates that tested negative by latex agglutination for all serotypes were 
further typed by a PCR method using primer sequences described by Poyart et al (Poyart et 
al., 2007). 
 
7.3.1 Measure of cellular immune response 
Cellular immune response was determined at Visit-1 (enrolment) by Interferon-γ 
(IFN-γ) release assays, performed by Enzyme-linked Immunospot (ELISpot) assay kit for 
human IFN-γ as per manufacturer instructions (Cat no: 3420-2A, Mabtech, Sweden). 
Briefly, peripheral blood mononuclear cells (PBMC) were isolated from the heparinised 
blood using ficoll gradient centrifugation and re-suspended in AIM-V medium (Gibco, 
Invitrogen, USA). Around, 0.25-0.3 x 106 PBMC’s were added per well onto ELISpot 
plates (MAIP S4510; Millipore, Ireland) coated with IFN-γ capture antibody (Mabtech, 
Sweden). PBMC’s were stimulated with GBS serotype-specific capsular polysaccharide 
(CPS) antigens separately (CPS-Ia, III and V) for 18-24 hours at 37°C in 5% CO2 with a 
final concentration of 40µg/ml (GBS CPS antigens were kindly provided by Novartis 
Vaccines, Italy). After incubation, ELISpot plates were developed using biotinylated anti-
IFN-γ detection antibody (Mabtech, Sweden) which detected with streptavidin-alkaline 
phosphatase (Mabtech, Sweden), and visualized with an AP conjugate substrate kit (Bio-
Rad, CA, USA). Checker board titrations were performed to optimize PBMC’s and antigen 
concentrations per well. AIM-V medium was used as negative control to assess 
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background levels and phytohaemagglutinin (Sigma, USA) was used as a positive control. 
Cellular immune responses against each antigen were detected in single well only. Spot 
forming units (SFU) were counted with a magnifying lens. Background (SFU in negative 
control) was subtracted and results were expressed as number of SFU/106 PBMC. An 
ELISpot response was considered as positive if the number of antigen-specific spots was 
≥7 SFU/106 PBMC and at least double the number of spots in the negative control well. 
 
In addition, serotype-specific serum CPS IgG antibody concentrations were 
measured by multiplex Luminex (serotypes Ia, III and V) and  opsonophagocytic activity 
(OPA) assay (Ia and III) (Chapter 6)  
 
7.3.2 Study definition  
A participant was considered to be colonized at a visit if GBS was cultured on 
either the vaginal or rectal swab; and non-colonized if no growth was detected from either 
site. The association of cellular immunity with clearance of serotype-specific GBS 
colonization was evaluated in women who were colonized by the specific serotype at visit-
1 and who completed all four study visits. The women were stratified into those in whom 
colonization of the specific serotypes was cleared by visit-4 (i.e. “cleared-colonization 
group”) and those who remained colonized throughout the study (i.e. “persistently-
colonized group”). Due to limitation associated with detecting multiple serotype carriage 
using traditional culture methods, participants colonized with any GBS serotype at visit-1 
and who acquired a different GBS serotype at a subsequent visit and remained colonized 
with that serotype thereafter were excluded from the analysis. 
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We also evaluated the association of cellular immunity on acquisition of serotype-
specific GBS colonization in women not colonized by a specific GBS serotype at Visit-1, 
who were subsequently colonized by that specific-serotype (irrespective of the number of 
study-visits completed) (“new-acquisition group”) to those not colonized with that 
specific-serotype at any study visit (“non-colonized group”). 
 
7.3.3 Statistical analysis   
For categorical variables, groups were compared with either chi-square test or 
Fisher’s two tailed exact test as appropriate. The Mann-Whitney test was used to detect 
differences in SFU/106 PBMC between groups (“persistently-colonized” versus “cleared-
colonization” groups). Correlation between serotype-specific serum IgG and serotype-
specific OPA titers in relation to number of SFU/106 PBMC by ELISpot at visit-1 were 
calculated using Spearman’s correlation coefficient. To explore the association between 
SFU/106 PBMC’s and clearance of GBS colonization, we used a Bayesian model to 
estimate the posterior distribution of the probability that a woman with a GBS homotypic 
SFU/106 PBMC’s greater than or equal to c, would clear GBS colonization, denoted by 
P(D=1|SFU>=c) (Carey et al., 2001). For each value c, we graphically display the 25%, 
50%, and 75% quantiles of the posterior distribution of P(D=1|SFU>=c). Data were 
analyzed using Graphpad version 5.0 software (Graphpad software, California, USA). R 
version 2.15 (Vienna, Austria)(Jags), A p-value of <0.05 was considered significant. 
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7.4 Results    
A detailed profile of participant demographics and follow up has been detailed in 
chapter 6. Briefly, of 661 participants, 76.7% (507/661) completed all four study-visits and 
95.1% (629/661) completed at least two study-visits. Of the 507 women who completed all 
scheduled visits, 71 (14.0%), 56 (11.1%) and 15 (2.9%) were colonized by serotypes Ia, III 
and V, respectively at enrolment. Of the women already colonized at enrolment, 21/71 
(29.6%), 27/56 (48.2%) and 2/15 (13.3%) were categorized as being “persistently-
colonized”; and 43 (60.6%), 18 (32.1%) and 9 (60.0%) were in the “cleared-colonization” 
groups for serotypes Ia, III and V, respectively. This excluded 22 participants colonized at 
enrolment who cleared the initial serotype (Ia (7/71; 9.8%), III (11/56; 19.6%) and V 
(4/15; 26.7%) but who acquired a new serotype at subsequent visit and remained colonized 
with subsequent serotype thereafter. There were no differences in the demographic 
characteristics between the persistently-colonized and those in the cleared-colonization 
groups. 
                
Of those not colonized by specific GBS serotype Ia, III and V at enrolment and 
who had at least one subsequent study visit, 9.6% (52/541), 7.0% (39/560) and 2.8% 
(17/603) subsequently become colonized by the respective serotypes (i.e. “new-
acquisition” group). Of the participants who completed all scheduled visits, 387 (76.3%), 
414 (81.6%) and 471 (92.9%) for serotype Ia, III and V, respectively (i.e. “non-colonized 
group) were never colonized by that specific serotype. There were no differences in the 
demographic characteristics between the new-acquisition and non-colonized group 
(chapter 6). 
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Of the 661 enrolled participants in whom cellular immune response was determined 
at visit-1, six participants were excluded from the analysis due to contamination detected in 
the assay. Of the remaining 655 participants, serotype-specific ELISpot responses were 
prevalent in 191(29.2%), 154(23.5%) and 143 (21.8%) for serotypes Ia, III and V 
respectively at visit-1. There was no correlation between serotype-specific serum IgG 
concentrations and number of SFU/106 PBMC from ELISpot assay for serotypes Ia 
(Rho=0.006; p=0.89), III (Rho=0.023; p=0.55) or V (Rho=0.021; p=0.59) (Figure 7.1). 
Similarly, there was no correlation observed between serotype-specific OPA titers and 
SFU/106 by ELISpot assay for either serotype Ia (Rho= 0.017; p=0.66) or III (Rho=0.042; 
p=0.28) (Figure 7.2). 
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Figure 7.1: Correlation between serotype-specific serum IgG concentration and spot 
forming units for IFN-γ at visit-1 for serotype Ia (a), III (b) and V(c) 
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Figure 7.2: Correlation between serotype-specific OPA titers and spot forming units 
for IFN-γ at visit-1 for serotype Ia (a) and III (b) 
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Among women colonized with serotype III at enrolment, ELISpot positivity was found in 
higher percentage of women who cleared colonization (44.4%) compared with those who 
remained persistently-colonized (7.4%; p=0.008), with a similar trend for serotype Ia 
(44.2% versus 19.0%, respectively; p=0.06) and serotype V (22.9% versus 0.0%, 
respectively); Figure 7.2. Serotype-specific median SFU tended to be higher among those 
who cleared colonization than persistently-colonized for serotypes III (p=0.055) and Ia 
(p=0.144), albeit not significant; Figure 7.3. 
   
 
 
 
Figure 7.3: Comparisons of ELISpot positivity at enrolment in pregnant women who 
has cleared colonization (Cleared colonization group) to those who remain colonized 
throughout by that serotype (Persistently colonized group) 
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Figure 7.4: Comparison of median SFU/106 at visit-1 for pregnant women who lost 
colonization by visit-4 (cleared colonization group) compared to those who remain 
colonized at all visits (persistently colonized group) for serotypes Ia (a) and III (b)  
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Using a Bayesian framework the probability of losing colonization increased with higher 
SFU; Figure 7.4. We observed a 50% and 70% probability of losing colonization with ≥7 
SFU/106 and ≥ 22 SFU/106 PBMC respectively for serotype III. For serotype Ia, we 
observed 82% probability of losing colonization with ≥7 SFU/106 PBMC. There was no 
correlation between serotype-specific ELISpot positivity and clearance of non-homotypic 
serotype. The lowest threshold associated with clearance of  serotype III colonization was 
≥7 SFU/106;  being prevalent among 44.4% (8/18) in “cleared-colonization” versus 7.4% 
(2/27) in “persistent-carrier” group (OR: 10.00, 95% CI: 1.80-55.55; p=0.008); and 48.8% 
(21/43) and 19% (4/21) in the respective group for serotype Ia (OR: 4.06, 95% CI: 1.17-
14.06; p=0.03); table 7.1.  
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Figure 7.5: Probability of clearance GBS serotype Ia (a) and serotype III (b) 
colonization at varying SFU/106 PBMC’s using a Bayesian model 
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Table 7.1: Association between quantitative serotype-specific spot forming unit (SFU) by ELISpot assay and clearance of homotypic 
GBS in pregnant women 
         a For Serotype Ia, two participants in the cleared colonization group who had ≥7 SFU/106 PBMC at baseline but failed in criteria of having double number of spots 
           as compared to negative control for being ELISpot positive were included in the quantitative analysis. 
          *Serotype V was not analysed due to insufficient numbers for comparison.  
 Serotype Ia a Serotype III 
SFU/106 
PBMC 
Cleared-
colonization 
group 
(n=43) 
Persistent-
colonized 
group  
(n=21) 
Odds ratio p-value Cleared 
colonization 
group 
(n=18) 
Persistent-
colonized 
group 
(n=27) 
Odds ratio p-value 
≥ 3 22 (51.2%) 9 (42.9%) 1.39(0.48-3.99) 0.53 12 (66.6%) 13 (48.1%) 2.15 (0.62-7.42) 0.22 
≥ 7 21 (48.8%) 4 (19.0%) 4.06 (1.17-
14.06) 
0.03 8 (44.4%) 2 (7.4%) 10.0 (1.80-
55.55) 
0.008 
≥ 10 9 (20.9%) 1 (4.8%) 5.29 (0.62-
44.96) 
0.15 3 (16.7%) 2 (7.4%) 2.50 (0.37-
16.73) 
0.37 
174 
 
Furthermore, whereas we previously reported significant associations between serotype-
specific antibody concentration and OPA in relation to subsequent new acquisition of GBS 
during pregnancy (Chapter 6), there was no significant difference in ELISpot positivity 
among women who became colonized (new-acquisition group) compared to those who 
remained uncolonized (non-colonized group) for serotypes Ia (21.6% (11/51) vs 29.4% 
(113/384); p=0.24), III (17.9% (7/39) vs 23.9% (98/410); p=0.40) or V (11.8%(2/17) vs 
21.8% (102/467); p=0.546). From the non-colonized group three participants for serotype 
Ia and four each for serotype III and V, and from the new-acquisition group one participant 
for serotype Ia, were excluded from the analysis due to contamination. 
 
7.5 Discussion                              
    
We have shown that clearance of serotype-specific GBS recto-vaginal colonization 
during pregnancy was associated with presence of homotypic capsular ELISpot IFN-γ 
positivity, whereas no such association was observed for serotype specific capsular 
antibody or OPA as reported for the same cohort (Chapter 6). Conversely, ELIspot 
positivity was not associated with a significantly reduced risk of GBS acquisition which 
was, however, positively associated with serotype specific capsular antibody and OPA for 
serotypes Ia and III as reported. These data suggest that presence of cell mediated immune 
response contributes to the clearance of recto-vaginal GBS colonization, whereas we have 
previously reported that humoral immunity is required to reduce the risk of recto-vaginal 
GBS acquisition during pregnancy (Chapter 6).  
                      
The results of the study are in accordance with studies on other capsular bacteria 
such as Streptococcus pneumoniae that shows cell-mediated immune response being 
175 
 
important for mucosal clearance of Streptococcus pneumoniae in animal models (McCool 
and Weiser, 2004, van Rossum et al., 2005). A serotype-specific capsular based GBS 
vaccine able to elicit both humoral and cell-mediated capsular immune responses could 
therefore confer protection against EOD by reducing the exposure of the newborn’s to 
GBS colonization during the peri-partum period. This could offer an additional mode of 
protection against invasive GBS disease especially for preterm newborn’s, who might not 
fully benefit from transplacental acquisition of maternal serotype specific capsular 
antibody which mainly occurs beyond 34 weeks gestational age.  Also, clearance of GBS 
recto-vaginal colonization during pregnancy, coupled with prevention of new acquisition 
mediated by presence of humoral immunity, could theoretically mitigate against other GBS 
associated illness such as chorioamnionitis and adverse birth outcomes of GBS-associated 
stillbirths and premature labour. This would, however, require for vaccination to occur 
early in the second trimester of pregnancy and to induce serotype-specific functional 
antibody and cellular immunity for it to impact wholly on the full spectrum of GBS 
associated morbidity and mortality in the women, fetus and newborn’s. 
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Chapter 8 Association between mucosal immune response and Group B 
Streptococcus colonization in pregnant women 
 
8.1 Abstract 
       
Background: Establishing association between mucosal immunity and Group B 
Streptococcus (GBS) colonization in pregnant women could contribute to the evaluation of 
GBS vaccines. We studied the association of serotype-specific mucosal antibodies on new 
acquisition and clearance of recto-vaginal GBS colonization in pregnant women and 
association between serum IgG and mucosal IgG. 
              
Methods: Serotype-specific GBS capsular mucosal IgG and IgA concentrations were 
measured by multiplex Luminex assay in vaginal mucosal secretions. Recto-vaginal swabs 
for GBS colonization was undertaken at 20-25 weeks of gestation and thereafter at 5-6 
weekly intervals. Standard microbiological methods were used for GBS culture and 
serotyping undertaken by latex agglutination and PCR if non-typeable by latex 
agglutination.   
 
Results: Serotype-specific capsular mucosal IgG trended to be higher in pregnant women 
who remained uncolonized compared to those who acquired homotypic GBS serotype. 
Mucosal IgG correlated significantly with serum IgG with rho values of 0.839, 0.621 and 
0.426 (all p<0.001) for serotypes Ia, III and V, respectively. 
177 
 
Conclusion: The results suggest that IgG in mucosal secretions is derived from serum IgG 
and could be responsible for the reduction of GBS colonization by preventing new 
acquisition. 
 
8.2 Introduction       
Maternal recto-vaginal colonization with Group B Streptococcus (GBS) is the 
major risk factor for GBS invasive disease in newborn (Verani et al., 2010, Chan SHS, 
2000). Vaccination may be used as an approach for reducing the prevalence of GBS 
colonization, possibly by inducing high levels of type-specific serum antibody and 
subsequent reduction in the transmission of GBS to the newborn (Chapter 6). The ability of 
vaccines to induce mucosal immunity and to reduce colonization has been demonstrated 
for other bacterial polysaccharide-protein conjugate vaccines, including against 
Haemophilus influenzae type b,  Streptococcus pneumoniae and Neisseria meningitides, 
where these conjugate vaccines not only decreases invasive disease, but also 
nasopharyngeal colonization (Barbour et al., 1995, Dagan et al., 2002, Maiden and Stuart, 
2002).  
 
Spontaneous clearance and acquisition of GBS are evident in pregnant women, 
however, the association of mucosal immune response GBS colonization during pregnancy 
remains unclear (Hansen et al., 2004, Goodman et al., 1997). A cross sectional study, 
reported higher mucosal serotype-specific capsular polysaccharide (CPS) antibody in 
colonized compared to non-colonized women (Hordnes et al., 1996).  
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The objective of our study was to evaluate the association between naturally 
induced serotype-specific mucosal IgG and IgA antibody to susceptibility for recto-vaginal 
acquisition and clearance of homotypic serotypes in pregnant women. Association between 
serotype- specific serum IgG and mucosal IgG was also investigated. 
  
8.3 Material and Methods 
The detailed methods of the study have been described in Chapter 2. Briefly, 
pregnant HIV-uninfected women aged 18-45 years and who were 20-25 weeks gestational 
age were enrolled at antenatal community clinics in Soweto, Johannesburg from August 
2010 to August 2011. Exclusion criteria included antibiotic treatment in the previous two 
weeks, any acute illness, symptomatic vaginal discharge and a known or suspected 
condition in which clinical vaginal examination was contraindicated. Study procedures 
included lower vaginal and rectal swabs collection for GBS culture starting at 20-25 weeks 
(visit-1), followed by three subsequent visits (visits 2-4) at 5-6 weekly intervals, up until 
37-40 weeks (visit-4) of gestational age. For GBS isolation, swabs were inoculated onto 
CHROMagar StrepB (CA; Media Mage, Johannesburg, South Africa). Serotyping was 
performed by the latex agglutination method as described (Afshar et al., 2011). Isolates 
that tested negative by latex agglutination for all serotypes were further typed by a PCR 
method using primer sequences described by Poyart et al (Poyart et al., 2007). Vaginal 
mucosal secretions were collected at 20-25 weeks of gestation and at the last visit. Mucosal 
secretions were collected with Oracol swabs and were extracted by centrifugation by 
adding 300ul of extraction buffer (10% FBS in PBS) and stored at −70 °C. 
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8.3.1 Measure of serotype-specific anti-capsular mucosal IgG and IgA 
Quantitative mucosal IgG and IgA, immunoassay was performed on the multiplex 
luminex platform using Polygam (pooled gamma globulin) and pooled human serum 
(PHS) as reference for mucosal IgG and IgA, respectively and has been detailed in chapter 
2. Serotype specific IgG and IgA values for reference serums were derived by calibrating 
to the standard serotype-specific GBS reference serums kindly provided by Prof. Carol J. 
Baker. All GBS capsular polysaccharide (CPS) antigens for assay were kindly provided by 
Novartis Vaccine, Italy. For the measurement of serotype-specific mucosal IgG and IgA, 
the optimal dilution was 1:2. The optimal secondary antibody dilutions were 1:100. The 
results for mucosal anti-GBS CPS IgG are given in ng per ml with lower detection limits of 
0.007, 0.091 and 0.224 for mucosal IgG and 0.01, 0.032 and 0.64 for mucosal IgA for 
serotype Ia, III and V, respectively. For statistical analysis, samples with values below 
these limits were assigned values of half of lower limit of detection. 
 
 For IgG all serotypes showed 90% or higher homologous inhibition except serotype 
V where it was 85% and more than 10% heterologous inhibition was only observed in case 
of serotype Ib and III, when inhibited by serotype Ia CPS with 40% and 11%, respectively 
and 17% for serotype V, when inhibited by serotype III CPS. For IgA all serotypes showed 
95% or higher homologous inhibition, however, very high heterologous inhibition of 82% 
was observed in case of serotype Ib antibodies when inhibited by serotype Ia CPS. As 
serotype Ia and Ib are structural isomers cross reactivity with heterologous CPS could be 
due to sharing of common isotopes that are identified by cross reacting antibodies. 
Furthermore, less than 10% cross reactivity was observed in between serotype Ia 
antibodies and serotype Ib CPS, therefore, it could be the presence of high Group B 
antigen contamination in serotype Ib CPS used for coating of beads that could have 
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overestimated the serotype Ib specific antibodies in reference serum which were further 
adsorbed by group B antigen present in the Ia CPS used for inhibition. More than 10% 
heterologous inhibition was also observed in case of serotype III (22%), when inhibited by 
serotype Ia CPS.  
  
8.3.2 Study definitions and statistical analysis 
The study definitions and statistical analysis has been detailed in chapter 6. 
Briefly, A new episode of GBS recto-vaginal colonization (New acquisition group) was 
defined as a subject not colonized by the specific serotype at Visit-1 and who became 
colonized at any subsequent visit (vaginal or rectal or both) by that serotype.  Participants 
not colonized with a specific serotype at Visit-1 and at all subsequent visits, were regarded 
as having been free of colonization for that serotype (non-colonized group) and used as the 
comparator group when evaluating the association between CPS antibody and risk for 
serotype-specific recto-vaginal acquisition. Furthermore, the association of mucosal IgG or 
IgA and clearance of serotype specific GBS colonization was evaluated in participants 
colonized by a specific serotype at Visit-1 who remained colonized throughout the study 
(persistent carriers) and compared them to those in whom colonization was cleared by 
Visit-4 (Intermittent carriers). 
 
Differences in GMC’s of serotype-specific anti-capsular antibodies between groups 
were analyzed on log transformed data by Student-t test. Evaluation of whether the 
serotype specific mucosal IgG or IgA were associated with new homotypic GBS 
acquisition, was undertaken using logistic regression analysis reporting the Odds ratio 
(OR) for the association between a serological variable and GBS acquisition (with 
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logarithmic mucosal IgG or IgA as a covariate). Correlations between serum IgG and 
mucosal IgG were determined on log transformed data by Spearman rank correlation. A p-
value of <0.05 was considered significant. 
    
8.4 Results  
Of 661 participants, 76.7% (507/661) completed all four study-visits and 95.1% 
(629/661) completed at least two study-visits. A detailed profile of participant 
demographics and follow-up has been reported (Chapter 6)  
    
8.4.1 Association between serotype-specific anti-CPS mucosal IgG and IgA and new 
acquisition of the homotypic serotype 
The logistic regression analysis for the association between homotypic serotype 
acquisition and serotype-specific mucosal IgG concentration at enrolment demonstrated 
OR<1.00, indicating that the probability of a new acquisition decreased with increasing 
serotype-specific mucosal IgG concentrations; Table 8.1. Participants who remain 
uncolonized throughout study trended toward higher GMCs of serotype-specific GBS CPS 
mucosal IgG concentrations than women who acquired the homotypic serotype;  Table 8.1. 
The distributions of serotype-specific mucosal IgG antibody levels for women who 
acquired GBS and those who remained un-colonized are summarized in Figure 8.1. For 
mucosal IgA, pregnant women who remained uncolonized trended to have higher GMC’s 
than those who became colonized for serotype V (2.15 vs 1.03, p=0.06), but not for any of 
the other serotypes.  
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Analysing women who completed all four study visits and were not colonized by a 
specific serotype at enrolment, serotype-specific new-acquisition was associated with 
increase in GMC’s between enrolment and visit-4 (Table 8.2). These increases were 
evident for mucosal IgG GMC’s for serotype Ia (p=0.003) and III (p<0.001); For serotype 
III and V, new acquisition event was also associated with increase in correlation between 
serotype-specific mucosal IgG and serum IgG with Rho values of 0.477 (p=0.004) and 
0.210 (p=0.45) at enrolment to Rho values of 0.764 (p<0.001) and 0.500 (p=0.58) at visit-4 
for serotype III and V, respectively. For mucosal IgA new acquisition event was associated 
with increase in GMC’s for serotypes V only (p=0.023, Table 8.2). 
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Table 8.1: Association between serotype specific anti-capsular mucosal IgG and 
mucosal IgA concentrations on acquisition of serotype-specific Group B streptococcus 
recto-vaginal colonization in pregnant women  
      
Variable and 
serotype 
Non-colonizeda 
GMC e, ng/ml 
(95% CI) 
New 
acquisitions b 
GMC, ng/ml 
(95% CI) 
p-value c Odds Ratio d 
(95% CI) 
Mucosal IgG     
Ia 
0.90                     
(0.68, 1.18) 
n=52g 
0.47                    
(0.22, 1.00) 
n=387 
0.10 0.81                 (0.63, 1.05) 
III  
0.97 
(0.81, 1.15) 
n=39 
0.72 
(0.40, 1.29) 
n=414 
0.33 0.80              (0.52, 1.25) 
V 
1.91 
(1.66, 2.19) 
n=17 
1.21 
(0.65, 2.24) 
n=471 
0.21 0.60                 (0.27, 1.34) 
Mucosal IgA     
Ia 
0.11 
(0.09, 0.13) 
0.09 
(0.05, 0.17) 
0.61 
0.92  
(0.68, 1.26) 
III  
0.20 
(0.16, 0.24) 
0.14 
(0.07, 0.27) 
0.29 
0.80  
(0.52, 1.21) 
V  
2.15 
(1.85, 2.49) 
1.03 
(0.51, 2.05) 
0.06 
0.46  
(0.20, 1.04) 
a Non-colonized: women who remained uncolonized by specific serotype; b New acquisition: women who 
acquired serotype-specific new acquisition; c p-value calculated by students-t test; d Odds ratio by  logistic 
regression analysis; e GMC : geometric mean concentration; g n: number of participants. 
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                             ( a )                                                                            ( b )                                       
           
                           ( c )                                                                            ( d ) 
        
               ( e )                                                                    ( f )                       
 
Figure 8.1: Reverse cumulative distribution curves of serotype-specific anti-capsular 
mucosal IgG (Fig 8.1 a-c) and mucosal IgA (Fig 8.1 d-f) in participants who acquired 
GBS serotype (New acquisition) and those who remained uncolonized by that 
serotype (Non-colonized)      
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Table 8.2: Comparisons of serum geometric mean concentration (GMC) serotype-specific capsular IgG antibody (µg/ml) and 
geometric mean opsonophagocytic titer (GMOPT) at enrolment and end of study in pregnant women who acquired GBS and those 
who remained uncolonized throughout 
 
Participants with serotype-specific new acquisition Correlation between serum IgG and Mucosal IgG 
Serotype Visit 1 Visit 4 p-valuea Visit 1 Visit 4 
Mucosal IgG GMCb (95% CI) GMC (95% CI)   Rho, p-value d Rho, p-value 
Ia  0.49 (0.20,  1.18); n=42c 1.88 (0.73,  4.87) 0.003 0.724, p<0.001 0.708, p<0.001 
III  0.68 (0.34,  1.33); n=35 1.18 (0.61,  2.26) 0.16 0.477, p=0.004 0.764, p<0.001 
V  0.95 (0.53, 1.71); n=15 3.16(1.61, 6.18) 0.003 0.211, p=0.45 0.500, p=0.06 
Mucosal IgA                                         
Ia 0.09 (0.05, 0.18) 0.18 (0.08, 0.38) 0.06 
III 0.14 (0.07, 0.30) 0.28 (0.14, 0.53) 0.12 
V 0.83 (0.43, 1.58) 2.56 (0.98, 6.66) 0.012 
       a p-value by paired students-t test; b GMC : geometric mean concentration; c n: number of participants;  d Rho value by Spearman correlation test 
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8.4.2 Correlation between serum IgG and mucosal IgG concentrations 
The concentration of GBS serotype specific CPS IgG in vaginal mucosal secretion 
correlated with the serum IgG concentrations with Rho values of 0.839, 0.621 and 0.418; 
all p < 0.001, for serotype Ia (figure 8.2), III (figure 8.3) and V (figure 8.4), respectively. 
The number of positive samples for CPS IgG in mucosal secretion were 99.6% (234/235), 
99.2% (133/134) and 97.8% (227/232) for serotype Ia, III and V, respectively, when CPS 
IgG concentration in serum exceeded 1µg/ml for the respective serotypes. 
Correspondingly, the number of IgG positive samples were 69.7% (297/426), 92.2% 
(486/527) and 91.8% (394/429) when concentration in serum was <1µg/ml. 
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Figure 8.2: Correlation between serum IgG and mucosal IgG for serotype Ia 
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Figure 8.3: Correlation between serum IgG and mucosal IgG for serotype III 
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Figure 8.4: Correlation between serum IgG and mucosal IgG for serotype V 
          
8.4.3 Association between serotype-specific CPS IgG and clearance of colonization 
evident at enrolment          
Serotype specific mucosal IgG antibody concentration was higher among women 
colonized compared to those not colonized by the homotypic serotype at visit-1 for 
188 
 
serotypes III (p=0.005) and at visit-4 for serotype-Ia (p=0.001), with similar trends 
observed for other serotypes; Table 8.3. For mucosal IgA, no association was observed 
between colonization and IgA concentration except for serotype Ia at visit-4 (p=0.004). 
There was no association between mucosal IgG or IgA and clearance of serotype-specific 
GBS colonization among women already colonized at Visit-1; Table 8.3. Women 
colonized at Visit-1 in whom carriage persisted, paradoxically, had higher IgG GMC 
compared to those in whom colonization was cleared; Table 8.4.  
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Table 8.3: Cross-sectional comparison of geometric mean concentration (GMC) of serotype-specific CPS antibody (ng/mL) in 
pregnant women who were colonized and not colonized by the homotypic serotype at visit-1 or visit-4 
 
Serotype Visit-1 Visit-4 
Mucosal 
IgG 
Colonized 
GMCa(95% CI)  
 
Not-colonized 
 GMC(95% CI) 
p-valueb Colonized 
GMC(95% CI) 
 
Not colonized 
GMC (95% CI) 
 
p-value 
Ia 1.39 
(0.75, 2.56); n=71c 
0.87 
(0.67, 1.12); n=436 
0.17 
 
 
4.79 
(2.24, 10.21); n=50 
1.23 
(0.95, 1.60); n=457 
0.001 
 
 III 1.90 
(1.15, 3.14); n=56 
0.94 
(0.79, 1.10); n=451 
0.005 
 
 
1.54 
(0.86, 2.73); n=52 
1.41 
(1.21, 1.64); n=455 
0.73 
 
 V 2.20 
(1.35, 3.60); n=15 
1.85 
(1.77, 2.17); n=492 
0.66 
 
 
3.59 
(2.07, 6.21); n=18 
2.47 
(2.19, 2.80); n=489 
0.26 
 
 Mucosal 
IgA 
 
GMCa(95% CI)  
 
 
 GMC(95% CI) 
  
GMC(95% CI) 
 
 
GMC (95% CI) 
 
 
Ia 0.12 
(0.07, 0.20); n=71 
0.11 
(0.90, 0.16); n=436 
0.75 
 
 
0.38 
(0.20, 0.70); n=50 
0.14 
(0.11, 0.17); n=457 
0.004 
 
 III 0.29 
(0.17, 0.49); n=56 
0.19 
(0.16, 0.22); n=451 
0.11 
 
 
0.30 
(0.16, 0.54); n=52 
0.29 
(0.24, 0.35); n=455 
0.89 
 
 V 2.17 
(1.01, 4.63); n=15 
2.05 
(1.77, 2.37); n=492 
0.89 
 
 
2.55 
(1.20, 5.40); n=18 
2.52 
(2.14, 2.96); n=489 
0.97 
 
 
aGMC: geometric mean concentration;b p-value by students-t test; cn: number of participants  
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Table 8.4: Comparisons of geometric means of Mucosal IgG and Mucosal IgA (ng/ml) 
concentrations at baseline (visit 1) for pregnant women who were colonized throughout 
by particular serotype (Persistent carriers) compared to those who lost colonization by 
4th visit (Intermittent carriers) 
       
Variable 
and 
Serotype 
Persistent carriers 
GMC b (95% CI) 
Intermittent carriers 
GMC (95% CI) 
 a p-value 
Mucosal 
IgG 
   
Ia 4.21(1.11, 16.0), n=21c 
 
 
0.77(0.39, 1.55),n=43 0.01 
III 1.63(0.87, 3.08), n=27 2.32(0.71, 7.51), n=18 0.56 
V 4.02 (0.34, 4.65), n=2 2.96 (0.86, 5.44), n=9 0.53 
Mucosal 
IgA 
 
  
Ia 0.37(0.12, 1.10) 0.08(0.04, 0.15) 0.01 
III 0.31(0.13, 0.70) 0.34(0.14, 0.78) 0.86 
V 6.39 d 1.21(0.53, 2.76) 0.10 
             a p-value by student-t test;  bGMC : geometric mean concentration; c number of   
         participants; d not presented due to very wide CI 
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8.5 Discussion 
Our study demonstrated a correlation between mucosal IgG and serum IgG and 
supports the notion that mucosal IgG is derived from serum (Nurkka et al., 2001). On the 
same cohort, we established that serum capsular specific antibody reduced the risk of new 
homotypic serotype acquisition between 20 to 37+ weeks of pregnancy (Chapter 6). As 
measurable amount of CPS IgG antibodies have been found in vaginal mucosal secretions 
and correlated with serum IgG concentrations measured in the same cohort, this suggesting 
that higher amount of diffused IgG on mucosal surface may have contributed to the 
reduced risk of colonization. For Streptococcus pneumoniae it has been suggested that, 
new acquisition of a serotype is reduced due to serum IgG of respective serotype diffused 
on the mucosal surface that binds to the polysaccharide capsule of the Streptococcus 
pneumoniae and create a steric inhibition of the interaction of pneumococcal surface 
proteins with binding sites on the mammalian epithelial cell surface (Dagan et al., 2005).  
 
 When the effect of naturally acquired mucosal IgG and IgA on new acquisition of 
GBS was analyzed, the coefficient of the logarithm antibody concentrations was negative 
in each of the regression analyses, which suggests that there is a lower probability of new 
acquisition of GBS with increasing mucosal IgG and IgA concentrations. No statistical 
significance was, however, identified for any of the studied serotypes. Also, the 
paradoxically higher GMC in women colonized with GBS serotype at enrolment and who 
remained persistently-colonized thereafter compared to those who lost colonization, 
indicates that the antibody which was likely induced by colonization, might not clear 
existing colonization. This further supports the previous finding on the same cohort that 
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cell-mediated immunity rather than humoral immune response is required for clearance of 
established GBS colonization (Chapter 7).  
 
 In summary, our results indicate that mucosal IgG is derived from serum and high 
concentrations of pre-existing mucosal GBS CPS-specific IgG in maternal sera during 
pregnancy may protect against colonization by the homotypic serotype.  
    
Our study has few limitations. Firstly, our study is limited by the sensitivity of 
detection of GBS on selective media which is estimated at 85% and by the fact that in most 
cases only the dominant serotype was determined and the serotypes carried in minority 
may be missed (Chapter 4). Therefore, it is possible that we missed continued colonization 
and potentially overestimated new acquisition or missed colonization altogether and 
underestimated new acquisition. Second limitation is lack of precise knowledge about the 
dilution factor introduced during extraction of vaginal mucous from the Oracol swab and 
furthermore, there might be an adsorption of antibodies in mucosal secretions of colonized 
women due to extraction of GBS along with secretions. 
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Chapter 9 Conclusion  
                                        
The series of studies undertaken in this PhD resulted in several novel findings. 
Foremost, the prevalence of GBS recto-vaginal colonization among pregnant women from 
South Africa was very high, including a high rate (25.9%; 89/344) of new acquisitions 
during the last half of pregnancy. We also observed a dynamic state in clearance of GBS 
during the latter half of pregnancy, with 46.6% (76/163) of women clearing GBS between 
26 to 37+ weeks of gestational age. The risk of new acquisition by the GBS serotype 
among pregnant women was inversely correlated with maternal serotype-specific 
antibodies, whereas loss of GBS colonization was positively correlated with serotype-
specific cellular immune responses. Furthermore, we also demonstrated chromogenic 
medium CHROMagar Strep B produced highest recovery of GBS from vaginal and rectal 
swabs as compared to the selective broth method recommended by CDC.    
 
These are the first findings that established sero-correlate of protection against GBS 
colonization among pregnant women and provides the foundation against which the 
efficacy of polysaccharide-protein GBS conjugate vaccines can be evaluated to determine 
whether it will protect against new GBS acquisition and/or clearance thereof during 
pregnancy. The thresholds of serum CPS serotype-specific antibody significantly 
associated with reduced odds of acquisition of GBS were ≥ 3µg/ml for serotypes Ia and III, 
and ≥1 µg/ml for serotype-V. Furthermore, we also demonstrated functional antibody titers 
determined by OPA assay correlated more strongly than serum IgG concentrations in 
relation to new-acquisition of serotype-Ia and III with serotype-specific OPA titers of ≥8 
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were significantly associated with reduction of new-acquisition of the homotypic serotype 
for serotypes Ia and III.  
  
The loss of serotype-specific GBS colonization during pregnancy was associated 
with presence of homotypic capsular ELISpot IFN-γ positivity, whereas no such 
association was observed for serotype specific capsular antibody. Conversely, ELISpot 
positivity was not associated with a significantly reduced risk of GBS acquisition, 
suggesting that the immune response required for clearance of recto-vaginal GBS 
colonization is cell-mediated, whereas humoral immunity is required to reduce the risk of 
recto-vaginal GBS acquisition during pregnancy. Our study demonstrated a correlation 
between mucosal IgG and serum IgG and supports the concept that mucosal IgG is derived 
from serum.     
  
The high incidence of new acquisition and loss of colonization during pregnancy 
supports late screening at 35-37 weeks’ gestational age for the IAP strategy to be effective. 
Our findings on the dominant serotypes in South Africa are comparable with serotype 
distribution data of maternal colonizing isolates from industrialized countries, which could 
further guide in the formulation of GBS polysaccharide based vaccines. Furthermore, 
identification of serotype IX in our population was notable in that it is rarely reported in 
colonization studies and not previously described in Africa. All GBS serotypes were 
variable in their colonization patterns, possibly due to the complex interaction between 
immunity and specific GBS serotypes or due to differences in pathogenesis, which is still 
incompletely understood and needs further investigation.    
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The prevalence of GBS colonization among pregnant women in this setting is very 
high and requires attention as maternal colonization is a major risk factor for EOD. Even 
though CDC has recommended universal screening for GBS recto-vaginal colonization in 
pregnant women at 35-37 weeks of gestational age, coupled with IAP during labor to 
reduce the incidence of EOD, the implementation of IAP would be costly and logistically 
challenging in our setting. Therefore, vaccination of pregnant women with GBS vaccine to 
induce protective antibody can be an alternate preventive strategy.  
 
In this study we also demonstrated the limitations of the selective broth enrichment 
method for the isolation of GBS from rectal swabs, and the advantage of using 
chromogenic medium for GBS isolation in terms of reduced processing time, better 
sensitivity and the ease with which GBS colonies can be identified on the plates. Based on 
the study results we recommend the use of chromogenic medium in regions with a high 
prevalence of antimicrobial resistant flora. 
 
In conclusion, high serotype-specific CPS antibody and more specifically presence 
of functional antibody measured by opsonophagocytic activity assay, was associated with a 
reduced risk of subsequent acquisition of serotype-specific GBS colonization during 
pregnancy. A serotype-specific capsular based GBS vaccine able to elicit both humoral and 
cell-mediated capsular immune responses in the mother may result in decreased 
colonization, therefore could confer protection against EOD by reducing the exposure of 
the newborn’s to GBS colonization during the peri-partum period. This could offer an 
additional mode of protection against invasive GBS disease especially for preterm 
newborn’s who might not fully benefit from transplacental acquisition of maternal serotype 
specific capsular antibody which mainly occurs beyond 34 weeks gestational age. 
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Moreover, reduction in colonization could result in lower fetal exposure to GBS and 
consequently lower the risk for GBS-associated premature labor and/or stillbirths. 
         
Recent developments in the clinical evaluation of a GBS polysaccharide-protein 
conjugate vaccine has  renewed interest in the potential of this vaccine to protect neonates 
against invasive GBS disease by reducing  recto-vaginal colonization during pregnancy. A 
trivalent GBS vaccine for pregnant women aimed at protecting newborns from invasive 
disease has recently completed phase-II evaluations. Further clinical evaluation of the 
vaccine is, however, challenging as large sample size of 60,000 would be required to 
demonstrate vaccine efficacy. An alternate pathway to licensure could be based on 
immunologic correlates of protection and by selecting surrogate markers for vaccine 
efficacy. Also, as maternal colonization is the prerequisite for invasive disease in infant, 
vaccine efficacy against colonization may be accepted as surrogate for reduction in 
especially EOD. If an efficacy end point is maternal GBS colonization rather than invasive 
disease, the sample size required for such a study would be much smaller compared to an 
infant invasive disease trial endpoint. The findings of our studies could inform the study 
design when evaluating the efficacy of maternal GBS vaccine in protecting against GBS 
recto-vaginal acquisition and colonization during pregnancy.       
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Evaluation of Trans-Vag Broth, Colistin-Nalidixic Agar, and
CHROMagar StrepB for Detection of Group B Streptococcus in
Vaginal and Rectal Swabs from Pregnant Women in South Africa
Gaurav Kwatra,a,b Shabir A. Madhi,a,b,c Clare L. Cutland,a,b Eckhart J. Buchmann,d Peter V. Adriana,b
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Maternal vaginal colonization with group B streptococcus (GBS) is a major risk factor for invasive GBS infection in newborns.
The CDC-recommendedmethod for detecting GBS colonization is to culture vaginal and rectal swabs in a selective broth fol-
lowed by subculture on blood agar or a selective medium. A high incidence of antimicrobial resistance in the fecal microflora can
compromise the recovery of GBS from the selective broth. Here, we compared CHROMagar StrepB (CA), Columbia colistin-
nalidixic agar (CNA), and Trans-Vag selective broth enrichment for the isolation of GBS from 130 vaginal and 130 rectal swabs
from pregnant women. The swabs were randomized for plating first on either CA or CNA, and they then were inoculated in
Trans-Vag broth. GBS was cultured from 37.7% of the vaginal swabs and 33.1% of the rectal swabs. There were no differences
in the detection rates for the vaginal swabs between CA (31.5%), CNA (26.2%), and the selective broth (30.0%). The sensitivities
in relation to a composite score were 83.7%, 69.4%, and 79.6%, respectively. However, recovery of GBS from the rectal swabs was
significantly higher from CA (29.2%; P< 0.0001) and CNA (23.8%; P 0.002) than from the selective broth (9.2%). The sensitiv-
ities were 88.4%, 72.1%, and 27.9%, respectively. The order of plating on the solid mediumwas significant (P 0.003), with GBS
detection rates of 30.8% and 24.6%when swabs were plated first and second, respectively. These findings show that a selective
broth is not suitable for the recovery of GBS from rectal swabs in settings such as ours, due to masking of the GBS colonies by
persistent microflora.
Infection by group B streptococcus (GBS) is one of the mostcommon infections in newborns (1). Maternal colonization has
been found to be a major risk factor for invasive GBS disease
within 6 days of birth. Approximately 10 to 40% of pregnant
women are colonizedwithGBS in either the vagina, the rectum, or
both areas (2). The rate of peripartum transmission of GBS to
newborns of colonized women is approximately 50%, after which
1 to 2% of these newborns develop invasive GBS infection in the
first week of life (3, 4). The Centers for Disease Control and Pre-
vention (CDC) has recommended that all pregnant women be
screened for rectovaginal carriage of GBS at 35 to 37 weeks’ gesta-
tion to identify women who should receive intrapartum antimi-
crobial prophylaxis (IAP). When successfully implemented, IAP
targeted at GBS-colonized pregnant women has reduced the inci-
dence of invasive GBS disease by 86 to 89% (5–7). The sensitivities
of screeningmethods for the identification ofmaternal carriage of
GBS depends on the timing of specimen collection, the source of
the specimen, and the culture technique used. Optimally, speci-
mens should be collected as close to delivery as possible. The use of
vaginal and rectal swab specimens has been shown to yield higher
GBS culture-positivity rates than vaginal swabs alone or cervical
specimens (8–10). The current CDC recommendation for the iso-
lation of GBS from vaginal and rectal or rectovaginal swabs is
growth in a selective broth medium (Todd-Hewitt broth with
gentamicin and colistin or nalidixic acid), followed by subculture
on blood agar or a selectivemedium (11). The reported sensitivity
of selective broth for the culture of GBS is 82% to 99% (12–15).
There are, however, limitations to this approach. The procedure
requires at least an additional 24 h of culture time compared to
that for direct plating on selective agar, and isolated GBS-like col-
onies require further identification with ancillary tests, e.g., the
CAMP factor or B antigen test (11). Furthermore, identification of
GBS-like colonies on blood agar requires laboratory expertise,
particularly when they aremixedwith othermicroflora (16). Con-
sideringmethods to decrease the GBS detection time, studies have
shown that direct plating on colistin-nalidixic agar (CNA) is a
low-cost alternative for GBS recovery, albeit with a lower sensitiv-
ity that has ranged from 59% to 83% (17–19). In recent years,
several commercial chromogenic media, such as Granada me-
dium, CHROMagar StrepB (CA), and chromID Strepto B agar,
have been tested for their suitability for detectingGBS (18, 20). CA
is a commercially available selective chromogenic medium that
inhibits most saprophytic bacteria and yeasts and produces
mauve-colored GBS colonies under aerobic conditions irrespec-
tive of their hemolytic properties, allowing direct visual identifi-
cation. The use of chromogenic media may improve the yield of
GBS while reducing labor costs and turnaround time. The clinical
sensitivities of these media vary from study to study, with most
studies reporting 93% to 98% for CA (16, 21), 40% to 91% for
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Granada medium (12, 18, 22), and 88% to 95% for chromID
Strepto B agar (13, 18). The aimof this studywas to evaluate direct
plating on CA and CNA and selective broth enrichment for the
isolation of GBS in swabs from pregnant women.
MATERIALS AND METHODS
Study design. The study was approved by the Human Research Ethics
Committee of the University of the Witwatersrand (IRB/Protocol-
M090937) and conducted at prenatal community clinics in Soweto, Jo-
hannesburg. Included were HIV-uninfected pregnant women at more
than 20 weeks of gestation whowere able to provide informed consent for
participation. Exclusion criteria were concurrent antibiotic use, an acute
illness, a symptomatic vaginal discharge, and a known or suspected con-
dition in which clinical vaginal examinations were contraindicated. A
convenience sampling of lower vaginal and rectal swabs was collected
from 130 pregnant women between January 2011 and April 2011 by
trained study nurses.
Sample collection. Samples were collected with rayon-tipped swabs
that were placed into 5 ml of Amies transport medium without charcoal
(catalog no. MW170, Transwab Amies; Medical Wire, UK). All samples
were transported to the laboratory within 4 h of collection, where they
were processed within 2 h.
Randomization and processing of samples. All vaginal and rectal
swabswere randomized using a randomization log. The swab numberwas
linked to three different randomly numbered labels, one for each culture
medium type. Each sample was randomized to be plated first on either
CNA or CA, after which the swab tip was inoculated into the selective
(Trans-Vag) broth (Todd-Hewitt broth with 8 g/ml gentamicin and 15
g/ml nalidixic acid) and incubated for 24 h before being plated on 5%
sheep blood agar (SBA) (Fig. 1). The randomization process ensured that
the technicians reading the plates and entering the data were blinded with
respect to the participant, the type of swab (rectal or vaginal), the order of
plating, and the swab/plate pairs. TheCNAand SBAplateswere incubated
at 37°C in 5%CO2 for 18 to 24 h, and theCAplates were incubated at 37°C
for 18 to 24 h under aerobic conditions. If the expected colonies were not
visible after 24 h of incubation, the plates were reincubated for an addi-
tional 24 h and reexamined for growth. Up to four GBS-like colonies were
isolated from the solid culture medium on the basis of the colony mor-
phology and mauve color on CA and the colony morphology and beta-
hemolysis on CNA and blood agar. Isolates were confirmed to be GBS by
testing for CAMP factor, an inability to hydrolyze esculin, catalase nega-
tivity, and group B antigen latex agglutination positivity (Omega Diag-
nostics, Scotland, UK). The CA and CNA prepoured plates were pur-
chased from Media Mage (Johannesburg, South Africa).
Statistical methods. Descriptive statistics included statements of fre-
quency with percentages, means standard deviations (SDs), and medi-
ans with interquartile ranges (IQRs). Sensitivities (detection rates) were
calculated by comparing the proportion of positive samples for each me-
dium in relation to a gold standard, which was a composite positive for all
test media. The McNemar test for correlated percentages and the chi-
square test with Yates’ correction were used to compare the culturemeth-
ods, with P values of0.05 being considered statistically significant.
RESULTS
Study population. The mean age (SD) of the women at swabbing
was 25.7 years (5.9 years), and the mean gestational age (SD)
was 23.8 weeks (3.2 weeks). The median parity and gravidity
were 1 (IQR, 0 to 1) and 2 (IQR, 1 to 2), respectively.
CA and CNA versus Trans-Vag selective broth enrichment.
Overall, 37.7% of the vaginal swabs and 33.1% of the rectal swabs
tested positive for GBS (Table 1). There were no statistically sig-
nificant differences in the detection rates for the vaginal swabs
between CA (31.5%), CNA (26.2%), and the selective broth
(30.0%). The sensitivities with respect to the composite scores
were 83.7%, 69.4%, and 79.6%, respectively. The recovery of GBS
from the rectal swabs, however, was significantly higher from CA
(29.2%; P 0.0001) and CNA (23.8%; P 0.002) than from the
selective broth medium (9.2%). The sensitivities were 88.4%,
72.1%, and 27.9%, respectively. Despite the higher sensitivity re-
ported for CA than for CNA for the vaginal and rectal swabs, these
differences were not statistically significant (P 0.05).
Accuracy. The accuracy of a medium was defined as the per-
Handing over to lab technician for processing
Transported to lab in Amies transport medium
Collection of  Vaginal and rectal swabs (130 subjects; 20 -30 wks gestation age)
Sample sequentially plated  first on either  CNA or  ChromagarStrep Bfollowing which, the swab  
tipwas inoculated into Trans-Vagbroth
1.Chromagar Strep B
3. Trans-Vag Broth
Identification of GBS by CAMP test, inability to hydrolyze esculin,   , catalase test, Group B antigen
Sensitivities were calculated by comparing the proportion of positive samples for each medium
in relation to composite positives for all test media.
2. CNA1. CNA
Randomization of samples 
2.Chromagar Strep B
FIG 1 Procedure for the collection, randomization, and laboratory handling of the vaginal and rectal swabs for the isolation of group B streptococcus.
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centage of isolated colonies that were identified as GBS by confir-
matory testing divided by the total number of GBS-like colonies
that were isolated fromaplate and subjected to confirmatory tests.
The denominator includes both confirmed GBS colonies (true
positives) and colonies having appearances similar to those ofGBS
but failing the confirmatory tests (false positives). For the vaginal
swabs, CAwas themost accurate for discriminating between true-
positive and false-positive isolates (92.8%), followed by selective
broth enrichment (90.6%) and CNA (84.3%). There were no sig-
nificant differences in the accuracies of primary identification be-
tween CA and the selective broth or between CNA agar and the
selective broth. However, after direct plating, colonies were signif-
icantly more likely to be GBS following isolation with CA than
with CNA (P 0.026).
The accuracy of GBS identification from the rectal swabs was
significantly better with CA (83.0%; P  0.0001) and CNA
(77.3%; P  0.0004) than with selective broth enrichment
(54.5%). CA was found to be more accurate than CNA, but these
differences were not statistically significant (P 0.26). The num-
bers of GBS-like colonies that were identified from the cultured
vaginal and rectal swabs were similar between CA (167 vaginal,
159 rectal) and CNA (153 vaginal, 150 rectal). However, about
half the numbers of GBS-like colonies were identified among the
other flora following selective broth enrichment from the rectal
swabs (171 vaginal, 88 rectal). A higher percentage of false-posi-
tive GBS isolates was reported from the rectal swabs than from the
vaginal swabs with CA (17.0% versus 7.2%; P  0.01), CNA
(22.7% versus 15.7%; P  0.16), and the selective broth (45.5%
versus 9.4%; P 0.0001) (Table 1).
Impact of randomization and the order of plating.The order
in which the swabs were plated onto the two selective media had a
significant effect on the culture positivity rate. Out of 260 swabs
tested directly on CNA and CA, a total of 86 (33.1%) swabs were
positive forGBS.Direct culture onCNAandCAyieldedGBS from
80 (30.8%) swabs when plated first compared to 64 (24.6%) when
plated second (P 0.003). GBS was isolated from both media in
58 (22.3%) of the swabs. The numbers of swabs from which GBS
was isolated from a single medium were 22 (8.5%) and 6 (2.3%)
from the first and second platings, respectively. When CNA and
CA were plated first, the sensitivities were 86.4% and 87.5%, re-
spectively, and when CNA and CA were plated second, the sensi-
tivities were 57.4% and 82.2%, respectively (Table 2).
DISCUSSION
Current CDC guidelines for prenatal GBS screening recommend
the collection of a single rectovaginal swab or separate vaginal and
rectal swabs that are enriched overnight in Todd-Hewitt broth
with antibiotics, followed by culture on blood agar or a selective
medium (11). While these guidelines were developed within the
context of high-income countries, there are few data on the valid-
ity of thismethod in low- tomiddle-income countries where there
are differences in the distributions of saprophytic organisms and
antimicrobial resistance is common (23–26). In this study, we
compared the recovery rates of GBS by standard methods with
direct plating onto either CNA or CA from either the vaginal or
rectal swabs from pregnant South African women to determine
whether these alternatives would provide better recovery rates.
One of the main reasons for this comparison was the presence of
vaginal flora that are resistant to antimicrobial agents, particularly
Proteus spp., which occur in a small percentage of swabs and are
able to persist in Trans-Vag broth and swarm the subcultured
blood agar plate, rendering it unreadable (P. V. Adrian, personal
communication). This necessitated the use of both Trans-Vag
TABLE 1 Performance characteristics of CA, CNA, and the selective broth for detection of GBS from vaginal and rectal swabs
Medium
Vaginal swabs (n 130) Rectal swabs (n 130)
No. (%)
positive for GBS
Sensitivity
(%)a Accuracy (%)b
No. (%)
positive for GBS
Sensitivity
(%)a Accuracy (%)b
CA 41 (31.5) 83.7 155/167 (92.8) 38 (29.2) 88.4 132/159 (83.0)
CNA 34 (26.2) 69.4 129/153 (84.3) 31 (23.8) 72.1 116/150 (77.3)
Selective broth 39 (30.0) 79.6 155/171 (90.6) 12 (9.2) 27.9 48/88 (54.5)
Total GBS isolated 49 (37.7) 43 (33.1)
a Sensitivity was calculated in comparison to composite scores of all media.
b Accuracy was calculated as the number of confirmed GBS colonies isolated/total number of GBS-like colonies that were confirmed as either positive or negative for GBS.
TABLE 2 Performance characteristics of CNA and CA with respect to the order of plating
Specimen
CNA CA Trans-Vaga
Total no. (%)
positive for GBS
No. (%)
positive for GBS
Sensitivity
(%)
No. (%)
positive for GBS
Sensitivity
(%)
No. (%)
positive for GBS
Sensitivity
(%)
Plated first on CAN
Vaginal (n 65) 20 (30.8) 80 21 (32.3) 84 23 (35.4) 92 25 (38.5)
Rectal (n 65) 18 (27.7) 94.7 16 (24.6) 84.2 8 (12.3) 42.1 19 (29.2)
Total (n 130) 38 (29.2) 86.4 37 (28.5) 84.1 31 (23.8) 70.4 44 (33.8)
Plated first on CA
Vaginal (n 65) 14 (21.5) 58.3 20 (30.8) 83.3 16 (24.6) 66.7 24 (36.9)
Rectal (n 65) 13 (20) 54.2 22 (33.8) 91.7 4 (6.2) 16.7 24 (36.9)
Total (n 130) 27 (20.8) 56.2 42 (32.3) 87.5 20 (15.4) 41.7 48 (36.9)
a After direct plating, the swab was placed in Trans-Vag broth.
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broth and direct plating on CNA in a previous study of vaginal
swabs from South Africa (27).
In our study, there were no statistically significant differences
in the recoveries of GBS from vaginal swabs between the different
media, suggesting that any of these three options is valid in our
clinical setting and the choice can be made based on cost, avail-
ability, and desired turnaround time. In contrast, the recovery of
GBS from rectal swabs following selective broth enrichment was
inferior to that with either of the direct platingmethods. Themain
reasons for the poor recovery of GBS were survival and over-
growth of non-GBS organisms in the Trans-Vag broth, which
masked the presence of GBS on the subculture plates. The results
of our study differ from those of several previously published re-
ports, in which it was shown that the selective broth method is
more sensitive than direct plating on a selective medium for re-
covering GBS from rectal or rectovaginal swabs (12–15). While
these results may be valid in settings such as those where the stud-
ies were conducted, other studies from Brazil, Denmark, and
Spain demonstrated better recoveries of GBS from rectal swabs
with a solid selective medium than with a selective broth (28–30).
Pigmented enrichment broth, such as StrepB carrot broth, has
been shown to increase the sensitivity of GBS detection by culture
over that with LIM broth (Todd-Hewitt broth with colistin and
nalidixic acid) (31) when used as an enrichment step prior to PCR
screening (32); however, GBS growth and pigment development
can still be suppressed by the overgrowth of fecal bacteria and
mask the presence of GBS on culture (32). Since the mechanism
behind the poor recovery of GBS from rectal swabs is related to
persistence and overgrowth of resistant fecal bacteria (30), it is
likely that the collection of a single rectovaginal swab or the co-
processing of vaginal and rectal swabs may be severely compro-
mised by the use of a selective broth in our setting.
Overall, CA produced the highest recovery rate of GBS from
the vaginal and rectal swabs. One advantage of the chromogenic
medium was that it was significantly easier to discriminate be-
tweenGBS and groupD streptococcus (GDS) in cocolonized sam-
ples due to differences in the color development of the colonies.
GBS turns mauve, whereas GDS turns blue. This is particularly
important in comparisons with samples plated on blood agar,
where the GBS colonies are in the minority and single GBS colo-
nies can be overlooked amid large numbers of morphologically
similar GDS. Despite CA being more expensive than CNA or a
selective broth-blood agar combination, CA offers cost savings in
terms of reduced processing time and the ease with which GBS
colonies can be identified on the plates. Moreover, due to the
increased accuracy of colony identification through pigment for-
mation, the number of confirmatory tests required is reduced, as
the need for additional tests to rule out the morphologically sim-
ilar colonies of group D streptococci is eliminated. While the cal-
culated values of accuracy will vary with the skill and experience of
the users, CA offers an easier learning curve compared to that for
a blood-based isolation medium. In a comparison of the two se-
lective solid agars, CA had higher sensitivity and accuracy than
CNA for the vaginal and rectal swabs, although these values were
not statistically significant, most likely due to a limited sample
size.
Froma reviewof the literature, no study in a clinical setting had
considered the order of platingwhen comparing and reporting the
sensitivities of culture media to isolate GBS. In this study, the
order of plating had a significant effect on the recovery of GBS,
which suggests that future studies where solid media are com-
pared should follow randomized protocols to prevent detection
bias based on plating order. Possible reasons for the lower recov-
ery rate of GBS from the swabs plated for a second time include
removal of the organisms from the surface of the swab in the first
plating and blockage of the swab surface by sterile agar from the
previous plating, preventing transfer of organisms. The sensitivity
of direct plating onCNAwhen plated first in this studywas similar
to that described by Louie et al. (19), who also inoculated swabs on
CNA first.
In conclusion, selective broth enrichment showed significantly
lower sensitivity for the recovery of GBS from rectal swabs. This
method is not suitable for the recovery ofGBS from rectal swabs or
rectovaginal swabs in regions with a high prevalence of antimicro-
bial-resistant flora. The recovery of GBS from the vaginal swabs
plated on CA appears to have sensitivity equal to that of the selec-
tive broth and offers a less time-consuming and less labor-inten-
sive process. For these reasons, our laboratory has started to use
CA for current and future studies.
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Abstract
Background: Maternal recto-vaginal colonization with Group B Streptococcus (GBS) and consequent vertical transmission to
the newborn predisposes neonates to early-onset invasive GBS disease. This study aimed to determine the acquisition and
loss of serotype-specific recto-vaginal GBS colonization from 20–37+ weeks of gestational age.
Methods: Vaginal and rectal swabs were collected from HIV-uninfected women at 20–25 weeks of gestation age and at 5–6
weekly intervals thereafter. Swabs were cultured for GBS and isolates were serotyped by latex agglutination. Serologically
non-typable isolates and pilus islands were characterized by PCR.
Results: The prevalence of recto-vaginal GBS colonization was 33.0%, 32.7%, 28.7% and 28.4% at 20–25 weeks, 26–30
weeks, 31–35 weeks and 37+ weeks of gestational age, respectively. The most common identified serotypes were Ia (39.2%),
III (32.8%) and V (12.4%). Of 507 participants who completed all four study visits, the cumulative overall recto-vaginal
acquisition rate of new serotypes during the study was 27.9%, including 11.2%, 8.2% and 4.3% for serotypes Ia, III and V,
respectively. Comparing the common colonizing serotypes, serotype III was more likely to be associated with persistent
colonization throughout the study (29%) than Ia (18%; p = 0.045) or V (6%; p = 0.002). The median duration of recto-vaginal
GBS colonization for serotype III was 6.35 weeks, which was longer than other serotypes. Pilus island proteins were detected
in all GBS isolates and their subtype distribution was associated with specific serotypes.
Conclusion: South African pregnant women have a high prevalence of GBS recto-vaginal colonization from 20 weeks of
gestational age onwards, including high GBS acquisition rates in the last pregnancy-trimesters. There are differences in
specific-serotype colonization patterns during pregnancy.
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Introduction
Maternal vaginal colonization with Group B Streptococcus (GBS)
is the major risk factor for early onset invasive GBS disease (EOD)
in newborns [1,2]. Screening of pregnant women for GBS
colonization during the third trimester, coupled with targeted
intrapartum antibiotic prophylaxis (IAP) of colonized women
during labor, has reduced the incidence of invasive GBS disease in
industrialized countries [3].
An alternate preventive strategy against EOD is vaccination of
pregnant women, which could enhance transplacental transfer of
anti-GBS antibody to the fetus. Studies have identified an
association between high maternal serotype-specific anti-capsular
polysaccharide (CPS) antibody concentrations with reduced risk of
recto-vaginal colonization and reduced risk of newborns develop-
ing EOD [4,5]. Since GBS CPS-protein conjugate vaccines are
serotype-specific, it is important to characterize the serotype
distribution of GBS in different regions of the world as well as
understand the changes which occur in GBS colonization during
pregnancy [6]. Other potential vaccine candidates include GBS
surface protein antigens such as pilus island (PI) proteins that are
present in all GBS isolates [7]. Although it has been shown that
maternal GBS colonization during pregnancy may fluctuate
[8,9,10], there are limited longitudinal studies on the rate of
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serotype-specific GBS acquisition and duration of colonization
during pregnancy.
We aimed to determine the acquisition and loss of GBS recto-
vaginal colonization, including serotype-specific changes, among
South African pregnant women from 20 weeks to at least 37 weeks
of gestational age. We also studied the PI distribution of recto-
vaginal colonizing GBS isolates and their association with capsular
serotype.
Materials and Methods
Study Population
The study was conducted at prenatal community clinics in
Soweto (Lillian Ngoyi, Diepkloof, Mofolo and Michael Maponya),
Johannesburg from August 2010 to August 2011. Inclusion criteria
were HIV-uninfected pregnant women confirmed by HIV ELISA
test non-reactivity at enrolment, from 20–25 weeks of gestational
age based on last menstrual cycle and who consented to study
participation. Exclusion criteria at enrolment included antibiotic
treatment in the previous two weeks, any acute illness, symptom-
atic vaginal discharge and a known or suspected condition in
which clinical vaginal examinations were contradicted. If antibi-
otics were taken after the first visit, the collection of specimens was
delayed for at least two weeks after the last antibiotic dose.
Swab collection and culture of GBS
Lower vaginal and rectal swabs were collected for GBS culture
starting at 20–25 weeks (Visit-1), followed by three subsequent
visits (Visits 2–4) at 5–6 weekly intervals, up to 37–40 weeks (Visit-
4) of gestational age. Demographic and pregnancy-related data
were collected at the first visit. All samples were collected by
trained study nurses with rayon-tipped swabs that were placed into
Amies transport medium without charcoal (cat #MW170,
Transwab Amies, Medical wire, U.K.). Swabs were transported
to the lab within 4 hours of collection, and processed within 2
hours. For GBS isolation, swabs were inoculated onto CHRO-
Magar StrepB (CA; Media Mage, Johannesburg, South Africa)
and the CA plates were incubated at 37uC for 18–24 hours in
aerobic conditions [11]. If GBS-like colonies were not visible
within 24 hours after incubation, the plates were incubated for a
further 24 hours and re-examined for growth. Up to four GBS-like
colonies were isolated and confirmed as GBS by testing for CAMP
factor, inability to hydrolyze esculin, catalase negativity and group
B antigen.
Capsular serotyping
Serotyping was performed by the latex agglutination method
with specific antisera against types Ia, Ib and II to IX CPS
antigens (Statens Serum Institute, SSI, Sweden) as described [12].
Isolates that tested negative by latex agglutination for all serotypes
were further typed by a PCR method for serotypes Ia, Ib, II, III,
IV and V using primer sequences described by Poyart et al [13].
The gene encoding dlts was used as a PCR positive control for
GBS identification.
Pilus typing
Pilus island proteins of all GBS isolates were detected by PCR
for PI-1, PI-2a and PI-2b, with primers that target the genomic
regions coding for the ancillary protein (AP)-1 of each PI. Isolates
that tested negative for all the AP1 genes, or isolates from which
neither PI-2a or PI-2b could be detected, were amplified by a
second set of primers representing conserved regions of AP-2 as
described previously [7].
Statistical analysis
Data were analyzed using SAS version 9.2 software (SAS
Institute, Inc., NC, USA). A visit sample pair of vaginal and rectal
swabs was considered negative if no GBS growth was evident on
either swab, and positive if GBS was grown from either swab. The
pregnant women were grouped into transient, intermittent and
persistent carriers according to the presence of GBS colonization
and to individual serotypes at the four sampling time points.
Transient carriers were defined as women who were colonized at
only one of the four visits, intermittent carriers as those who were
colonized at two or three of the visits and persistent carriers as
those colonized at all four study visits.
Descriptive statistics included the prevalence of colonization at
individual time points and changes of recto-vaginal colonization
status. Analysis of the changes in recto-vaginal colonization over
time was restricted to the 507 participants who completed all four
study visits. New acquisition of GBS was defined as positive culture
of a new serotype which was not previously present. The new
acquisition rate was defined as the number of new serotype
acquisitions divided by the number of participants who were at a
risk of acquiring the new serotype. Thus, women who were
already previously colonized by a particular serotype were
excluded subsequently from the denominator for estimating
acquisition rate for the homotypic serotype. The rate of new
acquisitions by all GBS serotypes were calculated from the sum of
acquisition rates for the individual serotypes, and by using the
above methods for GBS acquisition rates in a serotype indepen-
dent manner. Clearance of colonization was defined as a negative
GBS culture for a specific serotype following a positive sample at
the previous visit for the homotypic serotype. The rate of
colonization clearance was defined as the number of GBS-
negative participants at the analyzed time point divided by the
number of participants at the previous visit who were positive for
that serotype, and was also calculated in a serotype independent
manner.
Survival analysis methods were used to estimate the duration of
colonization of specific serotypes. A colonizing event was defined
as the period of time between acquisition and clearance of a GBS
serotype. Date of acquisition was calculated as the midpoint
between the last visit without serotype-specific colonization and
the first visit at which a positive sample was obtained for the
homotypic serotype, while date for termination of serotype-specific
colonization was calculated as the midpoint between the last visit
with colonization and the subsequent negative visit for that
serotype. In this analysis, if colonization occurred at the first visit,
this was taken as the start of colonization, and if colonization
occurred at the last visit, a right censoring approach was applied.
We used the Kaplan-Meier method to estimate the duration of
GBS colonization. The log-rank test was used to examine
differences in duration of carriage between serotypes.
Positive predictive value (PPV) and negative predictive value
(NPV) were calculated for the culture results at different sampling
points with the 37–40 week visit as the reference standard. For
participants who were colonized with same serotype on multiple
visits, only one serotype specific isolate was used to study PI
association with capsular serotype.
The chi-square test was used to compare proportions. Logistic
regression analysis was used to determine the association between
GBS colonization and demographic characteristics at enrolment.
A p-value of ,0.05 was considered significant.
Ethics statement
The study was approved by the Human Research Ethics
Committee of the University of the Witwatersrand (IRB/Protocol-
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M090937) and informed written consent was obtained from all
participating mothers. The trial is registered with South African
National Clinical Trials Register, number DOH-27-0210-3012.
Results
Demographic characteristics
Of the 661 enrolled participants, 621 (93.9%), 595 (90.0%) and
521 (78.8%) completed visits 2, 3 and 4, respectively. Five-hundred
and seven (76.7%) women completed all four study visits. A
detailed trial profile is indicated in figure 1. The main reason for
women not attending all four visits was birth of the baby (13%;
86/661) before the final visit. The demographic characteristics are
displayed in table 1. The mean age of the participants at
enrolment was 25.9 (standard deviation; S.D65.6) years. Only 5
(0.76%) pregnant women have taken antibiotic treatment during
the study.
Prevalence of GBS colonization
The overall prevalence of recto-vaginal GBS colonization was
33.0% (218), 32.7% (203), 28.7% (171) and 28.4% (148) at 20–25
weeks, 26–30 weeks, 31–35 weeks and 37+ weeks of gestational
age, respectively. The lower prevalence of colonization associated
with 31–35 weeks and 37+ weeks compared to 20–25 weeks and
26–30 weeks was specifically associated with a decrease in
prevalence of vaginal colonization, table 2 (23.3% to 19.0%). In
the 86 women who gave birth before the final visit, vaginal GBS
colonization was detected in 17(19.8%) at the last attended visit
compared to 99/521 (19.0%) who gave birth after visit-4
(p = 0.867). The inclusion of rectal swab GBS-culture increased
the overall detection of GBS colonization by approximately 10%
across the four study time-points (p,0.0001) and the prevalence of
rectal colonization remained similar at each study time-point.
Of several demographic characteristics evaluated at enrolment
independently by univariate analysis, parity (OR: 1.22; 95% CI:
1.02–1.47; p = 0.030) and gravidity (OR: 1.17; 95% CI: 1.01–1.36;
p = 0.046), (Table 3) were significantly associated with GBS recto-
vaginal colonization, with the highest colonization prevalence
observed among women with parity $3 (42.1%) and gravidity of
$4 (41.7%), (Table 1). In a multivariate analysis, none of the
demographic characteristics were found to be associated with GBS
recto-vaginal colonization, (Table 3). In a serotype-specific
univariate analysis at enrolment, multiparity was associated with
a higher prevalence of serotype III colonization (OR: 1.37; 95%
CI: 1.07–1.76; p = 0.012), gravidity also showed possible associ-
ation with serotype III colonization (p = 0.068). In the multivariate
analysis parity was found to be associated with serotype III
colonization (Adjusted OR: 6.69; 95% CI: 1.47–30.4; P= 0.014).
Gravidity (p = 0.053) and abortions (p = 0.057) also showed a
possible association with serotype III colonization, (Table 3). None
of the demographic characteristics were found to be associated
with serotype Ia colonization in the univariate or multivariate
analysis. There were no identifiable factors associated with a
higher prevalence of colonization with GBS at visit-4 alone.
Serotype and pilus island distribution
The proportional representation of serotypes remained consis-
tent at each of the consecutive sampling time-points. Of women
colonized, the proportional representation of the major serotypes
were 36.2% to 41.4% for Ia, 31.3% to 34.9% for III, 10.3% to
15.6% for V, 7.2% to 7.5% for II, 3.5% to 4.6% for Ib, 2.0% to
4.0% for IV and 0.0% to 3.3% for IX (Table S1 in file S1). The
concordance of serotypes for GBS cultured concurrently from
vaginal and rectal swabs was 91.3%, 89.5%, 94.1% and 94.1% for
the four consecutive visits, respectively. Only 1.6% of GBS isolates
were serologically non-typable by latex agglutination and were
serotyped by PCR.
All GBS isolates harbored one or more PIs, either PI-2a on its
own or with a combination of PI-2a or PI-2b in combination with
PI-1.The most common PI arrangement was PI-2a on its own,
which occurred in 103/227 (45.4%), 92/211 (43.6%), 79/175
(45.1%) and 63/152 (41.5%) of isolates at visits 1–4, respectively,
followed by PI combination PI-2b and PI-1, which occurred in
75/227 (33.0%), 69/211 (32.7%), 68/175 (38.9%) and 58/152
(38.2%) of isolates at visits 1–4, respectively. The least common PI
arrangement was a combination of PI-2a and PI-1 which occurred
in 49/227 (21.6%), 50/211 (23.7%), 29/175 (16.0%) and 31/152
(20.4%) of isolates at visits 1–4, respectively. There were no
significant changes in the prevalence of PI distribution with respect
to different visits, with the exception of PI-2a which was less
common at visit-4 (18.0%, 94/521) compared to visit-1 (23.0%,
152/661; p = 0.007), and which was attributable to a lower
prevalence of serotype Ia at visit-4 (10.6%, 55/521) compared to
visit-1 (14.2%, 94/661).
There was a strong correlation between the presence of
particular combinations of PI and the serotype; Figure 2. Most
serotype Ia isolates were associated with PI-2a (94.9%; 148/156),
whereas the majority of serotype III isolates were associated with
the combination of PI-1 and PI-2b (88.2%; 105/119). The
association between PIs and serotype V was more variable, with a
PI-1+PI-2a combination occurring in 64.7% (33/51) and PI-2a
alone occurring in 29.4% (15/51) of isolates.
Changes in GBS colonization overtime
Five hundred and seven participants who completed all four
study visits were similar in their demographic characteristics
compared to the 154 participants not included in this analysis
(data not shown). In the analyzed subset, the prevalence of recto-
vaginal GBS colonization was 32.1% (163), 30.4% (154), 29.0%
(147) and 27.8% (141) at 20–25 weeks, 26–30 weeks, 31–35 weeks
and 37+ weeks of gestational age, respectively. Two hundred and
fifty-two (49.7%) women were colonized at least once during the
study period, of whom 70 (27.8%) were persistent carriers, 83
(32.9%) transient carriers and 99 (39.3%) were intermittently
colonized for any serotype (Table S2 in file S1).
The cumulative serotype-specific prevalence across the study
period was 23.7% (120/507) for Ia, 18.3% (93/507) for III, 7.1%
(36/507) for V, 4.3% (22/507) for II and 2.8% (14/507) for Ib. All
GBS serotypes were variable in their colonization patterns.
Comparing the three most common colonizing serotype carriers,
29% (27/93) of serotype III carriers were associated with persistent
colonization compared to serotype Ia (18%; 21/120; p = 0.045) or
V (6%; 2/36; p = 0.002). Serotype V was the most dynamic, with
94.4% (34/36) of colonized women either being transient or
intermittent carriers compared to 82.5% (99/120; p= 0.106) for Ia
and 71.0% (66/93; p = 0.004) for III. Only one serotype was
detected in 83.3% (210/252) of GBS carriers during the study
period, with 85.7% (60/70) of women persistently colonized being
associated with the same serotype.
Of the 16.7% (42/252) women in whom multiple serotypes
were detected over the study period, two serotypes were detected
in 9.5% (24/252) and three serotypes in 7.1% (18/252)
participants. Among women in whom multiple serotypes were
detected, a new serotype was observed at the immediate next visit
in 85.7% (36/42) of cases, while a new serotype was detected
following a period of no colonization by the preceding serotype in
six women.
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New acquisition and clearance of colonization
Three hundred and forty-four participants who completed all
four study visits were not colonized at visit-1, of whom 89 (25.9%)
became colonized at one of the subsequent three visits. When
including new serotype acquisition in those previously colonized
by a heterotypic serotype (n = 39), the cumulative overall recto-
vaginal acquisition rate of new serotypes during the study,
calculated from the sum of acquisition rates for the individual
serotypes was 27.9%. The number of new acquisitions was highest
for serotypes Ia (11.2%, 49/436), III (8.2%, 37/451) and V (4.3%,
21/492); table S2 in file S1. The mean new acquisition rate of
GBS was 11.4% (S.D60.5%) at 5–6 week visit intervals, including
11.6% between visit-1 and visit-2, and 10.8% and 11.7% in the
Figure 1. Trial Profile.
doi:10.1371/journal.pone.0098778.g001
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intervals of subsequent consecutive visits. Of 163 participants who
were colonized at visit-1, 76 (46.6%) were no longer colonized by
visit-4. The rate of colonization-clearance was 75% (6/8) for
serotype Ib, 73.3% (11/15) for V and 63.4% (45/71) for Ia. The
overall clearance of any GBS colonization was 30.1% (49/163),
29.2% (45/154) and 32.7% (48/147) between visits-1 and -2,
visits-2 and -3, and visits-3 and -4, respectively. No demographic
characteristics were identified that were associated with either new
acquisition or clearance of colonization.
Duration of GBS colonization
The median duration of recto-vaginal GBS colonization was
6.35 weeks for serotype III, which tended to be longer than other
serotypes, including serotype Ia (median: 5.21 weeks; p = 0.02;
table 4) which was the second most common colonizing serotype.
The difference in duration of colonization between serotype III
and less prevalent serotypes was not statistically significant.
Table 1. Demographics of the study population at time of enrolment (n = 661).
Demographic characteristic Overall (n =661) GBS Colonized GBS Uncolonized
Age (years) ,20 92 (13.9%)a 27 (29.3%)b 65 (70.7%)c
Mean age: 25.9 (S.D65.6) 20–24 234 (35.4%) 78 (33.3%) 156 (66.6%)
25–28 161 (24.4%) 53 (32.9%) 108 (67.1%)
29–32 95 (14.4%) 29 (30.5%) 66 (69.5%)
33–35 40 (6.1%) 20 (50.0%) 20 (50.0%)
36+ 39 (5.9%) 11 (28.2%) 28 (71.8%)
Parity 0 338 (51.1%) 97 (28.7%) 241 (71.3%)
Median parity: 0 (range; 0–5) 1–2 304 (46.0%) 113 (37.2%) 191 (62.8%)
3–5 19 (2.9%) 8 (42.1%) 11 (57.9%)
Gravidity 1 286 (43.3%) 80 (28.0%) 206 (72.0%)
Median gravidity: 2 (range; 1–8) 2 221 (33.4%) 80 (36.2%) 141 (63.8%)
3 106 (16.0%) 38 (35.8%) 68 (64.2%)
$4 48 (7.3%) 20 (41.7%) 28 (58.3%)
Previous Abortion (spontaneous) 0 553 (83.7%) 176 (31.8%) 377 (68.2%)
Median abortion: 0 (range; 0–3) 1 88 (13.3%) 36 (40.9%) 52 (59.1%)
2 19 (2.9%) 6 (31.6%) 13 (68.4%)
3 1 (0.2%) 0 (0.0%) 1 (100%)
Stillborn 0 651 (98.5%) 214 (32.9%) 437 (67.1%)
Median stillbirths: 0 (range; 0–1) 1 10 (1.5%) 4 (40.0%) 6 (60.0%)
aData are no (%) of total participants, b,cData are row %.
doi:10.1371/journal.pone.0098778.t001
Table 2. Prevalence of Group B Streptococcus colonization during the study visits.
Site of colonization Visit-1 Visit-2 Visit-3 Visit-4
(20–25 weeks) (26–30 weeks) (31–35 weeks) 37+weeks)
n=661 n=621 n=595 n=521
Mean gestation age:
22.7 weeks Mean gestation age: 27.9 weeks
Mean gestation age: 32.5
weeks
Mean gestation age: 37.5
weeks
Vaginal only (%; 95% CI) 62 65 47 31
(9.4%; 7.2–11.6) (10.5%; 8.1–12.9) (7.9%; 5.7–10.1) (5.9%; 3.9–7.9)
Rectal only (%; 95% CI) 64 62 56 49
(9.7%; 7.5–12.0) (10%; 7.6–12.4) (9.4%; 7.1–12.0) (9.4%; 6.9–11.9)
Both vaginal and
rectal (%; 95% CI)
92 76 68 68
(13.9%; 11.3–16.5) (12.2%; 9.63–14.8) (11.4%; 8.9–14.0) (13.1%; 10.2–16.0)
Vaginal and/or rectal
(%; 95% CI)
218 203 171 148
(33.0%; 29.4–36.6) (32.7%; 29.0–36.4) (28.7%; 25.1–32.3) (28.4%; 24.5–32.3)
CI-Confidence interval, n = number of participants.
doi:10.1371/journal.pone.0098778.t002
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Predictive values for each visit culture with respect
culture status at visit-4
Positive and negative predictive values of serotype-specific
culture at 20–25 weeks, 26–30 weeks and 31–35 weeks of
gestational age compared to 37+ weeks colonization status are
presented in table 5. The overall positive predictive values were
53.4%, 61.7% and 67.4% for GBS-positive cultures at 20–25
weeks, 26–30 weeks and 31–35 weeks, respectively, relative to
positivity at 37+ weeks, while the negative predictive values for 20–
25 weeks, 26–30 weeks and 31–35 weeks ranged from 84.3% to
88.3%. Serotypes Ia and V had lower PPVs compared with
serotype III at each time-point. The observed PPVs at 31–35
weeks, were 55–70% for the three commonest serotypes.
Discussion
To our knowledge this is the first serotype-specific longitudinal
study conducted of recto-vaginal GBS colonization in pregnant
women, in whom we demonstrated a high prevalence and
acquisition rate of GBS recto-vaginal colonization. The overall
rate of new acquisition at 5–6 week interval is in agreement with a
previous study of non-pregnant women, although, the serotype-
specific rates differed [14]. All GBS serotypes were variable in
their colonization patterns, possibly due to the complex interaction
between immunity and specific GBS serotypes, which is still
incompletely understood. It may be that the higher frequency of
persistent colonization and longer overall duration of colonization
by serotype III, is related to a weaker natural immune response
Table 3. Univariate and multivariate association between serotype-specific colonization and observed demographic
characteristics at enrolment.
Characteristic
Overall GBS colonization at
enrolment Serotype III colonization at enrolment Serotype Ia colonization at enrolment
Univariate Multivariate Univariate Multivariate Univariate Multivariate
OR (95% CI), p AOR (95% CI), p OR (95% CI), p AOR (95% CI), p OR (95% CI), p AOR (95% CI), p
Age 0.98 (0.95–1.02), 1.01 (0.97–1.06), 0.98 (0.92–1.03), 1.00 (0.96–1.04), 0.99 (0.94–1.04),
0.536 0.527 0.45 0.96 0.656
Parity 1.99 (0.83–4.79), 1.37 (1.07–1.76), 6.69 (1.47–30.4), 1.05 (0.82–1.34), 0.71 (0.27–1.90),
0.121 0.012 0.014 0.69 0.499
Gravidity 0.63 (0.27–1.50), 1.22 (0.99–1.51), 0.22 (0.05–1.02), 1.11 (0.91–1.35), 1.48 (0.57–3.81),
0.296 0.068 0.053 0.317 0.422
Abortion 1.77 (0.73–4.30), 1.10 (0.66–1.81), 4.14 (0.96–18.0), 1.25 (0.82–1.91), 0.86 (0.31–2.38),
0.207 0.721 0.057 0.298 0.774
Stillborn 1.25 (0.32–4.94), 0.94 (0.12–7.51), 0.76 (0.08–7.30), 2.60 (0.66–10.3), 2.14 (0.49–9.29),
0.741 0.951 0.813 0.171 0.309
OR: odds ratio; AOR: adjusted OR; CI: confidence interval.
doi:10.1371/journal.pone.0098778.t003
Figure 2. Association of pilus island proteins and serotypes among Group B Streptococcus isolates.
doi:10.1371/journal.pone.0098778.g002
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associated with its colonization compared to other serotypes [15].
Consequently, there is a higher risk of exposure at birth to serotype
III in our population, which corroborates with it being responsible
for 49.2% to 57.7% of EOD in our setting [16,17]. The higher
acquisition rate of serotype Ia may result in there being inadequate
time for natural immunity to this serotype developing in the
pregnant woman, which consequently increases the newborn’s risk
of developing EOD from serotype Ia, associated with 22.6% to
31% of EOD cases in our setting [16,17].
The high incidence of new acquisition and loss of colonization
during pregnancy highlights why screening is required as late as
35–37 weeks’ gestational age for the IAP strategy to be effective,
which is concordant with another study in pregnant women [18].
In our study, if women had been screened at 31–35 weeks, 29.1%
(42/141) of those who were colonized at 37+ would not have had
IAP offered to them and a lesser proportion (13.3%; 48/366) may
have unnecessarily received IAP as they were no longer colonized
at 37+ weeks. Although we did not identify any demographic
characteristics associated with new acquisition or clearance of
GBS, additional risk factors such as sexual activity during
pregnancy were not fully explored [19]. The PPV of GBS cultures
obtained from 20–35 weeks varied in serotype distribution
compared to that at 37+ weeks. The prevalence of different
GBS serotypes in a particular population can affect the PPV of late
antenatal GBS cultures.
The high cumulative prevalence of GBS colonization (49.7%)
found in our study is comparable to longitudinal studies from
Denmark and Zimbabwe [8,10]. Furthermore, the prevalence of
colonization observed by us at 37+ weeks of gestational age was
28.4% (148/521), which was similar to that reported in cross-
sectional studies from Europe [20] and USA [21]. The prevalence
of GBS colonization from African countries ranges from 16.5% in
Malawi, 21–23% in The Gambia, Ethiopia and Tanzania and
31.6% in Zimbabwe [22,23,24,25,26]. Our results also showed a
decrease in the prevalence of GBS colonization with respect to
increase in gestational age. This finding agrees with studies from
the USA and Australia [9,27] but contrasts with others that
reported an increase in colonization with increasing gestational
age [28,29].
Our findings on the dominant serotypes are comparable with
serotype distribution data of maternal colonizing isolates from
industrialized countries, including 13% to 35% for serotype Ia and
15% to 44% for serotype III [6]. The identification of serotype IX
in our study was notable in that it is rarely reported in colonizing
studies and not previously described in Africa. To our knowledge,
only 8 GBS colonizing isolates have been identified as serotype IX,
including three from Denmark, two from Germany and one each
from Canada, Hong Kong and Australia [30]. Our data on PI
distribution is comparable to earlier published studies [7,31]
showing that all GBS isolates carried at least one PI, and were
Table 4. Estimated duration of Group B Streptococcus recto-vaginal colonization.
Serotype Colonization duration (weeks)*
Mean (95% CI) Median p-value{
Ia 7.52 (6.6–8.4) 5.21 0.026
Ib 5.22 (4.03–6.42) 3.62 0.358
II 6.11 (5.07–7.16) 4.24 0.736
III 9.15 (8.1–10.2) 6.35 Reference
IV 6.94 (3.8–10.0) 4.81 0.998
V 8.60 (6.80–10.39) 5.96 0.332
IX 6.21 (4.7–7.7) 4.31 0.651
*Time from enrolment, CI-Confidence interval,
{compared to serotype III.
doi:10.1371/journal.pone.0098778.t004
Table 5. Predictive value for 20–25, 26–30 and 31–35 weeks cultures in relation to culture status at 37+ weeks.
Serotype 20–25 weeks 26–30 weeks 31–35 weeks
PPV % (95% CI) NPV % (95% CI) PPV % (95% CI) NPV % (95% CI) PPV % (95% CI) NPV % (95% CI)
Overall GBS 53.4 (45.4–61.2) 84.3 (80.0–88.0) 61.7 (53.5–69.4) 87.0 (83.0–90.3) 67.4 (59.1–74.9) 88.3 (84.6–91.5)
Ia 36.6 (25.5–48.9) 94.5 (91.9–96.4) 49.2 (36.1–62.3) 95.5 (93.2–97.2) 55.0 (41.7–67.9) 96.2 (94.0–97.8)
Ib 25.0 (3.9–65.0) 99.0 (97.7–99.7) 66.7 (22.7–94.7) 99.4 (98.3–99.9) 75.0 (20.3–95.9) 99.2 (98.0–99.8)
II 38.5 (14.0–68.4) 98.8 (97.4–99.6) 54.6 (23.5–83.1) 99.0 (97.7–99.7) 75.0 (42.8–94.2) 99.6 (98.5–99.9)
III 58.9 (45.0–71.9) 95.8 (93.5–97.4) 62.8 (48.1–75.9) 95.6 (93.3–97.3) 67.9 (53.7–80.1) 96.5 (94.3–98.0)
IV 50.0 (12.4–87.6) 100 (99.2–100) 60.0 (15.4–93.5) 100 (99.2–100) 75.0 (20.3–95.9) 100 (99.3–100)
V 26.7 (8.0–55.1) 97.2 (95.3–98.4) 47.6 (25.8–70.2) 98.4 (96.8–99.3) 57.1 (28.9–82.2) 98.0 (96.3–99.0)
IX 100 (19.3–100) 99.6 (98.6–99.9) 50.0 (12.4–87.6) 99.8 (98.9–100) 100 (30.5–100) 99.8 (98.9–100)
PPV: Positive predictive value, NPV: Negative predictive value, CI-Confidence interval.
doi:10.1371/journal.pone.0098778.t005
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associated with the presence of either PI-2a or PI-2b identified
alone or in combination with PI-1.
Our study is limited by the sensitivity of detection of GBS on
selective media which is estimated at 85% [11] and by the fact that
in most cases only the dominant serotype was determined. This
can lead to an underestimation of persistent colonization, an
overestimation of new acquisitions, and an underestimation of the
duration of carriage.
Recent developments in the clinical evaluation of a tri-valent
GBS polysaccharide-protein conjugate vaccine has renewed
interest in the potential of this vaccine to protect neonates against
invasive GBS disease by reducing recto-vaginal colonization
during pregnancy [32]. The findings of this study will be important
in considering study design when evaluating the efficacy of
maternal GBS vaccination protecting against GBS recto-vaginal
acquisition and colonization during pregnancy as surrogate
information on clinical vaccine efficacy may be gained by
determining the immune responses that correlate with protection
against serotype-specific GBS acquisition and colonization during
pregnancy.
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Appendix 3ORIGINAL ARTICLE BACTERIOLOGYNatural acquired humoral immunity against serotype-speciﬁc group B
Streptococcus rectovaginal colonization acquisition in pregnant womenG. Kwatra1,2, P. V. Adrian1,2, T. Shiri1,2, E. J. Buchmann3, C. L. Cutland1,2 and S. A. Madhi1,2,4
1) Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, University of the Witwatersrand, Johannesburg, South Africa, 2) Department of
Science and Technology/National Research Foundation, Vaccine Preventable Diseases, University of the Witwatersrand, Johannesburg, South Africa, 3) Department
of Obstetrics and Gynecology, University of The Witwatersrand and 4) National Institute for Communicable Diseases, Division of National Health Laboratory
Service, Johannesburg, South AfricaAbstractGroup B Streptococcus (GBS) rectovaginal colonization in pregnant women is associated with invasive GBS disease in newborns, preterm
delivery and stillbirths. We studied the association of GBS serotype-speciﬁc capsular polysaccharide (CPS) antibody on new acquisition
and clearance of rectovaginal GBS colonization in pregnant women from 20 weeks until 37 to 40 weeks’ gestation. Serum serotype-
speciﬁc CPS IgG antibody concentration was measured by multiplex enzyme-linked immunosorbent assay and opsonophagocytic activity
(OPA) titres. Rectovaginal swabs were evaluated for GBS colonization, using standard culture methods and serotyping by latex
agglutination, at ﬁve to six weekly intervals. Higher serotype III CPS antibody concentration was associated with lower risk of rectovaginal
acquisition of serotype III during pregnancy (p 0.009). Furthermore, serotype-speciﬁc OPA titres to Ia and III were higher in women who
remained free of GBS colonization throughout the study compared to those who acquired the homotypic serotype (p <0.001 for both
serotypes). Serum CPS IgG values of 1 μg/mL for serotype V and 3 μg/mL for serotypes Ia and III were signiﬁcantly associated with
protection against rectovaginal acquisition of the homotypic serotype. A GBS vaccine that induces sufﬁcient capsular antibody in pregnant
women, including high OPA titres, could protect against rectovaginal colonization during the latter half of pregnancy.
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E-mail: shabirm@nicd.ac.zaIntroductionMaternal rectovaginal colonization with group B Streptococcus
(GBS) is the major risk factor for GBS invasive disease in
newborns under 7 days of age (early-onset disease; EOD) [1,2].
Vertical transmission of GBS occurs to approximately 50% of
newborns of GBS-colonized pregnant women, of whom 1% toMicrobiol Infect 2015; 21: 568.e13–568.e21
nical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infect
p://dx.doi.org/10.1016/j.cmi.2015.01.0302% develop EOD in the absence of intrapartum antibiotic
prophylaxis (IAP) [3,4]. Rectovaginal GBS colonization of
pregnant women has also been associated with preterm birth
and stillbirth [5]. Screening for GBS rectovaginal colonization in
pregnant women at 35 to 37 weeks’ gestation, coupled with IAP
during labor, has reduced the incidence of EOD in high-income
settings [6]. However, implementation of IAP would be costly
and logistically challenging for most resource-constrained
countries [7,8].
An alternate preventive strategy against invasive GBS disease
in newborns and young infants could be vaccination of pregnant
women with a GBS vaccine to induce humoral immunity, with
protective antibodies transplacentally transferred to the fetus
[9]. An association between low maternal serotype-speciﬁcious Diseases. Published by Elsevier Ltd. All rights reserved 242
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GBS disease among newborns has been observed [10–12].
Furthermore, if GBS vaccination before or during the early
stages of pregnancy could prevent or reduce subsequent rec-
tovaginal colonization in women, this could lower fetal/
newborn exposure to GBS and contribute to reducing EOD
among term and preterm births as well as potentially reduce
GBS-associated premature labor and stillbirth.
Although spontaneous clearance and acquisition of GBS has
been reported in pregnant women, the association of host
immune mediators and GBS colonization during pregnancy
remains unclear [13,14]. A few predominantly cross-sectional
studies have reported higher serotype-speciﬁc capsular poly-
saccharide (CPS) antibody in colonized compared to non-
colonized women [15–22]. We are, however, unaware of any
longitudinal cohort study which evaluated the association be-
tween serotype-speciﬁc CPS antibody and subsequent risk of
GBS rectovaginal acquisition during the latter half of pregnancy.
The primary objective of our study was to evaluate the as-
sociation between natural serotype-speciﬁc serum CPS IgG
antibody and opsonophagocytic activity (OPA) in relation to
GBS rectovaginal acquisition in pregnant women from 20 to
37 + weeks’ gestation. Furthermore, we evaluated the associ-
ation between CPS antibody and clearance of GBS colonization.MethodsStudy population
The study was conducted at four antenatal community clinics in
Soweto, Johannesburg, from August 2010 to August 2011. In-
clusion criteria were HIV-uninfected pregnant women
(conﬁrmed by HIV enzyme-linked immunosorbent assay non-
reactivity) at 20 to 25 weeks’ gestation. Exclusion criteria
included antibiotic treatment in the previous 2 weeks, any acute
illness, symptomatic vaginal discharge and a known or sus-
pected condition contraindicating a vaginal examination. If an-
tibiotics were taken after the ﬁrst visit, the collection of study
specimens was delayed for at least 2 weeks after the last dose.
Swab collection for GBS culture and serotyping
Lower vaginal and rectal swabs were collected for GBS culture
at 20 to 25 weeks’ gestation (visit 1), followed at ﬁve to six
weekly intervals (visits 2 and 3), and ﬁnally at 37 to 40 weeks’
gestation (visit 4). Samples were collected by trained study
nurses with rayon-tipped swabs that were placed into Amies
transport medium without charcoal (Transwab Amies; Medical
Wire, UK). For GBS isolation, swabs were inoculated onto
CHROMagar StrepB (CA; Media Mage, South Africa) as previ-
ously described [23]. Serotyping was performed by the latexClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infeagglutination method with speciﬁc antisera (Statens Serum
Institute, Sweden) to serotypes Ia, Ib and II to IX CPS antigens,
as previously described [24]. Isolates testing negative by latex
agglutination were further typed by PCR using primer se-
quences described by Poyart et al. [25].
Measurement of serotype-speciﬁc anticapsular serum
IgG
Blood was collected at enrolment and visit 4. Serum was
separated by centrifugation and stored at −70 °C until analysis.
Quantitative serum serotype-speciﬁc CPS IgG antibody con-
centrations were measured with the multiplex Luminex plat-
form. All GBS CPS antigens were kindly provided by Novartis
Vaccines, Italy, and were coupled to the microsphere beads
(Bio-Rad, USA) with the cross-linking agent 4-(4,6-dimethoxy
[1,3,5]triazin-2-yl)-4-methyl-morpholinium (DMTMM) as pre-
viously described [26]. An in-house reference serum
composed of puriﬁed pooled human IgG (Polygam; National
Bioproducts, South Africa) was calibrated with the standard
serotype-speciﬁc GBS reference serum kindly provided by C.
J. Baker (Section of Infectious Diseases, Department of Pedi-
atrics, Baylor College of Medicine, AHouston, TX, USA). As-
says were performed in true duplicate and each plate included
high and low control sera. Bead ﬂuorescence was read with
the Bio-Plex 200 instrument (Bio-Rad) using Bio-Plex manager
5.0 software (Bio-Rad). In each assay, an uncoated control
bead was included to determine nonspeciﬁc binding. For
control beads, the coupling procedure was followed, except
that no GBS CPS was added. In case of nonspeciﬁc binding, the
ﬂuorescence intensity values were subtracted from the
antigen-speciﬁc results. The optimal serum and secondary
antibody dilution was 1:100. The results for serum CPS IgG
are given in μg per mL with lower detection limits of 0.0003,
0.005 and 0.009 for serotype Ia, III and V, respectively. For
statistical analysis, samples with values below these limits were
assigned values of half of lower limit of detection.
The multiplex assay was validated by comparing the
serotype-speciﬁc mean ﬂuorescence intensity values for Poly-
gam obtained with the multiplex assay with those for each
serotype run in single plex. The ﬂuorescence intensity values
obtained for Polygam with the multiplex assay were between
79% and 112% (median 103%) of those obtained with the single-
plex assays. To assess analytical speciﬁcity of each GBS–
microsphere set, Polygam was incubated at 1:100 dilution with
each GBS CPS (100 μg/mL) and incubated at 37°C for 2 hours.
The speciﬁcity was recorded as the difference in reactivity
between the absorbed and unabsorbed sera in a multiplex
assay. Homologous inhibition was >95% for all serotypes, with
the exception of serotype V (85%). Heterologous inhibition
across serotypes was <10%, except for serotypes Ib and III,ctious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 568.e13–568.e21
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respectively, and serotype V (18%) was inhibited by serotype III
CPS.
Serum IgG OPA assay
The functional activity of serum IgG was determined by OPA
assay for serotypes Ia and III using the HL-60 cell line as
described [27]. Brieﬂy, 1000 CFU (20 μL of 5 × 104 CFU/mL)
of GBS type Ia strain (A909) or type III strain (COH-1) cells
were mixed with an appropriate dilution of heat-inactivated
serum sample (10 μL), then mixed and incubated for 15 mi-
nutes at 37°C in a 5% CO2 incubator. Baby rabbit complement
(10 μL) and HL-60 cells (40 μL of 1 × 107, cultured for 5 days
in the presence of dimethyl formamide) were added to the
mixture and incubated at 37°C with 5% CO2 for 1 hour with
gentle agitation. Aliquots were removed and plated on Todd-
Hewitt agar plates for quantitative culture. OPA was
expressed as the titre at which the serum dilution yielded 50%
killing compared to the bacterial growth in the complement
controls. The limit of detection was 8. For statistical analysis,
samples below the detection were assigned an arbitrary titre
of 4.
Study deﬁnitions
A participant was considered to be colonized at a visit if GBS
was cultured on the vaginal and/or rectal swab, and non-
colonized if no growth was detected from either swab. A new
episode of serotype-speciﬁc GBS rectovaginal colonization (i.e.
new acquisition group) was deﬁned as a participant not colo-
nized by a speciﬁc GBS serotype at visit 1 who was subse-
quently colonized by that speciﬁc serotype (irrespective of the
number of study visits completed). Concurrent identiﬁcation of
different serotypes from the vaginal and rectal swabs at a visit
among participants with new acquisitions were treated as in-
dividual events. Participants not colonized with a speciﬁc
serotype at any study visit were categorized as being the non-
colonized group for that serotype and were used as the
comparator group when evaluating the association between
CPS antibody and risk for serotype-speciﬁc rectovaginal
acquisition.
The association of CPS antibody with clearance of serotype-
speciﬁc GBS colonization was evaluated in participants who
were colonized by the speciﬁc serotype at visit 1 and who
completed all study visits. The participants were stratiﬁed into
those who remained colonized throughout (i.e. persistently
colonized group) and those in whom colonization of speciﬁc
serotype was cleared by visit 4 (i.e. intermittently colonized
group). As a result of limitations associated with detecting
multiple serotype carriage using traditional culture methods
[28], participants with GBS serotype colonization at visit 1 whoClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectacquired a different GBS serotype at a subsequent visit were
excluded from the analysis on CPS antibody and serotype-
speciﬁc GBS acquisition or clearance.
Statistical analysis
Differences in geometric mean concentration (GMC) of
serotype-speciﬁc CPS antibody and geometric mean OPA titre
(GMOPT) between groups (new acquisition vs. noncolonized
groups; and persistently colonized vs. intermittent colonized
groups) were analysed on log-transformed data by Student’s t
test. GMC values at visits 1 and 4 for each group were analysed
by paired Student’s t test. Evaluation of whether the serotype-
speciﬁc CPS antibody was associated with new homotypic GBS
acquisition was undertaken using univariate logistic regression
analysis reporting the odds ratio (OR) for the association be-
tween the serological variable and GBS acquisition, with loga-
rithmic IgG or OPA titre as a covariate. Univariate logistic
regression analysis was also used for comparison between
groups by demographic and obstetric factors at visit 1.
For categorical variables, groups were compared by either
the chi-square test or Fisher’s two-tailed exact test, as appro-
priate. Correlations between serum IgG and OPA titres were
determined on log-transformed data by Spearman rank corre-
lation. Data were analysed using SAS software, version 9.2 (SAS
Institute, USA). A p value of <0.05 was considered signiﬁcant.
Ethics Statement
The study was approved by the Human Research Ethics
Committee of the University of the Witwatersrand (IRB/Pro-
tocol-M090937), and informed written consent was obtained
from all participants. This observational study was registered
with the South African National Clinical Trials Register (DOH-
27-0210-3012).ResultsOf 661 enrolled participants, 95.1% (n = 629) completed at
least two and 76.7% (n = 507) all four study visits. The main
reasons for not completing all study visits were related to ob-
stetric outcomes such as premature birth (n = 86; 13.0%) and
miscarriage (n = 13; 2.0%; Supplementary Fig. 1). A detailed
proﬁle of subject follow-up, serotype distribution and dynamics
of GBS colonization has been previously published [29].
The overall prevalence of any serotype GBS colonization at
enrolment was 33.0% (218/661).
Of those not colonized by GBS serotypes Ia, III or V at
enrolment, 9.6% (52/541), 7.0% (39/560) and 2.8% (17/603)
subsequently become colonized by the respective serotypes
(i.e. new acquisition group). This included six participants forious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 568.e13–568.e21
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rectal site at the same visit and excluded 15 participants who
were colonized at visit 1 and acquired a different serotype at a
subsequent visit. Of 507 participants who completed all
scheduled visits, participants not colonized with a speciﬁc
serotype at any visit were 387 (76.3%), 414 (81.6%) and 471
(92.9%) for serotypes Ia, III and V, respectively (i.e. non-
colonized group). There were no differences in the de-
mographic characteristics between the new acquisition and
noncolonized groups (Table 1).
Of the 507 participants who completed all scheduled visits,
the overall GBS colonization prevalence at enrolment was
32.1% (163/507), including 14.0% (n = 71), 11.1% (n = 56) and
2.9% (n = 15) for serotypes Ia, III and V, respectively. The
prevalence of serotypes Ia, III and V colonization among the
persistently colonized group were 4.1% (21/507), 5.3% (27/507)
and 0.4% (2/507), respectively; and 8.5% (43/507), 3.6% (18/
507) and 1.8% (9/507), respectively, in the intermittent colo-
nized group. This excluded 22 intermittently colonized partic-
ipants in whom colonization was not cleared by visit 4 or who
acquired a new serotype at subsequent visits and who remained
colonized with that serotype thereafter. There were no dif-
ferences in the demographic characteristics between the
persistently colonized and intermittent colonized groups (data
not shown).
Association between serotype-speciﬁc CPS IgG and
new acquisition of the homotypic serotype
The logistic regression analysis for the association between
homotypic serotype acquisition and serotype-speciﬁc IgG
concentration at enrolment demonstrated an OR of <1.00,
indicating that the probability of a new acquisition decreased
with increasing serotype-speciﬁc IgG concentrations (Table 2).
Homotypic serotype antibody GMC was higher at enrolment
among the noncolonized than the new acquisition group for
serotype III (0.33 μg/mL vs. 0.17 μg/mL, respectively; p 0.009),TABLE 1. Demographic characteristics of women who acquired
compared to those who remained noncolonized by that serotype t
Characteristic
Serotype Ia Serotype II
New acquisition Not colonized
p
New acquis
(n [ 52) (n [ 387) (n [ 39)
Age (years), mean ± SD 25.65 ± 5.76 26.06 ± 5.54 0.619 26.13 ± 6.2
Parity, median (range) 1 (0–5) 0 (0–5) 0.582 0 (0–3)
Gravidity, median (range) 2 (1–6) 2 (1–8) 0.891 1 (1–4)
Previous spontaneous
abortion, n (%)
6 (11.5) 64 (16.5) 0.358 4 (10.2)
Previous stillbirth, n (%) 2 (3.8) 4 (1.0) 0.127 0 (0.0)
New acquisition was deﬁned as women who acquired serotype-speciﬁc new acquisition; nonc
four study visits; spontaneous abortion was deﬁned as the spontaneous abortion of pregnancy
at 28 weeks’ gestation or later. p values were calculated by univariate logistic regression an
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infewith a similar trend for serotype V (0.75 μg/mL vs. 0.42 μg/mL,
respectively; p 0.057) (Table 2).
Reverse cumulative distribution plots of serotype-speciﬁc
CPS antibody concentrations of the noncolonized and new
acquisition groups are shown in Fig. 1a–c. The lowest threshold
of CPS antibody concentration associated with lower odds of
acquisition of the homotypic serotype varied between sero-
types. The lowest antibody threshold signiﬁcantly associated
with remaining noncolonized throughout the study was 3 μg/
mL for serotype Ia (22.0% in noncolonized vs. 9.6% in new
acquisition group, OR 0.37; 95% conﬁdence interval (CI)
0.14,0.98), 3 μg/mL for serotype III (10.6% in noncolonized
vs. 0.0% in new acquisition group, OR 0.11; 95% CI 0.01–1.75)
and 1 μg/mL for serotype V (36.5% in noncolonized vs. 11.8%
in new acquisition group, OR 0.23; 95% CI 0.05–1.02; Table 3).
This strength of association increased at higher CPS antibody
thresholds for serotypes Ia and III (Table 3). None of the
women who acquired serotype Ia had antibody concentration
of 15 μg/mL (compared to 8.5% of noncolonized women, p
0.025) at enrolment; and none with new acquisition of sero-
types III had homotypic CPS antibody 3 μg/mL (compared to
10.6% (p 0.023) of those who remained noncolonized; Table 3).
Association between serotype-speciﬁc OPA and new
acquisition of GBS
Reverse cumulative distribution plots of serotype-speciﬁc OPA
titres of the noncolonized and new acquisition groups for se-
rotypes Ia and III are shown in Fig. 1d, e. The logistic regression
analysis for the probability of acquisition of GBS serotypes Ia
and III as a function of homotypic serotype OPA titre at
enrolment had an OR of <1.00, indicating that the probability of
a new acquisition decreased with increasing serotype-speciﬁc
OPA titre (Table 2). Noncolonized women had higher
serotype-speciﬁc GMOPT than the new acquisition group for
serotypes Ia (GMOPT: 14 vs. 5, respectively; p < 0.001) and III
(GMOPT: 132 vs. 20, respectively, p < 0.001; Table 2). Thea speciﬁc group B Streptococcus serotype (new acquisition)
hroughout the study
I Serotype V
ition Not colonized
p
New acquisition Not colonized
p(n [ 414) (n [ 17) (n [ 471)
26.10 ± 5.6 0.969 26.01 ± 4.77 26.06 ± 5.66 0.955
0 (0–5) 0.556 1 (0–1) 0 (0–5) 0.751
2 (1–8) 0.353 2 (1–3) 2 (1–8) 0.500
70 (16.9) 0.289 1 (5.9) 80 (17.0) 0.253
6 (1.4) 0.449 0 (0.0) 7 (1.5) 0.612
olonized was deﬁned as women who remained uncolonized by speciﬁc serotype at all
occurring before 28 weeks’ gestation; and stillbirth was deﬁned as fetal death occurring
alysis.
ctious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 568.e13–568.e21
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TABLE 2. Comparison of mean titres (μg/mL) at visit 1 for pregnant women for speciﬁc serotypes
Serotype
New acquisition Noncolonized
pa Odds ratio (95% CI)bGMC (95% CI) GMC (95% CI)
Ia 0.28 (0.17, 0.47); n = 52 0.35 (0.27, 0.44); n = 387 0.529 0.91 (0.68, 1.21)
III 0.17 (0.11, 0.26); n = 39 0.33 (0.28, 0.38); n = 414 0.009 0.47 (0.26, 0.84)
V 0.42 (0.26, 0.65); n = 17 0.75 (0.66, 0.84); n = 471 0.057 0.39 (0.15, 1.01)
OPA GMOPT (95% CI) GMOPT (95% CI)
Ia 5 (4, 6); n = 52 14 (11, 17); n = 387 <0.001 0.28 (0.12, 0.63)
III 20 (11, 36); n = 39 132 (105, 164); n = 414 <0.001 0.43 (0.30, 0.62)
New acquisition indicates women who acquired serotype-speciﬁc new acquisition; noncolonized indicates women who remained uncolonized by speciﬁc serotype.
CI, conﬁdence interval; GMC, geometric mean concentration; GMOPT, geometric mean opsonophagocytic activity titre; OPA, opsonophagocytic activity.
ap value calculated by Student’s t test.
bOdds ratio calculated by logistic regression analysis.
568.e17 Clinical Microbiology and Infection, Volume 21 Number 6, June 2015 CMIpresence of detectable OPA titres (8) was signiﬁcantly asso-
ciated with lower odds of acquiring the homotypic serotype for
Ia (p 0.002) and III (<0.001). The strength of association be-
tween OPA titres and odds of new acquisitions trended to be
stronger at higher OPA threshold for serotypes Ia and III
(Table 3).
There were signiﬁcant correlations between serum IgG
concentration and OPA titre with r values of 0.684 for serotype
Ia and 0.393 for serotype III (p <0.001 for both) (Supplementary
Fig. 2a, b). OPA activity (titre 8) was detectable to the
homotypic serotype in 92% (138/150) of serum samples with
IgG concentration 3 μg/mL for serotype Ia and 94.1% (192/
204) of samples with IgG concentration 0.5 μg/mL for sero-
type III.
Association between serotype-speciﬁc CPS IgG and
clearance of colonization at enrolment
Serotype-speciﬁc CPS antibody concentration was greater
among women colonized compared to those not colonized by
the homotypic serotype at visit 1 for serotype Ia (p 0.025) and
serotype III (p 0.018); and at visit 4 for serotype Ia (p < 0.001)
with similar trend for serotype III (p 0.060), although this was
not statistically signiﬁcant for OPA at visit 1 (Supplementary
Table 1). Among women colonized at enrolment, higher CPS
GMC (1.49 vs. 0.44 μg/mL, p 0.049) and GMOPT (41 vs. 12; p
0.025) were observed for serotype Ia in those categorized as
persistently colonized than those with intermittent coloniza-
tion, respectively, but not so for serotypes III and V
(Supplementary Table 2).
Effect of GBS colonization on kinetics of serotype-
speciﬁc antibody
When we analysed women who completed all four study visits
and who were not colonized by a speciﬁc serotype at enrol-
ment, serotype-speciﬁc new acquisition was associated with an
increase in GMC and GMOPT values between enrolment and
visit 4. These increases were evident for GMC for serotype IaClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infect(p 0.001), III (p 0.004) and V (p 0.034), as well as GMOPT for
serotypes Ia and III (p < 0.001 for both; Table 4). For serotype
Ia, a new acquisition event was also associated with an increase
in correlation between serotype-speciﬁc serum IgG concen-
tration and OPA titres, with r values of 0.524 at enrollment
(p < 0.001) and 0.792 at visit 4 (p < 0.001) (Supplementary
Fig. 2c, d). In contrast, for serotype III, a decrease in correla-
tion between enrollment (r = 0.354, p 0.037) and visit 4
(r = 0.266, p 0.122) was observed, despite signiﬁcant increases
in OPA titres (Supplementary Fig. 2e, f). No change was
observed in GMC between visits 1 and 4 among women who
remained noncolonized by the speciﬁc serotype throughout the
study for serotypes Ia or III, although an increase was observed
for serotype V (0.83 vs. 0.75 μg/mL, p 0.011).DiscussionOur study demonstrated an association between naturally ac-
quired serum serotype-speciﬁc CPS antibody and the risk of
subsequent rectovaginal colonization by the homotypic sero-
type in pregnant women not colonized at enrolment. New
acquisition of GBS was inversely correlated with serotype-
speciﬁc CPS IgG concentration (serotypes III and V) and OPA
titre (serotypes Ia and III) at time of enrolment. These data
suggest that strategies such as vaccination of women with GBS
CPS–protein conjugate vaccine which induces antibody re-
sponses (Hyderman RF, et al. Program and Abstracts of the
32nd European Society for Paediatric Infectious Diseases) could
reduce the risk of GBS rectovaginal acquisition of vaccine se-
rotypes. The potential beneﬁt to the women and their new-
borns would, however, be dependent on the timing of
vaccination in the women and durability of persistence of suf-
ﬁciently high antibody concentrations or OPA titres to prevent
GBS acquisition during pregnancy. The potential of protein–
polysaccharide conjugate vaccine to induce mucosal immunity
has been demonstrated for vaccines against Haemophilusious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 568.e13–568.e21
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(a) (b)
(c)
(d) (e)
FIG. 1. Reverse cumulative distribution curves of serotype-speciﬁc anticapsular serum IgG (a–c) and OPA titre (d–e) in participants who acquired
GBS serotype (new acquisition) and those who remained uncolonized by the speciﬁc serotype (noncolonized).
CMI Kwatra et al. Immunity against Streptococcus rectovaginal colonization 568.e18inﬂuenzae type b, Streptococcus pneumoniae and Neisseria men-
ingitidis in which reduced risks of nasopharyngeal mucosal
colonization acquisition of the targeted serotypes are evident
[30–32].
In our study, the CPS antibody, including functional antibody
measured by OPA, was most likely induced by rectovaginal
colonization, as indicated by the rise in serotype-speciﬁc GMC
and GMOPT among those with new acquisitions of homotypic
serotypes. It is this increase in CPS antibody which likelyClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infereduces the risk of these women becoming colonized by the
same serotype. Although our study was not designed to
establish the durability of this natural-acquired humoral-medi-
ated immunity, the strengthening of association between higher
serotype-speciﬁc antibody thresholds and OPA titres and the
reduced odds of becoming colonized by the homotypic sero-
type indicates that this protection is likely to be transient, with
waning of antibody over time. Also, the paradoxically higher
GMC and GMOPT in women colonized with serotype Ia atctious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 568.e13–568.e21
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Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectenrolment who remained persistently colonized thereafter,
compared to those who were only intermittently colonized,
indicates that the antibody which was likely induced by colo-
nization might not clear existing colonization. This clearance of
established colonization may be due to other immune media-
tors, including cell-mediated immunity.
Our study indicated that the threshold of CPS antibody
associated with signiﬁcantly reduced odds of acquisition of GBS
was 3 μg/mL for serotypes Ia and III and 1 μg/mL for
serotype V. Furthermore, serotype-speciﬁc OPA titres of 8
were associated with similarly reduced odds of new acquisition
of the homotypic serotype for serotypes Ia and III. The OPA
titres correlated more strongly than IgG concentrations in
relation to new acquisition of serotypes Ia and III. This shows
the importance of measuring functional antibody in the evalu-
ation of immune responses to GBS conjugate vaccine. Also, the
correlation between OPA titres and CPS IgG concentration
was modest, suggesting either impaired functional activity of
antibody or limitations of the serology assay with respect to
purity of antigens used or possible role of IgM antibodies in
opsonophagocytosis [33].
Previous studies on the association of GBS colonization and
serum IgG antibody have mainly been cross-sectional studies
and have generally reported higher serotype-speciﬁc CPS
antibody in colonized compared to noncolonized pregnant
women for the homotypic serotype [15–22]. These studies
were, however, not designed to address whether CPS antibody
reduces the risk of GBS colonization during pregnancy, as
shown by us. Nevertheless, the ﬁndings of the previous studies
are conﬁrmed in our study, where higher serotype-speciﬁc CPS
IgG concentrations were also observed in women colonized by
the homotypic serotype compared to those not colonized
when analysed cross-sectionally at either visit 1 or visit 4 for
serotypes Ia and III. This higher antibody concentration in
colonized women in such studies likely reﬂect recent acquisi-
tion of that serotype, which induced the higher antibody levels
compared to women not colonized, as demonstrated by the
kinetics of the antibody response to new acquisitions in our
study.
Our study has certain limitations. Firstly, although we
explored for thresholds of serotype-speciﬁc CPS IgG and OPA
titres associated with reduced odds of new acquisition by
homotypic serotypes, the ﬁndings need to be interpreted with
caution in the absence of a standardized reference assay to
measure either CPS antibody or OPA titres [34]. We tried to
optimize the comparability of our assay to that of other labo-
ratories by calibrating our in-house reference (Polygam) with
reference sera from C. J. Baker, who has published widely in the
ﬁeld. Secondly, the sensitivity of detection of GBS on selective
media is estimated at 85% and mainly identiﬁes the dominantious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 568.e13–568.e21
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TABLE 4. Comparison of mean titres (μg/mL) at visits 1 and 4 for pregnant women for speciﬁc serotypes who acquired GBS and
those who remained uncolonized
Serotype
Serotype-speciﬁc new acquisition Uncolonized by speciﬁc serotype
Visit 1 Visit 4
pa
Visit 1 Visit 4
paSerum IgG GMC (95% CI) GMC (95% CI) GMC (95% CI) GMC (95% CI)
Ia 0.32 (0.18, 0.57); n = 42 0.86 (0.44, 1.70) 0.001 0.36 (0.28, 0.46); n = 387 0.40 (0.32, 0.51) 0.169
III 0.14 (0.09, 0.22); n = 35 0.26 (0.15, 0.46) 0.004 0.32 (0.28, 0.38); n = 414 0.30 (0.26, 0.36) 0.272
V 0.38 (0.23, 0.61); n = 15 0.76 (0.43, 1.33) 0.034 0.75 (0.66, 0.84); n = 471 0.83 (0.74, 0.93) 0.011
OPA GMOPT (95% CI) GMOPT (95% CI)
Ia 5 (4, 6); n = 42 110 (53, 227) <0.0001 Not doneb
III 17 (9, 32); n = 35 776 (528, 1143) <0.0001
Comparisons of serum GMC serotype-speciﬁc capsular IgG antibody (μg/mL) and GMOPT at enrolment and end of study in pregnant women who acquired GBS and those who
remained uncolonized throughout.
CI, conﬁdence interval; GBS, group B Streptococcus; GMC, geometric mean concentration; GMOPT, geometric mean opsonophagocytic activity titre; OPA, opsonophagocytic
activity.
ap value by paired Student’s t test.
bOPA at visit 4 was done only for participants who acquired GBS serotype.
CMI Kwatra et al. Immunity against Streptococcus rectovaginal colonization 568.e20colonizing serotype, with lower-density co-colonizing serotypes
likely being missed [23]. Therefore, it is possible that we
overestimated new acquisition through missing colonization
episodes not detectable by standard culture methods at visit 1,
and we similarly may also have missed some new acquisitions.
In summary, our results indicate that the effect of GBS
conjugate vaccine on rectovaginal GBS colonization warrants
further investigation. This could provide rectovaginal coloni-
zation as a surrogate end point to evaluate the potential effect
of GBS conjugate vaccine in protecting newborns (including
those born prematurely) from exposure to GBS at birth and
hence reduce their risk of EOD. A monovalent GBS serotype III
conjugate vaccine has already been reported to signiﬁcantly
reduce the rate of rectovaginal GBS acquisition among
nonpregnant women (Hillier SL, et al. Program and Abstracts of
the 47th Infectious Diseases Society of America annual meeting,
abstract 186). This potential effect of vaccination with GBS
vaccine targeted at women against rectovaginal colonization
may be over and above the additional protection of vaccination
against invasive GBS disease in young infants born at full term,
which is likely to be conferred through transplacental acquisi-
tion of protective serotype-speciﬁc CPS antibody. Further-
more, it is plausible that reducing the risk of GBS acquisition
during pregnancy could reduce the incidence of GBS-associated
chorioamnionitis, premature labor and stillbirth [5].Transparency declarationThis work was funded by research supported by the South
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Serotype-Speciﬁc Cell-Mediated
Immunity Associated With Clearance
of Homotypic Group B Streptococcus
Rectovaginal Colonization in Pregnant
Women
Gaurav Kwatra,1,2 Peter V. Adrian,1,2 Tinevimbo Shiri,1,2 Alane Izu,1,2 Clare L. Cutland,1,2
Eckhart J. Buchmann,3 and Shabir A. Madhi1,2,4
1Medical Research Council: Respiratory and Meningeal Pathogens Research Unit, 2Department
of Science and Technology/National Research Foundation: Vaccine Preventable Diseases, and
3Department of Obstetrics and Gynecology, University of the Witwatersrand, and 4National
Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg,
South Africa
We investigated the association between group B Streptococcus
(GBS) serotype-speciﬁc capsular polysaccharide cellular immu-
nity, measured with enzyme-linked immunospot (ELISPOT)
interferon γ release assay at 20 weeks gestation in pregnant
women, and its effect on rectovaginal serotype-speciﬁc GBS col-
onization up to 37 weeks gestation. Among women colonized
by serotype III at enrollment, interferon γ ELISPOT positivity
was more common in those in whom colonization was cleared
(44.4%) than in those in whom colonization persisted (7.4%;
P = .008), with a similar trend observed for serotype Ia. Presence
of serotype-speciﬁc capsular polysaccharide cell-mediated
immunity contributes to the clearance of GBS rectovaginal
colonization.
Keywords. group B Streptococcus; cellular immunity;
colonization.
Maternal rectovaginal colonization with group B Streptococcus
(GBS) and its vertical transmission to newborns is the primary
source of early-onset (<7 days age) invasive GBS disease [1] and
has also been associated with stillbirths and premature deliver-
ies [2]. Spontaneous clearance and acquisition of GBS has been
reported in pregnant women [3, 4]; however, the host immune
mediators inﬂuencing the dynamics of GBS colonization re-
main to be fully elucidated. We established in an earlier study
that capsular-speciﬁc antibody and opsonophagocytic activity
reduced the risk of new homotypic serotype acquisition between
20 and 37+ weeks of pregnancy, but neither was associated with
clearance of GBS colonization [5]. The aim of this study was to
determine the association between the presence of GBS cellular
immunity, as assessed by enzyme-linked immunospot (ELI-
SPOT) interferon (IFN) γ release assays, and the dynamics of
GBS colonization in women during the latter half of pregnancy.
MATERIAL AND METHODS
Study Participants and Design
Detailed study methods have been published elsewhere [6].
Brieﬂy, pregnant women aged 18–45 years, who were without
human immunodeﬁciency virus infection and at 20–25 weeks
gestation, were enrolled at antenatal community clinics in
Soweto, Johannesburg, from August 2010 to August 2011. Ex-
clusion criteria included antibiotic treatment in the previous
2 weeks, any acute illness, symptomatic vaginal discharge, and
a known or suspected condition in which clinical vaginal exam-
ination was contraindicated.
Study procedures included lower vaginal and rectal swab
sample collection for GBS culture starting at 20–25 weeks
(visit 1), followed by 3 subsequent visits (visits 2–4) at 5–6
weekly intervals, until 37–40 weeks gestation (visit 4). For
GBS isolation, swab samples were inoculated onto CHROMagar
StrepB agar (CA; Media Mage), as described elsewhere [7].
Serotyping was performed using the latex agglutination method,
as described elsewhere [8]. Isolates that tested negative at latex
agglutination for all serotypes were further typed with a poly-
merase chain reaction method, using primer sequences
described by Poyart et al [9].
Measure of Cellular Immune Response
Cellular immune response was determined at visit 1 (enroll-
ment) by IFN-γ release assays, with an ELISPOT assay kit for
human IFN-γ according to the manufacturer’s instructions (cat-
alog No. 3420-2A; Mabtech). Brieﬂy, peripheral blood mono-
nuclear cells (PBMCs) were isolated from the heparinized
blood using Ficoll gradient centrifugation and resuspended in
AIM-V medium (Gibco, Invitrogen). About 0.25–0.3 × 106
PBMCs per well were added to ELISPOT plates (MAIP
S4510; Millipore) coated with IFN-γ capture antibody (Mab-
tech). PBMCs were stimulated with GBS serotype-speciﬁc cap-
sular polysaccharide (CPS) antigens separately (CPS Ia, III, and
V) for 18–24 hours at 37°C in 5% carbon dioxide, with a ﬁnal
concentration of 40 µg/mL. (GBS CPS antigens were provided
by Novartis Vaccines).
After incubation, ELISPOT plates were developed using bio-
tinylated anti–IFN-γ detection antibody (Mabtech), detected
with streptavidin–alkaline phosphatase (Mabtech) and visual-
ized with an alkaline phosphatase conjugate substrate kit
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Appendix 4
(Bio-Rad). Checkerboard titrations were performed to optimize
PBMCs and antigen concentrations per well. AIM-V medium
was used as a negative control to assess background levels,
and phytohaemagglutinin (Sigma) was used as a positive con-
trol. Cellular immune responses against each antigen were de-
tected in single wells only. Spot-forming units (SFUs) were
counted with a magnifying lens. Background (SFUs in negative
control) was subtracted, and results were expressed as SFUs per
106 PBMCs. An ELISPOT response was considered positive if the
number of antigen-speciﬁc spots was ≥7 SFUs/106 PBMCs and
at least double the number in the negative control well. In ad-
dition, serotype-speciﬁc serum CPS immunoglobulin (Ig) G
antibody concentrations were measured by means multiplex Lu-
minex (serotypes Ia, III, and V) and opsonophagocytic activity
(OPA) (serotypes Ia and III) assay, as described elsewhere [5].
Study Deﬁnition
A participant was considered colonized at a visit if GBS was cul-
tured on either the vaginal or rectal swab sample and noncolon-
ized if no growth was detected from either site. The association
of cellular immunity with clearance of serotype-speciﬁc GBS
colonization was evaluated in women who were colonized by
the speciﬁc serotype at visit 1 and who completed all 4 study
visits. The women were stratiﬁed into those in whom coloniza-
tion of the speciﬁc serotypes was cleared by visit 4 (the “cleared-
colonization” group) and those who remained colonized
throughout the study (the “persistently colonized” group). Be-
cause of limitations associated with detecting multiple serotype
carriage using standard culture methods, we excluded from
analysis participants colonized with any GBS serotype at visit
1 who acquired a different GBS serotype at a subsequent visit
and remained colonized with that serotype thereafter. We also
evaluated the association of cellular immunity and acquisition
of serotype-speciﬁc GBS colonization in women not colonized
by a speciﬁc GBS serotype at visit 1, who were subsequently col-
onized by that speciﬁc serotype (irrespective of the number of
study visits completed) (“new-acquisition” group), compared
with that in women not colonized with that speciﬁc serotype
at any study visit (“noncolonized” group).
Statistical Analysis
For categorical variables, groups were compared with either
χ2 or Fisher 2-tailed exact tests, as appropriate. The Mann–
Whitney test was used to detect differences in SFU counts be-
tween groups (persistently colonized vs cleared colonization).
The correlations between serotype-speciﬁc serum IgG and sero-
type-speciﬁc OPA titers and the ELISPOT SFU count (per 106
PBMCs) at visit 1 were calculated using Spearman correlation
coefﬁcients. To explore the association between SFU counts
and clearance of GBS colonization, we used a Bayesian model
to estimate the posterior distribution of the probability that a
woman with a GBS homotypic SFU count (per 106 PBMCs)
greater or equal to c would clear GBS colonization (D), denoted
by Probability (P) (clearance of GBS colonization (D) = 1|
SFU ≥ c) [10]. For each value c, we graphically display the
25%, 50%, and 75% quantiles of the posterior distribution of
P(D = 1|SFU≥ c). Data were analyzed using GraphPad (version
5.0; GraphPad Software) and R (version 2.15) software [11].
Differences were considered signiﬁcant at P < .05.
Ethics Statement
The study was approved by the Human Research Ethics Com-
mittee of the University of the Witwatersrand (institutional re-
view board protocol M090937), and informed written consent
was obtained from all participants.
RESULTS
Of 661 participants, 76.7% (507 of 661) completed all 4 study
visits and 95.1% (629 of 661) completed at least 2 study visits.
A detailed proﬁle of participant demographics (Supplementary
Table 1) and follow-up has been reported elsewhere [6]. Of the
507 women who completed all scheduled visits, 71 (14.0%), 56
(11.1%), and 15 (2.9%) were colonized by serotypes Ia, III, and
V, respectively at enrollment. Of the women already colonized
at enrollment, 21 of 71 (29.6%), 27 of 56 (48.2%), and 2 of 15
(13.3%) were categorized as being persistently colonized; and
43 (60.6%), 18 (32.1%), and 9 (60.0%) were in the cleared-
colonization groups for serotypes Ia, III, and V, respectively.
This excluded 22 participants colonized at enrollment who
cleared the initial serotype (Ia (7 of 71; 9.8%), III (11 of 56;
19.6%), and V (4 of 15; 26.7%) but who acquired a new serotype
at a subsequent visit and remained colonized with the subse-
quent serotype thereafter. There were no differences in demo-
graphic characteristics between the persistently colonized and
cleared-colonization groups (data not shown).
Of those not colonized by speciﬁc GBS serotype Ia, III,
or V at enrollment and who had ≥1 subsequent study visit,
9.6% (52 of 541), 7.0% (39 of 560), and 2.8% (17 of 603)
subsequently become colonized by the respective serotypes
(ie, new-acquisition group). Of participants who completed
all scheduled visits, 387 (76.3%), 414 (81.6%), and 471
(92.9%) for serotype Ia, III, and V, respectively (ie, non-
colonized group), were never colonized by that speciﬁc serotype.
There were no differences in demographic characteristics
between the new-acquisition and noncolonized group [5].
Of the 661 enrolled participants in whom cellular immune
response was determined at the ﬁrst visit, 6 participants were
excluded from the analysis owing to contamination detected in
the assay. Of the remaining 655 participants, serotype-speciﬁc
ELISPOT responses were prevalent in 191(29.2%), 154(23.5%),
and 143 (21.8%) for serotypes Ia, III, and V, respectively, at
visit 1. There was no correlation between serotype-speciﬁc
serum IgG concentrations and SFU counts at ELISPOT assay
for serotypes Ia (ρ = 0.006; P = .89), III (ρ = 0.023; P = .55), or
V (ρ = 0.021; P = .59) (Supplementary Figure 1A–C). Similarly,
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no correlation was observed between serotype-speciﬁc OPA
titers and SFU count for either serotype Ia (ρ = 0.017; P = .66)
or III (ρ = 0.042; P = .28) (Supplementary Figure 1D and 1E).
Among women colonized with serotype III at enrollment,
ELISPOT positivity was found in higher percentage of those
who cleared colonization (44.4%) than of those who remained
persistently colonized (7.4%; P = .008), with a similar trend for
serotype Ia (44.2% vs 19.0%, respectively; P = .06) and serotype
V (22.9% vs 0.0%, respectively; Figure 1). Serotype-speciﬁc me-
dian SFU counts tended to be higher among those who cleared
colonization than among those persistently colonized for sero-
types III (P = .055) and Ia (P = .14), albeit not signiﬁcant (Supple-
mentary Figure 2).
In a Bayesian framework, the probability of losing colo-
nization increased with higher SFU counts (Supplementary
Figure 3). For serotype III, we observed 50% and 70% probabil-
ity of losing colonization with SFU counts ≥7/106 and ≥22/106
PBMCs, respectively. For serotype Ia, we observed 82% proba-
bility of losing colonization with SFU counts ≥7/106 PBMCs.
There was no correlation between serotype-speciﬁc ELISPOT
positivity and clearance of nonhomotypic serotype. The lowest
threshold associated with clearance of serotype III colonization
was ≥7 SFUs/106, with prevalences of 44.4% (8 of 18) in the
cleared-colonization versus 7.4% (2 of 27) in the persistently
colonized group (odds ratio, 10.00; 95% conﬁdence interval,
1.80–55.55; P = .008) and 48.8% (21 of 43) and 19% (4 of 21)
in the respective groups for serotype Ia (4.06; 1.17–14.06;
P = .03) (Table 1).
Furthermore, whereas we previously reported signiﬁcant as-
sociations between serotype-speciﬁc antibody concentration
and OPA in relation to subsequent new acquisition of GBS dur-
ing pregnancy [5], there was no signiﬁcant difference in ELI-
SPOT positivity between women who became colonized
(new-acquisition group) and those who remained uncolonized
(noncolonized group) for serotypes Ia (21.6% [11 of 51] vs
29.4% [113 of 384]; P = .24), III (17.9% [7 of 39] vs 23.9% [98
of 410]; P = .40) or V (11.8% [2 of 17] vs 21.8% [102 of 467];
P = .55). Excluded from analysis owing to contamination were
3 participants for serotype Ia and 4 each for serotypes III and
V from the noncolonized group and 1 participant for serotype
Ia from the new-acquisition group.
DISCUSSION
We have shown that clearance of serotype-speciﬁc GBS rectova-
ginal colonization during pregnancy was associated with pres-
ence of homotypic capsular ELISPOT IFN-γ positivity, whereas
no such association was observed for serotype-speciﬁc capsular
antibody or OPA, as reported for the same cohort [5]. Con-
versely, ELISPOT positivity was not associated with a signiﬁ-
cantly reduced risk of GBS acquisition, which was, however,
positively associated with serotype-speciﬁc capsular antibody
and OPA for serotypes Ia and III, as reported. These data sug-
gest that presence of cell-mediated immune response contrib-
utes to the clearance of rectovaginal GBS colonization,
whereas we have reported elsewhere that humoral immunity
is required to reduce the risk of rectovaginal GBS acquisition
during pregnancy [5].
The results of the current study are in accordance with ﬁnd-
ings of studies on other capsular bacteria, such as Streptococcus
pneumoniae, for which cell-mediated immune response is
important for mucosal clearance in animal models [12, 13].
A serotype-speciﬁc capsular-based GBS vaccine able to elicit
Figure 1. Comparisons of enzyme-linked immunospot (ELISPOT) positivity at en-
rollment in pregnant women who has cleared colonization (Cleared colonization
group) to those who remain colonized throughout by that serotype (Persistently col-
onized group).
Table 1. Association Between Serotype-Specific SFU Counts by ELISPOT Assay and Clearance of Homotypic GBS in Pregnant Womena
SFU Count,
SFUs/106
PBMCs
Serotype Iab Serotype III
Cleared-
Colonization
Group, No. (%)
(n = 43)
Persistently
Colonized Group,
No. (%) (n = 21) OR (95% CI) P-Value
Cleared-
Colonization
Group, No. (%)
(n = 18)
Persistently
Colonized Group,
No. (%) (n = 27) OR (95% CI) P-Value
≥3 22 (51.2) 9 (42.9) 1.39 (.48–3.99) .53 12 (66.6) 13 (48.1) 2.15 (.62–7.42) .22
≥7 21 (48.8) 4 (19.0) 4.06 (1.17–14.06) .03 8 (44.4) 2 (7.4) 10.0 (1.80–55.55) .008
≥10 9 (20.9) 1 (4.8) 5.29 (.62–44.96) .15 3 (16.7) 2 (7.4) 2.50 (.37–16.73) .37
Abbreviations: CI, confidence interval; ELISPOT, enzyme-linked immunospot; GBS, group B Streptococcus; OR, odds ratio; PBMCs, peripheral blood mononuclear cells; SFU, spot-forming unit.
a Serotype V was not analyzed because the numbers were insufficient for comparison.
b For serotype Ia, we included in the quantitative analysis 2 participants in the cleared-colonization group who had SFU counts ≥7 SFU/106 PBMCs at baseline but failed to meet the criterion for
ELISPOT positivity of having at least double the spots of the negative control.
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both humoral and cell-mediated capsular immune responses
could therefore confer protection against early-onset disease
by reducing the exposure of newborns to GBS colonization dur-
ing the peripartum period. This could offer an additional mode
of protection against invasive GBS disease, especially for pre-
term newborns, who might not fully beneﬁt from transplacental
acquisition of maternal serotype-speciﬁc capsular antibody,
which mainly occurs beyond 34 weeks of gestation. Moreover,
clearance of GBS rectovaginal colonization during pregnancy,
coupled with prevention of new acquisition mediated by the
presence of humoral immunity, could theoretically mitigate
against other GBS-associated illness, such as chorioamnionitis,
and adverse birth outcomes, such as stillbirths and premature
labor. However, to affect the full spectrum of GBS-associated
morbidity and mortality in women, fetuses, and newborns, vac-
cination would need to occur early in the second trimester of
pregnancy and induce serotype-speciﬁc functional antibody
and cellular immunity.
Supplementary Data
Supplementary materials are available at http://jid.oxfordjournals.org.
Consisting of data provided by the author to beneﬁt the reader, the posted
materials are not copyedited and are the sole responsibility of the author, so
questions or comments should be addressed to the author.
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Prevalence of maternal colonisation with group B 
streptococcus: a systematic review and meta-analysis
Gaurav Kwatra*, Marianne C Cunnington*, Elizabeth Merrall, Peter V Adrian, Margaret Ip, Keith P Klugman, Wing Hung Tam, Shabir A Madhi
Summary
Background The most important risk factor for early-onset (babies younger than 7 days) invasive group B streptococcal 
disease is rectovaginal colonisation of the mother at delivery. We aimed to assess whether diﬀ erences in colonisation 
drive regional diﬀ erences in the incidence of early-onset invasive disease.
Methods We did a systematic review of maternal group B streptococcus colonisation studies by searching MEDLINE, 
Embase, Pascal Biomed, WHOLIS, and African Index Medicus databases for studies published between January, 1997, 
and March 31, 2015, that reported the prevalence of group B streptococcus colonisation in pregnant women. We also 
reviewed reference lists of selected studies and contacted experts to identify additional studies. Prospective studies in 
which swabs were collected from pregnant women according to US Centers for Disease Control and Prevention 
guidelines that used selective culture methods were included in the analyses. We calculated mean prevalence 
estimates (with 95% CIs) of maternal colonisation across studies, by WHO region. We assessed heterogeneity using 
the I² statistic and the Cochran Q test. 
Findings 221 full-text articles were assessed, of which 78 studies that included 73 791 pregnant women across 
37 countries met prespeciﬁ ed inclusion criteria. The estimated mean prevalence of rectovaginal group B streptococcus 
colonisation was 17·9% (95% CI 16·2–19·7) overall and was highest in Africa (22·4, 18·1–26·7) followed by the 
Americas (19·7, 16·7–22·7) and Europe (19·0, 16·1–22·0). Studies from southeast Asia had the lowest estimated 
mean prevalence (11·1%, 95% CI 6·8–15·3). Signiﬁ cant heterogeneity was noted across and within regions (all 
p≤0·005). Diﬀ erences in the timing of specimen collection in pregnancy, selective culture methods, and study sample 
size did not explain the heterogeneity.
Interpretation The country and regional heterogeneity in maternal group B streptococcus colonisation is unlikely to 
completely explain geographical variation in early-onset invasive disease incidence. The contribution of socio-
demographic, clinical risk factor, and population diﬀ erences in natural immunity need further investigation to 
understand these regional diﬀ erences in group B streptococcus maternal colonisation and early-onset disease.
Funding None. 
Introduction
Group B streptococcus is a substantial cause of severe 
infection in infants younger than 3 months, most often 
manifesting as sepsis, pneumonia, and meningitis. 
Infant invasive group B streptococcal disease occurs as a 
con tinuum over the ﬁ rst 3 months of life, but is com-
monly divided into early-onset disease, occurring within 
0–6 days of birth, or late-onset disease, occurring 
within 7–90 days of birth. Early-onset disease is vertically 
acquired from the mother, whereas late-onset disease can 
also be acquired nosocomially or in the community.1 
Case fatality ratios remain as high as 36% even in 
high-income settings such as Norway and the USA.2,3 
Moreover, among survivors of group B strepto-
coccal meningitis, 46–50% develop moderate-to-severe 
neuro logical impairment.4–6
Substantial variation exists in invasive disease incidence 
both within and across geographical regions, ranging 
from 0·02 per 1000 livebirths in southeast Asia to 
1·21 per 1000 livebirths in Africa.7 Some variation is 
probably attributable to the introduction of antibiotic-
based interventions. Intrapartum antibiotic prophylaxis 
(IAP), given to mothers with rectovaginal colonisation 
with group B streptococcus in late pregnancy, has resulted 
in a substantial decrease in the incidence of early-onset 
disease.8 However, substantial variation in incidence of 
early-onset disease remains in low-income and middle-
income countries, where the logistic and cost challenges 
associated with routine culture-based screening and IAP 
have limited its implementation. Factors underlying this 
variation might include diﬀ erences in case ascertainment 
and laboratory diagnostics, or population diﬀ erences in 
exposure and susceptibility.9
The most important risk factor for invasive early-onset 
group B streptococcal disease is rectovaginal colonisation 
of the mother at the time of birth.10 Vertical transmission 
of group B streptococcus occurs in about 50% of newborn 
babies of mothers with group B streptococcus 
colonisation, of whom 1–2% develop early-onset disease.11 
If population-based diﬀ erences in exposure are driving 
the reported diﬀ erences in early-onset disease incidence, 
one would expect to ﬁ nd similar disparities in the 
prevalence of maternal colonisation during pregnancy. 
In a 1998 systematic review12 of maternal group B 255
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streptococcus colonisation data from low-income and 
middle-income countries, mean prevalence ranged from 
8% in the Asia–Paciﬁ c region to 18% in sub-Saharan 
Africa. The microbiological method of group B strepto-
coccus isolation was identiﬁ ed as a key driver of this 
variation.12 In recent years, the sensitivity of culture 
methods has increased and published guidance now 
exists for recommended methods of specimen collection, 
processing, and group B streptococcus isolation,1 which 
should allow a clearer interpretation of any population 
diﬀ erences in colonisation.
We did a systematic review and meta-analysis of 
prospective epidemiological studies in which group B 
streptococcus carriage was investigated by recommended 
microbiological methods1 to assess whether the 
prevalence of maternal group B streptococcus 
colonisation matched the patterns of invasive disease 
incidence across geographical regions.
Methods
Search strategy and selection criteria
We searched ﬁ ve databases (MEDLINE, Embase, Pascal 
Biomed, WHOLIS, and African Index Medicus) to 
identify studies reporting the prevalence of group B 
streptococcus colonisation in pregnant women. We used 
the following search terms: “Streptococcus agalactiae” or 
“group B streptococcus” or “streptococcus group B” and 
“colonization” or “colonisation”. The WHOLIS and 
Research in context
Evidence before this study
Group B streptococcus rectovaginal colonisation of the mother 
at the time of birth is the most important risk factor for 
early-onset (babies younger than 7 days) invasive group B 
streptococcal disease. Marked diﬀ erences in prevalence of 
invasive group B streptococcal disease exist across geographical 
regions, ranging from 0·02 per 1000 livebirths in southeast Asia 
to 1·21 per 1000 livebirths in Africa. In a 1998 systematic review 
of maternal group B streptococcus colonisation, prevalence 
ranged from 8% to 18% by geographical region. This variability 
was partly attributed to diﬀ erences in the microbiological 
methods used for group B streptococcus isolation between 
studies. Since then, the US Centers for Disease Control and 
Prevention and others have recommended methods for 
rectovaginal sample collection and culture of group B 
streptococcus, aimed at improving sensitivity of detection of 
maternal colonisation. We did a systematic review and 
meta-analysis of prospective, epidemiological studies to assess 
the prevalence of rectovaginal group B streptococcus 
colonisation globally, and explore whether this was associated 
with the reported geographical variation in incidence of invasive 
disease. We searched ﬁ ve databases (MEDLINE, Embase, Pascal 
Biomed, WHOLIS, and African Index Medicus) to identify studies 
that reported the prevalence of group B streptococcus 
colonisation in pregnant women. Searches were restricted to 
those published between January, 1997, and March 31, 2015. 
No language restrictions were applied. Searches were done using 
the following terms: “Streptococcus agalactiae” or “group B 
streptococcus” or “streptococcus group B” and “colonization” or 
“colonisation”. For WHO databases, searches were done using the 
following terms: “group B streptococcus colonization” or 
“Streptococcus agalactiae colonization”. The inclusion criteria were 
limited to prospective studies in pregnant women that used 
robust recommended methods of sample collection and culture 
methods, to enhance comparability across studies.
Added value of this study
The global mean prevalence estimate of rectovaginal group B 
streptococcus colonisation was 17·9% (95% CI 16·2–19·7). 
Signiﬁ cant heterogeneity was noted both within and across 
geographical regions. The mean prevalence estimate of 
maternal rectovaginal group B streptococcus colonisation was 
highest in studies from Africa (22·4%, 95% CI 18·1–26·7) and 
lowest in southeast Asia (11·1%, 6·8–15·3). Stratiﬁ cation by 
timing of specimen collection, type of selective culture method, 
and sample size did not explain the heterogeneity in mean 
prevalence of group B streptococcus colonisation between 
studies or geographical regions. Among 17 studies reporting 
serotype distribution of colonising strains, none of which were 
from southeast Asia, serotypes Ia, Ib, II, III, and V accounted for 
more than 91% of isolates. A group B streptococcus vaccine 
that targets these ﬁ ve serotypes would provide coverage 
against most serotypes to which newborn babies are exposed; 
however, similar data are needed for those from low-income 
and middle-income countries. 
Implications of all the available evidence
In this meta-analysis, we identiﬁ ed signiﬁ cant variation in the 
prevalence of maternal colonisation both within and across 
geographical regions, which does not seem to be due to 
diﬀ erences in sample collection or culture methods as 
previously proposed. Nevertheless, the diﬀ erence in prevalence 
of maternal group B streptococcus colonisation between 
studies from Africa and southeast Asia, regions where 
intrapartum antibiotic prophylaxis for pregnant women with 
group B streptococcus colonisation is not done, was less 
marked than the diﬀ erence in incidence of invasive group B 
streptococcal disease in young infants reported between these 
regions. This ﬁ nding suggests that other factors, including 
sociodemographic indices, threshold for detection of invasive 
disease, clinical risk factors, population diﬀ erences in natural 
immunity, and possibly diﬀ erences in serotypes and strain 
virulence of colonising isolates, need further investigation to 
understand the regional diﬀ erences in group B streptococcus 
maternal colonisation and early-onset disease. An improved 
understanding of these factors would be informative for the 
selection of serotypes to be included in a group B streptococcus 
serotype-speciﬁ c polysaccharide vaccine. Such a vaccine would 
be developed for immunisation of pregnant women, as well as 
her fetus and oﬀ spring, against group B streptococcus.
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For the WHO regions see http://
www.who.int/about/regions/en/
African Index Medicus searches were completed using 
the following terms: “group B streptococcus colonization” 
or “Streptococcus agalactiae colonization”. We restricted 
searches to human studies published between 
January, 1997, and March 31, 2015. No language 
restrictions were applied. We also screened reference 
lists of selected studies and contacted experts in group B 
streptococcus epidemiology for any potentially relevant 
studies that had not been identiﬁ ed through the searches.
After an initial selection, based on review of the 
publication titles and abstracts, we did a full-text review 
of remaining studies. Studies were included if they met 
the following criteria: suﬃ  cient methodological detail to 
allow an assessment of specimen collection and micro-
biological methods; collection of rectovaginal or vaginal 
and rectal swabs done according to guidelines from the 
US Centers for Disease Control and Prevention (CDC) 
for specimen collection and microbiological identiﬁ cation 
of group B streptococcus; use of selective culture 
methods for isolation and identiﬁ cation of group B 
streptococcus; prospective data collection; pregnant 
population; and original research article describing data 
not published previously. We used these criteria to focus 
the systematic review on studies with robust methods 
and to increase comparability across studies.
Data analysis
We identiﬁ ed, screened, and excluded studies according 
to the Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA). Two investigators (GK 
and MCC) independently examined titles, abstracts, 
full-text articles, and abstracted data using the same 
data abstraction forms and selection criteria. 
Disagreements were resolved by consensus among the 
investigators. Data were abstracted for the following 
study characteristics: geographical region (as deﬁ ned by 
WHO: Africa, the Americas, southeast Asia, Europe, 
eastern Mediterranean, and western Paciﬁ c); study 
period; study population; timing (late pregnancy 
[≥35 weeks of gestation] vs at delivery vs <35 weeks) and 
site of specimen collection (single rectovaginal swab vs 
separate vaginal and rectal swabs); method of group B 
streptococcus isolation (selective broth followed by 
subculture on blood agar or selective agar vs direct 
plating on selective media); sample size; and proportion 
of women colonised with group B streptococcus. 
Culture methods could include those recommended by 
the CDC (group B streptococcus growth on selective 
broth followed by subculture on blood agar or selective 
media) or those outside of the CDC recommendations 
using some form of selectivity in the medium for 
group B streptococcus isolation.1
We did a random-eﬀ ects meta-analysis to calculate 
mean prevalence estimates (with 95% CIs) of maternal 
colonisation across studies and by region. Studies were 
categorised by region and sorted by study size, and 
heterogeneity between studies was assessed, ﬁ rst visually 
by the overlap of 95% CIs and then quantitatively by the 
I² statistic13 and the Cochran Q test for heterogeneity with 
a signiﬁ cance level of 5%.14 The I² statistic is interpreted 
as the proportion of the total variation in the estimates of 
mean prevalence that is due to the heterogeneity between 
studies. We explored potential drivers of statistical 
variation (ie, heterogeneity), including timing of 
specimen collection and culture method, using 
descriptive stratiﬁ ed analyses. We used funnel plots to 
investigate how estimated mean prevalence varied by 
study size, in case of small study eﬀ ects.15,16 Additionally, 
for studies with available data on the distribution of 
serotypes, we did a random-eﬀ ects meta-analysis to 
calculate the mean prevalence of women with serotypes 
Figure: Selection of group B streptococcus colonisation studies
CDC=US Centers for Disease Control and Prevention.
1852 articles identiﬁed from 
 database searches
 784 MEDLINE
 916 Embase
 152 Pascal Biomed
  0 WHOLIS and African 
 Index Medicus
30 articles identiﬁed from 
 reference lists and experts
1882 articles identiﬁed overall
657 duplicates removed
1255 articles included after 
 removing duplicates
337 article titles and abstracts 
 assessed for eligibility
221 full-text articles accessed 
 for eligibility
918 titles did not mention group B
        streptococcus colonisation
116 abstracts did not describe group B
        streptococcus colonisation
143 did not meet inclusion criteria
 44 insuﬃcient methodological details
 20 non-selective culture methods
 35 specimen collection did not follow
               CDC guidelines
 16 retrospective data collection
 10 duplicate dataset
 18 other
78 studies included in meta-analysis
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Ia, Ib, or III, and serotypes Ia, Ib, II, III, or V. Statistical 
analyses were completed using R software (version 2.15.2) 
and SAS (version 9.2).
The CDC recommendation for rectovaginal swab 
collection meant that studies in which lower vaginal swabs 
only were collected were excluded. To investigate any 
potential bias introduced, we did a separate sensitivity 
analysis of studies that met all predeﬁ ned criteria, but that 
reported estimates for lower vaginal colonisation only. 
Studies were categorised by region, as classiﬁ ed by WHO 
criteria. Because the western Paciﬁ c region includes an 
ethnically diverse range of countries (within this meta-
analysis: Australia, China [including Hong Kong], Japan, 
South Korea, and New Zealand), we did a separate 
sensitivity analysis that excluded Australia and New 
Zealand.
Role of the funding source 
There was no funding source for this study. The 
corresponding author had full access to all the data in the 
study and all authors had ﬁ nal responsibility for the 
decision to submit for publication. 
Results
We identiﬁ ed 1852 articles from the literature search and 
30 through a search of reference lists and expert opinion 
(ﬁ gure). After an initial review of titles and abstracts and 
the removal of duplicates, we assessed the full text 
of 221 articles for eligibility, of which 78 met the 
meta-analysis inclusion criteria.17–94
Most identiﬁ ed reports were from Europe and the 
Americas, whereas the fewest reports were from Africa 
(table 1). The proportion of studies meeting inclusion 
criteria was lowest for studies from Africa and the eastern 
Mediterranean (table 1). The most common reasons for 
exclusion were did not follow CDC guidelines for specimen 
collection (lower vaginal and rectal swabbing) in 35 (24%) 
of 143 studies, non-selective culture methods in 20 (14%), 
and insuﬃ  cient methodological detail in 44 (31%).1
73 791 pregnant women were included in 78 studies 
across 37 countries (median number of women per study 
391, IQR 251–1011), of whom 13 100 were positive for 
rectovaginal colonisation with group B streptococcus 
(table 2). The 23 studies from Europe had the highest 
number of women (n=31 642), whereas the seven studies 
from the eastern Mediterranean region had the lowest 
number (n=2729). The highest median number of 
women per study was in the western Paciﬁ c (1049, 
IQR 404–1700) and the lowest was in the eastern 
Mediterranean (300, 248–318). The appendix (pp 1–5) 
provides further details of the included studies. 
The study-speciﬁ c mean prevalence estimates ranged 
from 0·5% (95% CI 0·0–1·1) in Mexico17 to 37·9% 
(25·4–50·4) in Denmark.18 Table 2 summarises the 
random-eﬀ ects meta-analysis by region. Regional mean 
prevalence estimates ranged from 11·1% (95% CI 
6·8–15·3) in southeast Asia to 22·4% (18·1–26·7) in 
Africa. The global mean prevalence estimate of 17·9% 
(95% CI 16·2–19·7) was similar to the estimates for the 
two most studied regions: Europe and the Americas.
The appendix (pp 6–11) summarises the colonisation 
mean prevalence estimates for all studies included in 
the meta-analysis, by geographical region.17–94 The 
overall heterogeneity was 98·1% and remained 
signiﬁ cant within each region (lowest I² 82·7%, 
p=0·005 for the four studies from Africa), and although 
mean prevalence estimates from the same country were 
often similar (eg, Tunisia19,20) this was not always the 
case (eg, India21,22).
We also investigated other sources of heterogeneity. 
Several diﬀ erent selective culture methods were reported, 
Number 
identiﬁ ed
Included Excluded
Africa 14 4 (29%) 10 (71%)
Americas 76 29 (38%) 47 (62%)
Eastern Mediterranean 32 7 (22%) 25 (78%)
Europe 59 23 (39%) 36 (61%)
Southeast Asia 20 7 (35%) 13 (65%)
Western Paciﬁ c 19 8 (42%) 11 (58%)
International* 1 0 (0%) 1 (100%)
Total 221 78 (35%) 143 (65%)
*USA, Ireland, Thailand, Myanmar, Philippines, and Zimbabwe. 
Table 1: Inclusion and exclusion of studies by region 
Number of 
studies
Number of 
women
Median number of 
women per study (IQR)
Number of women 
with GBS
Estimated mean 
prevalence (95% CI)
I²* p value
Africa 4 2735 599 (415–867) 619 22·4 (18·1–26·7) 82·7% 0·005
Americas 29 23 163 316 (222–962) 4360 19·7 (16·7–22·7) 98·4% <0·0001
Eastern Mediterranean 7 2729 300 (248–318) 443 16·7 (11·7–21·7) 91·9% <0·0001
Europe 23 31 642 500 (275–942) 6113 19·0 (16·1–22·0) 97·2% <0·0001
Southeast Asia 7 3749 406 (310–727) 389 11·1 (6·8–15·3) 95·1% <0·0001
Western Paciﬁ c 8 9773 1049 (404–1700) 1176 13·3 (7·8–18·8) 98·7% <0·0001
Total 78 73 791 391 (251–1011) 13 100 17·9 (16·2–19·7) 98·1% <0·0001
GBS=group B streptococcus. *Within-region test for heterogeneity. 
Table 2: Meta-analysis of studies reporting prevalence of maternal colonisation by region 
See Online for appendix
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including selective broth subcultured on sheep blood 
agar, selective broth subcultured on selective media, and 
direct plating on selective agar media (appendix 
pp 12–13). To explore the contribution of these methods 
to the reported heterogeneity, we did a restricted analysis 
of studies with at least 400 women that used selective 
broth subcultured on sheep blood agar culture as the 
most common method (appendix p 14). However, the 
patterns of mean prevalence estimates across regions 
remained similar to the primary analysis, with high 
heterogeneity estimates (I² ≥90% across all regions).
We also investigated stratiﬁ cation according to 
maternal demographic characteristics, but analyses were 
limited by variation in the ways studies reported this 
information. Few studies had suﬃ  cient numbers of 
women to allow stratiﬁ cation by maternal age (<20 years 
vs ≥20 years), which precluded heterogeneity estimates 
for most regions (appendix p 15). We identiﬁ ed no 
diﬀ erence in heterogeneity by study period (using year of 
publication as a proxy; appendix pp 16–17).
To investigate any potential bias introduced by the 
exclusion of studies reporting colonisation from lower 
vaginal swabs only, we did a separate meta-analysis. 
17 studies were identiﬁ ed, including 18 495 women, with 
a mean prevalence estimate of 14·2% (95% CI 10·7–17·6) 
and a similar heterogeneity to the primary meta-analysis 
(I² 97·5%; appendix p 18).
We also reassessed the ethnic diversity of the western 
Paciﬁ c region. For this region, eight studies were 
included originally, from China (including Hong Kong), 
Japan, South Korea, Australia, and New Zealand. The two 
Australian and New Zealand studies accounted for 
1336 (14%) of 9773 women included in the original 
analysis. The exclusion of these two studies led to a 
numerical but non-signiﬁ cant reduction in the mean 
prevalence estimate from 13·3% (95% CI 7·8–18·8) to 
10·1% (5·2–15·1), which is similar to the southeast Asian 
estimate of 11·1% (6·8–15·3; appendix p 19).
Serotype distribution was reported in 22 studies, but ﬁ ve 
were excluded because they reported combined serotype 
data only (n=2),51,52 combined maternal and neonatal 
isolate data (n=1),84 or did not report raw data (n=2).75,82 
Table 3 summarises data from the remaining 17 studies. 
Lower proportions of women with serotypes Ia, Ib, or III 
were reported in studies from the Americas (mean 
prevalence estimate 55·0%, 95% CI 52·3–57·7) and 
Europe (58·3%, 52·2–64·5) than for other regions, mainly 
as a result of a higher proportion of serotype II isolates in 
Country Number of 
serotypes 
isolated
Serotypes Ia, Ib, or III Serotypes Ia, Ib, II, III, or V
Number of women 
with at least one of 
these serotypes
Estimated mean 
prevalence (%, 95% CI)
I² Number of women 
with at least one of 
these serotypes
Estimated mean 
prevalence (%, 95% CI)
I²
Overall 3391 2029 63·3% (57·7–68·8) 90·4% 3105 91·5% (88·9–94·0) 88·0%
Africa 542 362 69·2% (57·2–81·3) 88·1% 524 96·6% (94·1–99·0) 46·2%
Kwatra et al (2014)24 South Africa 152 115 75·7% (68·8–82·5) ·· 144 94·7% (91·2–98·3) ··
Gray et al (2011)25 Malawi 390 247 63·3% (58·6–68·1) ·· 380 97·4% (95·9–99·0) ··
Americas 1289 709 55·0% (52·3–57·7) 0·0% 1189 89·6% (82·6–96·6) 92·9%
Campbell et al (2000)26 USA 856 472 55·1% (51·8–58·5) ·· 806 94·2% (92·6–95·7) ··
Davies et al (2001)27 Canada 233 126 54·1% (47·7–60·5) ·· 201 86·3% ( 81·8–90·7) ··
Hickman et al (1999)28 USA 153 88 57·5% (49·7–65·3) ·· 146 95·4% (92·1–98·7) ··
Simoes et al (2007)29 Brazil 47 23 48·9% (34·6–63·2) ·· 36 76·6% (64·5–88·7) ··
Europe 1085 612 58·3% (52·2–64·5) 72·6% 946 88·9% (84·7–93·2) 79·2%
Hakansson et al (2008)30 Sweden 356 170 47·8% (42·6–52·9) ·· 295 82·9% (79·0–86·8) ··
Tsolia et al (2003)31 Greece 67 36 53·7% (41·8–65·7) ·· 60 89·6% (82·2–96·9) ··
Kunze et al (2011)32 Germany 155 98 63·2% (55·6–70·8) ·· 140 90·3% (85·7–95·0) ··
Jones et al (2006)33* UK 159 108 67·9% (60·7–75·2) ·· 153 96·2% (93·3–99·2) ··
Kieran et al (1998)83 Ireland 129 78 60·5% (52·0–68·9) ·· 116 89·9% (84·7–95·1) ··
Roccasalva et al (2008)34 Italy 7 5 71·4% (38·0–100·0) ·· 7 93·8% (77·0–100·0) ··
Liébana-Martos Mdel et al (2015)91 Spain 212 117 55·2% (48·5–61·9) ·· 175 82·5% ( 77·4–87·7) ··
Western Paciﬁ c 475 346 76·5% (65·4–87·5) 86·8% 446 94·2% (90·6–97·7) 56·1%
Lu et al (2014)35 China 201 151 75·1% (69·1–81·1) ·· 195 97·0% (94·7–99·4) ··
Uh et al (1997)36 South Korea 193 132 68·4% (61·8–75·0) ·· 175 90·7% (86·6–94·8) ··
Grimwood et al (2002)37 New Zealand 29 27 93·1% (83·9–100·0) ·· 27 93·1% (83·9–100·0) ··
Lee et al (2010)23 South Korea 52 36 69·2% (56·7–81·8) ·· 49 94·2% (87·9–100·0) ··
*Serotyping was done on isolates that were positive between two diﬀ erent culture methods with overall group B streptococcus positive only shown for US Centers for Disease Control and Prevention method. 
Table 3: Meta-analysis of serotypes isolated 
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those regions (appendix pp 20–21). In a post-hoc analysis, 
serotypes VI, VII, and VIII were rare everywhere, although 
in one study from South Korea,23 these serotypes were 
present in 14 (7%) of 192 vaginal and rectal group B 
streptococcus isolates (appendix pp 20–21).
To investigate how mean prevalence estimates varied 
by study size, we produced a funnel plot, which showed 
little asymmetry on either side of the overall mean 
prevalence estimate (appendix p 23; regression test with 
study size as a predictor p=0·89).
Discussion
In this systematic review and meta-analysis, the overall 
mean prevalence estimate of group B streptococcus in 
pregnant women was almost 20%, with the highest 
prevalence reported among African studies. The mean 
prevalence estimates reported from studies in the 
Americas, Europe, and the eastern Mediterranean regions 
were similar and the lowest prevalence estimates were 
from studies from southeast Asia and the western Paciﬁ c.
We selected studies for this meta-analysis, primarily 
based on CDC recommendations for group B strepto-
coccus screening and identiﬁ cation using selective 
culture methods,1 with the aim of focusing on robust 
data and limiting between-study heterogeneity due to 
methodological variation. However, we still identiﬁ ed 
signiﬁ cant heterogeneity across all studies and across 
studies within individual regions. A sensitivity analysis 
of studies with lower vaginal swab collection showed a 
similar pattern of regional heterogeneity. Further 
stratiﬁ cation by variables poorly controlled for by 
inclusion criteria (eg, timing of specimen collection and 
type of selective culture method) did not lead to a 
reduction in heterogeneity of mean prevalence estimates 
across studies. Additional variables, such as demo-
graphics, were diﬃ  cult to explore because few studies 
reported these with suﬃ  cient detail. The colonisation 
prevalence range reported in the previous review12 was 
8–18%, which was similar to the 11–22% in this meta-
analysis, despite greater standardisation in culture 
methods used in studies included in this meta-analysis, 
which was judged to be an important driver for the 
variability in colonisation between studies in the earlier 
meta-analysis. However, because the studies included in 
these two meta-analyses were not done in the same 
places, a direct comparison of these estimates must be 
interpreted with caution, since even within-country 
diﬀ erences in colonisation were noted in the present 
meta-analysis. Nevertheless, these data suggest that other 
factors probably contribute towards regional variations in 
group B streptococcus colonisation in pregnant women 
and consequently risk for early-onset disease in their 
newborn babies.
Furthermore, the heterogeneity might have been 
driven by unmeasured variables; diﬀ erences in study 
population selection might have led to higher or lower 
risk populations being represented, which was diﬃ  cult 
to assess across studies. Several obstetric variables, such 
as parity and premature rupture of membranes, have 
been associated with higher risk of group B streptococcus 
colonisation,24 but without access to individual-level data 
this was diﬃ  cult to explore.
Diﬀ erential sensitivity of culture methods between 
populations has been reported. For example, in South 
Africa, in one study95 selective broth was not suitable for 
the recovery of group B streptococcus from rectal swabs 
because of masking of the group B streptococcus colonies 
by persistent microﬂ ora. In that population, direct 
plating on selective agar was the most sensitive method 
of isolation. Findings from studies from Denmark,96 
Spain,97 and Brazil98 have also shown increased group B 
streptococcus recovery using direct plating on selective 
media compared with selective broth. Further 
optimisation of microbiological techniques in diﬀ erent 
populations will contribute to a better understanding of 
potential ascertainment diﬀ erences and their eﬀ ect on 
group B streptococcus colonisation prevalence estimates.
The pattern of prevalence of group B streptococcus 
colonisation, with the highest estimates from Africa and 
lowest from southeast Asia and the western Paciﬁ c, 
matches the pattern of incidence of group B streptococcus 
neonatal disease.7 An algorithm to predict early-onset 
disease incidence on the basis of maternal colonisation 
prevalence can be used to explore these patterns further; 
50% of infants born to women colonised with group B 
streptococcus will themselves be colonised and 2% of 
those colonised infants will develop early-onset group B 
streptococcal disease.11,99 Data from South Africa and the 
USA, before the introduction of routine screening and 
IAP, where about 20% of pregnant women had group B 
streptococcus vaginal colonisation, conﬁ rmed the 
expected prevalence of early-onset disease of two per 
1000 livebirths.11,100,101 Based on this algorithm, and 
regional prevalence estimates from the present meta-
analysis, one would expect the prevalence of early-onset 
group B streptococcal disease in the southeast Asian and 
western Paciﬁ c studies to be half that in the African 
studies. However, the overall prevalence of invasive 
disease in those regions is commonly reported to be 
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Although diﬀ erences in colonisation prevalence might 
explain some of the regional diﬀ erences in disease 
incidence, other factors including natural immunity and 
serotype distribution with varying virulence between 
serotypes and surveillance methods might also contribute 
and need to be investigated further.
In this systematic review and meta-analysis, we aimed 
to identify studies from all geographical regions by 
searching ﬁ ve diﬀ erent literature databases and by 
assessing publications in all languages. However, few 
studies from Africa, which has a high proportion of low-
income countries, were identiﬁ ed from initial searches, 
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To ensure quality and to avoid bias in the identiﬁ ed 
studies, we used stringent inclusion criteria on the basis 
of rigorous methods and aimed to standardise studies 
with respect to factors known to aﬀ ect the estimated 
prevalence of colonisation (eg, culture method for 
group B strepto coccus isolation and identiﬁ cation). 
Nevertheless, we noted substantial variation in the 
prevalence of maternal colonisation both within and 
across geographical regions. The within-region dif-
ferences were not explained by diﬀ erences in specimen 
collection or microbiological culture techniques, although 
additional analyses with individual-level data are 
recommended to better understand the role of population 
selection, obstetric, and socio demographic risk factors. A 
further limitation of the available data was that few data 
on serotype distribution by region were available, with 
only 17 studies contributing to this analysis, none of 
which were from southeast Asia or the eastern 
Mediterranean.
Underlying population diﬀ erences in natural 
immunity through transplacental acquisition of 
serotype-speciﬁ c capsular antibodies by the fetus 
remain an alternative explanation that should be 
explored in future studies to establish the disparity 
between rates of exposure to and prevalence of group B 
streptococcus across geographical regions. A clearer 
understanding of the factors underlying this variation 
will be crucial to enable more eﬃ  cient design of 
screening and prevention programmes for maternal 
and infant group B streptococcal disease.
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